

Sunday, 23. April 2023*Non-Profit Symposium*

08:30 - 10:00

Room 141

IS02 - Non-Profit - Mesenchymal Stem Cells : Therapeutic applications| SFGM-TC*Chair:* Dominique Farge, FR*Chair:* Raynier Devillier, FR

IS02-1	MSC in allo-HSCT <i>Speaker:</i> Danièle Bensoussan, FR	08:30 - 08:55
IS02-2	Q&A	08:55 - 09:05
IS02-3	MSC and systemic sclerosis <i>Speaker:</i> Alain Lescoat, FR	09:05 - 09:25
IS02-4	Q&A	09:25 - 09:35
IS02-5	MSC and ocular GVHD <i>Speaker:</i> Eric Gabison, FR	09:35 - 09:55
IS02-6	Q&A	09:55 - 10:00

Non-Profit Symposium

08:30 - 10:00

Room 143

IS03 - Advances in multiple myeloma - ATERHIT /IFM*Chair:* Mohamad Mohty, FR

IS03-1	Introduction <i>Speaker:</i> Mohamad Mohty, FR	08:30 - 08:35
IS03-2	From alkylating agents to immunotherapy: a journey in time <i>Speaker:</i> Jean-Luc Harousseau, FR	08:35 - 08:55
IS03-3	Immunotherapy in elderly patients <i>Speaker:</i> Thierry Facon, FR	08:55 - 09:15
IS03-4	Immunotherapy in young and fit patients <i>Speaker:</i> Mohamad Mohty, FR	09:15 - 09:35
IS03-5	Nobel Prize laureate special lecture: "How do you feel? The Molecules that sense pressure" <i>Speaker:</i> Ardem Patapoutian, US	09:35 - 09:55
IS03-6	Conclusion <i>Speaker:</i> Mohamad Mohty, FR	09:55 - 10:00

Non-Profit Symposium

08:30 - 10:00

Room 151

IS04 - GMMG Symposium*Chair:* Igor-Wolfgang Blau, DE*Chair:* Hartmut Goldschmidt, DE

IS04-1	Role of cellular therapy in multiple myeloma	08:30 - 08:43
--------	---	---------------

	<i>Speaker:</i> Christof Scheid, DE	
IS04-2	Current induction therapy strategies in newly-diagnosed multiple myeloma <i>Speaker:</i> Elias Mai, DE	08:43 - 08:56
IS04-3	Update in Amyloidosis <i>Speaker:</i> Stefan Schoenland, DE	08:56 - 09:09
IS04-4	Treatment of high-risk multiple myeloma <i>Speaker:</i> Lisa Leypoldt, DE	09:09 - 09:22
IS04-5	Therapy of newly-diagnosed, non-transplant eligible multiple myeloma patients <i>Speaker:</i> Maximilian Merz, DE	09:22 - 09:35
IS04-6	Therapeutic developments for refractory multiple myeloma <i>Speaker:</i> Marc Raab, DE	09:35 - 09:48
IS04-7	Q&A	09:48 - 10:00

Patient, Family, and Donor Day

08:30 - 10:00

Room 153

PFD01 - Patient, Family and Donor Day 1 - What's new in combatting chronic graft vs. host disease (GVHD)?*Chair:* Riikka-Leena Manninen, FI*Chair:* Guy Bouguet, FR

PFD01-1	Welcome to the Patient, Family and Donor Day <i>Speaker:</i> Natacha Bolaños, ES	08:30 - 08:45
PFD01-2	Introduction - setting the scene: GVHD The cost of a cure <i>Speaker:</i> Riikka-Leena Manninen, FI <i>Speaker:</i> Guy Bouguet, FR	08:45 - 08:50
PFD01-3	Is all chronic GVHD the same? How to improve QoL? <i>Speaker:</i> David Michonneau, FR	08:50 - 09:05
PFD01-4	Coping With Graft-Versus-Host-Disease: What practical things you can do <i>Speaker:</i> Mathilde Cantin, FR	09:05 - 09:20
PFD01-5	What's New in Tackling Graft-Versus-Host Disease? Targeted GVHD treatments bring hope	09:20 - 09:35
PFD01-6	Discussion, Q&A	09:35 - 10:00

Nurses Group

08:30 - 10:00

Room 242 AB

NG01 - Nurses Education Day 1 - Nursing challenges in 2023: Transplant nursing now*Chair:* Thomas Jezequel, FR*Chair:* Kathy Goris, BE

NG01-1	Welcome and introduction <i>Speaker:</i> Kathy Goris, BE	08:30 - 08:35
--------	--	---------------

NG01-2	Who to transplant in 2023 <i>Speaker:</i> Remy Dulery, FR	08:35 - 09:00
NG01-3	Who receives cellular therapy in 2023 <i>Speaker:</i> Annalisa Ruggeri, IT	09:00 - 09:25
NG01-4	Maintaining nurse competencies in an ever changing world <i>Speaker:</i> Ruth Elizabeth Clout, GB	09:25 - 09:50
NG01-5	Q&A	09:50 - 10:00

ePoster

08:30 - 18:00

ePoster Area

Non-haematopoietic Stem Cells and Regenerative Medicine

P272	SARS-COV-2 FAILS TO INFECT MESENCHYMAL STROMAL CELLS (MSCS) AND DOES NOT ACTIVATE COAGULATION – PRE-CLINICAL INVESTIGATIONS IN SUPPORT OF THERAPEUTIC USE OF MSCS FOR SEVERE COVID-19 <i>Poster Presenter:</i> Lisa-Marie Pfeffermann, DE	08:30 - 08:30
P273	EXPLORING THE THERAPEUTIC POTENTIAL OF AUTOLOGOUS BONE MARROW MONONUCLEAR CELLS <i>VERSUS</i> ALLOGENIC WHARTON JELLY-DERIVED MESENCHYMAL STEM CELLS IN CHRONIC LIMB-THREATENING ISCHEMIA IN DIABETIC PATIENTS <i>Poster Presenter:</i> Claudia L. Sossa, CO	08:30 - 08:30

ePoster

08:30 - 18:00

ePoster Area

ePoster Viewing*ePoster*

08:30 - 18:00

ePoster Area

Chronic Leukaemia and Other Myeloproliferative Disorders

P830	FEASIBILITY OF EARLY DOSE REDUCTION OF FRONTLINE DASATINIB IN CHRONIC MYELOID LEUKEMIA PATIENTS: A 3-YEAR FOLLOW UP RESULTS OF DAS-CHANGE STUDY <i>Poster Presenter:</i> Dong-Yeop Shin, KR	08:30 - 08:30
P831	TKI IN RELAPSE PROPHILAXIS AFTER ALLOGENEIC TRANSPLANTATION IN CML/ADVANCED PHASES <i>Poster Presenter:</i> Antonella Gozzini, IT	08:30 - 08:30
P832	THE CLINICAL VALUE OF NEUTROPHIL-TO-LYMPHOCYTE RATIO AT THE DIAGNOSIS OF MYELOPROLIFERATIVE NEOPLASM <i>Poster Presenter:</i> Jong-Ho Won, KR	08:30 - 08:30

ePoster

08:30 - 18:00

ePoster Area

Multiple Myeloma

P801	LONG TERM OUTCOMES FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANTATION FOR LIGHT CHAIN DEPOSITION DISEASE: A RETROSPECTIVE STUDY ON BEHALF OF THE CMWP OF THE EBMT <i>Poster Presenter:</i> Laurent Garderet, FR	08:30 - 08:30
P802	INTERNATIONAL DIFFERENCES IN BASELINE CHARACTERISTICS AND PRACTICE PATTERNS IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA UNDERGOING UPFRONT AUTOLOGOUS STEM CELL TRANSPLANTATION <i>Poster Presenter:</i> Laurent Garderet, FR	08:30 - 08:30
P803	WORLDWIDE NETWORK FOR BLOOD AND MARROW TRANSPLANTATION GLOBAL STUDY ON BASELINE CHARACTERISTICS/CLINICAL OUTCOMES IN MULTIPLE MYELOMA PATIENTS UNDERGOING ASCT, A STUDY OFF 61,725 PATIENTS <i>Poster Presenter:</i> Laurent Garderet, FR	08:30 - 08:30
P804	POLYMORPHISMS WITHIN AUTOPHAGY-RELATED GENES AS SUSCEPTIBILITY BIOMARKERS FOR MULTIPLE MYELOMA: A META-ANALYSIS OF THREE LARGE COHORTS <i>Poster Presenter:</i> Antonio José Cabrera-Serrano, ES	08:30 - 08:30
P805	IMPACT OF THE ADDITION OF DARATUMUMAB TO THE STANDARD VTD REGIMEN ON HEMATOPOIETIC STEM CELL MOBILIZATION AND COLLECTION, POST-TRANSPLANT ENGRAFTMENT AND INFECTIOUS COMPLICATIONS <i>Poster Presenter:</i> Gianluca Cavallaro, IT	08:30 - 08:30
P807	REVISITING THE UTILITY OF G-CSF POST-AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Poster Presenter:</i> Andrew Portuguese, US	08:30 - 08:30
P808	IS THERE STILL A ROLE FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN REFRACTORY MULTIPLE MYELOMA? A RETROSPECTIVE MULTICENTER ANALYSIS IN THE AGE OF MODERN THERAPIES <i>Poster Presenter:</i> Tim Richardson, DE	08:30 - 08:30
P809	BUSULFAN PLUS CYCLOPHOSPHAMIDE AND ETOPOSIDE VERSUS HIGH-DOSE MELPHALAN AS CONDITIONING IN AUTOLOGOUS STEM CELL TRANSPLANTATION FOR NEWLY DIAGNOSED MULTIPLE MYELOMA <i>Poster Presenter:</i> Sunnam Lim, KR	08:30 - 08:30
P810	DOES THE CONSOLIDATION TREATMENT EFFICIENT AFTER HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL TRANSPLANTATION IN MYELOMA PATIENTS? WHICH REGIMEN IS FEASIBLE? <i>Poster Presenter:</i> Zübeyde Nur Özkurt, TR	08:30 - 08:30
P811	EMAGINE/CARTITUDE-6: RANDOMIZED PHASE 3 STUDY COMPARING DVRD FOLLOWED BY CILTACABTAGENE AUTOLEUCEL VERSUS DVRD FOLLOWED BY ASCT IN	08:30 - 08:30

	TRANSPLANT ELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA <i>Poster Presenter:</i> Salomon Manier, FR	
P812	NATION-WIDE RETROSPECTIVE ANALYSIS OF ALLOGENEIC STEM CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA: A STUDY FROM KOREAN MULTIPLE MYELOMA WORKING PARTY (KMM1913) <i>Poster Presenter:</i> Ho-Jin Shin, KR	08:30 - 08:30
P813	FEASIBILITY AND OUTCOME OF FIRST-LINE AUTOTRANSPLANT-BASED TREATMENT IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS AGED >65 YEARS: MONOCENTRIC RETROSPECTIVE EXPERIENCE <i>Poster Presenter:</i> Alessandro Rambaldi, IT	08:30 - 08:30
P814	EFFECT OF MELPHALAN 140 MG/M² OR 200 MG/M² OUTCOMES IN MULTIPLE MYELOMA PATIENTS UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION A MULTIPLE CENTER EXPERIENCE IN SPAIN	08:30 - 08:30
P815	ADEQUATE ENGRAFTMENT AND COST REDUCTION WITH NON-CRYOPRESERVED (NC) PERIPHERAL BLOOD STEM CELLS (PBSC) IN MULTIPLE MYELOMA PATIENTS UNDERGOING AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION (APBSCT) <i>Poster Presenter:</i> Ahmad Ibrahim, LB	08:30 - 08:30
P816	LONG-TERM RESULTS OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN 42 PATIENTS WITH MULTIPLE MYELOMA (MM) <i>Poster Presenter:</i> Malek Benakli, DZ	08:30 - 08:30
P817	AUTOLOGOUS STEM CELL TRANSPLANTATION IN AL AMYLOIDOSIS: A SINGLE-CENTER EXPERIENCE <i>Poster Presenter:</i> Irene Romera Martínez, FR	08:30 - 08:30
P818	ROLE OF DYNAMIC EASIX AS A FEASIBLE PREDICTIVE MARKER FOR EARLY RELAPSE AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION FOR MULTIPLE MYELOMA <i>Poster Presenter:</i> Young Hoon Park, KR	08:30 - 08:30
P819	STEM CELL MOBILIZATION AND AUTOLOGOUS STEM CELL TRANSPLANTATION AFTER INDUCTION WITH BENDAMUSTINE, PREDNISONE AND BORTEZOMIB (BPV) IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS WITH RENAL IMPAIRMENT <i>Poster Presenter:</i> Song-Yau Wang, DE	08:30 - 08:30
P820	THE OUTCOMES OF AUTOLOGOUS BONE MARROW TRANSPLANTATION IN ELDERLY MULTIPLE MYELOMA PATIENTS: A DOUBLE-CENTERED RETROSPECTIVE STUDY <i>Poster Presenter:</i> Meral Ulukoylu Menguc, TR	08:30 - 08:30
P821	REAL-WORLD SAFETY AND EFFICACY OF DARATUMUMAB	08:30 - 08:30

	BASED INDUCTION QUADRUPLETS IN TRANSPLANT ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS (TE-NDMM): A SINGLE CENTRE EXPERIENCE	
	<i>Poster Presenter:</i> Sotiria Dimou-Besikli, GR	
P822	UP-FRONT HIGH DOSE MELPHALAN AND AUTOLOGOUS STEM CELL TRANSPLANTATION FOR NEWLY DIAGNOSED MULTIPLE MYELOMA: SINGLE CENTER RETROSPECTIVE ANALYSIS OF 124 CASES	08:30 - 08:30
	<i>Poster Presenter:</i> Nobuhiro Tsukada, JP	
P823	ISATUXIMAB INTERFERENCE OF ALLOGENEIC CROSSMATCH IMPACTING IMMUNOLOGICAL ASSESSMENT IN MULTIPLE MYELOMA TRANSPLANTATION	08:30 - 08:30
	<i>Poster Presenter:</i> Milda Rudzianskiene, LT	
P824	EXPERIENCE IN THE USE OF AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH SYSTEMIC AMYLOID LIGHT CHAIN AMYLOIDOSIS: A SINGLE-CENTRE OBSERVATIONAL EVALUATION	08:30 - 08:30
	<i>Poster Presenter:</i> Jorge Illarramendi Esteban, ES	
P826	AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IS FEASIBLE, EFFECTIVE, AND SAFE IN PATIENTS WITH MULTIPLE MYELOMA OVER 70 YEARS	08:30 - 08:30
	<i>Poster Presenter:</i> Sebastian Galeano, UY	
P827	SAFETY, FEASIBILITY AND OUTCOMES OF STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA PATIENTS WITH UNDERLYING CHRONIC RENAL FAILURE	08:30 - 08:30
	<i>Poster Presenter:</i> Akshay Lahoti, IN	
P828	TWO CASES OF B-ALL IN MYELOMA PATIENTS RECEIVING LONG MAINTENANCE IMiD THERAPY AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION	08:30 - 08:30
	<i>Poster Presenter:</i> Ali Unal, TR	
P829	TANDEM VS SINGLE ASCT FOR MM PATIENTS - CLINICAL EXPERIENCE OF CIC 859 – FIRST RESULTS	08:30 - 08:30
	<i>Poster Presenter:</i> Penka Ganeva, BG	
<i>ePoster</i>		
08:30 - 18:00		ePoster Area
	Inborn Errors, Granulocyte and Osteoclast Disorders	
P750	ALLOGENEIC HSCT IMPROVES QUALITY OF LIFE IN PATIENTS WITH STAT3 DOMINANT-NEGATIVE HYPER-IGE SYNDROME	08:30 - 08:30
	<i>Poster Presenter:</i> Christo Tsilifis, GB	
P751	HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN WITH CHRONIC GRANULOMATOUS DISEASE. THE SPANISH EXPERIENCE	08:30 - 08:30
	<i>Poster Presenter:</i> Laura Alonso, ES	
P752	COMPOUND HETEROZYGOUS HLH IN A YOUNG ADULT:	08:30 - 08:30

MULTIMODAL AND MULTIPROFESSIONAL TREATMENT*Poster Presenter:* Katharina Wustrau, DE

P753 **INFLAMMATION IN WOLMAN DISEASE IS GENERATED BY SUBSTRATE ACCUMULATION IN THE MACROPHAGE** 08:30 - 08:30

Poster Presenter: Anthea Guha, GB

P754 **UNDERGOING TRANSPLANT FOR MALIGNANT OSTEOPETROSIS: DON'T GIVE UP** 08:30 - 08:30

Poster Presenter: Giulia Pisano, ES*ePoster*

08:30 - 18:00

ePoster Area

Haemoglobinopathy

P742 **HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PEDIATRIC SICKLE CELL DISEASE WITHIN THE POST-TRANSPLANT CYCLOPHOSPHAMIDE ERA** 08:30 - 08:30

Poster Presenter: Lisa V.E. Oostenbrink, NL

P743 **HLA ALLELE AND HAPLOTYPE FREQUENCIES IN SICKLE CELL DISEASE AND THALASSEMIA PATIENTS: A JOINT STUDY ON BEHALF OF EUROCORD AND SFGM-TC** 08:30 - 08:30

Poster Presenter: Graziana Maria Scigliuolo, MC

P744 **FEASIBILITY AND SAFETY OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN SICKLE CELL DISEASE PATIENTS WITH ADVANCED KIDNEY AND LIVER DISEASE** 08:30 - 08:30

Poster Presenter: Israa Saib, SA

P745 **THE EFFECT OF POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PEDIATRIC PATIENTS WITH BETA-MAJOR THALASSEMIA** 08:30 - 08:30

Poster Presenter: AmirAli Hamidieh, IR

P746 **ALEMTUZUMAB REVERSES SECONDARY GRAFT REJECTION IN ALLOGENEIC STEM CELL TRANSPLANTATION IN PATIENTS WITH SICKLE CELL DISEASE** 08:30 - 08:30

Poster Presenter: Erfan Nur, NL

P747 **LONGITUDINAL ASSESSMENT OF QUALITY OF LIFE IN PATIENTS WITH SICKLE CELL DISEASE POST BONE MARROW TRANSPLANTATION** 08:30 - 08:30

Poster Presenter: Asaad Al Hinai, OM

P748 **NON-MYELOABLATIVE HAPLOIDENTICAL BMT WITH PTCY FOR CHILDREN AND ADULTS WITH SICKLE CELL DISEASES: THE BRAZILIAN EXPERIENCE** 08:30 - 08:30

Poster Presenter: Carmem Bonfim, BR

P749 **HAPLOIDENTICAL RELATED DONOR PERIPHERAL BLOOD STEM CELL TRANSPLANT FOR THALASSEMIA MAJOR WITH POST TRANSPLANT CYCLOPHOSPHAMIDE AND THIOTEPA, FLUADARABNE AND TREOSULFAN OR BUSULFAN** 08:30 - 08:30

CONDITIONING*Poster Presenter:* Satya Prakash Yadav, IN*ePoster*

08:30 - 18:00

ePoster Area

Myeloproliferative Neoplasm

- P736 **LONG-TERM SURVIVAL AFTER DONOR LYMPHOCYTE INFUSION FOR MOLECULAR AND HEMATOLOGICAL RELAPSE AFTER HEMATOPOIETIC CELL TRANSPLANTATION FOR MYELOFIBROSIS** 08:30 - 08:30
Poster Presenter: Nico Gagelmann, DE
- P737 **EFFICACY OF PACRITINIB FOR SPLEEN REDUCTION IN PATIENTS WITH MYELOFIBROSIS ACROSS THE CYTOPENIC SPECTRUM** 08:30 - 08:30
Poster Presenter: Nico Gagelmann, DE
- P738 **THIOTEPA-TREOSULFAN-FLUDARABINE (TTF) AS CONDITIONING REGIMEN IN PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLOHSCT) FOR MYELOFIBROSIS** 08:30 - 08:30
Poster Presenter: Filippo Antonio Canale, IT
- P739 **ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT FOR MYELOFIBROSIS IN BRAZIL: A MULTICENTRIC STUDY** 08:30 - 08:30
Poster Presenter: Vaneuza Araujo Moreira Funke, BR
- P740 **RUXOLITINIB AND DLI AS EARLY SALVAGE THERAPY FOR MYELOFIBROSIS RELAPSE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION** 08:30 - 08:30
Poster Presenter: Matteo Parma, IT
- P741 **HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH MYELOFIBROSIS IN A RETROSPECTIVE COHORT – CHALLENGES AND UNMET NEEDS** 08:30 - 08:30
Poster Presenter: Blanca de Felipe Noguerales, ES

ePoster

08:30 - 18:00

ePoster Area

Autoimmune Diseases

- P733 **EXPERIENCE IN THE USE OF ABATACEPT FOR THE MANAGEMENT OF REFRACTORY AUTOIMMUNE HEMOLYTIC ANEMIA IN PEDIATRIC PATIENTS AFTER ALLOGENIC STEM CELL TRANSPLANTATION** 08:30 - 08:30
Poster Presenter: Carlos Echevarria Parente, ES
- P734 **SARS-COV-2 VACCINATION IN SYSTEMIC SCLEROSIS PATIENTS TREATED BY AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION, ON BEHALF OF MATHEC-SFGM-TC GROUP** 08:30 - 08:30
Poster Presenter: Carlotta Cacciatore, FR

P735	THE FIRST AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANT FOR A MULTIPLE SCLEROSIS PATIENT IN THE UNITED ARAB EMIRATES <i>Poster Presenter: Inas El-Najjar, AE</i>	08:30 - 08:30
<i>ePoster</i> 08:30 - 18:00		ePoster Area
Aplastic Anaemia		
P720	COMPARISON OF THE OUTCOMES OF IMMUNOSUPPRESSIVE THERAPY WITH RABBIT - VS. HORSE-ANTI-THYMOCYTE GLOBULIN FOR THE TREATMENT OF SEVERE APLASTIC ANEMIA IN CHILDREN <i>Poster Presenter: Ayami Yoshimi, DE</i>	08:30 - 08:30
P721	OUTCOMES OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR CONGENITAL AMEGAKARYOCYTIC THROMBOCYTOPENIA, A PDWP/EBMT STUDY <i>Poster Presenter: Clémence Aldebert, FR</i>	08:30 - 08:30
P722	OUTCOMES AFTER CORD BLOOD TRANSPLANTATION FOR INHERITED BONE MARROW FAILURE SYNDROMES: A REPORT FROM THE JSTCT INHERITED DISEASE WORKING GROUP <i>Poster Presenter: NAO YOSHIDA, JP</i>	08:30 - 08:30
P723	PREGNANCY OUTCOMES AND MANAGEMENT IN ACQUIRED BONE MARROW FAILURE SYNDROME AND PAROXYSMAL NOCTURNAL HAEMOGLOBINURIA: A SINGLE CENTRE EXPERIENCE <i>Poster Presenter: Marta Bortolotti, GB</i>	08:30 - 08:30
P724	SHORT TELOMERES BEFORE TRANSPLANT ARE ASSOCIATED WITH GRAFT FAILURE FOLLOWING HEMATOPOIETIC CELL TRANSPLANT FOR CHILDREN WITH APLASTIC ANEMIA <i>Poster Presenter: Atsushi Narita, JP</i>	08:30 - 08:30
P725	PEDIATRIC PATIENTS WITH VERY SEVERE APLASTIC ANEMIA AND HIGH-RISK TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY CAN BE SUCCESSFULLY TREATED WITH ECULIZUMAB <i>Poster Presenter: Maria Isabel Benitez Carabante, ES</i>	08:30 - 08:30
P726	COMPARABLE OUTCOMES OF PTCY AND BUCY REGIMENS FOR FIRST-LINE HEMATOPOIETIC STEM CELL TRANSPLANTATION FROM UNRELATED AND MATCHED SIBLING DONORS IN PATIENTS WITH SEVERE APLASTIC ANEMIA <i>Poster Presenter: Xiaowei Chen, CN</i>	08:30 - 08:30
P727	LIVER AND KIDNEY IRON OVERLOAD IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA <i>Poster Presenter: Vitalii Latyshev, RU</i>	08:30 - 08:30

P728	SUCCESSFUL OUTCOMES OF UPFRONT HAPLOIDENTICAL TRANSPLANT USING 4GY TBI AND POST TRANSPLANT CYCLOPHOSPHAMIDE IN PEDIATRIC SEVERE APLASTIC ANEMIA <i>Poster Presenter: Esha Kaul, IN</i>	08:30 - 08:30
P729	THERAPEUTIC MODALITIES AND EVOLUTION PATTERNS IN 597 PATIENTS WITH INHERITED AND ACQUIRED BONE MARROW FAILURE DISORDERS: A LARGE AND COMPREHENSIVE SINGLE CENTRE EXPERIENCE <i>Poster Presenter: Marta Bortolotti, GB</i>	08:30 - 08:30
P730	SINGLE CENTRE STUDY OF ROMIPLOSTIM ADDED TO IMMUNOSUPPRESSIVE THERAPY AS A FIRST-LINE TREATMENT IN SEVERE APLASTIC ANAEMIA: A CASE SERIES <i>Poster Presenter: Ashok Kumar Rajoreya, IN</i>	08:30 - 08:30
P731	INCIDENCE AND RISK FACTORS FOR SECONDARY GRAFT FAILURE IN UNIFORMLY TREATED SEVERE APLASTIC ANEMIA PATIENTS RECEIVING SAME CONDITIONING AND MATCHED SIBLING BONE MARROW GRAFT <i>Poster Presenter: Ahmed Kotb Abdrabou, SA</i>	08:30 - 08:30
P732	QUALITY OF LIFE AFTER IMMUNE SUPPRESSIVE TREATMENT FOR APLASTIC ANEMIA <i>Poster Presenter: Iris Nicola Lommerse, NL</i>	08:30 - 08:30
<i>ePoster</i> 08:30 - 18:00		ePoster Area
Conditioning Regimens		
P540	FLUDARABINE EXPOSURE IMPACTS OUTCOMES OF LARGE B-CELL LYMPHOMA PATIENTS RECEIVING TREATMENT WITH CHIMERIC ANTIGEN RECEPTOR T-CELLS <i>Poster Presenter: Mario Andres Sanchez-Salinas, ES</i>	08:30 - 08:30
P541	AGE IMPACTS RISK OF MIXED CHIMERISM FOLLOWING RIC HCT FOR NON-SCID INBORN ERRORS OF IMMUNITY <i>Poster Presenter: Taylor Fitch, US</i>	08:30 - 08:30
P542	INAPPROPRIATE ANTIDIURETIC HORMONE SECRETION AFTER HIGH-DOSE THIOTEPA AND CONCURRENT PHENYTOIN <i>Poster Presenter: Maria Assunta Limongiello, IT</i>	08:30 - 08:30
P543	CHIMERISM ANALYSIS POST-HSCT WITH A TREOSULFAN-BASED CONDITIONING REGIMEN FOR PEDIATRIC NONMALIGNANT DISEASES <i>Poster Presenter: Ehud Even-Or, IL</i>	08:30 - 08:30
P544	FLUDARABINE, BUSULFAN AND MELPHALAN BASED CONDITIONING REDUCED RELAPSE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULT PATIENTS WITH MYELOID MALIGNANCIES: A MULTICENTER RETROSPECTIVE ANALYSIS <i>Poster Presenter: Hu Jiong, CN</i>	08:30 - 08:30

P545	REDUCED INTENSITY ALLOGENEIC TRANSPLANTATION COMBINED WITH STRATEGIC DONOR LYMPHOCYTE INFUSION USE OFFERS AN EFFECTIVE AND TOLERABLE CURATIVE THERAPY FOR OLDER PATIENTS WITH MYELOID DISEASE <i>Poster Presenter:</i> Chris Armstrong, IE	08:30 - 08:30
P546	TOTAL BODY IRRADIATION PROCEDURES IN THE FORUM TRIAL <i>Poster Presenter:</i> Bianca Hoeben, NL	08:30 - 08:30
P547	RETROSPECTIVE COMPARATIVE ANALYSIS OF TWO DIFFERENT FORMS OF ANTI THYMOCYTE GLOBULIN (ATG) IN PEDIATRIC AND YOUNG ADULT PATIENTS UNDERGOING ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANT <i>Poster Presenter:</i> Gaurav Kharya, IN	08:30 - 08:30
P548	TREOSULFAN BASED CONDITIONING IN PEDIATRIC PATIENTS WITH NON-MALIGNANT HAEMATOLOGICAL INDICATIONS FOR TRANSPLANT IS ASSOCIATED WITH VERY LOW TREATMENT RELATED MORTALITY AND HIGH OVERALL SURVIVAL <i>Poster Presenter:</i> Daniel Farrugia, GB	08:30 - 08:30
P549	COMPARISON OF FLUDARABINE/MELPHALAN(FM140) WITH FLUDARABINE/MELPHALAN/BCNU(FBM110) IN PATIENTS WITH RELAPSED/REFRACTORY AML UNDERGOING ALLOGENEIC TRANSPLANTATION – A REGISTRY STUDY ON BEHALF OF THE EBMT ACUTE LEUKEMIA WORKING PARTY <i>Poster Presenter:</i> Jesus Duque Afonso, DE	08:30 - 08:30
P550	OUTCOMES OF TBI 8-GRAY CONDITIONING IN ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKAEMIA IN FIRST COMPLETE REMISSION <i>Poster Presenter:</i> Clinton Lewis, NZ	08:30 - 08:30
P551	COMBINATION OF FLUDARABINE AND CYCLOPHOSPHAMIDE AS A CONDITIONING REGIMEN IN SECOND HSCT FOR GRAFT FAILURE <i>Poster Presenter:</i> Tatiana Rudakova, RU	08:30 - 08:30
P552	COMPARISONS OF ATG-THYMOGLOBULIN (ATG-T) WITH ATG-FRESENIUS (ATG-F) TO OPTIMIZE CONDITIONING REGIMENS FOR HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA <i>Poster Presenter:</i> Xing-Yu Cao, CN	08:30 - 08:30
P553	TREOSULFAN-BASED CONDITIONING FOR ALLOGENEIC HSCT IN CHILDREN: A CASE SERIES USING PK DATA AND AUC OF TREOSULFAN IN SINGLE CENTER EXPERIENCE - ADANA, TURKEY <i>Poster Presenter:</i> Bulent Antmen, TR	08:30 - 08:30
P554	SEQUENTIAL ALLOGENEIC TRANSPLANTATION IN ACUTE MYELOID LEUKAEMIA AND MYELODYSPLASTIC SYNDROME: EXPERIENCE FROM A SINGLE CENTRE	08:30 - 08:30

	<i>Poster Presenter:</i> Maria Huguet Mas, ES	
P556	RECIPIENT STEM CELL MOBILIZATION WITH PLERIXAFOR IN PRE-HSCT CONDITIONING REGIMEN FOR NON-MALIGNANT CONDITIONS <i>Poster Presenter:</i> Dmitry Balashov, RU	08:30 - 08:30
P557	INCIDENCE OF HEMORRHAGIC CYSTITIS USING CYCLOPHOSPHAMIDE VERSUS ETOPOSIDE COMBINED WITH TOTAL BODY IRRADIATION AS CONDITIONING FOR HEMATOPOIETIC STEM CELL TRANSPLANT IN PAEDIATRIC ACUTE LYMPHOBLASTIC LEUKAEMIA <i>Poster Presenter:</i> Sushil Gunaseelan, GB	08:30 - 08:30
P558	ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION USING REDUCED TOXICITY VS MYELOABLATIVE CONDITIONING FOR THE TREATMENT OF CHILDREN WITH MYELOID MALIGNANCIES <i>Poster Presenter:</i> Asaf D Yanir, IL	08:30 - 08:30
P559	PREVIOUS BUSULFAN IS NOT A CONTRAINDICATION FOR SECOND ALLOGRAFT WITH REDUCED INTENSITY TREOSULFAN-BASED CONDITIONING REGIMEN FOLLOWED BY ALLOGENEIC HAEMATOPOIETIC STEM-CELL TRANSPLANT FROM UNRELATED DONORS <i>Poster Presenter:</i> Daniele Avenoso, GB	08:30 - 08:30
P560	SINGLE CENTRE REVIEW OF THE OUTCOME, MORBIDITY AND HEALTH RESOURCE UTILISATION USING BEAM-ALEMTUZUMAB CONDITIONING IN LYMPHOID MALIGNANCIES; A BASIS FOR IMPLEMENTING CHANGE <i>Poster Presenter:</i> Louisa Shackleton, IE	08:30 - 08:30
P561	IMPROVED CLINICAL OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION FOLLOWING TBI-BASED CONDITIONING REGIMEN. A SINGLE-CENTER EXPERIENCE <i>Poster Presenter:</i> Alessandra Algarotti, IT	08:30 - 08:30
P562	COMPARISON OF CONDITIONING WITH FLUDARABINE/BUSULFAN AND FLUDARABINE/MELPHALAN IN ALLOGENEIC TRANSPLANTATION RECIPIENTS WITH ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROME <i>Poster Presenter:</i> Laura Pardo Gambarte, ES	08:30 - 08:30
P563	TREOSULFAN, THIOTEPA AND FLUDARABINE CONDITIONING REGIMEN PRIOR TO ALLOGENEIC STEM CELL TRANSPLANTATION IN ACUTE MYELOID LEUKEMIA AND HIGH-RISK MYELODYSPLASTIC SYNDROMES: A SINGLE CENTER EXPERIENCE <i>Poster Presenter:</i> Francesco Onida, IT	08:30 - 08:30
P564	THIOTEPA, TREOSULFAN AND FLUDARABINE (TTF) VERSUS THIOTEPA, BUSULFAN AND FLUDARABINE (TBF) CONDITIONING FOR MATCHED RELATED DONOR	08:30 - 08:30

	PERIPHERAL BLOOD STEM CELL TRANSPLANT FOR THALASSEMIA MAJOR <i>Poster Presenter: Satya Prakash Yadav, IN</i>	
P565	POST-TRANSPLANTATION CYCLOPHOSPHAMIDE-BASED GVHD PROPHYLAXIS AFTER FLU-TBI MYELOABLATIVE CONDITIONING IS ASSOCIATED WITH FAVORABLE OUTCOMES IN ADULT PATIENTS WITH ALL TREATED WITH CONTEMPORARY INDUCTION REGIMENS <i>Poster Presenter: Nadia Bambace, US</i>	08:30 - 08:30
P566	INFERIOR OUTCOMES WITH MELPHALAN BASED CONDITIONING COMPARED TO BUSULFAN WITH FLUDARABINE IN CHILDREN UNDERGOING HSCT <i>Poster Presenter: Sohini Chakraborty, IN</i>	08:30 - 08:30
P567	LOMUSTINE, ETOPOSIDE AND CYCLOPHOSPHAMIDE IN CONDITIONING REGIMEN FOR LYMPHOMAS: THE EXPERIENCE OF A BRAZILIAN INSTITUTION <i>Poster Presenter: Fernando Barroso Duarte, BR</i>	08:30 - 08:30
P568	PREVIOUS BUSULFAN EXPOSURE IS NOT A CONTRAINDICATION FOR SECOND ALLOGRAFT WITH REDUCED INTENSITY TREOSULFAN BASED CONDITIONING FOLLOWED BY IN-VIVO T-CELL DEPLETED UNRELATED DONOR HAEMATOPOIETIC TRANSPLANT <i>Poster Presenter: Daniele Avenoso, GB</i>	08:30 - 08:30
P569	COMBINATION OF FLUDARABINE WITH TOTAL BODY IRRADIATION IS ASSOCIATED WITH REDUCED EARLY TRANSPLANT-RELATED TOXICITIES IN ACUTE LYMPHOBLASTIC LEUKEMIA ADULT PATIENTS UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION <i>Poster Presenter: Gianluca Cavallaro, IT</i>	08:30 - 08:30
P570	THE IMPACT OF TREOSULFAN -BASED CONDITIONING FOR PRIMARY IMMUNE DEFICIENCIES: SINGLE CENTER EXPERIENCE <i>Poster Presenter: Gizem Zengin Ersoy, TR</i>	08:30 - 08:30
P571	POST-TRANSPLANT CYCLOPHOSPHAMIDE IN UNRELATED DONOR PERIPHERAL BLOOD STEM CELL TRANSPLANT RESULTS IN SUCCESSFUL ENGRAFTMENT AND SUBSTANTIALLY LOW INCIDENCE OF CHRONIC GRAFT VERSUS HOST DISEASE <i>Poster Presenter: Ifigeneia Tzannou, GR</i>	08:30 - 08:30
P572	LONG-TERM SAFETY AND EFFICACY OF REDUCED TOXICITY CONDITIONING REGIMENS IN OLDER RECIPIENTS OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR ACUTE LEUKEMIAS <i>Poster Presenter: Eleni Gavriilaki, GR</i>	08:30 - 08:30
P573	WOULD MONITORING TREOSULFAN LEVELS IN PATIENTS TRANSPLANTED FOR TRANSFUSION DEPENDENT	08:30 - 08:30

	THALASSEMIA BE BENEFICIAL IN TERMS OF CHIMERISM? A SINGLE CENTER EXPERIENCE	
	<i>Poster Presenter: Basak Adakl? Aksoy, TR</i>	
P574	HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH EARLY ANTITHYMOCYTE GLOBULIN AND LOW DOSE POST-TRANSPLANT CYCLOPHOSPHAMIDE IN CHILDREN AND YOUNG ADULTS	08:30 - 08:30
	<i>Poster Presenter: Hee Young Ju, KR</i>	
P575	OUTCOMES OF ATTENUATED DOSE FLUDARABINE AND MELPHALAN BASED CONDITIONING REGIMEN IN PATIENTS UNDERGOING MATCHED RELATED AND UNRELATED DONOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT	08:30 - 08:30
	<i>Poster Presenter: Radowan Elnair, US</i>	
P576	HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR HEMATOLOGIC MALIGNANCIES USING FLUDARABINE AND TOTAL BODY IRRADIATION CONDITIONING AND POS-TRANSPLANT CYCLOPHOSPHAMIDE-BASED GVHD PROPHYLAXIS RESULTS IN HIGH DISEASE-FREE SURVIVAL	08:30 - 08:30
	<i>Poster Presenter: Afraa Fadul, QA</i>	
P577	BE-EAM HIGH-DOSE CHEMOTHERAPY FOLLOWED BY ASCT: A SINGLE CENTER EXPERIENCE	08:30 - 08:30
	<i>Poster Presenter: Handan Haydaroglu Sahin, TR</i>	
P579	CYCLOPHOSPHAMIDE FOLLOWED BY BUSULFAN CONDITIONING FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION – UMC LJUBLJANA, SLOVENIA SINGLE CENTER EXPERIENCE	08:30 - 08:30
	<i>Poster Presenter: Klara Šlajpah, SI</i>	
P580	ANTI-THYMOCYTE GLOBULIN IN CONDITIONING IN PATIENTS WITH ACUTE MYELOID LEUKEMIA UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION – A RETROSPECTIVE SINGLE CENTER ANALYSIS	08:30 - 08:30
	<i>Poster Presenter: Lazar Chadievski, MK</i>	
<i>ePoster</i>		
08:30 - 18:00		ePoster Area
Non-infectious Early Complications		
P460	MANAGEMENT OF SINUSOIDAL-OCCLUSION-SYNDROME IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION AFTER INTRODUCING DIAGNOSIS BY EBMT CRITERIA AND TREATMENT WITH DEFIBROTIDE: A SINGLE CENTER EXPERIENCE	08:30 - 08:30
	<i>Poster Presenter: Hirotohi Sakaguchi, JP</i>	
P461	EFFECT OF THE KNOCKOUT OF GSTA1 ON HEPATIC CELLS AND CELLULAR RESPONSE TO DRUGS USED IN HEMATOPOIETIC STEM CELL TRANSPLANTATION	08:30 - 08:30

	<i>Poster Presenter:</i> Vid Mlakar, CH	
P462	NON-INFECTIOUS COMPLICATIONS AFTER THE USE OF POST-TRANSPLANT CYCLOPHOSPHAMIDE OR ANTI-T-LYMPHOCYTE GLOBULIN AS GVHD PROPHYLAXIS <i>Poster Presenter:</i> Juan Manuel Cerezo Martín, ES	08:30 - 08:30
P463	EFFECTS OF HYPERBARIC OXYGEN THERAPY ON SALIVARY AND FECAL MICROBIOTA IN PATIENTS WITH MULTIPLE MYELOMA UNDERGOING AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION <i>Poster Presenter:</i> Bassil Said, US	08:30 - 08:30
P464	LOW PLASMA CONCENTRATIONS OF INSULIN-LIKE GROWTH FACTOR-I ARE ASSOCIATED WITH INCREASED GUT DAMAGE DURING PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Poster Presenter:</i> Maria Ebbesen Sørum, DK	08:30 - 08:30
P465	VON WILLEBRAND FACTOR AS A POTENTIAL PREDICTIVE BIOMARKER OF EARLY COMPLICATIONS OF ENDOTHELIAL ORIGIN AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION <i>Poster Presenter:</i> Guillaume Dachy, BE	08:30 - 08:30
P466	OPTIMIZING THE EASIX CAPACITY FOR PREDICTING NRM IN ADULTS UNDERGOING ALLO-HCT USING POST-TRANSPLANT CYCLOPHOSPHAMIDE <i>Poster Presenter:</i> Silvia Escribano Serrat, ES	08:30 - 08:30
P467	ELTROMBOPAG IS AN EFFECTIVE TREATMENT OF POOR GRAFT FUNCTION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A GITMO SURVEY <i>Poster Presenter:</i> Maura Faraci, IT	08:30 - 08:30
P468	VENO-OCCLUSIVE DISEASE AFTER HSCT: THE IMPACT OF NEW DIAGNOSTIC CRITERIA, ULTRASOUND AND ELASTOGRAPHY FINDINGS <i>Poster Presenter:</i> Alba Puyuelo, ES	08:30 - 08:30
P469	OUTCOMES OF VENO-OCCLUSIVE DISEASE (VOD) IN INFANTS AND TODDLERS POST-HEMATOPOIETIC STEM CELL TRANSPLANT (HCT) <i>Poster Presenter:</i> Miki Nishitani, US	08:30 - 08:30
P470	HIGH-RISK TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY (TA-TMA), SINGLE CENTRE EXPERIENCE <i>Poster Presenter:</i> Maria Gabelli, IT	08:30 - 08:30
P471	INCIDENCE OF LGL AFTER USING DUAL T CELL DEPLETION (ATG AND PTCY) AND ITS' CORRELATION WITH LONG TERM OUTCOME <i>Poster Presenter:</i> Vered Stavi, IL	08:30 - 08:30
P472	INTENSIVE CARE UNIT UTILIZATION AND OUTCOMES IN STEM CELL TRANSPLANT PATIENTS DURING INITIAL TRANSPLANT	08:30 - 08:30

HOSPITALIZATION*Poster Presenter:* Richard Maziarz, US

- | | | |
|------|---|---------------|
| P473 | PRE-TRANSPLANT ANTI-CD20 MONOCLONAL ANTIBODY THERAPY AFFECTS THE DONOR-DERIVED HEMATOPOIETIC COMPARTMENT IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) RECIPIENTS
<i>Poster Presenter:</i> Dimana Dimitrova, US | 08:30 - 08:30 |
| P474 | RISK FACTORS FOR TRANSPLANT ASSOCIATED THROMBOTIC MICROANGIOPATHY (TA-TMA) AMONG PATIENTS WITH PHILADELPHIA POSITIVE (PH+) LEUKEMIAS UNDERGOING ALLOGENEIC STEM CELL TRANSPLANT
<i>Poster Presenter:</i> Sachin Punatar, IN | 08:30 - 08:30 |
| P476 | THE VALIDATION OF SIMPLIFIED COMORBIDITY INDEX FOR PREDICTION OF NON-RELAPSE MORTALITY
<i>Poster Presenter:</i> Yunsuk Choi, KR | 08:30 - 08:30 |
| P477 | RELATIONSHIP OF FLUID OVERLOAD IN THE PERITRANSPLANT PERIOD WITH ADVERSE OUTCOMES IN PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTS
<i>Poster Presenter:</i> Mateusz Kubarek, PL | 08:30 - 08:30 |
| P478 | NUTRITIONAL ENERGY REQUIREMENTS IN PEDIATRIC PATIENTS UNDERGOING STEM CELL TRANSPLANTATION MEASURED BY INDIRECT CALORIMETRY
<i>Poster Presenter:</i> Louise Lindkvist Pedersen, DK | 08:30 - 08:30 |
| P479 | OUTCOMES FOLLOWING SECOND ALLOGENEIC STEM CELL TRANSPLANT FOR GRAFT FAILURE OR POOR GRAFT FUNCTION: A SINGLE CENTRE EXPERIENCE
<i>Poster Presenter:</i> Jowon L. Kim, CA | 08:30 - 08:30 |
| P480 | VARIATION IN EASIX SCORE AS A PREDICTOR OF SINUSOIDAL OBSTRUCTION SYNDROME AND OVERALL SURVIVAL
<i>Poster Presenter:</i> Guillermo Ramos Moreno, ES | 08:30 - 08:30 |
| P481 | RETROSPECTIVE ANALYSIS AND COMPARISON OF SINUSOIDAL OBSTRUCTION SYNDROME DIAGNOSIS CRITERIA: CAN WE ANTICIPATE DIAGNOSIS?
<i>Poster Presenter:</i> Monica Cabrero, ES | 08:30 - 08:30 |
| P482 | LOW DOSE DEFIBROTIDE WITH HIGH DOSE METHYLPREDNISOLONE IN MANAGEMENT OF SINUSOIDAL OBSTRUCTION SYNDROME IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
<i>Poster Presenter:</i> Pranoti Kini, IN | 08:30 - 08:30 |
| P483 | PURE RED CELL APLASIA IN MAJOR ABO INCOMPATIBLE ALLOGENEIC STEM CELL TRANSPLANT: RETOSPECTIVE ANALYSIS FROM A SINGLE CENTER EXPERIENCE
<i>Poster Presenter:</i> David Alonso Castronuño, ES | 08:30 - 08:30 |

P484	MANAGEMENT OF DIARRHOEA IN HAEMATO-ONCOLOGY: CHANGING THE FLOW <i>Poster Presenter: Seda Cakmak, GB</i>	08:30 - 08:30
P485	SINGLE-CYCLE PLASMAPHERESIS IN PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH MAJOR OR BIDIRECTIONAL ABO- INCOMPATIBILITY IS SAFE BUT INSUFFICIENT TO PREVENT PURE RED CELL APLASIA <i>Poster Presenter: Israel Henig, IL</i>	08:30 - 08:30
P486	EFFICACY AND SAFETY OF NETUPITANT/PALONOSETRON COMBINATION (NEPA) AND LOW DOSE OF DEXAMETHASONE IN PREVENTING NAUSEA AND VOMITING IN PATIENTS UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION <i>Poster Presenter: Alessandro Spina, IT</i>	08:30 - 08:30
P487	TRIAL IN PROGRESS: AN OPEN-LABEL, MULTI-CENTER PHASE 2 STUDY EVALUATING EFFICACY AND SAFETY OF NARSOPLIMAB FOR THE TREATMENT OF PEDIATRIC HIGH- RISK HSCT-TMA <i>Poster Presenter: Carolina Soto, US</i>	08:30 - 08:30
P488	PRE-TRANSPLANTATION VITAMIN D DEFICIENCY INCREASES ACUTE GRAFT-VERSUS-HOST DISEASE AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION IN THALASSEMIA MAJOR PATIENTS	08:30 - 08:30
P489	OUTCOMES OF CD34-SELECTED STEM CELL BOOST OF CRYOPRESERVED PERIPHERAL BLOOD HEMATOPOIETIC CELLS FOR POOR ALLOGRAFT FUNCTION <i>Poster Presenter: Richard C. Godby, US</i>	08:30 - 08:30
P490	DRUG-INDUCED LUNG INJURY IN PATIENTS AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Poster Presenter: Ivan Moiseev, RU</i>	08:30 - 08:30
P491	NUTRITIONAL STATUS EVALUATION VIA BIOIMPEDANCE AND INDIRECT CALORIMETRY IN ADULT PATIENTS WITH ALLOGENEIC HSCT <i>Poster Presenter: Maxim Kucher, RU</i>	08:30 - 08:30
P492	SYSTEMATIC SCREENING FOR VENOUS OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTIVE SYNDROME (VOD/SOS) IS ASSOCIATED WITH EARLIER DIAGNOSIS AND PROMPT INSTITUTION OF DEFIBROTIDE TREATMENT AND ENABLES DIAGNOSIS OF LATE-ONSET VOD/SOS <i>Poster Presenter: Daniele Avenoso, GB</i>	08:30 - 08:30
P493	EVALUATION OF TOLERANCE AND NUTRITIONAL IMPACT OF PRODUCTS ENRICHED WITH FERULIC-ACID IN HEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS <i>Poster Presenter: Monica Cabrero, ES</i>	08:30 - 08:30
P494	CLINICAL RESPONSE TO NOMACOPAN IN THE PAEDIATRIC	08:30 - 08:30

HSCT-TMA SETTING*Poster Presenter:* Claire Horgan, GB

P495	ULCERATIVE COLITIS POST HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH FEATURES OF ISOLATED INTESTINAL THROMBOTIC MICROANGIOPATHY PROVOKED BY COVID19 – A PEDIATRIC CASE REPORT <i>Poster Presenter:</i> Peter Svec, SK	08:30 - 08:30
P496	IMMUNE-MEDIATED INFLAMMATORY SYNDROMES OTHER THAN GRAFT-VERSUS-HOST DISEASE (GVHD) AND TRANSPLANTATION WITH CRYOPRESERVED HAEMATOPOIETIC STEM CELLS: A POSSIBLE CORRELATION <i>Poster Presenter:</i> Anita Betulla, IT	08:30 - 08:30
P497	INCIDENCE OF GRAFT FAILURE AND DELAYED ENGRAFTMENT AFTER ASCT IN SPANISH HOSPITAL: SUCCESSFUL OUTCOME WITH THE USE OF CYCLOSPORINE <i>Poster Presenter:</i> Maria Calbacho Robles, ES	08:30 - 08:30
P498	OUTCOMES OF OUTPATIENT AUTO-HSCT <i>Poster Presenter:</i> Juan Carlos Caballero Hernández, ES	08:30 - 08:30
P499	ENERGY INTAKE, LEVEL OF NUTRITION SUPPORT AND SYMPTOMS FOLLOWING STEM CELL TRANSPLANTATION. A RETROSPECTIVE, OBSERVATIONAL STUDY <i>Poster Presenter:</i> Victoria Mace, GB	08:30 - 08:30
P500	RISK FACTORS OF SINUSOIDAL OBSTRUCTION SYNDROME IN ACUTE LEUKEMIA PATIENTS RECEIVED ALLOGENEIC STEM CELL TRANSPLANTATION <i>Poster Presenter:</i> Zübeyde Nur Özkurt, TR	08:30 - 08:30
P501	EFFICACY AND ADVERSE EFFECTS OF ABO MISMATCH TRANSFUSIONS IN PATIENTS WITH HIGH-TITER MAJOR ABO MISMATCH BEFORE ALLOGENEIC STEM CELL TRANSPLANTATION <i>Poster Presenter:</i> Judith Schaffrath, DE	08:30 - 08:30
P502	ACUTE KIDNEY INJURY IN PATIENTS UNDERGOING HSCT: A RETROSPECTIVE COHORT STUDY <i>Poster Presenter:</i> Fernando Barroso Duarte, BR	08:30 - 08:30
P503	POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME FOLLOWING PEDIATRIC ALLOGENEIC BONE MARROW TRANSPLANTATION: A CASE SERIES OF SINGLE CENTER EXPERIENCE <i>Poster Presenter:</i> Hatice Ilgen Sasmaz, TR	08:30 - 08:30
P504	PERCUTANEOUS GASTROSTOMY IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Poster Presenter:</i> Maxim Kucher, RU	08:30 - 08:30
P505	CLINICAL EFFICACY AND SAFETY OF NARSOPLIMAB IN A PATIENT WITH WORSENING HSCT-TMA FOLLOWING	08:30 - 08:30

DISCONTINUATION OF CALCINEURIN INHIBITORS*Poster Presenter:* Felix Mensah, US

P506 **OVERLAP OF TA-TMA VS ACUTE GVHD IN THE GASTROINTESTINAL TRACT: TWO CHALLENGING CASE REPORTS** 08:30 - 08:30

Poster Presenter: Matteo Parma, IT

P507 **EVALUATING THE INCIDENCE, RISK FACTORS AND OUTCOME OF ACUTE KIDNEY INJURY AMONG PEDIATRIC PATIENTS RECEIVING HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)** 08:30 - 08:30

P508 **INVESTIGATION OF THE FREQUENCY AND RISK FACTORS OF CARDIAC COMPLICATIONS AFTER INITIAL ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION** 08:30 - 08:30

Poster Presenter: Ryu Yanagisawa, JP

P509 **INTENSIVE CARE OUTCOMES IN ADULT HEMATOPOIETIC STEM CELL TRANSPLANTATION PATIENTS AT A SINGLE CENTER** 08:30 - 08:30

Poster Presenter: José Luis López Lorenzo, ES

P510 **EVALUATION OF IMPACT OF AUTOLOGOUS HEMATOPOIETIC STEM CELL MOBILIZATION ON LEFT HEART FUNCTION AND SIZES** 08:30 - 08:30

Speaker: Domas Vaitiekus, LT

P511 **EVALUATION OF EFFICACY IN FOLINIC ACID PREVENTING ORAL MUCOSITIS AFTER METHOTREXATE CONTAINED GVHD PROPHYLAXIS FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION** 08:30 - 08:30

Poster Presenter: Ajda Güne?, TR

P512 **MANAGEMENT OF PEDIATRIC SINUSOIDAL OBSTRUCTION SYNDROME/VENO-OCCLUSIVE DISEASE IN A RESOURCE-LIMITED SETTING: A CASE REPORT** 08:30 - 08:30

Poster Presenter: Sara M Makkeyah, EG*ePoster*

08:30 - 18:00

ePoster Area

Infectious Complications

P389 **POST-TRANSPLANTATION CYCLOPHOSPHAMIDE FACILITATES LONG-TERM IMMUNOLOGICAL RECONSTITUTION AFTER ALLOHCT COMPARED TO ATG AND NON-ATG BASED GVHD PROPHYLAXIS** 08:30 - 08:30

Poster Presenter: Thomas Meyer, DE

P390 **EVALUATION OF COVID-19 VACCINE ANTIBODY RESPONSES IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS: USING RUXOLUTINIB OR IBRUTINIB NEGATIVELY EFFECTS VACCINE ANTIBODY RESPONSES** 08:30 - 08:30

Poster Presenter: Zübeyde Nur Özkurt, TR

P391	RISK FACTORS AND PROGNOSIS OF NOCARDIA INFECTION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: AN INFECTIOUS DISEASES WORKING PARTY AND FRANCO-BELGIAN NOCARDIA STUDY GROUP CASE-CONTROL STUDY <i>Poster Presenter:</i> Julien De Greef, BE	08:30 - 08:30
P392	PREDICTORS OF LENGTH OF SARS-COV-2 POSITIVITY IN HOSPITAL-ADMITTED HSCT RECIPIENTS WITH COVID-19: AN INFECTIOUS DISEASE WORKING PARTY STUDY <i>Poster Presenter:</i> Malgorzata Mikulska, IT	08:30 - 08:30
P393	MRNA-1273 SARS-COV-2 VACCINE IN RECENTLY TRANSPLANTED ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS: CELLULAR AND HUMORAL IMMUNE RESPONSES AND BOOSTER EFFECT <i>Speaker:</i> Irene García-Cadenas, ES	08:30 - 08:30
P394	TIME SERIES CLUSTERING OF CMV KINETICS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION DISTINGUISHES PHENOTYPES WITHIN CMV-PEAK-TITER-DEFINED RISK GROUPS <i>Poster Presenter:</i> Amin Turki, DE	08:30 - 08:30
P395	LONG-TERM IMMUNITY AGAINST TETANUS AND DIPHTHERIA AFTER VACCINATION OF STEM CELL TRANSPLANT RECIPIENTS <i>Poster Presenter:</i> Sigrun Einarsdottir, SE	08:30 - 08:30
P396	TREATMENT DELAY DURING THE COVID-19 PANDEMIC DID NOT SIGNIFICANTLY IMPACT THE OUTCOME OF STEM CELL TRANSPLANT AND CELLULAR THERAPY: A SINGLE INSTITUTION EXPERIENCE <i>Poster Presenter:</i> Eden Biltibo, US	08:30 - 08:30
P397	EVALUATION OF URINE BKV BY DAY 40 POST-HEMATOPOIETIC CELL TRANSPLANT AS PREDICTOR OF BKV-ASSOCIATED HEMORRHAGIC CYSTITIS <i>Poster Presenter:</i> Yeon Joo Lee, US	08:30 - 08:30
P398	CMV REACTIVATION – A TWO-EDGED SWORD AGAINST RELAPSE <i>Poster Presenter:</i> Vered Stavi, IL	08:30 - 08:30
P399	CD4⁺ T CELLS ARE THE MAJOR PREDICTOR OF HCMV CONTROL IN ALLOGENEIC STEM CELL TRANSPLANT RECIPIENTS ON LETERMOVIR PROPHYLAXIS <i>Poster Presenter:</i> Chris David Lauruschkat, DE	08:30 - 08:30
P400	NIRMATRELVIR/RITONAVIR AND TIXAGEVIMAB/CILGAVIMAB AS SARS-COV-2 TREATMENT IN PEDIATRIC AND YOUNG ADULT PATIENTS AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) OR CD19-DIRECTED CAR T-CELL TREATMENT <i>Poster Presenter:</i> Pietro Merli, IT	08:30 - 08:30

P401	PRE-EMPTIVE RITUXIMAB FOR EBV REACTIVATION IN TIMES OF COVID-19: IS IT REALLY NECESSARY? <i>Poster Presenter: Clarisse Martins Machado, BR</i>	08:30 - 08:30
P402	IMPACT OF TIXAGEVIMAB/CILGAVIMAB PROPHYLAXIS IN PATIENTS UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTS AND CAR-T CELLS THERAPY: A PROSPECTIVE SINGLE CENTER EXPERIENCE <i>Poster Presenter: Raffaella Greco, IT</i>	08:30 - 08:30
P403	CLINICAL EXPERIENCE WITH LETERMOVIR FOR CMV-PROPHYLAXIS IN HEMATO-ONCOLOGICAL PATIENTS UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION (CELESTIAL): AN OBSERVATIONAL STUDY <i>Poster Presenter: Sebastian Wingen-Heimann, DE</i>	08:30 - 08:30
P404	LETERMOVIR FOR CMV INFECTION IN PEDIATRIC PATIENTS UNDERGOING ALLOGENIC HSCT: REAL-LIFE RETROSPECTIVE ANALYSIS BY INFECTIOUS DISEASES WORKING GROUP OF ITALIAN ASSOCIATION OF PEDIATRIC HEMATOLOGY-ONCOLOGY (AIEOP) <i>Poster Presenter: Francesco Baccelli, IT</i>	08:30 - 08:30
P405	DOSAGE, SAFETY AND EFFICACY OF POSACONAZOLE AS PRIMARY ANTIFUNGAL PROPHYLAXIS IN HIGH-RISK RECIPIENTS OF ALLOGENEIC STEM CELL TRANSPLANTATION <i>Poster Presenter: Amandine Le Bourgeois, FR</i>	08:30 - 08:30
P406	INDUCED SPUTUM IS AN ACCEPTABLE METHOD OF OBTAINING DEEP RESPIRATORY SAMPLES IN UNWELL HAEMATOLOGY PATIENTS; THE RESULTS OF THE SPITFIRE FEASIBILITY TRIAL <i>Poster Presenter: Jonathan Ayling-Smith, GB</i>	08:30 - 08:30
P407	CMV HYPERIMMUNE GLOBULIN AS SALVAGE THERAPY FOR RECURRENT OR REFRACTORY CMV INFECTION IN CHILDREN UNDERGOING ALLOGENEIC HSCT <i>Poster Presenter: Melissa Panesso, ES</i>	08:30 - 08:30
P408	IN VITRO PROFILING OF POST-TRANSPLANT IMMUNOSUPPRESSANTS FOR THEIR IMPACT ON ANTIVIRAL MEMORY EFFECTOR T CELLS <i>Poster Presenter: Britta Maecker-Kolhoff, DE</i>	08:30 - 08:30
P409	MULTINATIONAL STUDY OF TREATMENT PRACTICES AND OUTCOMES FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS WITH POST-TRANSPLANT CYTOMEGALOVIRUS <i>Poster Presenter: Genoveva Papanicolau, US</i>	08:30 - 08:30
P410	EVALUATION OF BK POLYOMAVIRUS INFECTION FREQUENCY, RISK FACTORS AND EFFECT ON SURVIVAL FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE <i>Poster Presenter: Nur Akad Soyer, TR</i>	08:30 - 08:30

P411	EPIDEMIOLOGY OF INFECTIOUS COMPLICATIONS IN PATIENTS WITH GRAFT-VERSUS-HOST DISEASE <i>Poster Presenter:</i> Aleksandr Siniaev, RU	08:30 - 08:30
P412	COMPASSIONATE USE PROGRAMME OF MARIBAVIR FOR ADULT PATIENTS WITH POST-TRANSPLANT CMV INFECTION AND/OR DISEASE REFRACTORY (WITH OR WITHOUT RESISTANCE) TO ONE OR MORE PRIOR THERAPY <i>Poster Presenter:</i> Catherine Cordonnier, FR	08:30 - 08:30
P413	GRAM NEGATIVE BLOODSTREAM INFECTION IN AUTOLOGOUS STEM CELL TRANSPLANTATION: A COMPARATIVE STUDY BETWEEN AT HOME AND HOSPITAL CARE MODEL <i>Poster Presenter:</i> Sara Fernandez-Luis, ES	08:30 - 08:30
P414	MONITORING AND MANAGEMENT OF CMV AND EBV AFTER AUTOLOGOUS HAEMATOPOIETIC CELL TRANSPLANTATION FOR AUTOIMMUNE DISEASES: A SURVEY OF THE EBMT AUTOIMMUNE DISEASES WORKING PARTY (ADWP) <i>Poster Presenter:</i> Tobias Alexander, DE	08:30 - 08:30
P415	INFECTIONS WITH <i>PSEUDOMONAS AERUGINOSA</i> IN CHILDREN UNDERGOING ANTICANCER THERAPY OR HEMATOPOIETIC CELL TRANSPLANTATION: A MULTICENTER NATIONWIDE STUDY <i>Poster Presenter:</i> Monika Richert-Przygonska, PL	08:30 - 08:30
P416	THE IMPACT OF CARBAPENEMIC RESISTANT ENTEROBACTERIACEAE COLONIZATION IN ALLOGENEIC STEM CELL TRANSPLANT: SINGLE CENTRE EXPERIENCE IN THE ERA OF NEW AGENTS AND SARS-COVID19 PANDEMIC <i>Poster Presenter:</i> Maria Celentano, IT	08:30 - 08:30
P417	THIRD PARTY FECAL MICROBIOTA TRANSPLANTATION RESULTS IN DECOLONIZATION OF MDR BACTERIA FROM THE GUT ALLOWING SAFER ALLOGENEIC HSCT <i>Poster Presenter:</i> Pietro Merli, IT	08:30 - 08:30
P418	IDENTIFICATION OF NOVEL T-CELL EPITOPES SPECIFIC FOR THE NON-FREQUENT HAPLOTYPES HLA-A*03 AND HLA-B*15 FOR MONITORING OF ALLOSCT PATIENTS <i>Poster Presenter:</i> Alice Rein, DE	08:30 - 08:30
P419	COMPARISON BETWEEN RIFAXIMIN AND CIPROFLOXACIN IN MICROBIOTA DIVERSITY AS NEUTROPENIA PROPHYLAXIS IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION <i>Poster Presenter:</i> Eleni Gavriilaki, GR	08:30 - 08:30
P420	CLINICAL IMPACT OF ANTIBIOTIC ADEQUACY BASED ON MULTI-DRUG RESISTANT ORGANISM TESTING IN STEM-CELL TRANSPLANTATION <i>Poster Presenter:</i> Pablo Palomo Rumschisky, ES	08:30 - 08:30
P421	FAVOURABLE OUTCOMES OF COVID-19 IN VACCINATED	08:30 - 08:30

	HAEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS: A SINGLE CENTRE EXPERIENCE <i>Poster Presenter:</i> Jing Yuan Tan, SG	
P422	EVALUATION OF THE USEFULNESS OF INTERFERON-GAMMA RELEASE ASSAY FOR THE DETECTION OF LATENT MYCOBACTERIUM TUBERCULOSIS INFECTIONS IN PATIENTS WHO UNDERWENT HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Poster Presenter:</i> Sunghnam Lim, KR	08:30 - 08:30
P423	CYTOMEGALOVIRUS-SPECIFIC T CELL EXPANSION KINETICS AND VIRAL CONTROL IN HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Poster Presenter:</i> Sung Han Kang, KR	08:30 - 08:30
P424	COADMINISTRATION OF ISAVUCONAZOLE AND SIROLIMUS IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS: A SINGLE-CENTER EXPERIENCE <i>Poster Presenter:</i> Andrea Acerbis, IT	08:30 - 08:30
P425	EVALUATION OF CYTOMEGALOVIRUS INFECTION FREQUENCY, RISK FACTORS AND EFFECT ON SURVIVAL FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE <i>Poster Presenter:</i> Filiz Vural, TR	08:30 - 08:30
P427	SUCCESSFUL TREATMENT OF REFRACTORY COVID19 WITH "SARS-COV2 SPECIFIC OFF-THE-SHELF T CELLS (VST)" IN A HEMATOLOGIC MALIGNANCY (HM) AND AN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT (HCT) PATIENT <i>Poster Presenter:</i> Sanjeet Dadwal, US	08:30 - 08:30
P428	RISK FACTOR ASSOCIATED WITH HEMORRHAGIC CYSTITIS SECONDARY TO BK VIRUS INFECTION IN CHILDREN AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION: EXPERIENCE OF AN INSTITUTION IN MÉXICO <i>Poster Presenter:</i> Alberto Olaya-Vargas, MX	08:30 - 08:30
P429	COMPARISON OF INFECTIOUS COMPLICATIONS BETWEEN SUBJECTS WHO RECEIVED HYPERBARIC OXYGEN THERAPY VERSUS CONTROLS IN AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTS FOR MULTIPLE MYELOMA <i>Poster Presenter:</i> Purba Gupta, US	08:30 - 08:30
P431	IDENTIFICATION OF RISK FACTORS FOR CMV PRE-EMPTY THERAPY IN CHILDREN AFTER ALLOGENEIC HSCT <i>Poster Presenter:</i> Giulia Ferrando, IT	08:30 - 08:30
P432	SUCCESSFUL TREATMENT OF JC-ENCEPHALITIS WITH PEMBROLIZUMAB AFTER ALLOGENIC STEM CELL TRANSPLANTATION <i>Poster Presenter:</i> Martina Crysandt, DE	08:30 - 08:30
P434	CYTOMEGALOVIRUS PROPHYLAXIS WITH LETERMOVIR IN	08:30 - 08:30

	PATIENTS UNDERGOING ALLOGENEIC STEM CELL TRANSPLANT USING EX VIVO CD34+ SELECTED GRAFTS <i>Poster Presenter:</i> Carla Alonso-Martínez, ES	
P435	FEASIBILITY OF HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN A HIGHLY VACCINATED ASIAN POPULATION DURING THE ACUTE CORONAVIRUS DISEASE 2019 PANDEMIC <i>Poster Presenter:</i> Christopher Shwei Wen Tham, SG	08:30 - 08:30
P436	USE OF CMV HYPERIMMUNOGLOBULINS (CYTOTECT) AS PREEMPTIVE TREATMENT OF CMV INFECTION IN PATIENTS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION - A SINGLE CENTRE EXPERIENCE <i>Poster Presenter:</i> Lana Desnica, HR	08:30 - 08:30
P437	CYTOMEGALOVIRUS INFECTION IN PATIENTS WHO UNDERWENT ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT): A SINGLE-CENTER EXPERIENCE <i>Poster Presenter:</i> Laura Pardo Gambarte, ES	08:30 - 08:30
P438	HHV-6 VIRUS REACTIVATION AFTER ALLO-HSCT: A SINGLE CENTRE CASE SERIES <i>Poster Presenter:</i> João Gaião Santos, PT	08:30 - 08:30
P439	LETERMOVIR PROPHYLAXIS FOR HIGH-RISK ALLOGENIC HEMATOPOIETIC-CELL TRANSPLANT RECIPIENTS: EARLY REAL-LIFE EXPERIENCE AND PARTICULARITIES OF THE SPANISH IMPLEMENTATION <i>Poster Presenter:</i> Nuria González, ES	08:30 - 08:30
P440	FLUCONAZOLE PROPHYLAXIS FOR PEDIATRIC ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANT <i>Poster Presenter:</i> Amit Jain, IN	08:30 - 08:30
P441	A SINGLE INSTITUTION PRE-/POST-COMPARISON AFTER THE INTRODUCTION OF SUBCUTANEOUS IMMUNOGLOBULIN REPLACEMENT THERAPY IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION RECIPIENTS <i>Poster Presenter:</i> Makiko Suga, JP	08:30 - 08:30
P442	TREATMENT WITH INTRAVESICAL CIDOFOVIR IN HEMORRHAGIC CYSTITIS DUE TO BK VIRUS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: EXPERIENCE IN OUR CENTER <i>Poster Presenter:</i> Maria Cuesta Casas, ES	08:30 - 08:30
P443	COVID-19 AFTER ALLO-HSCT: A SINGLE CENTER OBSERVATIONAL STUDY <i>Poster Presenter:</i> Daria Mironova, RU	08:30 - 08:30
P445	IMPACT OF FLUOROQUINOLONE (FQP) PROPHYLAXIS ON INFECTIONS INCIDENCE IN AUTOLOGOUS STEM CELL TRANSPLANTATION (AUTO-HSCT) FOR MULTIPLE MYELOMA.	08:30 - 08:30

A SINGLE CENTER EXPERIENCE*Poster Presenter:* Ilaria Cutini, IT

- | | | |
|------|--|---------------|
| P446 | CLINICAL CHARACTERISTICS AND OUTCOMES OF PERI-HSCT COVID-19 INFECTION IN CHILDREN WITH INBORN ERRORS OF IMMUNITY (IEI) | 08:30 - 08:30 |
| | <i>Poster Presenter:</i> Subramaniam Ramanathan, GB | |
| P447 | DOES PROPHYLACTIC GRANULOCYTE TRANSFUSION IMPROVE OUTCOMES IN HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS? A STUDY IN A TERTIARY CARE CENTER IN INDIA | 08:30 - 08:30 |
| | <i>Poster Presenter:</i> Shruti Dabhade, IN | |
| P448 | INFECTIOUS COMPLICATIONS IN RUXOLITINIB-TREATED PATIENTS WITH CORTICOSTEROID-REFRACTORY GRAFT VERSUS HOST DISEASE AFTER HEMATOPOIETIC CELL TRANSPLANTATION: EXPERIENCE OF A SINGLE CENTRE | 08:30 - 08:30 |
| | <i>Poster Presenter:</i> Isabel Izquierdo Garcia, ES | |
| P449 | EBV REACTIVATION AND PTLD AFTER ALLO-HSCT. A SINGLE CENTER EXPERIENCE IN T-CELL DEPLETED TRANSPLANTS WITH ADOPTIVE IMMUNOTHERAPY AND IN UNMANIPULATED TRANSPLANTS WITH POST-TRANSPLANT GVHD PROPHYLAXIS | 08:30 - 08:30 |
| P450 | THE ROLE OF CHEST RADIOGRAPHY IN THE EVALUATION OF FIRST FEBRILE NEUTROPENIA IN PATIENTS UNDERGOING HSCT | 08:30 - 08:30 |
| | <i>Poster Presenter:</i> Guillermo Ramos Moreno, ES | |
| P451 | VIRAL INFECTION PROFILE AFTER HEMATOPOETIC STEM CELL TRANSPLANTATION IN A REFERENCE HOSPITAL IN BRAZIL | 08:30 - 08:30 |
| | <i>Speaker:</i> Fernando Barroso Duarte, BR | |
| P452 | WEST-NILE VIRUS MENINGOENCEPHALITIS IN IMMUNOCOMPROMISED HOST AFTER ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION – A PEDIATRIC CASE REPORT | 08:30 - 08:30 |
| | <i>Poster Presenter:</i> Marta Adavastro, IT | |
| P453 | HUMAN-HERPES-VIRUS-6 B ENCEPHALITIS AFTER HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION | 08:30 - 08:30 |
| | <i>Poster Presenter:</i> Nina Kristin Steckel, DE | |
| P454 | A CASE REPORT OF DIGESTIVE CRYPTOSPORIDIOSIS: A CHALLENGING DIAGNOSIS | 08:30 - 08:30 |
| | <i>Poster Presenter:</i> Maria Cuesta Casas, ES | |
| P455 | BACTEREMIA IN BONE MARROW TRANSPLANTATION PATIENTS: INCIDENCE AND CLINICAL RISK FACTORS IN A MIDDLE-INCOME COUNTRY TRANSPLANTATION UNIT | 08:30 - 08:30 |
| | <i>Poster Presenter:</i> Jorge Cuervo-Sierra, CO | |

P456	EFFICACY COMPARISON OF LEVOFLOXACIN AND RIFAXIMIN PROPHYLAXIS IN PATIENTS UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION <i>Poster Presenter: Muzaffer Keklik, TR</i>	08:30 - 08:30
P457	CASPOFUNGIN PROPHYLAXIS IN THE PRE-ENGRAFTMENT PERIOD IN PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC TRANSPLANTATION: A SINGLE CENTER EXPERIENCE <i>Poster Presenter: Annamaria Vincenzi, IT</i>	08:30 - 08:30
P458	SUCCESSFUL EXPERIENCE OF USING GRANULOCYTE CONCENTRATE IN PATIENTS WITH SEVERE APLASTIC ANEMIA NCSH «OHMATDYT», KYIV, UKRAINE <i>Poster Presenter: Andrii Budzyn, UA</i>	08:30 - 08:30
P459	CLOSTRIDIUM DIFFICILE INFECTION, CYTOMEGALOVIRUS REACTIVATION AND GASTROINTESTINAL GRAFT VERSUS HOST DISEASE IN RECIPIENTS OF ALLOGENEIC STEM CELL TRANSPLANTATION	08:30 - 08:30
P899	RETROSPECTIVE CHART REVIEW OF TRANSPLANT RECIPIENTS WITH CYTOMEGALOVIRUS INFECTION WHO RECEIVED MARIBAVIR IN THE PHASE 3 SOLSTICE TRIAL: DATA AT 52 WEEKS POST-MARIBAVIR TREATMENT INITIATION <i>Oral Presenter: Ishan Hirji, US</i>	08:30 - 08:30
<i>ePoster</i> 08:30 - 18:00		ePoster Area
Graft-versus-host Disease – Clinical		
P302	MULTICENTER RANDOMIZED PHASE II CLINICAL TRIAL TO COMPARE GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS WITH TACROLIMUS AND MYCOPHENOLATE MOFETIL VERSUS RUXOLITINIB AFTER POST-TRANSPLANT CYCLOPHOSPHAMIDE (PTCYRUXO) <i>Poster Presenter: Ivan Moiseev, RU</i>	08:30 - 08:30
P303	EFFICACY OF PTCY-BASED GVHD-PROPHYLAXIS IN ADULTS OLDER THAN 55 WITH MYELOID MALIGNANCIES UNDERGOING ALLO-HCT ACCORDING TO DONOR TYPE: STUDY FROM THE TCWP OF THE EBMT <i>Poster Presenter: Maria Queralt Salas, ES</i>	08:30 - 08:30
P304	REFINED ANALYSIS AT THE PEPTIDE-BINDING GROOVE LEVEL OF HLA AND GRAFT-VERSUS-HOST DISEASE ASSOCIATION IN PATIENTS WITH ACUTE LEUKEMIA WHO UNDERWENT UMBILICAL CORD BLOOD TRANSPLANTATION <i>Poster Presenter: Wahid Boukouaci, FR</i>	08:30 - 08:30
P305	SUPERIOR GRAFT-VERSUS-LEUKEMIA EFFECT IN MATCHED UNRELATED DONOR VERSUS HLA-IDENTICAL SIBLING PEDIATRIC RECIPIENTS TRANSPLANTED FOR ACUTE LYMPHOBLASTIC LEUKEMIA WITHIN THE FORUM STUDY	08:30 - 08:30

	<i>Poster Presenter:</i> Jean-Hugues Dalle, FR	
P306	TWO DISTINCT IMMUNE PROFILES ARE IDENTIFIED IN PEDIATRIC CHRONIC GVHD BY MACHINE LEARNING IN THE ABLE STUDY COHORT <i>Poster Presenter:</i> Kirk R. Schultz, CA	08:30 - 08:30
P307	REDUCED BACTERIAL ABUNDANCE IS ASSOCIATED WITH DEVELOPMENT OF SKIN GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENIC HEMATOPOIETIC CELL TRANSPLANTATION <i>Poster Presenter:</i> Thilo Thanscheidt, DE	08:30 - 08:30
P308	DISTINCT CLINICAL AND IMMUNOLOGICAL EFFECTS OF TWO BRANDS OF ANTI-THYMOCYTE GLOBULIN (ATG) IN THE PROPHYLAXIS OF GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Poster Presenter:</i> Marie Thérèse Rubio, FR	08:30 - 08:30
P310	ENDOTHELIAL DAMAGE MEASURED USING ENDOTHELIAL ACTIVATION BIOMARKERS AND EASIX PREDICTED ACUTE GRAFT-VERSUS-HOST DISEASE IN ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Poster Presenter:</i> Alexandra Pedraza, ES	08:30 - 08:30
P311	CHRONIC GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION OVER 30 YEARS - A MULTICENTER RETROSPECTIVE STUDY BY TRANSPLANT COMPLICATIONS WORKING PARTY OF EBMT <i>Poster Presenter:</i> Dražen Pulani?, HR	08:30 - 08:30
P312	IL-12 AND IL-18 ARE ASSOCIATED WITH CHRONIC GRAFT-VERSUS-HOST DISEASE BUT INVERSE CLINICAL OUTCOMES <i>Poster Presenter:</i> Thomas Luft, DE	08:30 - 08:30
P313	EFFICACY AND SAFETY OF THE ADDITION OF RGI-2001 IV INFUSION TO TACROLIMUS AND METHOTREXATE FOR ACUTE GVHD PREVENTION IN MYELOABLATIVE HSCT <i>Poster Presenter:</i> Zachariah DeFilipp, US	08:30 - 08:30
P314	BRONCHIOALVEOLAR LAVAGE AND BLOOD BIOMARKERS SUPPORT TH2 UPREGULATION IN BOS AFTER HCT <i>Poster Presenter:</i> Kirsten Williams, US	08:30 - 08:30
P315	VORINOSTAT FOR GVHD PROPHYLAXIS IN CHILDREN, ADOLESCENT, AND YOUNG ADULTS IS WELL-TOLERATED, ASSOCIATED WITH LOW INCIDENCE OF ACUTE GVHD, AND MAY REDUCE POST-TRANSPLANT COGNITIVE DIFFICULTIES <i>Poster Presenter:</i> Sung Won Choi, US	08:30 - 08:30
P316	POST-TRANSPLANT CYCLOPHOSPHAMIDE VERSUS ANTITHYMOCYTE GLOBULIN AS GVHD PROPHYLAXIS IN PATIENTS UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION FROM 10/10 HLA MATCHED UNRELATED	08:30 - 08:30

DONORS – A SINGLE CENTER ANALYSIS*Poster Presenter:* Veronika Valkova, CZ

- | | | |
|------|---|---------------|
| P318 | SUBCUTANEOUS ABATACEPT FOR PROPHYLAXIS OF ACUTE GRAFT-VERSUS-HOST DISEASE AFTER HAPLOIDENTICAL DONOR HEMATOPOIETIC CELL TRANSPLANTATION: EFFICACY, SAFETY AND IMMUNOLOGIC EFFECTS
<i>Poster Presenter:</i> Yuhua Ru, CN | 08:30 - 08:30 |
| P319 | THE ROLE OF ANTI-THYMOCYTE GLOBULIN IN ALLOGENEIC STEM CELL TRANSPLANTATION FROM HLA MATCHED UNRELATED DONORS (MUD) FOR SECONDARY AML: A STUDY FROM THE ALWP /EBMT
<i>Poster Presenter:</i> Arnon Nagler, IL | 08:30 - 08:30 |
| P320 | CLINICAL TRIAL OF NOVEL POST-TRANSPLANT CYCLOPHOSPHAMIDE, ABATACEPT AND SHORT COURSE OF TACROLIMUS (CAST) COMBINATION FOR GRAFT-VERSUS-HOST DISEASE PREVENTION FOLLOWING HAPLOIDENTICAL PERIPHERAL BLOOD STEM CELL TRANSPLANTATION
<i>Poster Presenter:</i> A. Samer Al-Homsy, US | 08:30 - 08:30 |
| P321 | ECP VERSUS RUXOLITINIB IN STEROID-REFRACTORY ACUTE GVHD – A RETROSPECTIVE STUDY BY THE EBMT TRANSPLANT COMPLICATIONS WORKING PARTY
<i>Poster Presenter:</i> Olaf Penack, DE | 08:30 - 08:30 |
| P322 | FINAL SAFETY AND EFFICACY RESULTS FROM EQUATE, AN OPEN-LABEL STUDY EVALUATING ITOLIZUMAB, A NOVEL TARGETED ANTI-CD6 THERAPY, IN NEWLY DIAGNOSED ACUTE GRAFT-VERSUS-HOST DISEASE
<i>Poster Presenter:</i> Corey Cutler, US | 08:30 - 08:30 |
| P323 | ABATACEPT REDUCES ACUTE GVHD INCIDENCE IN PEDIATRIC PATIENTS TRANSPLANTED FROM HLA-MISMATCHED UNRELATED DONORS
<i>Poster Presenter:</i> Pietro Merli, IT | 08:30 - 08:30 |
| P325 | RAPAMYCIN VERSUS CYCLOSPORINE IN COMBINATION WITH PTCY FOR GVHD PROPHYLAXIS IN MATCHED RELATED AND UNRELATED TRANSPLANTATION: A TWO-CENTRES ANALYSIS ON 213 CONSECUTIVE PATIENTS
<i>Poster Presenter:</i> Simona Piemontese, IT | 08:30 - 08:30 |
| P326 | THE IMPACT OF ADJUVANT IMMUNOSUPPRESSORS WITH POST-TRANSPLANT-CYCLOPHOSPHAMIDE FOR HLA-MATCHED ALLOGENEIC HEMATOPOIETIC TRANSPLANTATION: A MATCHED-PAIR ANALYSIS ON BEHALF OF THE ALWP OF THE EBMT
<i>Poster Presenter:</i> Giorgia Battipaglia, IT | 08:30 - 08:30 |
| P328 | IN VIVO DUAL T-CELL DEPLETION (TCD) IMPROVES TRANSPLANT OUTCOMES IN ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS >40 WHO UNDERGO ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) | 08:30 - 08:30 |

	<i>Poster Presenter:</i> Ayman Sayyed, CA	
P329	ECP VERSUS RUXOLITINIB IN STEROID-REFRACTORY CHRONIC GVHD – A RETROSPECTIVE STUDY BY THE EBMT TRANSPLANT COMPLICATIONS WORKING PARTY <i>Poster Presenter:</i> Olaf Penack, DE	08:30 - 08:30
P330	ABATACEPT FOR GRAFT VERSUS HOST DISEASE PROPHYLAXIS IN PATIENTS 60 YEARS AND OLDER RECEIVING MISMATCHED UNRELATED DONOR TRANSPLANTATION FOR HEMATOLOGIC MALIGNANCIES <i>Poster Presenter:</i> Sharmila Raghunandan, US	08:30 - 08:30
P331	TREATMENT WITH RUXOLITINIB IN COMBINATION WITH EXTRACORPOREAL PHOTOPHERESIS IN STEROID-REFRACTORY ACUTE AND CHRONIC GRAFT VERSUS HOST DISEASE: A SINGLE-CENTRE REAL-WORLD EXPERIENCE <i>Poster Presenter:</i> Verena Wais, DE	08:30 - 08:30
P332	IMMUNE ACTIVATION AND ENDOTHELIAL DYSFUNCTION IN ACUTE GRAFT-VERSUS-HOST DISEASE <i>Poster Presenter:</i> Thomas Luft, DE	08:30 - 08:30
P333	MACHINE LEARNING FOR RISK BIOMARKERS OF CHRONIC GRAFT-VERSUS-HOST DISEASE IN 936 PATIENTS FROM BMTCTN 0201 & 1202 COHORTS <i>Poster Presenter:</i> Sophie Paczesny, US	08:30 - 08:30
P334	IMPACT OF GVHD AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION IN YOUNG ADULTS ON SURVIVAL AND RELAPSE RATE IN GERMANY <i>Poster Presenter:</i> Jochen J. Frietsch, DE	08:30 - 08:30
P335	THE NEWLY DEVELOPED CORE-HCT SCORE INFORMS OUTCOME OF PATIENTS WITH ACUTE GVHD <i>Poster Presenter:</i> Gunnar Weise, DE	08:30 - 08:30
P336	POST-TRANSPLANT CYCLOPHOSPHAMIDE (PTCY), ABATACEPT AND VEDOLIZUMAB IN GVHD PROPHYLAXIS IN HEMATOPOIETIC STEM CELLS TRANSPLANTATION FROM MATCHED UNRELATED AND HAPLOIDENTICAL DONORS IN PEDIATRIC ACUTE LEUKEMIA PATIENTS <i>Poster Presenter:</i> Larisa Shelikhova, RU	08:30 - 08:30
P337	ADVANTAGE OF FIRST-LINE TDM-DRIVEN USE OF INFLIXIMAB FOR TREATING ACUTE INTESTINAL AND LIVER GVHD IN CHILDREN: A PROSPECTIVE, SINGLE-CENTER STUDY <i>Speaker:</i> Natalia Maximova, IT	08:30 - 08:30
P338	ALPHA-1-ANTITRYPSIN EXPERIENCE FOR STEROID-RESISTANT ACUTE GRAFT-VERSUS-HOST DISEASE <i>Poster Presenter:</i> Meltem Kurt Yüksel, TR	08:30 - 08:30
P339	MASS CYTOMETRIC IMMUNE CELL PROFILING AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT) IN AML IDENTIFIED AGVHD-	08:30 - 08:30

SPECIFIC PROFILES*Poster Presenter: Pål Tore Bentsen, NO*

- | | | |
|------|---|---------------|
| P340 | PREVALENCE AND FACTORS ASSOCIATED WITH METABOLIC SYNDROME IN PATIENTS WITH CHRONIC GRAFT-VERSUS-HOST DISEASE
<i>Poster Presenter: Aaron Zhao, US</i> | 08:30 - 08:30 |
| P341 | TRIPLE-DRUG GVHD PROPHYLAXIS AFTER HLA-MATCHED NON-MYELOABLATIVE ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
<i>Poster Presenter: Alma Wegener, DK</i> | 08:30 - 08:30 |
| P342 | NOVEL MACHINE LEARNING TECHNIQUES IMPROVE THE ACCURACY OF DEMOGRAPHIC DATA-DERIVED ALGORITHMS PREDICTING ACUTE GVHD AFTER REDUCED-INTENSITY ALLOGENEIC HSCT
<i>Poster Presenter: Vaish Balaji, GB</i> | 08:30 - 08:30 |
| P343 | RUXOLITINIB FOR TREATMENT OF ACUTE GRAFT-VERSUS-HOST DISEASE: A RETROSPECTIVE SINGLE CENTER ANALYSIS
<i>Poster Presenter: Alexander Denk, DE</i> | 08:30 - 08:30 |
| P344 | EFFICACY OF POSTTRANSPLANT CYCLOPHOSPHAMIDE FOR CHRONIC GRAFT-VERSUS-HOST DISEASE IN HLA-MISMATCHED TRANSPLANTS: A SINGLE-CENTER EXPERIENCE DURING 10 YEARS
<i>Poster Presenter: Valle Gomez Garcia de Soria, ES</i> | 08:30 - 08:30 |
| P345 | GVHD ASSESSMENT IN PHASE 1 STUDY OF BRIQUILIMAB (JSP191), LOW DOSE IRRADIATION AND FLUDARABINE CONDITIONING IN OLDER ADULTS WITH MDS/AML UNDERGOING ALLOGENEIC HCT
<i>Poster Presenter: Minyoung Youn, US</i> | 08:30 - 08:30 |
| P346 | POST-TRANSPLANTATION CYCLOPHOSPHAMIDE, TACROLIMUS AND LOW-DOSE POST-ENGRAFTMENT ANTI-THYMOGLOBULIN AS GVHD PROPHYLAXIS FOR PATIENTS UNDERGOING PERIPHERAL BLOOD STEM CELL TRANSPLANTATION FROM HAPLO DONORS: A SINGLE CENTER ANALYSIS
<i>Poster Presenter: Jiong Hu, CN</i> | 08:30 - 08:30 |
| P347 | REAL-WORLD OUTCOMES OF GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN JAPAN: RETROSPECTIVE ANALYSIS OF TRANSPLANT REGISTRY UNIFIED MANAGEMENT PROGRAM REGISTRY
<i>Poster Presenter: Junya Kanda, JP</i> | 08:30 - 08:30 |
| P348 | COMPARISON OF THE MODIFIED GLUCKSBERG CRITERIA VS. THE MAGIC CRITERIA FOR DIAGNOSIS OF AGVHD IN CHILDREN UNDERGOING HSCT
<i>Poster Presenter: Sarah Weischendorff, DK</i> | 08:30 - 08:30 |

P350	TREATMENT OF GRAFT-VERSUS-HOST DISEASE WITH EXTRACORPOREAL PHOTOPHERESIS (ECP): A LARGE MONOCENTRIC EXPERIENCE <i>Poster Presenter:</i> Massimiliano Gambella, IT	08:30 - 08:30
P351	HAPLOIDENTICAL VERSUS MATCHED UNRELATED HSCT WITH POST TRANSPLANT CYCLOPHOSPHAMIDE BASED GVHD PROPHYLAXIS IN CHILDREN WITH ACUTE LEUKEMIA <i>Poster Presenter:</i> Liubov Tsvetkova, RU	08:30 - 08:30
P352	THE IMPACT OF ATG REAL-DOSE (RD) /THERORETICAL-ALC-BASED-DOSE (TD) RATIO ON OUTCOME IN ADULT PATIENTS UNDERWENT ALLOGENEIC-STEM-CELL-TRANSPLANT AFTER MYELOABLATIVE CONDITIONING FOR MYELOID MALIGNANCIES: A RETROSPECTIVE-SINGLE-CENTER ANALYSIS <i>Poster Presenter:</i> Giuseppe Sapienza, IT	08:30 - 08:30
P354	RUXOLITINIB IMPROVES ENDOTHELIAL SYNDROMES AND PROLONGS SURVIVAL AFTER ALLOGENEIC STEM CELL TRANSPLANTATION – UMC LJUBLJANA, SLOVENIA EXPERIENCE <i>Poster Presenter:</i> Polona Novak, SI	08:30 - 08:30
P355	THE CLINICAL BENEFIT OF ACUTE GVHD DEPENDS ON THE AGE AT TRANSPLANTATION IN PATIENTS WITH ADULT T-CELL LEUKEMIA–LYMPHOMA <i>Poster Presenter:</i> Shigeo Fujii, JP	08:30 - 08:30
P356	THE PROBABILITY OF BEING IN RESPONSE: A NOVEL EFFICACY ENDPOINT FOR CHRONIC GRAFT VERSUS HOST DISEASE APPLIED TO THE REACH-3 STUDY OF RUXOLITINIB VERSUS BAT <i>Speaker:</i> Tommaso Stefanelli, CH	08:30 - 08:30
P357	RESULTS OF FEASIBILITY STUDY WITH SELF-LEARNING, ARTIFICIAL INTELLIGENCE BASED, MACHINE LEARNING TOOL PREDICTING THE ABSOLUTE INDIVIDUAL RISK OF ACUTE GRAFT-VERSUS-HOST-DISEASE IN A RETROSPECTIVE PEDIATRIC COHORT <i>Poster Presenter:</i> Madlen Reschke, DE	08:30 - 08:30
P358	RENAL CHRONIC GRAFT-VERSUS-HOST DISEASE AS A RARE POSTTRANSPLANT COMPLICATION: A RETROSPECTIVE STUDY FROM A SINGLE CENTER EXPERIENCE <i>Poster Presenter:</i> Monica Cabrero, ES	08:30 - 08:30
P359	PILOT STUDY OF USING LOW DOSE PTCY FOR GVHD PREVENTION AFTER MATCHED SIBLING AND UNRELATED ALLOGENIC TRANSPLANTATION <i>Poster Presenter:</i> Alex Juarez Cusirimay, ES	08:30 - 08:30
P360	EXERCISE PHYSIOLOGY APPLIED TO THE CLINICAL SETTING OF PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION	08:30 - 08:30

	<i>Poster Presenter:</i> Francesca Limido, IT	
P361	THYMIC STROMAL LYMPHOPOIETIN LEVELS ARE ASSOCIATED WITH INFLAMMATION AND ACUTE GVHD IN PEDIATRIC HSCT <i>Poster Presenter:</i> Kristine Bohn Sørensen, DK	08:30 - 08:30
P362	SURVIVAL DIFFERENCES BETWEEN ADULTS AND CHILDREN IN TREATMENT WITH ETANERCEPT FOR GRADE III-IV SD/SR-AGVHD: A RETROSPECTIVE SINGLE-CENTER COHORT STUDY <i>Poster Presenter:</i> Ehud Even-Or, IL	08:30 - 08:30
P363	PRE-TRANSPLANTATION DIABETES MELLITUS AND OBESITY AND ACUTE GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: A STUDY FROM THE EBMT TRANSPLANT COMPLICATIONS WORKING PARTY <i>Poster Presenter:</i> Lars Klingen Gjørde, DK	08:30 - 08:30
P364	COMPARISON OF EFFICACY AND TOLERABILITY OF A RUXOLITINIB-BASED THERAPY VERSUS OTHER TREATMENT OPTIONS FOR STEROID REFRACTORY ACUTE GVHD IN A REAL LIFE EXPERIENCE <i>Poster Presenter:</i> Gabriele Facchin, IT	08:30 - 08:30
P365	FEASIBILITY AND EFFICACY OF PARTIAL OR COMPLETE REPLACEMENT OF POST-TRANSPLANTATION CYCLOPHOSPHAMIDE WITH BENDAMUSTINE IN PATIENTS UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION <i>Poster Presenter:</i> Manthan Kathrotiya, IN	08:30 - 08:30
P366	A PHASE 1B STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF AN INVESTIGATIONAL MICROBIOME THERAPEUTIC, SER-155, IN ADULTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Poster Presenter:</i> Doris Ponce, US	08:30 - 08:30
P367	BELUMOSUDIL AND RUXOLITINIB COMBINATION THERAPY FOR TREATMENT OF STEROID-REFRACTORY CHRONIC GRAFT-VERSUS-HOST DISEASE <i>Poster Presenter:</i> Iskra Pusic, US	08:30 - 08:30
P368	CYCLOSPORINE AND METHOTREXATE VERSUS CYCLOSPORINE FOR PROPHYLAXIS OF GRAFT-VERSUS-HOST DISEASE IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FROM AN HLA-IDENTICAL SIBLING FOR PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA <i>Poster Presenter:</i> Nour Abdeljelil, TN	08:30 - 08:30
P369	OUTCOMES OF PATIENTS DIAGNOSED WITH STEROID-REFRACTORY CHRONIC GRAFT-VERSUS-HOST DISEASE RESISTANT OR INTOLERANT TO SECOND-LINE RUXOLITINIB <i>Poster Presenter:</i> Maria Sola, ES	08:30 - 08:30
P370	CD52 EXPRESSION ON T CELLS PREDICT DEVELOPMENT OF	08:30 - 08:30

	ACUTE GVHD IN PATIENTS AFTER ALEMTUZUMAB BASED CONDITIONING <i>Poster Presenter:</i> Pascal Woelfinger, DE	
P371	CHRONIC GRAFT-VERSUS-HOST DISEASE IN CHILDREN AFTER ALLOGENEIC HSCT- SINGLE-CENTER RETROSPECTIVE ANALYSIS OF INCIDENCE, SEVERITY, RISK FACTORS AND IMPACT ON OUTCOME <i>Poster Presenter:</i> Jaroslava Adamcakova, SK	08:30 - 08:30
P373	CHRONIC GRAFT-VERSUS-HOST DISEASE ASSOCIATED POLYMYOSITIS: A SINGLE-CENTER CASE SERIES, DIAGNOSTIC AND MANAGEMENT APPROACH <i>Poster Presenter:</i> Jing Yuan Tan, SG	08:30 - 08:30
P374	SAFETY AND EFFICACY OF DOSE-ADJUSTED IBRUTINIB FOR STEROID-REFRACTORY AGVHD AND CGVHD IN PATIENTS TAKING ORAL ANTIFUNGAL AZOLES <i>Poster Presenter:</i> Rong Xie, CN	08:30 - 08:30
P375	STUDY DESIGN AND RATIONALE OF STARGAZE – A PHASE 2 CLINICAL TRIAL EVALUATING APRAGLUTIDE IN PATIENTS WITH STEROID-REFRACTORY GASTROINTESTINAL (GI) ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD) <i>Poster Presenter:</i> Robert Zeiser, DE	08:30 - 08:30
P376	SAFETY AND EFFICACY OF COMBINATION DOSE-ADJUSTED ATG AND ANTI-CD25 ANTIBODY IN PATIENTS WITH HAPLO-HSCT <i>Poster Presenter:</i> Lidan Zhu, CN	08:30 - 08:30
P378	RUXOLITINIB FOR TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE: A SINGLE CENTER RETROSPECTIVE ANALYSIS <i>Poster Presenter:</i> Alexander Denk, DE	08:30 - 08:30
P379	EXPERIENCE IN REDUCED DOSE OF POST-TRANSPLANTATION CYCLOPHOSPHAMIDE AS GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS IN PATIENTS RECEIVING HLA-IDENTICAL RELATED DONOR TRANSPLANTS <i>Poster Presenter:</i> Maria Calbacho Robles, ES	08:30 - 08:30
P380	COULD USTEKINUMAB BE AN ALTERNATIVE IN PATIENTS WITH REFRACTORY CUTANEOUS GRAFT-VERSUS-HOST DISEASE? A SINGLE CENTER EXPERIENCE <i>Poster Presenter:</i> María Casado Sánchez, ES	08:30 - 08:30
P381	REAL-LIFE EXPERIENCE WITH RUXOLITINIB AS A SECOND-LINE TREATMENT IN ACUTE AND CHRONIC GRAFT-VERSUS-HOST DISEASE <i>Poster Presenter:</i> Carmen Martín Calvo, ES	08:30 - 08:30
P382	EFFECTIVENESS OF BARICITINIB FOR CHRONIC GVHD. ONE CENTRE EXPERIENCE <i>Poster Presenter:</i> Luisa Sisinni, ES	08:30 - 08:30

P384	NEUROOPHTHALMOLOGIC COMPLICATIONS IN GVHD. A CASE REPORT <i>Poster Presenter: Isabel Izquierdo Garcia, ES</i>	08:30 - 08:30
P385	ECP AND COMBINATORY THERAPY FIRST-LINE FOR CHRONIC GVHD AFTER HEMATOPOIETIC STEM CELL TRANSPLANT <i>Poster Presenter: Giorgia Mancini, IT</i>	08:30 - 08:30
P386	SALVAGE THERAPY WITH MESENCHYMAL STROMAL CELLS “MSC-FFM” FOR A SEVERE GASTRO-INTESTINAL STEROID REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE IN A 12-YEAR-OLD BOY WITH SICKLE CELL DISEASE <i>Poster Presenter: Mélanie Valpacos, CH</i>	08:30 - 08:30
P387	TAILORED-MADE PHOTOPHERESIS TREATMENT IN A PEDIATRIC PATIENT WITH CHRONIC GRAFT-VERSUS-HOST DISEASE <i>Poster Presenter: Teresa Mota, PT</i>	08:30 - 08:30
P388	ABDOMINAL PAIN AND PERSISTENT DIARRHEA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: DIFFERENTIAL DIAGNOSIS <i>Poster Presenter: Isabel Izquierdo Garcia, ES</i>	08:30 - 08:30
<i>ePoster</i> 08:30 - 18:00		ePoster Area
Graft-versus-host Disease – Preclinical and Animal Models		
P300	IMMUNE CELL COMPOSITION OF THE GASTROINTESTINAL MUCOSA IN PATIENTS WITH AND WITHOUT STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE <i>Poster Presenter: Lukas Gaksch, AT</i>	08:30 - 08:30
P301	ACUTE GVHD IS DISTINGUISHED BY AN ERYTHROID SIGNATURE <i>Poster Presenter: Sara Deola, QA</i>	08:30 - 08:30
<i>ePoster</i> 08:30 - 18:00		ePoster Area
Stem Cell Source		
P274	UNRELATED BONE MARROW VERSUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION IN HEMATOLOGICAL MALIGNANCIES <i>Poster Presenter: Hiromi Hayashi, JP</i>	08:30 - 08:30
P275	OPTIMIZED DOUBLE-UNIT CORD BLOOD TRANSPLANTATION MITIGATES TRANSPLANT RELATED MORTALITY RESULTING IN HIGH PROGRESSION-FREE SURVIVAL IN ADULTS WITH HEMATOLOGIC MALIGNANCIES <i>Poster Presenter: Ioannis Politikos, US</i>	08:30 - 08:30
P276	SINGLE VS DOUBLE CORD BLOOD TRANSPLANTATION WITH MYELOABLATIVE CONDITIONING: COMPARABLE OUTCOMES	08:30 - 08:30

IN A SINGLE-INSTITUTION EXPERIENCE*Poster Presenter:* Mizuki Watanabe, JP

- | | | |
|------|--|---------------|
| P277 | DOES THE LENGTH OF TIME IN CRYOPRESERVATION AFFECT THE QUALITY OF CORD BLOOD UNITS (CBUS) OR IMPACT ENGRAFTMENT? | 08:30 - 08:30 |
| | <i>Poster Presenter:</i> Alex Ross, GB | |
| P278 | HIGH PROPORTIONS OF CD3+ CELLS IN CORD BLOOD UNITS ARE ASSOCIATED WITH LOWER DISEASE RELAPSE FOLLOWING HAEMATOPOIETIC CELL TRANSPLANTATION | 08:30 - 08:30 |
| | <i>Poster Presenter:</i> Richard Duggleby, GB | |
| P279 | SPLITTING CORDS AND SAVING LIVES: USING THE SAME CORD BLOOD UNIT TO CORRECT SIBLINGS WITH GENETIC DISEASE, THE MANCHESTER EXPERIENCE | 08:30 - 08:30 |
| | <i>Poster Presenter:</i> Ramya Nataraj, GB | |
| P280 | UMBILICAL CORD BLOOD TRANSPLANTATION WITH REDUCED INTENSITY CONDITIONING IN ACUTE MYELOID LEUKEMIA AND HIGH-RISK MYELOYDYSPLASTIC SYNDROME: A RETROSPECTIVE, SINGLE CENTER EXPERIENCE | 08:30 - 08:30 |
| | <i>Poster Presenter:</i> Nancy Torres, US | |
| P281 | DKMS BMST FOUNDATION INDIA: GIVING INDIAN PATIENTS A SECOND CHANCE AT LIFE | 08:30 - 08:30 |
| | <i>Poster Presenter:</i> Nitin Agarwal, IN | |
| P282 | LOW DOSE TOTAL BODY IRRADIATION-BASED ANTI-THYMOCYTE GLOBULIN-FREE CONDITIONING IS HIGHLY SAFE AND EFFECTIVE IN CORD BLOOD TRANSPLANTATION FOR PATIENTS WITH SEVERE APLASTIC ANEMIA | 08:30 - 08:30 |
| | <i>Poster Presenter:</i> Hee Won Cho, KR | |

ePoster

08:30 - 18:00

ePoster Area

New Drugs and Cell-based Immune Therapies

- | | | |
|------|---|---------------|
| P263 | IDALLO STUDY: A RETROSPECTIVE MULTICENTER STUDY OF THE SFGM-TC EVALUATING THE EFFICACY AND SAFETY OF IVOSIDENIB, IN RELAPSED AML AFTER ALLOGENEIC STEM CELL TRANSPLANTATION | 08:30 - 08:30 |
| | <i>Poster Presenter:</i> Ana Berceanu, FR | |
| P264 | ALLOGENEIC STEM CELL TRANSPLANT RECIPIENTS FOR LYMPHOID MALIGNANCIES AFTER SALVAGE THERAPY WITH BISPECIFIC ANTIBODIES. A SHORT CASE SERIES | 08:30 - 08:30 |
| | <i>Poster Presenter:</i> Marta Peña Domingo, ES | |
| P265 | IMPROVED SURVIVAL SINCE THE INCORPORATION OF NEW THERAPIES FOR THE TREATMENT OF RELAPSED-REFRACTORY AGGRESSIVE B-CELL LYMPHOMA. ANALYSIS BASED ON RELINF REGISTRY OF THE GELTAMO GROUP | 08:30 - 08:30 |
| | <i>Poster Presenter:</i> Mariana Bastos-Oreiro, ES | |

P266	IMPACT OF (LEUKAEMIA-DERIVED) DENDRITIC CELLS GENERATED FROM AML-PATIENTS' WHOLE BLOOD- VERSUS WHOLE BONE MARROW CELLS ON THE MEDIATION OF ANTILEUKAEMIC PROCESSES AFTER MIXED LYMPHOCYTE CULTURE <i>Poster Presenter: Helga Maria Schmetzer, DE</i>	08:30 - 08:30
P267	NEXT GENERATION THERAPY: INNOVATIVE AND SAFE RNA DELIVERY MEDIATED BY LENTIFLASH® PARTICLES FOR AN EFFICIENT CRISPR/CAS9-MEDIATED GENE KNOCKOUT IN HUMAN INDUCED PLURIPOTENT STEM CELLS <i>Poster Presenter: Christine Duthoit, FR</i>	08:30 - 08:30
P268	A REAL-WORLD STUDY OF LENALIDOMIDE COMBINED WITH LOW-DOSE VENECLA IN MAINTENANCE THERAPY AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR RECURRENT AND REFRACTORY HEMATOLOGICAL MALIGNANCIES <i>Poster Presenter: Zhihui Li, CN</i>	08:30 - 08:30
P269	USE OF MESENCHYMAL STROMAL CELLS IN COMBINATION TREATMENT FOR SEVERE STEROID REFRACTORY GRAFT VERSUS HOST DISEASE: A SINGLE CENTRE EXPERIENCE <i>Poster Presenter: Matteo Parma, IT</i>	08:30 - 08:30
P270	UTILIZATION OF NK CELLS IN PREVENTION OF RELAPSE AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION – CLINICAL STUDY PHASE IB/II <i>Poster Presenter: Jiri Sramek, CZ</i>	08:30 - 08:30
<i>ePoster</i> 08:30 - 18:00		ePoster Area
	Stem Cell Mobilization, Collection and Engineering	
P104	PERIPHERAL BLOOD STEM CELL PRE HARVEST XN-HPC COUNT AS AN EFFECTIVE SURROGATE FOR CD34+ CELL COUNT IN A MAJOR HAEMOPOIETIC STEM CELL TRANSPLANTATION CENTRE <i>Poster Presenter: Sen Mui Tan, MY</i>	08:30 - 08:30
P105	AUTOLOGOUS PERIPHERAL BLOOD STEM CELL MOBILISATION TECHNIQUES, CELL YIELDS AND PRACTICE VARIATION-BY-COUNTRY IN MYELOMA PATIENTS UNDERGOING FIRST AUTOLOGOUS STEM CELL TRANSPLANTS IN EBMT CENTRES (2012-2021) <i>Poster Presenter: Patrick Hayden, IE</i>	08:30 - 08:30
P106	EFFICACY AND SAFETY OF THE G-CSF BIOSIMILAR FILGRASTIM-AAFI COMPARED TO FILGRASTIM: A REPORT FROM THE NATIONAL MARROW DONOR PROGRAM <i>Poster Presenter: Steven Devine, US</i>	08:30 - 08:30
P107	OPTIMIZING BONE MARROW HARVEST MANIPULATION FOR RBC REDUCTION IN PEDIATRIC ALLOGENIC STEM CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE	08:30 - 08:30

	<i>Poster Presenter:</i> Dunia Jawdat, SA	
P108	EVALUATION OF A NOVEL FLOW CYTOMETRIC CFU ASSAY IN CD34+ HEMATOPOIETIC STEM AND PROGENITOR CELLS EXPANDED <i>EX VIVO</i> <i>Poster Presenter:</i> Anne Louise Schacht Revenfeld, DK	08:30 - 08:30
P109	CLINICAL OUTCOMES AFTER TRANSPLANTATION OF CRYOPRESERVED OR FRESH PERIPHERAL BLOOD HEMATOPOIETIC CELLS: A SINGLE CENTRE REPORT <i>Poster Presenter:</i> Imran Ahmad, CA	08:30 - 08:30
P110	FLOW CYTOMETRIC CHARACTERIZATION OF HSC SUBPOPULATIONS IN AUTOLOGOUS PBSC PREPARATIONS AFTER CRYOPRESERVATION <i>Poster Presenter:</i> Patrick Wuchter, DE	08:30 - 08:30
P111	STEM-CELL MOBILIZATION AFTER ANTI-CD38-BASED QUADRUPLET INDUCTION THERAPY IN NEWLY DIAGNOSED MULTIPLE MYELOMA <i>Poster Presenter:</i> Vladan Vucinic, DE	08:30 - 08:30
P112	FACTORS INFLUENCING PBSC MOBILIZATION IN ADULT ALLOGENEIC DONORS <i>Poster Presenter:</i> Silvia Monsalvo, ES	08:30 - 08:30
P113	CHANGES TO MOBILISATION AND CRYOPRESERVATION DURING COVID-19: RESULTS FROM A SINGLE CENTRE <i>Poster Presenter:</i> Wendy Merrison, GB	08:30 - 08:30
P114	THE OUTCOME OF CRYOPRESERVED PRODUCTS COMPARED TO FRESH PRODUCTS IN PEDIATRIC ALLOGENIC STEM CELL TRANSPLANTATION DURING COVID-19 PANDEMIC: SINGLE CENTER STUDY <i>Poster Presenter:</i> Mohammed Essa, SA	08:30 - 08:30
P115	HAPLOIDENTICAL TRANSPLANT FROM PBSC WITH POST TRANSPLANTATION CYCLOPHOSPHAMIDE AND CONTROLLED NUMBER OF T LYMPHOCYTES <i>Poster Presenter:</i> Elena Soncini, IT	08:30 - 08:30
P116	STEM-CELL MOBILIZATION WITH CYCLOPHOSPHAMIDE 4 G/M² ALLOWS COLLECTION OF HIGH NUMBERS OF CD34+ CELLS AFTER DARA-VTD INDUCTION FOR MULTIPLE MYELOMA <i>Poster Presenter:</i> Tommaso Perini, IT	08:30 - 08:30
P117	STEM CELL MOBILIZATION WITH ETOPOSIDE AND G-CSF IN PATIENTS WITH RELAPSED/REFRACTORY CLASSIC HODGKIN LYMPHOMA <i>Poster Presenter:</i> Galina Petrova, RU	08:30 - 08:30
P118	THE ASSESSMENT OF VIABILITY AND POST-THAW CELL RECOVERY OF CRYOPRESERVED PERIPHERAL BLOOD STEM CELLS AND LEUKOCYTES SUBPOPULATION USING THE ANNEXIN V STAINING METHOD	08:30 - 08:30

	<i>Poster Presenter:</i> Ines Bojani?, HR	
P119	THE USE OF PRE-CD34 RESULTS AS A PREDICTOR OF END-CD34 RESULTS <i>Poster Presenter:</i> Yona Skosana, ZA	08:30 - 08:30
P120	TAILORED MOBILIZATION IN AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANT	08:30 - 08:30
P122	THE IMPACT OF COVID-19 PANDEMIC ON HPC DONATION AND DONOR UNAVAILABILITY: SINGLE CENTER ANALYSIS <i>Poster Presenter:</i> Grzegorz Hensler, PL	08:30 - 08:30
P123	CRYOPRESERVATION OF ALLOGENEIC HAEMATOPOIETIC STEM CELLS – THE SOUTH AFRICAN COVID-19 EXPERIENCE <i>Poster Presenter:</i> Tanya Nadia Glatt, ZA	08:30 - 08:30
P124	IMMUNOPHENOTYPIC CHARACTERIZATION AND CLINICAL CORRELATION OF A MANIPULATION TECHNIQUE BASED ON CD34+ STEM CELL SELECTION WITH CD3+ T CELL ADD-BACK <i>Poster Presenter:</i> Elena Soncini, IT	08:30 - 08:30
P125	NEW METHOD FOR BONE MARROW COLLECTION AND FILTRATION: APPROVED, COST-EFFICIENT AND COMPATIBLE WITH CURRENT EU-MDR <i>Poster Presenter:</i> Emanuel Berger, DE	08:30 - 08:30
P126	STEM CELL MOBILIZATION WITH PLERIXAFOR IN PATIENTS WITH MYELOMA AND LYMPHOMA – A SINGLE-CENTER RETROSPECTIVE ANALYSIS <i>Poster Presenter:</i> Vladan Vucinic, DE	08:30 - 08:30
P127	HIGH DOSE PLERIXAFOR AND LARGE VOLUME LEUKAPHERESIS – IS IT THE ANSWER FOR AUTOLOGOUS STEM CELL TRANSPLANTS IN ABSOLUTE POOR MOBILIZERS? <i>Poster Presenter:</i> Amit Jain, IN	08:30 - 08:30
P129	SUCCESSFUL COLLECTION OF PERIPHERAL HEMATOPOIETIC STEM CELLS 4 HOURS AFTER PLERIXAFOR ADMINISTRATION IN POOR MOBILIZER HEALTHY DONORS <i>Poster Presenter:</i> Aurora Vassanelli, IT	08:30 - 08:30
P131	ERYTHROCYTE REDUCTION OF BONE MARROW GRAFTS VIA 1xG SEDIMENTATION WITH GELAFUNDIN: A TECHNICAL NOTE <i>Poster Presenter:</i> Maya Yordanova, BG	08:30 - 08:30
P132	PLERIXAFOR FOR AUTOLOGOUS STEM-CELL MOBILIZATION AND COLLECTION IN A PORTUGUESE CENTRE <i>Poster Presenter:</i> Rita Pombal, PT	08:30 - 08:30
P133	STEM CELL APHERESIS: PREDICTION OF THE STEM CELL YIELD USING PRE-APHERESIS CD34+ CELL COUNT - COMPARISON BETWEEN THE ALLOGENEIC AND AUTOLOGOUS SETTING	08:30 - 08:30

	<i>Poster Presenter:</i> Johannes Gaertner, DE	
P134	INTER-LABORATORY METHOD VALIDATION OF CD34+ FLOW-CYTOMETRY ASSAY: THE EXPERIENCE OF TURIN METROPOLITAN TRANSPLANT CENTRE <i>Poster Presenter:</i> Ivana Ferrero, IT	08:30 - 08:30
P135	PRECLINICAL EVALUATION OF DIFFERENT SOLUTIONS FOR WASHING OUT DMSO FROM PERIPHERAL BLOOD STEM CELL GRAFTS AFTER THAWING <i>Poster Presenter:</i> Iwona Mitrus, PL	08:30 - 08:30
P136	STEM CELLS COLLECTION IN MULTIPLE MYELOMA PATIENTS: COMPARISON BETWEEN PATIENTS RANDOMISED TO DARA PROTOCOLS VERSUS OTHER TREATMENTS AND CANDIDATE TO STEM CELL COLLECTION FROM PERIPHERAL BLOOD <i>Poster Presenter:</i> Emanuela Sergio, IT	08:30 - 08:30
P138	DOES INFUSION TIME REALLY AFFECT IN THE CELL VIABILITY IN THE AUTOLOGOUS STEM CELL TRANSPLANT? <i>Poster Presenter:</i> María Casado Sánchez, ES	08:30 - 08:30
P139	GENERIC/BIOSIMILAR G-CSF ARE EFFECTIVE FOR PERIPHERAL BLOOD STEM CELL MOBILIZATION AND NON-CRYOPRESERVED AUTOLOGOUS TRANSPLANTATION IN MULTIPLE MYELOMA. A SINGLE CENTER EXPERIENCE IN ORAN (ALGERIA) <i>Poster Presenter:</i> Nabil Yafour, DZ	08:30 - 08:30
P140	CYTARABINE FOR MOBILIZATION OF HEMATOPOIETIC STEM CELLS IN A REFERENCE HOSPITAL IN THE NORTHEAST OF BRAZIL: A RETROSPECTIVE COHORT ANALYSIS <i>Poster Presenter:</i> Luís Fábio Botelho, BR	08:30 - 08:30
P141	CHEMOMOBILIZATION WITH ETOPOSIDE IN A CHILD WITH HIGH-RISK NEUROBLASTOMA WHO FAILED STEM CELL HARVEST WITH PLERIXAFOR <i>Poster Presenter:</i> Young Bae Choi, KR	08:30 - 08:30
P142	HIGH EFFICIENCY CD34+ APHERESIS COLLECTION IN A MULTIPLE SCLEROSIS PATIENT: A CASE REPORT <i>Poster Presenter:</i> Yandy Marx Castillo-Aleman, AE	08:30 - 08:30
<i>ePoster</i> 08:30 - 18:00		ePoster Area
Stem Cell Donor		
P283	GLOBAL TRENDS IN DEMAND FOR MISMATCHED UNRELATED DONOR TRANSPLANTS HAVE POSITIVELY IMPACTED RACIALLY AND ETHNICALLY DIVERSE CANDIDATES FOR HEMATOPOIETIC CELL TRANSPLANTATION <i>Poster Presenter:</i> Steven Devine, US	08:30 - 08:30
P285	YOUNGER DONORS MIGHT BE PREFERRED FOR THE	08:30 - 08:30

	ELDERLY MDS/AML RECIPIENTS OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION-RETROSPECTIVE ANALYSIS ON BEHALF OF THE POLISH ADULT LEUKEMIA STUDY GROUP (PALG) <i>Poster Presenter: Jan Zaucha, PL</i>	
P286	IDENTIFYING PERMISSIBLE HLA MISMATCHES IN PEDIATRIC SCT USING HLA-EMMA <i>Poster Presenter: Erik G. J. Von Asmuth, NL</i>	08:30 - 08:30
P288	OUTCOME COMPARISON BETWEEN HLA-MATCHED SIBLING DONOR ALLOGENIC HSCT AND MATCHED RELATED NON-SIBLING DONOR ALLOGENIC HSCT IN PEDIATRIC PATIENTS; SINGLE CENTER RETROSPECTIVE STUDY <i>Poster Presenter: Mohammed Essa, SA</i>	08:30 - 08:30
P289	COMPARABLE CLINICAL OUTCOMES AFTER CORD BLOOD TRANSPLANTATION IN THE US AND JAPAN: RESULT FROM A COLLABORATIVE STUDY <i>Poster Presenter: Mizuki Watanabe, JP</i>	08:30 - 08:30
P290	ACCESS: A MULTI-CENTER, PHASE II TRIAL OF HLA-MISMATCHED UNRELATED DONOR HEMATOPOIETIC CELL TRANSPLANTATION WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE FOR PATIENTS WITH HEMATOLOGIC MALIGNANCIES <i>Poster Presenter: Steven Devine, US</i>	08:30 - 08:30
P291	BLUSTAR – A PROJECT TO RECRUIT NON-CAUCASIAN HEMATOPOIETIC STEM CELL DONORS RESULTING IN MORE THAN 8,000 DONORS AND MORE THAN 10 PBSC APHERESSES SO FAR <i>Poster Presenter: Lambros Kordelas, DE</i>	08:30 - 08:30
P293	RETROSPECTIVE REVIEW OF DONOR LYMPHOCYTE REQUESTS TO ANTHONY NOLAN REGISTRY SHOW EXCELLENT DONOR AVAILABILITY AND VERY LOW RATES OF DONOR ATTRITION AND MEDICAL CLEARANCE FAILURE <i>Poster Presenter: Angharad Pryce, GB</i>	08:30 - 08:30
P294	POSTTRANSPLANT CYCLOPHOSPHAMIDE BASED T CELL REplete HAPLOIDENTICAL STEM CELL TRANSPLANTATION IN PEDIATRIC HEMATOLOGICAL MALIGNANCIES: A SINGLE CENTER EXPERIENCE <i>Poster Presenter: Rajesh Patil, IN</i>	08:30 - 08:30
P295	CURRENT DEMAND AND PROVISION OF UNRELATED DONOR LYMPHOCYTES TO UK TRANSPLANT CENTRES FROM ANTHONY NOLAN UK STEM CELL REGISTRY <i>Poster Presenter: Angharad Pryce, GB</i>	08:30 - 08:30
P296	OVERVIEW OF MATCHED UNRELATED DONOR SEARCH - LIMITED EXPERIENCE WITH THE ROMANIAN NATIONAL VOLUNTARY STEM CELL DONOR REGISTRY (RNDVSCH) <i>Poster Presenter: Zsofia Varady, RO</i>	08:30 - 08:30

P297	TRENDS IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION OVER THE PAST 21 YEARS – A SINGLE CENTRE ANALYSIS <i>Poster Presenter: Pavel Jindra, CZ</i>	08:30 - 08:30
P298	EXPERIENCES OF PARENTS WHO CONCEIVED SAVIOR SIBLINGS FOR BEING HEMATOPOIETIC STEM CELL DONORS TO THEIR SICK CHILDREN AND SUCCESSFULLY COMPLETED THE PROCESS: A QUALITATIVE STUDY <i>Poster Presenter: ?brahim Eker, TR</i>	08:30 - 08:30
P299	ALTERNATE DONOR TRANSPLANTATION USING SINGLE-ANTIGEN MISMATCHED GRAFTS – THE IRISH EXPERIENCE <i>Poster Presenter: Alanna Allen, IE</i>	08:30 - 08:30
<i>ePoster</i> 08:30 - 18:00		ePoster Area
Experimental Transplantation and Gene Therapy		
P249	INITIAL FIRST-IN-HUMAN RESULTS: CD33-DELETED HEMATOPOIETIC STEM AND PROGENITOR CELLS DISPLAY NORMAL ENGRAFTMENT AFTER HEMATOPOIETIC CELL TRANSPLANT (HCT) AND TOLERATE POST-HCT GEMTUZUMAB OZOGAMICIN (GO) WITHOUT CYTOPENIAS <i>Poster Presenter: Brenda Cooper, US</i>	08:30 - 08:30
P250	LENTIVIRAL-MEDIATED GENE THERAPY FOR SEVERE PYRUVATE KINASE DEFICIENCY: RESULTS FROM AN ONGOING GLOBAL PHASE 1 STUDY <i>Poster Presenter: Jonathan Schwartz, ES</i>	08:30 - 08:30
P251	LENTIVIRAL-MEDIATED GENE THERAPY FOR PATIENTS WITH FANCONI ANEMIA [GROUP A]: UPDATED RESULTS FROM GLOBAL RP-L102 CLINICAL TRIALS	08:30 - 08:30
P252	FIRST-IN-HUMAN INTRAVENOUS FBX-101 (AAVRH10.HGALC) AFTER UCBT PREVENTS IMMUNE RESPONSE TO VECTOR'S CAPSID AND TRANSGENE, INCREASES GALC ACTIVITY, BRAIN AND MOTOR DEVELOPMENT IN KRABBE DISEASE <i>Poster Presenter: Maria Escolar, US</i>	08:30 - 08:30
P253	CRISPR-BASED TRANSCRIPTIONAL HEMATOPOIETIC STEM CELL EDITING FOR ENHANCED ANTI-LEUKEMIC GRAFT FUNCTION <i>Poster Presenter: Martin Sauer, DE</i>	08:30 - 08:30
P255	HAPLOIDENTICAL STEM-CELL TRANSPLANTATION FOR CHILDREN WITH NON-MALIGNANT DISORDERS, USING ??+ T CELL /CD19+ B-CELL DEPLETION, A SINGLE CENTER EXPERIENCE <i>Poster Presenter: Gal Hai Dadi, IL</i>	08:30 - 08:30
P256	EARLY IN VIVO GENERATION OF V?9V?2 T CELLS AFTER HAPLOIDENTICAL STEM CELL TRANSPLANT WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE: A MONOCENTRIC	08:30 - 08:30

PHASE 1 STUDY*Poster Presenter:* Maxime Jullien, FR

P257	DISCOVERY OF NEOANTIGENS USING ARTIFICIAL INTELLIGENCE (NEO-ARS™) IN AML: A PILOT STUDY	08:30 - 08:30
	<i>Poster Presenter:</i> Su-young Choi, KR	
P258	LOW DOSE OF FLUDARABINE IS AN EFFECTIVE CONDITIONING TREATMENT TO SUPPRESS RELAPSE RATE IN PT-CY-BASED HAPLOIDENTICAL PERIPHERAL BLOOD STEM CELL TRANSPLANTATION	08:30 - 08:30
	<i>Poster Presenter:</i> Jeong A. Kim, KR	
P259	DIFFERENT RECOVERY PATTERNS OF CMV-SPECIFIC AND WT1-SPECIFIC T CELLS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA UNDERGOING ALLO-HSCT: IMPACT OF CMV INFECTION AND LEUKEMIA RELAPSE	08:30 - 08:30
	<i>Poster Presenter:</i> Xiao-Hua Luo, CN	
P260	ANALYSIS OF MARROW INFILTRATING T CELL AT 3 MONTHS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES	08:30 - 08:30
	<i>Poster Presenter:</i> Thi Thuy Duong Pham, KR	
<i>ePoster</i>		
08:30 - 18:00		ePoster Area
CAR-based Cellular Therapy – Preclinical		
P143	INHIBITION OF MITOCHONDRIAL ISOCITRATE DEHYDROGENASE ENHANCES CAR-T CELL IMMUNOTHERAPY BY PROMOTING ANTIOXIDANT ACTIVITY	08:30 - 08:30
	<i>Poster Presenter:</i> Mi Shao, CN	
P144	THE CHOICE OF CO-STIMULATION DETERMINES THE FATE OF CD5 TARGETING CAR-NK CELLS	08:30 - 08:30
	<i>Poster Presenter:</i> May Daher, US	
P145	INHIBITION OF CD38 ENZYMATIC ACTIVITY ENHANCES CAR-T CELL IMMUNOTHERAPEUTIC FUNCTIONS	08:30 - 08:30
	<i>Poster Presenter:</i> Yue Huang, CN	
P146	GENERATION OF EX VIVO AUTOLOGOUS HEMATOPOIETIC STEM CELL-DERIVED T LYMPHOCYTES FOR OFF-THE-SHELF CANCER IMMUNOTHERAPY	08:30 - 08:30
	<i>Poster Presenter:</i> Jakrawadee Julamanee, TH	
P148	BLOCKADE OF CD95/CD95L PATHWAY ENHANCES CAR T CELL PERSISTENCE AND ANTI-TUMOR EFFICACY IN VITRO AND IN VIVO	08:30 - 08:30
	<i>Poster Presenter:</i> Michael Schmitt, DE	
P150	SUPERIOR ANTI-TUMOR EFFICACY OF CD4⁺ CAR-T CELLS IN HEMATOLOGICAL MALIGNANCIES	08:30 - 08:30
	<i>Poster Presenter:</i> Qian Chen, DE	

P151	EXTRACORPOREAL PHOTOPHERESIS CONSTITUTES A PROMISING STRATEGY FOR THE TREATMENT OF GVHD AFTER CAR-T CELL THERAPY <i>Poster Presenter: Huixiu Han, DE</i>	08:30 - 08:30
P152	PROTEASOMAL INHIBITION SENSITIZES AML CELLS TO CAR NK-CELL MEDIATED KILLING <i>Poster Presenter: David Sedloev, DE</i>	08:30 - 08:30
P153	PD-1 CHECKPOINT INHIBITION IMPROVES FUNCTIONALITY OF TOLEROGENTIC CD19-CAR-INKT CELLS AGAINST CD19+ MALIGNANCIES <i>Poster Presenter: Dominik Schneidawind, DE</i>	08:30 - 08:30
P154	INDIGENOUS DEVELOPMENT OF NEXT-GENERATION CAR MOLECULES TO OVERCOME ANTIGEN LOSS AND LIMITED IN-VIVO PERSISTENCE OF CONVENTIONAL CAR-T CELLS, CHALLENGES AND SUCCESSES: INITIAL EXPERIENCE FROM INDIA <i>Poster Presenter: Gaurav Kharya, IN</i>	08:30 - 08:30
P155	CHANGES IN PHENOTYPE OF T CELLS / CD19 CAR-T CELLS IN THE COURSE OF PATIENT TREATMENT <i>Poster Presenter: Jonas Wißkirchen, DE</i>	08:30 - 08:30
P156	A PERSONALIZED BIOMARKER-TARGETED CAR-T THERAPY IS POSSIBLE BASED ON IMMUNOPHENOTYPE FOR ACUTE MYELOID LEUKEMIA PATIENTS <i>Speaker: William Hwang, SG</i>	08:30 - 08:30
P157	NK CELLS ENGINEERING USING ADVANCED LENTIVIRAL VECTORS QUALITY AND DESIGN <i>Poster Presenter: Christine Duthoit, FR</i>	08:30 - 08:30
P158	A NOVEL MULTICOLOR FLUORESCENT SPOT ASSAY FOR THE FUNCTIONAL ASSESSMENT OF CAR T CELL PRODUCTS	08:30 - 08:30
P159	PROCESSING AND CRYOPRESERVATION OF PERIPHERAL BLOOD LEUKAPHERESIS FOR DLI ADMINISTRATION OR CAR-T MANUFACTURING <i>Poster Presenter: Riccardo Saccardi, IT</i>	08:30 - 08:30

ePoster

08:30 - 18:00

ePoster Area

Haematopoietic Stem Cells

P001	AZACYTIDINE MAINTENANCE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IMPROVES OUTCOME IN HIGH RISK MDS AND AML PATIENTS: A PROPENSITY SCORE ANALYSIS FROM THE SFGM-TC <i>Poster Presenter: Ambroise Marçais, FR</i>	08:30 - 08:30
P002	PONATINIB AS A PROPHYLACTIC OR PRE-EMPTIVE STRATEGY TO PREVENT CYTOLOGICAL RELAPSE AFTER ALLO-SCT IN PATIENTS WITH PH-POSITIVE ACUTE	08:30 - 08:30

	LYMPHOBLASTIC LEUKEMIA TRANSPLANTED IN COMPLETE CYTOLOGICAL REMISSION <i>Poster Presenter:</i> Anna Candoni, IT	
P003	COMPARISONS OF SAFETY AND EFFICACY OF ALLO-HSCT AFTER CAR T-CELL OR CHEMOTHERAPY-BASED COMPLETE REMISSION IN PEDIATRIC T-ALL <i>Poster Presenter:</i> Rui-Juan Sun, CN	08:30 - 08:30
P004	RISK FACTORS INFLUENCING TRANSPLANT OUTCOMES OF ADULTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA IN FIRST COMPLETE REMISSION: A RETROSPECTIVE ANALYSIS FROM THE ALWP OF THE EBMT <i>Poster Presenter:</i> Martina Calabrò, FR	08:30 - 08:30
P005	DIAGNOSIS BY LIVER STIFFNESS MEASUREMENT OF VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION: RESULTS FROM THE ITALIAN MULTICENTRIC PROSPECTIVE STUDY (ELASTOVOD) <i>Poster Presenter:</i> Federico Ravaioli, IT	08:30 - 08:30
P006	OUTCOMES OF UPFRONT UNRELATED HEMATOPOIETIC STEM CELL TRANSPLANTATION AND IMMUNOSUPPRESSIVE THERAPY FOR ADULT WITH SEVERE APLASTIC ANEMIA: A MULTICENTER RETROSPECTIVE AND PROPENSITY SCORE-MATCHED STUDY <i>Poster Presenter:</i> Shunqing Wang, CN	08:30 - 08:30
P007	ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN PATIENTS WITH THERAPY-RELATED MYELOID NEOPLASM FOLLOWING TREATMENT FOR LYMPHOMA: A STUDY OF THE CHRONIC MALIGNANCIES WORKING PARTY OF THE EBMT <i>Poster Presenter:</i> Marie Robin, FR	08:30 - 08:30
P009	SMART CONDITIONING WITH VENETOCLAX ENHANCED SEQUENTIAL FLAMSA+ALKYLATOR IN PATIENTS WITH HIGH-RISK MYELOID MALIGNANCIES <i>Poster Presenter:</i> Guido Kobbe, DE	08:30 - 08:30
P010	DONOR-SPECIFIC ANTI-HLA ANTIBODIES (DSAS) IN PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FROM MISMATCHED DONORS, ON BEHALF OF GITMO AND AIBT <i>Poster Presenter:</i> Anna Paola Iori, IT	08:30 - 08:30
P011	IMPROVED OUTCOME OVER TIME AFTER SECOND ALLOGENEIC STEM CELL TRANSPLANTATION IN RELAPSED AML. AN ANALYSIS OF 1540 PATIENTS ON BEHALF OF THE ALWP OF EBMT <i>Poster Presenter:</i> Ann-Kristin Schmaelter, DE	08:30 - 08:30
P012	AKKERMANSIA AS EARLY GUT MICROBIOTA SIGNATURE PROTECT FROM ACUTE GRAFT-VERSUS-HOST DISEASE AND PROMOTE SURVIVAL AFTER ALLOGENEIC HEMATOPOIETIC	08:30 - 08:30

CELL TRANSPLANTATION*Poster Presenter:* He Huang, CN

P013	AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH HIV-RELATED LYMPHOMA: RESULTS OF PROSPECTIVE MULTICENTER MATCHED CASE-CONTROL STUDY <i>Poster Presenter:</i> Marina Popova, RU	08:30 - 08:30
P014	TOWARD A CLINICAL PHENOTYPE INSPIRED DIAGNOSIS OF AUTOIMMUNE MANIFESTATIONS IN VEXAS SYNDROME: A GUIDE TO <i>UBA1</i>-TESTING FOR THE GENERALIST <i>Poster Presenter:</i> Raffaella Greco, IT	08:30 - 08:30
P016	A BIOMARKER-BASED PROGNOSTIC FOR VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME (VOD/SOS) AFTER HEMATOPOIETIC CELL TRANSPLANTATION (HCT) – AN UPDATE ON VALIDATION <i>Poster Presenter:</i> Polly Pine, GB	08:30 - 08:30
P017	HIGHER PROPORTIONS OF MONOCYTIC-MYELOID-DERIVED SUPPRESSIVE CELLS (MMDSC) BEFORE ALLOTRANSPLANT PREDICT RELAPSE IN ACUTE LEUKEMIA PATIENTS <i>Poster Presenter:</i> Pierre Peterlin, FR	08:30 - 08:30
P019	LATE CYTOLOGIC RELAPSE FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA IN ADULT PATIENTS <i>Poster Presenter:</i> Chloé Antier, FR	08:30 - 08:30
P020	DONOR LYMPHOCYTE INFUSION FOR THE TREATMENT OF RELAPSED HEMATOLOGICAL MYELOID MALIGNANCIES: RESULTS OF A RETROSPECTIVE MULTICENTER STUDY FROM THE EBMT REGISTRY <i>Poster Presenter:</i> Louis Dumeignil, FR	08:30 - 08:30
P021	A REAL-WORLD EXPERIENCE IN THE ADEQUATION OF CONDITIONING CHEMOTHERAPY FOR AUTOLOGOUS TRANSPLANTATION IN LYMPHOMA PATIENTS WITHOUT CD34 CRYOPRESERVATION <i>Poster Presenter:</i> Mauricio Sarmiento, CL	08:30 - 08:30
P022	TREOSULFAN BASED CONDITIONING FOR HAEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN PAEDIATRIC MALIGNANT DISORDERS: ON BEHALF OF THE UK PAEDIATRIC BMT GROUP <i>Poster Presenter:</i> Archana Rauthan, GB	08:30 - 08:30
P024	ONE DAY BUSULFAN FOR REDUCED TBF, IN PATIENTS WITH MYELOFIBROSIS OVER THE AGE OF 50: ENCOURAGING LOW TRANSPLANT RELATED MORTALITY AND CONTROL OF MYELOFIBROSIS <i>Poster Presenter:</i> Federica Sorà, IT	08:30 - 08:30
P025	ROLE OF AUTOLOGOUS AND ALLOGENEIC STEM CELL	08:30 - 08:30

	TRANSPLANTATION IN PATIENTS WITH RELAPSED/REFRACTORY T-CELL LYMPHOMAS <i>Poster Presenter:</i> Jihyun Na, KR	
P026	LOSS OF HETEROZYGOSITY (LOH) IN THE HLA REGION IN PEDIATRIC PATIENTS WITH RELAPSE OF HEMATOLOGICAL MALIGNANCIES AFTER HAPLOIDENTICAL HSCT <i>Poster Presenter:</i> Liubov Tsvetkova, RU	08:30 - 08:30
P029	DISEASE STATUS AT TRANSPLANT IS NOT IMPACTING ON LONG TERM SURVIVAL IN PATIENTS WITH ACUTE MYELOID LEUKEMIA ALIVE AT 2 YEARS: ANALYSIS ON 511 PATIENTS <i>Poster Presenter:</i> Maria Teresa Lupo Stanghellini, IT	08:30 - 08:30
P030	THE SARS-COV-2 PANDEMIC DID NOT DISRUPT THE SUPPLY OF HAEMATOPOIETIC STEM CELLS BUT IMPOSED AN UNNECESSARILY HIGH BURDEN ON DONORS: A WMDA REVIEW <i>Poster Presenter:</i> Thilo Mengling, DE	08:30 - 08:30
P031	TBI-BASED <i>VERSUS</i> CHEMOTHERAPY-BASED AMSA/ARA-C CONDITIONING REGIMENS IN PRIMARY REFRACTORY AML – SIGNIFICANTLY WORSE OUTCOMES IN YOUNGER PATIENTS CONDITIONED WITH TBI <i>Poster Presenter:</i> Rama Al Hamed, US	08:30 - 08:30
P032	MOBILE HEALTH IN THE MANAGEMENT OF ALLOGENIC STEM CELL TRANSPLANT RECIPIENTS (MY-MEDULA STUDY): IMPLEMENTATION PHASES AND PILOT STUDY RESULTS <i>Poster Presenter:</i> Sara Redondo, ES	08:30 - 08:30
P033	R-IPSS STRATIFICATION AND SURVIVAL AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MYELODYSPLASTIC SYNDROME <i>Poster Presenter:</i> Fernando Barroso Duarte, BR	08:30 - 08:30
P034	NO EFFECT OF VITAMIN C ADMINISTRATION ON NEUTROPHIL RECOVERY IN AUTOLOGOUS STEM CELL TRANSPLANTATION FOR MYELOMA OR LYMPHOMA: A BLINDED, RANDOMIZED PLACEBO-CONTROLLED TRIAL <i>Poster Presenter:</i> Gwendolyn van Gorkom, NL	08:30 - 08:30
P035	IMPACT OF CELL DOSES ON ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION OUTCOMES <i>Poster Presenter:</i> Luisa Giaccone, IT	08:30 - 08:30
P036	TRAINING IN TRANSPLANTATION AND CELLULAR THERAPY IN LATIN AMERICA: A CROSS-SECTIONAL STUDY OF THE LABMT <i>Poster Presenter:</i> Rafaella Muratori, BR	08:30 - 08:30
P037	LONG-TERM OUTCOME ANALYSIS OF ALLOGENEIC STEM CELL TRANSPLANTATION (ALLOHCT) IN PATIENTS WITH LYMPHOMA: RETROSPECTIVE EXPERIENCE FROM SINGAPORE OVER A 15-YEAR PERIOD	08:30 - 08:30

	<i>Poster Presenter:</i> Jean Catapia, SG	
P038	THROMBOPOIETIN RECEPTOR AGONISTS IMPROVED PLATELET ENGRAFTMENT AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA <i>Poster Presenter:</i> Xiaozhe Li, CN	08:30 - 08:30
P040	PROHYLACTIC DONOR LYMPHOCYTE INFUSION FOR PREVENTION OF RELAPSE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN PATIENTS WITH HIGH-RISK ACUTE LEUKEMIA <i>Poster Presenter:</i> Maria Liga, GR	08:30 - 08:30
P041	GAMMA DELTA T CELLS RECONSTITUTION IN LONG-TERM SURVIVORS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Poster Presenter:</i> Faisal Alagrafi, SE	08:30 - 08:30
P042	SAFETY AND EFFICACY OF ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANT IN INHERITED PLATELET DISORDERS: A SINGLE CENTER EXPERIENCE FROM PAKISTAN <i>Poster Presenter:</i> Saima Humayun Toor, PK	08:30 - 08:30
P043	AN EFFICIENT AND SIMPLE MULTIPARAMETER FLOW CYTOMETRY PROTOCOL TO DETECT MINIMAL RESIDUAL DISEASE (MRD) FOR ACUTE MYELOID LEUKEMIA (AML) <i>Poster Presenter:</i> Hui Wang, CN	08:30 - 08:30
P044	AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR HIGH RISK EWING SARCOMA IN CHILDREN <i>Speaker:</i> Eunsun Song, KP	08:30 - 08:30
P045	IMPACT OF 3 DOSES OF ANTI-SARS-COV-2 MRNA VACCINE ON SEROLOGICAL AND CELLULAR RESPONSES AND CLINICAL INFECTION IN RECIPIENTS OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Poster Presenter:</i> Gabriele Facchin, IT	08:30 - 08:30
P047	INCIDENCE AND RISK FACTORS OF GRAFT FAILURE AFTER CORD BLOOD HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN WITH MUCOPOLYSACCHARIDOSIS : A SFGM-TC RETROSPECTIVE MULTICENTER STUDY <i>Poster Presenter:</i> Laura Danhardt, FR	08:30 - 08:30
P048	RESULTS OF ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN FANCONI ANEMIA: SINGLE-CENTER EXPERIENCE OF 10 YEARS <i>Poster Presenter:</i> Blanca Molina, ES	08:30 - 08:30
P049	HIGH-RISK CYTOKINE PROFILES PREDICT LOWER SURVIVALS IN AML AFTER ALLOTRANSPLANTATION	08:30 - 08:30

	<i>Poster Presenter:</i> Pierre Peterlin, FR	
P050	THE ROLE OF AUTOLOGOUS VERSUS ALLOGENEIC STEM CELL TRANSPLANT FOR RELAPSED OR REFRACTORY PERIPHERAL T CELL LYMPHOMA IN SINGAPORE <i>Poster Presenter:</i> Natasha Fay Anthony, SG	08:30 - 08:30
P051	MYELODYSPLASTIC SYNDROME PATIENT'S JOURNEY TO HEMATOPOIETIC STEM CELL TRANSPLANTATION: SURVEY OF THE LATIN AMERICAN REGISTRY <i>Poster Presenter:</i> Fernando Barroso Duarte, BR	08:30 - 08:30
P052	SAFETY AND FEASIBILITY OF RH-GCSF COMBINED WITH LOW-DOSE DECITABINE AS POST ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT MAINTENANCE THERAPY FOR HIGH-RISK MYELOID NEOPLASM <i>Poster Presenter:</i> Hassan Alkhateeb, US	08:30 - 08:30
P053	EARLY-TO-MODERATE STAGE CHRONIC KIDNEY DISEASE IMPACT ON HOSPITALIZATION OUTCOMES IN ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS: A NATIONWIDE ANALYSIS USING THE NATIONAL INPATIENT SAMPLE DATABASE <i>Poster Presenter:</i> Moazzam Shahzad, US	08:30 - 08:30
P054	PROGNOSTIC IMPACT OF LOW SERUM MAGNESIUM LEVELS IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Poster Presenter:</i> Zeynep Arzu Ye?in, TR	08:30 - 08:30
P056	5-AZACITIDINE MAINTENANCE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT FOR PATIENTS WITH HIGH RISK AML AND MDS <i>Poster Presenter:</i> Bruna Puglisi, IT	08:30 - 08:30
P057	SECOND ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA: RESULTS OF A TRANSPLANT CENTER WITH A LONG-FOLLOW UP COHORT <i>Poster Presenter:</i> Irati Ormazabal Vélez, ES	08:30 - 08:30
P058	NO EVIDENCE FOR IMPROVED OVERALL SURVIVAL OR PROGRESSION-FREE SURVIVAL IN MULTIPLE MYELOMA PATIENTS AGED 70-75 UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION COMPARED TO A NON-TRANSPLANT STRATEGY <i>Poster Presenter:</i> Laurent Garderet, FR	08:30 - 08:30
P059	THE EFFECTIVENESS OF A PREHABILITATION PHYSIOTHERAPY SERVICE FOR PATIENTS UNDERGOING HAEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) AND CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY (CAR-T) <i>Poster Presenter:</i> Evelyn Evans, GB	08:30 - 08:30
P061	LOW DOSE ALEMTUZUMAB FOR GRAFT VERSUS HOST	08:30 - 08:30

	DISEASE PROPHYLAXIS IN MATCHED SIBLING DONOR HEMATOPOIETIC CELL TRANSPLANTATION <i>Poster Presenter: Maria Liga, GR</i>	
P062	COMPARABLE OUTCOMES OF ALLOGENEIC PERIPHERAL BLOOD VERSUS BONE MARROW HEMATOPOIETIC STEM CELL TRANSPLANTATION FROM A SIBLING DONOR FOR PEDIATRIC PATIENTS <i>Poster Presenter: Bo Kyung Kim, KR</i>	08:30 - 08:30
P063	DAY+120 CD4 OR CD 19 LYMPHOPENIA IS ASSOCIATED WITH INFERIOR SURVIVAL AND INCREASE NRM FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION	08:30 - 08:30
P064	EFFECT OF AUTOLOGOUS STEM CELL TRANSPLANTATION ON SUBSEQUENT TREATMENT AFTER FIRST RELAPSE IN PATIENTS WITH MULTIPLE MYELOMA	08:30 - 08:30
P065	VIABILITY OF HAEMATOPOIETIC STEM CELLS – FROM LABORATORY TO BEDSIDE <i>Poster Presenter: Tanya Nadia Glatt, ZA</i>	08:30 - 08:30
P068	CRP/ALBUMIN RATIO MAY PREDICT SURVIVAL AND NON RELAPSE MORTALITY IN AML/MDS PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Poster Presenter: Zeynep Arzu Ye?in, TR</i>	08:30 - 08:30
P069	THE ADDITION OF THIOTEPA TO HAPLO HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR THE TREATMENT OF ACUTE LEUKEMIA WITH EXTRAMEDULLARY LESIONS IS SAFE AND EFFECTIVE <i>Poster Presenter: Wei Zhao, CN</i>	08:30 - 08:30
P070	ROLE OF INTERFERON-GAMMA IN POST-ALLOGENEIC HSCT COMPLICATIONS AND IN PATIENTS WITH IMPAIRED HAEMATOPOIETIC STEM CELL PROLIFERATION AT DIAGNOSIS: PROSPECTIVE CLINICAL STUDY DESIGN <i>Poster Presenter: Régis Peffault de Latour, FR</i>	08:30 - 08:30
P071	THE CRYOPRESERVATION MEDIA USED FOR PRESERVING CD34+ STEM CELLS INFLUENCES THE CELL COUNT, SURVIVAL AND APOPTOSIS OF THESE CELLS POST-THAWING <i>Poster Presenter: Lyda M Osorio Fernandez, SE</i>	08:30 - 08:30
P072	IN VIVO EVIDENCE IN FAVOR OF BETTER MYELOID ENGRAFTMENT FOLLOWING AMNIOTIC FLUID ADMINISTRATION IN A XENOGENIC MOUSE CORD BLOOD TRANSPLANTATION MODEL <i>Poster Presenter: Meral Beksac, TR</i>	08:30 - 08:30
P074	SHARED TRANSPLANT <i>Poster Presenter: Anabelle Chinaea, ES</i>	08:30 - 08:30
P075	PRETRANSPLANT MYELOID AND IMMUNE SUPPRESSION	08:30 - 08:30

(PMIS) FOR THALASSEMIA PATIENTS RECEIVING MATCHED RELATED DONOR ALLOGRAFT		
P076	THE ROLE OF SECOND ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION OVER THE YEARS: SINGLE-CENTER EXPERIENCE <i>Poster Presenter: Cristina García Herce, ES</i>	08:30 - 08:30
P078	IMPACT OF ABO INCOMPATIBILITY ON THE OUTCOME OF HEMATOPOIETIC STEM CELL TRANSPLANTATION-A SINGLE CENTER STUDY FROM PAKISTAN <i>Poster Presenter: Munira Borhany, PK</i>	08:30 - 08:30
P080	PRECLINICAL VALIDATION OF FULLY-AUTOMATED WASHING OF THAWED PERIPHERAL BLOOD STEM CELLS (PBSC) WITH SUCCINYLATED GELATINE <i>Poster Presenter: Riccardo Saccardi, IT</i>	08:30 - 08:30
P081	PEDIATRIC ALLOGENEIC STEM CELL TRANSPLANTATION: A REPORT OF 30 YEARS OF A SINGLE CENTER'S EXPERIENCE <i>Poster Presenter: Charline Pegon, FR</i>	08:30 - 08:30
P082	RENAL OUTCOME AND POSSIBLE ASSOCIATIONS IN SICKLE CELL PATIENTS WITH STEM CELL TRASPLANT IN OUR CENTER: A RETROSPECTIVE STUDY <i>Poster Presenter: Jose Manuel Marco Sanchez, ES</i>	08:30 - 08:30
P083	ESTABLISHING A PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION PROGRAM IN A LIMITED-RESOURCES COUNTRY: A SUCCESSFUL JOURNEY IN A UNIVERSITY CENTER	08:30 - 08:30
P084	HIGH RATE OF COMPLETE HEMATOPOIETIC RECOVERY FOLLOWING CD34+ SELECTED STEM CELL BOOST IN ALLO-HSCT RECIPIENTS WITH PERSISTENT POOR GRAFT FUNCTION <i>Poster Presenter: Nerea Castillo, ES</i>	08:30 - 08:30
P086	DESCRIPTION OF THE ACTIVITY OF BONE MARROW TRANSPLANTATION IN A COLOMBIAN BMT UNIT: A SINGLE CENTER EXPERIENCE <i>Poster Presenter: Jorge Cuervo-Sierra, CO</i>	08:30 - 08:30
P087	PLERIXAFOR IN AUTOLOGOUS STEM CELL TRANSPLANTATION: DOES IT AFFECT ENGRAFTMENT KINETICS?	08:30 - 08:30
P088	HEMATOPOIETIC STEM CELL TRANSPLANTS AND TREATMENT OF SEVERE BLOOD DISORDERS: ROLE OF PROVIDERS IN MEDICAL TOURISM <i>Poster Presenter: Deepika Khanna, US</i>	08:30 - 08:30
P089	MACROPHAGE ACTIVATION SYNDROME AND TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY: A RETROSPECTIVE/PROSPECTIVE SINGLE CENTER STUDY	08:30 - 08:30

	<i>Poster Presenter:</i> Giuseppe Sapienza, IT	
P090	A SUCCESSFUL OUTCOME OF DONOR-SPECIFIC ANTIBODIES MITIGATION IN HAEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Poster Presenter:</i> Sreejith Ramachandrakurup, GB	08:30 - 08:30
P091	ALLOGENEIC STEM CELL TRANSPLANTATION IN PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA: TUNISIAN EXPERIENCE <i>Poster Presenter:</i> Nour Ben Abdeljelil, TN	08:30 - 08:30
P092	HLA LOSS RELAPSE DETECTION APPLYING NGS-BASED HLA TYPING: PRELIMINARY RESULTS OF A PROSPECTIVE STUDY <i>Poster Presenter:</i> Marta Canelo-Vilaseca, ES	08:30 - 08:30
P093	HSCT ACTIVITY IN A SINGLE CENTER OF BANGLADESH <i>Poster Presenter:</i> Abu Jafar Saleh, BD	08:30 - 08:30
P095	HAEMATOPOIETIC STEM CELL TRANSPLANTATION: SUPPORT AND EXPECTATIONS' PATIENTS FOR PATIENTS <i>Poster Presenter:</i> Claudia L. Sossa, CO	08:30 - 08:30
P096	EFFECT OF PHARMACOKINETICS AND PHARMACOGENOMICS IN ADULTS WITH ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION CONDITIONED WITH BUSULFAN <i>Poster Presenter:</i> Claire Seydoux, CH	08:30 - 08:30
P097	SUCCESSFUL TREATMENT WITH GRANULOCYTE TRANSFUSION AND EARLY NEUTROPHIL ENGRAFTMENT IN ALLOGENEIC TRANSPLANT PATIENTS WITH FEBRILE NEUTROPENIA; DOES GRANULOCYTE TRANSFUSION SHORTEN THE NEUTROPHIL ENGRAFTMENT TIME? <i>Poster Presenter:</i> Ali Unal, TR	08:30 - 08:30
P098	OUTCOMES OF ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN PAEDIATRIC PATIENTS WITH MALIGNANT DISEASES IN ARGENTINA: IMPACT OF HLA MISMATCH <i>Poster Presenter:</i> Silvia Mariana Pizzi, AR	08:30 - 08:30
P099	RESULTS OF ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR RELAPSED AND REFRACTORY ACUTE LEUKEMIA: SINGLE CENTER EXPERIENCE <i>Poster Presenter:</i> Irina Kostareva, RU	08:30 - 08:30
P100	MANAGEMENT OF ADULT PATIENTS UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION IN AN OUT-PATIENT SETTING, THE EXPERIENCE OF THE VENEZUELAN PUBLIC TRANSPLANT CENTER "DR. ABRAHAM SUMOZA" <i>Poster Presenter:</i> Laura Saavedra, VE	08:30 - 08:30
P101	NON TBI BASED T CELL REplete HAPLO-IDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH POST TRANSPLANT CYCLOPHOSPHAMIDE – EARLY EXPERIENCE FROM A NEWLY ESTABLISHED CENTER IN INDIA	08:30 - 08:30

	<i>Poster Presenter:</i> Divya Doval, IN	
P103	SUCCESSFUL HAPLO-IDENTICAL HSCT FOR HODGKIN LYMPHOMA AFTER 4TH RELAPSE <i>Poster Presenter:</i> Abu Jafar Saleh, BD	08:30 - 08:30
<i>ePoster</i> 08:30 - 18:00		ePoster Area
Lymphoma and Chronic Lymphocytic Leukaemia		
P769	ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IS EFFECTIVE FOR PATIENTS WITH ADULT T CELL LEUKEMIA/ LYMPHOMA AND CAN ERADICATE HTLV-1 INFECTION: A RETROSPECTIVE MONOCENTRIC STUDY <i>Poster Presenter:</i> Ambroise Marçais, FR	08:30 - 08:30
P770	VENETOCLAX, CHIDAMIDE, AND DECITABINE AS A BRIDGING THERAPY IN RELAPSED/REFRACTORY T LYMPHOBLASTIC CELL LYMPHOMAS WITH LARGE MEDIASTINAL MASSES PRIOR TO CD7 CAR-T CELL THERAPY <i>Poster Presenter:</i> Lefu Huang, CN	08:30 - 08:30
P771	EXCELLENT SURVIVAL AFTER ALLOGENEIC HAEMATOPOIETIC CELL TRANSPLANTATION IN PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA IN THE ERA OF IMMUNOTHERAPY <i>Poster Presenter:</i> Anna Czyz, PL	08:30 - 08:30
P772	IDENTIFICATION OF PULMONARY AND CLINICAL RISK FACTORS IN PATIENTS WITH LYMPHOMA CONDITIONED WITH BEAM AND TEAM BEFORE AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Poster Presenter:</i> Radu-Florian Gherman, DE	08:30 - 08:30
P773	LIQUID BIOPSY BY ULTRA-DEEP SEQUENCING MONITORING IMPROVES EARLY RELAPSE DETECTION AFTER CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY IN FOLLICULAR LYMPHOMA PATIENTS <i>Poster Presenter:</i> Maria Calbacho Robles, ES	08:30 - 08:30
P774	OUTCOME OF HIGH DOSE CHEMOTHERAPY FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION IN RELAPSED/REFRACTORY HODGKIN LYMPHOMA ACHIEVING DISEASE RESPONSE AFTER DIFFERENT NUMBERS OF SALVAGE REGIMENS <i>Poster Presenter:</i> Chiara de Philippis, IT	08:30 - 08:30
P775	ENCOURAGING OUTCOMES IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR RELAPSED/REFRACTORY LYMPHOMA PATIENTS: EFFICACY OF A NEW INTENSIFIED APPROACH USING LYMPHOMA-ORIENTED CHEMOTHERAPY AND REDUCED-INTENSITY CONDITIONING REGIMEN <i>Poster Presenter:</i> Mizuki Watanabe, JP	08:30 - 08:30

P776	AUTOLOGOUS VERSUS ALLOGENEIC STEM CELL TRANSPLANTATION IN PATIENTS WITH ANGIO-IMMUNOBLASTIC T-CELL LYMPHOMA <i>Poster Presenter:</i> Mesire Aydin, NL	08:30 - 08:30
P778	IMPACT OF THIOTEPA DOSE-INTENSITY IN PATIENTS WITH PRIMARY LARGE B-CELL LYMPHOMA OF THE CENTRAL NERVOUS SYSTEM (PCNSL) UNDERGOING AUTOLOGOUS TRANSPLANTATION (AUTOHCT) WITH THIOTEPA/CARMUSTINE (TT-BCNU) CONDITIONING <i>Poster Presenter:</i> Shanze Arshad, US	08:30 - 08:30
P779	AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION FOR MARGINAL ZONE LYMPHOMAS – MULTICENTER ANALYSIS BY THE POLISH LYMPHOMA RESEARCH GROUP <i>Poster Presenter:</i> Joanna Drozd-Sokolowska, PL	08:30 - 08:30
P780	THE OUTCOME OF PATIENTS WITH MANTLE CELL LYMPHOMA AFTER HIGH DOSE CHEMOTHERAPY FOLLOWED AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION AT A SINGLE INSTITUTION BETWEEN 2005-2021 <i>Poster Presenter:</i> Joanna Romejko Jarosinska, PL	08:30 - 08:30
P782	T DEplete ALLOGENEIC HAEMATOPOETIC STEM CELL TRANSPLANT FOR RELAPSED/REFRACTORY HODGKIN'S LYMPHOMA: HIGH RATES OF RESPONSE POST TRANSPLANT EVEN IN THE SETTING OF PRE TRANSPLANT RESIDUAL DISEASE <i>Poster Presenter:</i> Emma Nicholson, GB	08:30 - 08:30
P783	INTERIM REPORT OF A STUDY OF SAFETY AND EFFICACY OF PET-ADAPTED TREATMENT WITH NICE-40 IN PATIENTS WITH RELAPSED/REFRACTORY HODGKIN LYMPHOMA (NCT04981899) <i>Poster Presenter:</i> Andrey Chekalov, RU	08:30 - 08:30
P784	ALLOGENEIC TRANSPLANTATION AFTER ADOPTIVE IMMUNOTHERAPY AND CHECKPOINT INHIBITOR FOR RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA <i>Poster Presenter:</i> Chiara de Philippis, IT	08:30 - 08:30
P785	FLUDARABINE-MELPHALAN-CAMPATH FOLLOWED BY UNMANIPULATED PERIPHERAL-BLOOD HAEMATOPOIETIC STEM CELLS CAN STILL CURE LYMPHOMA. THE KING'S COLLEGE HOSPITAL 10 YEARS' EXPERIENCE IN RELAPSED AND REFRACTORY LYMPHOMAS <i>Poster Presenter:</i> Daniele Avenoso, GB	08:30 - 08:30
P787	HAPLOIDENTICAL STEM CELL TRANSPLANTATION IN CUTANEOUS T-CELL LYMPHOMAS: A MONOCENTRIC RETROSPECTIVE STUDY <i>Poster Presenter:</i> Fabio Serpenti, IT	08:30 - 08:30
P788	AUTO-HSCT AND ALLO-HSCT IN THE TREATMENT OF PATIENTS WITH PERIPHERAL T-CELL LYMPHOMAS:	08:30 - 08:30

	MULTICENTER EXPERIENCE OF RUSSIA AND KAZAKHSTAN <i>Poster Presenter:</i> Elena Lepik, RU	
P789	RELAPSED OR REFRACTORY DOUBLE-EXPESSOR DIFFUSE LARGE B-CELL LYMPHOMAS ARE ASSOCIATED WITH INFERIOR SURVIVAL OUTCOMES AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION - A SINGLE CENTRE EXPERIENCE <i>Poster Presenter:</i> Cindy Krisnadi, SG	08:30 - 08:30
P790	ALLOGENEIC HEMATOPOETIC STEM CELL TRANSPLANT FOR PATIENTS WITH ADVANCED T-CELL-NON-HODGKIN LYMPHOMAS <i>Poster Presenter:</i> Radwan Massoud, DE	08:30 - 08:30
P791	ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN RELAPS/REFRACTORY LYMPHOMA PATIENTS: A SINGLE CENTER EXPERIENCE <i>Poster Presenter:</i> Pervin Topçuo?lu, TR	08:30 - 08:30
P792	IMPROVED SURVIVAL OUTCOMES OF AUTOLOGOUS STEM CELL TRANSPLANTATION IN RELAPSED/REFRACTER HODGKIN'S LYMPHOMA IN THE BRENTUXIMAB VEDOTIN ERA REAL WORLD DATA FROM HUNGARY <i>Poster Presenter:</i> Zsófia Miltényi, HU	08:30 - 08:30
P793	FAVORABLE OUTCOME OF PATIENTS WITH HL AND NHL UNDERGOING ALLOGENEIC HCT: A SINGLE CENTER EXPERIENCE FROM SAUDI ARABIA <i>Poster Presenter:</i> Mohsen Alzahrani, SA	08:30 - 08:30
P794	ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH ANAPLASTIC LARGE CELL LYMPHOMA (ALK+) <i>Speaker:</i> Polina Tolkunova, RU	08:30 - 08:30
P795	EFFICACY AND SAFETY OF BRENTUXIMAB VEDOTINE AS A SALVAGE TREATMENT BEFORE AUTOLOGOUS SCT IN PATIENTS WITH RELAPSED AND REFRACTORY HODGKIN LYMPHOMA- UKRAINIAN EXPERIENCE <i>Poster Presenter:</i> Kateryna Filonenko, PL	08:30 - 08:30
P796	SUCCESSFUL TREATMENT OF CNS LYMPHOMA WITH HIGH DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE <i>Poster Presenter:</i> Isik Kaygusuz Atagündüz, TR	08:30 - 08:30
P797	A COMPREHENSIVE ANALYSIS OF RELAPSE PATTERN IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA AFTER CHEMOIMMUNOTHERAPY USING NATIONAL HEALTH INSURANCE DATABASE OF SOUTH KOREA <i>Poster Presenter:</i> Hyun Jung Lee, KR	08:30 - 08:30
P798	DO GWAS-IDENTIFIED RISK VARIANTS FOR CHRONIC LYMPHOCYTIC INFLUENCE OVERALL PATIENT SURVIVAL? <i>Poster Presenter:</i> Antonio José Cabrera-Serrano, ES	08:30 - 08:30

P799	AUTOLOGOUS STEM CELL TRANSPLANTATION IN RELAPSED OR REFRACTORY B-NON-HODGKIN LYMPHOMA - A RETROSPECTIVE SINGLE-CENTER EXPERIENCE OF LONG TERM OUTCOME AND DEVELOPMENT OVER TWO DECADES	08:30 - 08:30
P800	COMPLETE REMISSION AFTER RELAPSE FOLLOWING ALLOGENIC STEM CELL TRANSPLANTATION IN A PATIENT WITH PERIPHERAL T NON-HODGKIN LYMPHOMA UNDERGOING EXTRACORPOREAL PHOTOPHERESIS <i>Poster Presenter: Igor Age Kos, DE</i>	08:30 - 08:30
<i>ePoster</i> 08:30 - 18:00		ePoster Area
CAR-based Cellular Therapy – Clinical		
P161	PROPHYLACTIC CORTICOSTEROID USE WITH AXICABTAGENE CILOLEUCEL (AXI-CEL) IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA (R/R LBCL): 2-YEAR FOLLOW-UP OF ZUMA-1 COHORT 6 <i>Poster Presenter: Olalekan O. Oluwole, US</i>	08:30 - 08:30
P162	TREATMENT OF SYSTEMIC SCLEROSIS AND ANTI-SYNTHEASE SYNDROME WITH CD19-CAR T CELLS <i>Poster Presenter: Fabian Müller, DE</i>	08:30 - 08:30
P163	THIRD-GENERATION CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS IN ADULT ALL PATIENTS <i>Poster Presenter: Michael Schmitt, DE</i>	08:30 - 08:30
P164	ASSOCIATION OF METABOLIC TUMOR VOLUME (MTV) AND CLINICAL OUTCOMES IN SECOND-LINE RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA FOLLOWING AXICABTAGENE CILOLEUCEL (AXI-CEL) VERSUS STANDARD-OF-CARE (SOC) THERAPY IN ZUMA-7 <i>Poster Presenter: Olalekan O. Oluwole, US</i>	08:30 - 08:30
P165	SUBGROUP ANALYSES OF BREXUCABTAGENE AUTOLEUCEL (BREXU-CEL), AN ANTI-CD19 CAR T-CELL THERAPY, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (R/R B-ALL) IN ZUMA-3 <i>Poster Presenter: Bijal D. Shah, US</i>	08:30 - 08:30
P166	TORQUE TENO VIRUS PLASMA DNA LOAD: A NOVEL PROGNOSTIC BIOMARKER IN CAR-T THERAPY <i>Poster Presenter: Rafael Hernani, ES</i>	08:30 - 08:30
P167	OUTCOMES OF SUBSEQUENT ANTI-LYMPHOMA THERAPIES IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA (LBCL) TREATED WITH AXICABTAGENE CILOLEUCEL (AXI-CEL) OR STANDARD OF CARE (SOC); ZUMA-7) <i>Poster Presenter: Olalekan O. Oluwole, US</i>	08:30 - 08:30
P168	IMMUNE RECONSTITUTION AND INFECTIONS AFTER TREATMENT WITH COMMERCIAL CAR-T CELL THERAPY	08:30 - 08:30

	<i>Poster Presenter:</i> Eva Catalá, ES	
P169	OUTCOMES AFTER ANTI-BCMA CAR T-CELLS FOR MULTIPLE MYELOMA, A RETROSPECTIVE ANALYSIS ON BEHALF OF THE CTIWP OF THE EBMT <i>Poster Presenter:</i> Florent Malard, FR	08:30 - 08:30
P170	REAL-WORLD EXPERIENCE OF TISAGENLEUCEL FOR CHILDREN, ADOLESCENTS AND YOUNG ADULTS WITH ALL IN JAPAN <i>Poster Presenter:</i> Itaru Kato, JP	08:30 - 08:30
P171	3-YEAR FOLLOW-UP ANALYSIS OF ZUMA-5: A PHASE 2 STUDY OF AXICABTAGENE CILOLEUCEL (AXI-CEL) IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) INDOLENT NON-HODGKIN LYMPHOMA (INHL) <i>Poster Presenter:</i> Olalekan O. Oluwole, US	08:30 - 08:30
P173	POINT-OF-CARE CART MANUFACTURE AND DELIVERY FOR THE TREATMENT OF MULTIPLE MYELOMA AND AL AMYLOIDOSIS: THE EXPERIENCE OF HADASSAH MEDICAL CENTER <i>Poster Presenter:</i> Miri Assayag, IL	08:30 - 08:30
P175	MODIFIED EASIX PREDICTS DISSEMINATED INTRAVASCULAR COAGULOPATHY, CRS AND PROGNOSIS IN PATIENTS TREATED WITH ANTI-CD19 CAR-T CELLS <i>Poster Presenter:</i> Eugenio Galli, IT	08:30 - 08:30
P177	ADOPTION OF BENDAMUSTINE LYMPHODEPLETION AS STANDARD OF CARE IN SETTING OF DRUG SHORTAGES <i>Poster Presenter:</i> Richard Maziarz, US	08:30 - 08:30
P178	EFFICACY AND TOXICITY FOR CD7 CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY T-CELL LYMPHOMA <i>Speaker:</i> Fan Yang, CN	08:30 - 08:30
P179	EARLY POST-CAR-T MARKERS OF PROGRESSION, DESPITE CONCOMITANT PET REMISSION: A MONOCENTRIC EXPERIENCE IN THE SETTING OF AGGRESSIVE B-CELL LYMPHOMA <i>Poster Presenter:</i> Massimiliano Gambella, IT	08:30 - 08:30
P180	BREXUCABTAGENE AUTOLEUCEL FOR ADULT PATIENTS WITH REFRACTORY/RELAPSED ACUTE LYMPHOBLASTIC LEUKEMIA: COST-EFFECTIVENESS IN THE CLINICAL SUBSETS <i>Poster Presenter:</i> Monia Marchetti, IT	08:30 - 08:30
P181	OPTIMIZING MULTITARGET APPROACH IN THE PEDIATRIC PATIENT: NEW PERSPECTIVES OF DUAL CD19/CD22 CAR-T <i>Poster Presenter:</i> Víctor Galán-Gómez, ES	08:30 - 08:30
P182	SEQUENTIAL BIRD REGIMEN FOLLOWED BY ANTI-BCMA CAR T-CELL IMMUNOTHERAPY FOR NEWLY DIAGNOSED	08:30 - 08:30

MULTIPLE MYELOMA*Poster Presenter:* Yue Zhou, CN

P183	RETROSPECTIVE MULTICENTRIC COMPARISON OF OUT-OF-SPECIFICATION AND STANDARD-OF-CARE TISAGENLEUCEL INFUSION FOR DIFFUSE LARGE B-CELL LYMPHOMA	08:30 - 08:30
P184	MANAGEMENT OF CRS AND ICANS WITH SILTUXIMAB AND ANAKINRA: A SYSTEMATIC REVIEW OF EVIDENCE TO INFORM SIES-GITMO-SIDEM RECOMMENDATIONS <i>Poster Presenter:</i> Monia Marchetti, IT	08:30 - 08:30
P185	EFFICACY OF EARLY LYMPHOPHERESIS TO IMPROVE CAR-T FITNESS AND PATIENT'S OUTCOMES IN HIGH RISK LARGE B CELL LYMPHOMA- A SINGLE CENTER, OPEN-LABEL PROSPECTIVE STUDY <i>Poster Presenter:</i> Ron Ram, IL	08:30 - 08:30
P186	A REAL-WORLD ANALYSIS OF CAR T-CELL CANCELLATIONS FROM A CANADIAN CELL THERAPY REFERRAL CENTRE <i>Poster Presenter:</i> Eshrak Al-Shaibani, CA	08:30 - 08:30
P187	EASIX AS A PREDICTOR INDEX FOR NEUROLOGICAL COMPLICATIONS AFTER ANTI-CD19 CAR-T CELL THERAPY IN AGGRESSIVE B-CELL LYMPHOMAS: A STUDY FROM THE GETH-TC GROUP <i>Poster Presenter:</i> Marta Peña Domingo, ES	08:30 - 08:30
P188	OUTCOMES OF CAR-T CELL THERAPY FOR LARGE B CELL LYMPHOMA IN PATIENTS OF 70 YEARS AND OLDER: MULTICENTRIC REAL WORLD EXPERIENCE <i>Poster Presenter:</i> Rebeca Bailen, ES	08:30 - 08:30
P189	CORRELATION OF CAR-T EXPANSION WITH EARLY TUMOR RESPONSE AND TOXICITY OF CD19 CAR T THERAPY AMONG CHILDREN WITH RELAPSED/REFRACTORY B-ALL <i>Poster Presenter:</i> Dmitriy Pershin, RU	08:30 - 08:30
P190	CELL AND GENE THERAPY FOR SOLID TUMORS <i>Poster Presenter:</i> Patrizia Comoli, IT	08:30 - 08:30
P192	PREDICTIVE ROLE OF PRE-LYMPHODEPLETION ALC/AMC RATIO IN PEDIATRIC PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA RECEIVING CAR T-CELL THERAPY <i>Poster Presenter:</i> Hannah Lust, US	08:30 - 08:30
P193	CAR-T CELL DYNAMICS ARE ASSOCIATED WITH CLINICAL OUTCOME IN PATIENTS TREATED WITH ANTI-CD19 CAR-T CELL THERAPY FOR RELAPSED/REFRACTORY B-CELL MALIGNANCIES: A REAL-LIFE COHORT STUDY <i>Poster Presenter:</i> Maddalena Noviello, IT	08:30 - 08:30
P194	MANUFACTURING OF CAR T CELLS FROM PATIENTS WITH	08:30 - 08:30

AUTO-IMMUNE DISEASES*Poster Presenter:* Michael Aigner, DE

- | | | |
|------|---|---------------|
| P195 | LISOCABTAGENE MARALEUCEL FOR RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA: FEASIBILITY, SAFETY AND EFFICACY IN A REAL-WORLD SETTING
<i>Poster Presenter:</i> Andrew Portuguese, US | 08:30 - 08:30 |
| P196 | LONG TERM IMMUNE RECONSTITUTION AFTER CD19 CAR-T CELL THERAPY IN THE REAL WORLD PRACTICE
<i>Speaker:</i> Maria Teresa Lupo Stanghellini, IT | 08:30 - 08:30 |
| P198 | COMMERCIAL MANUFACTURING EXPERIENCE OF AXICABTAGENE CILOLEUCEL DELIVERY IN EUROPE: FROM THE FIRST 2 YEARS TO THE LATEST 2 YEARS
<i>Poster Presenter:</i> Harry W. Smith, US | 08:30 - 08:30 |
| P199 | DEVELOPING IN-HOUSE, POINT-OF-CARE MANUFACTURED ANTI-CD19 CHIMAERIC ANTIGEN RECEPTOR (CAR)-T CELLS
<i>Poster Presenter:</i> Nelson Chun Ngai Chan, GB | 08:30 - 08:30 |
| P200 | OUTCOMES FOR ANTI-CD19+ CHIMERIC ANTIGEN RECEPTOR T (CAR-T) CELL THERAPY FOR NON HODGKIN LYMPHOMA (NHL) ACROSS A LARGE COMMUNITY TRANSPLANT AND CELLULAR THERAPY NETWORK
<i>Poster Presenter:</i> Minoo Battiwalla, US | 08:30 - 08:30 |
| P201 | OUTCOMES OF IDECABTAGENE VICLEUCEL IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA PREVIOUSLY TREATED WITH BELANTAMAB MAFODOTIN
<i>Poster Presenter:</i> Megan Melody, US | 08:30 - 08:30 |
| P202 | DURABLE RESPONSES FOLLOWING CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA AFTER MULTIPLE LINES OF TREATMENT: THE HELLENIC REAL-WORLD EXPERIENCE
<i>Poster Presenter:</i> Vasiliki Bampali, GR | 08:30 - 08:30 |
| P203 | BREXUCABTAGENE AUTOLEUCEL FOR ADULT PATIENTS WITH B-ACUTE LYMPHOBLASTIC LEUKEMIA - THE ITALIAN REAL LIFE FROM THE COMPASSIONATE USE PROGRAM
<i>Poster Presenter:</i> Eugenio Galli, IT | 08:30 - 08:30 |
| P205 | VIRAL REACTIVATION AFTER CAR-T CELL THERAPY: ACTIVE SURVEILLANCE, PROPHYLAXIS AND TREATMENT STRATEGIES
<i>Poster Presenter:</i> Raffaella Greco, IT | 08:30 - 08:30 |
| P206 | OUTCOMES WITH AXICABTAGENE CILOLEUCEL IN RELAPSE/REFRACTORY FOLLICULAR LYMPHOMA: PILOT STUDY OF A NOVEL COMPOSITE ENDPOINT OF TOXICITY AND PROGRESSION-FREE SURVIVAL
<i>Poster Presenter:</i> Razan Mohty, US | 08:30 - 08:30 |

P208	CYTOKINE-BASED MODELS FOR EFFICIENT DIFFERENTIATION OF INFECTION AND CYTOKINE RELEASE SYNDROME IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES	08:30 - 08:30
P209	CAR-T CELL EXPANSION DYNAMICS AND THEIR CLINICAL IMPLICATIONS IN LYMPHOMA PATIENTS TREATED WITH AXICABTAGEN CILOLEUCEL AND TISAGENLECLEUCEL <i>Poster Presenter: Eva Catalá, ES</i>	08:30 - 08:30
P210	FROM MNC COLLECTION TO CAR T CELL INFUSION: EXPERIENCE OF A CELLULAR THERAPY CENTRE <i>Poster Presenter: Susana Roncon, PT</i>	08:30 - 08:30
P211	ACCESS BARRIERS FOR ANTI-CD19+ CHIMERIC ANTIGEN RECEPTOR T (CAR-T) CELL THERAPY FOR NON-HODGKIN LYMPHOMA (NHL) ACROSS A LARGE COMMUNITY TRANSPLANT AND CELLULAR THERAPY NETWORK <i>Poster Presenter: Minoo Battiwalla, US</i>	08:30 - 08:30
P212	ADDITION OF NIVOLUMAB TO ANTI-CD-19 CAR-T CELLS IN PATIENTS WITH STABLE/PROGRESSIVE DLBCL AT LYMPHODEPLETION – A SINGLE ARM, PHASE 2, PROSPECTIVE INTERVENTIONAL STUDY <i>Poster Presenter: Ron Ram, IL</i>	08:30 - 08:30
P213	COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSES OF AXICABTAGENE CILOLEUCEL VS SALVAGE CHEMOTHERAPY IN ADULTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA FROM SINGAPORE'S HEALTHCARE SYSTEM PERSPECTIVE <i>Poster Presenter: Tza Kai Diong, SG</i>	08:30 - 08:30
P215	POSSIBLE EFFECT OF PRE CAR-T RADIOTHERAPY ON TIME-TO-RELAPSE: A MONOCENTRIC EXPERIENCE <i>Poster Presenter: Massimiliano Gambella, IT</i>	08:30 - 08:30
P216	CD19 CAR-T-CELL THERAPY IN POST HSCT RELAPSE OF MIXED PHENOTYPE ACUTE LEUKEMIA (MPAL) WITH PHENOTYPIC LINEAGE SWITCH FROM MYELOID TO LYMPHOID CLONE <i>Poster Presenter: Aleksandra Oszer, PL</i>	08:30 - 08:30
P217	VALIDATION OF DIGITAL PCR-BASED MONITORING OF TISAGENLECLEUCEL EXPANSION AND PERSISTENCE IN CLINICAL SAMPLES - A SINGLE CENTRE EXPERIENCE IN SINGAPORE <i>Poster Presenter: Hein Than, SG</i>	08:30 - 08:30
P218	BREXUCABTAGENE AUTOLEUCEL THERAPY FOR ADULT PATIENTS AFFECTED BY RELAPSED/ REFRACTORY B-ACUTE LYMPHOBLASTIC LEUKEMIA: THE ITALIAN REAL LIFE EXPERIENCE IN A CONTEXT OF THE NAMED PATIENT USE <i>Poster Presenter: Federica Sorà, IT</i>	08:30 - 08:30

P219	CAR-T THERAPY IN LATIN AMERICA: REALITY AND EXPECTATIONS OF HEMATOPOIETIC STEM CELL TRANSPLANTATION CENTERS <i>Poster Presenter: Fernando Barroso Duarte, BR</i>	08:30 - 08:30
P220	CHALLENGES IN OPTIMIZING CELL COLLECTION FOR MANUFACTURING OF CART-T CELLS IN RELAPSED ACUTE LYMPHOBLASTIC LEUKEMIA <i>Poster Presenter: Ines Bojani?, HR</i>	08:30 - 08:30
P221	LYMPHOCYTE APHERESIS IN HEALTHY DONORS FOR VALIDATING CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS PRODUCTION <i>Poster Presenter: Yandy Marx Castillo-Aleman, AE</i>	08:30 - 08:30
<i>ePoster</i> 08:30 - 18:00		ePoster Area
Non-infectious Late Effects, Quality of Life and Fertility		
P513	HCT FRAILTY SCALE FOR YOUNGER AND OLDER ADULTS UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION <i>Poster Presenter: Maria Queralt Salas, ES</i>	08:30 - 08:30
P514	TEN-YEAR FOLLOW UP STUDY OF CHILDREN WITH THALASSAEMIA MAJOR POST TRANSPLANTATION USING TREOSULFAN, THIOTEPA, FLUDARABINE BASED CONDITIONING REGIMEN AND ITS IMPACT ON GROWTH AND PUBERTY <i>Poster Presenter: Revathi Raj, IN</i>	08:30 - 08:30
P515	IMPACT OF HYDROXYUREA AND VASO-OCCLUSIVE CRISIS ON OVARIAN FOLLICLE DENSITY IN GIRLS AND YOUNG FEMALES WITH SICKLE CELL DISEASE <i>Poster Presenter: Tamara Diesch-Furlanetto, CH</i>	08:30 - 08:30
P516	METABOLIC SYNDROME AFTER PEDIATRIC ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR NONMALIGNANT DISEASES <i>Poster Presenter: Joëll E. Bense, NL</i>	08:30 - 08:30
P517	GERIATRIC ASSESSMENT AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN OLDER PATIENTS <i>Poster Presenter: Parastoo B. Dahi, US</i>	08:30 - 08:30
P518	EFFECT OF BUSULFAN AND TREOSULFAN ON GONADAL FUNCTION AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN CHILDREN AND ADOLESCENTS WITH NONMALIGNANT DISEASES IS NOT EXPOSURE-DEPENDENT <i>Poster Presenter: Mey Yin Eileen Christina van der Stoep, NL</i>	08:30 - 08:30
P519	IDENTIFYING HEALTH MEASURES DIRECTLY INFLUENCING PATIENT REPORTED OUTCOME MEASURES (PROMS) TO DIRECT PATIENT CENTRED LONG TERM FOLLOW UP CARE	08:30 - 08:30

	AFTER ALLOGENEIC HAEMOPOIETIC STEM CELL TRANSPLANTATION <i>Poster Presenter:</i> Tricia Wright, AU	
P520	PREVALENCE, CAUSES AND SURVIVAL IMPACT OF CHRONIC KIDNEY DISEASE IN 1564 RECIPIENTS OF ALLOGENIC HEMATOPOIETIC CELL TRANSPLANTATION <i>Poster Presenter:</i> Alexandra Kutilina, DE	08:30 - 08:30
P521	NEUROLOGIC COMPLICATIONS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH CALCINEURIN-FREE GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS <i>Poster Presenter:</i> Aitana Balaguer Roselló, ES	08:30 - 08:30
P522	PREVALENCE OF ENDOCRINE DYSFUNCTION IN RECIPIENTS OF ALLOGENIC HSCT AFTER TOTAL BODY IRRADIATION (TBI) – CYCLOPHOSPHAMIDE BASED CONDITIONING, FOR MALIGNANT HAEMATOLOGICAL CONDITIONS: AN 11-YEAR SINGLE-CENTRE FOLLOW-UP <i>Poster Presenter:</i> Subramaniam Ramanathan, GB	08:30 - 08:30
P523	AVASCULAR BONE NECROSIS: HIGH MORBIDITY AND IMPACT ON QUALITY OF LIFE IN PEDIATRIC ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION SURVIVORS <i>Poster Presenter:</i> Maria Luz Uria Oficialdegui, ES	08:30 - 08:30
P524	RANDOMIZED CONTROLLED TRIAL OF ISHA KRIYA VERSUS OBSERVATION TO IMPROVE THE QUALITY OF LIFE IN HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS <i>Poster Presenter:</i> Deepesh Lad, IN	08:30 - 08:30
P525	LONG TERM FOLLOW UP CLINIC AFTER ALLOGENEIC HAEMOPOIETIC STEM CELL TRANSPLANT, THE PATIENT EXPERIENCE <i>Poster Presenter:</i> Tricia Wright, AU	08:30 - 08:30
P526	RISK FACTORS ASSOCIATED TO SECONDARY MALIGNANCIES IN HEMATOPOIETIC STEM CELL ALLO-TRANSPLANTED PATIENTS: THE EMERGENT ROLE OF POST-TRANSPLANTATION CYCLOPHOSPHAMIDE <i>Poster Presenter:</i> Chiara de Philippis, IT	08:30 - 08:30
P527	PREDICTIVE ROLE OF PRE-TRANSPLANT WELL-BEING PROFILES OF PATIENTS FOR THEIR LONG-TERM FUNCTIONING TRAJECTORIES FOLLOWING HCT <i>Poster Presenter:</i> Malgorzata Sobczyk-Kruszelnicka, PL	08:30 - 08:30
P528	A PROSPECTIVE COHORT STUDY TO EVALUATE MICROVASCULOPATHY AND ENDOTHELIAL DYSFUNCTION BY USING NON-INVASIVE TESTS IN HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS <i>Poster Presenter:</i> Sayan Sinha Roy, IN	08:30 - 08:30
P529	MARKERS OF BONE REMODELING IN SURVIVORS OF	08:30 - 08:30

	PEDIATRIC ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: IMPACT OF HEAVY RESISTANCE TRAINING	
	<i>Poster Presenter:</i> Lise Marie Krogh, DK	
P533	LONG-TERM THYROID DISORDERS AFTER PAEDIATRIC HCT FOR MALIGNANT UNDERLYING DISEASES	08:30 - 08:30
	<i>Poster Presenter:</i> Natalia Zubarovskaya, AT	
P534	PREDICTING MORTALITY AND RELAPSE IN REDUCED INTENSITY TRANSPLANTATION FOR MYELOID DISEASE: THE EASIX SCORE IN PRACTICE	08:30 - 08:30
	<i>Poster Presenter:</i> Chris Armstrong, IE	
P535	IRON OVERLOAD FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION: PREVALENCE, SEVERITY AND MANAGEMENT IN CHILDREN AND ADOLESCENTS WITH MALIGNANT AND NON-MALIGNANT DISEASES	08:30 - 08:30
	<i>Poster Presenter:</i> Marta Adavastro, IT	
P536	THROMBOPOIETIN RECEPTOR AGONISTS FOR PERSISTENT SEVERE THROMBOCYTOPENIA AFTER ALLOGENEIC STEM CELL TRANSPLANTATION – 5 YEARS SINGLE CENTRE RETROSPECTIVE ANALYSIS	08:30 - 08:30
	<i>Poster Presenter:</i> Kristina Pahek, HR	
P537	SUCCESSFUL TREATMENT OF A CASPR2/LGI1-ANTIBODY POSITIVE AUTOIMMUNE ENCEPHALITIS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION FOR MYELOFIBROSIS	08:30 - 08:30
	<i>Poster Presenter:</i> Edgar Jost, DE	
P538	SERIAL QUALITY OF LIFE EVALUATIONS OF MYELOMA PATIENTS TREATED WITH UPFRONT ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOLLOWED BY BORTEZOMIB MAINTENANCE	08:30 - 08:30
	<i>Poster Presenter:</i> Imran Ahmad, CA	
P539	IMPACT OF PRE - TRANSPLANT PULMONARY FUNCTION TESTS (PFTS) IN PATIENTS UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANT FOR (AUTO SCT) MULTIPLE MYELOMA (MM) PATIENTS	08:30 - 08:30
	<i>ePoster</i>	
	08:30 - 18:00	ePoster Area
	Nurses Posters - Adult	
NP001	HELPING PREVENT 'BURN OUT' AND THE EFFECTIVE SUPPORT OF STAFF: A NEW INITIATIVE TO HELP SUPPORT HAEMATOLOGY/BMT NURSES	08:30 - 08:30
NP002	IMPLEMENTATION OF A HAEMATOPOIETIC STEM CELL TRANSPLANT E-LEARNING THEORY MODULE: DOES LEARNING THE THEORY BEHIND THE PRACTICE IMPROVE NURSING CARE AND CONFIDENCE?	08:30 - 08:30
	<i>Poster Presenter:</i> Danielle Casey, GB	

NP003	FROM PROJECT TO PRACTICE - FINDING FREEDOM WITH SELF-ADMINISTRATION ON THE WAY TO HSCT <i>Poster Presenter: Cecilia Engberg de Carvalho, SE</i>	08:30 - 08:30
NP004	SUCCESSES AND CHALLENGES OF ESTABLISHING A NURSE LED LATE EFFECTS CLINIC <i>Poster Presenter: Naomi Dean, GB</i>	08:30 - 08:30
NP005	NURSING INTERVENTIONS TO REDUCE THE INCIDENCE OR DURATION OF DELIRIUM IN PATIENTS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) <i>Poster Presenter: Tabea Büter, DE</i>	08:30 - 08:30
NP006	COLLABORATIVE EDUCATION AND KNOWLEDGE SHARING IN THE CONTEXT OF CYTOKINE RELEASE SYNDROME <i>Poster Presenter: Maria Farrell, GB</i>	08:30 - 08:30
NP007	DOES EXTRACORPOREAL PHOTOPHERESIS INFLUENCE THE PROGRESSION OF BRONCHIOLITIS OBLITERANS SYNDROME IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS? <i>Poster Presenter: Alba Pons Cornadó, NO</i>	08:30 - 08:30
NP008	EFFICACY OF A MULTI-DISCIPLINARY TEAM APPROACH TO PREHABILITATION WITHIN HAEMATOPOIETIC STEM CELL TRANSPLANT: A CASE STUDY <i>Poster Presenter: Abigail Dean, GB</i>	08:30 - 08:30
NP009	THE IMPACT OF THE COVID-19 PANDEMIC ON THE MENTAL HEALTH OF HEALTH CARE WORKERS (HCW) OF HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT) UNITS <i>Poster Presenter: Clarisse Martins Machado, BR</i>	08:30 - 08:30
NP010	STEM CELL TRANSPLANT SURVIVORSHIP CARE, LATE EFFECTS, AND NURSING ROLE IN HEALTH PROMOTION <i>Poster Presenter: Amani Alharbi, SA</i>	08:30 - 08:30
NP011	IMPROVED CLINICAL INCIDENT REPORTING: PROMOTING A SAFETY PATIENT CULTURE IN A HAEMATOPOIETIC STEM CELL TRANSPLANT UNIT <i>Poster Presenter: Khevein Dan Sarmiento, GB</i>	08:30 - 08:30
NP012	SEPSIS: RAISING AWARENESS OF THE SILENT KILLER AMONG WARD BASED HAEMATO-ONCOLOGY AND HAEMATOPOIETIC STEM CELL TRANSPLANT NURSES <i>Poster Presenter: Gian Alcantara, GB</i>	08:30 - 08:30
NP013	ADDRESSING THE TRAINING NEEDS OF NEWLY QUALIFIED NURSES ON A SPECIALIST HAEMATOLOGY & TRANSPLANT UNIT <i>Poster Presenter: Amy Dunn, GB</i>	08:30 - 08:30
NP014	PREREQUISITES FOR PERFORMING NURSING CARE WITHIN ALLOGENEIC STEM CELL TRANSPLANTATION: A CHALLENGE!	08:30 - 08:30

	<i>Poster Presenter:</i> Katarina Holmberg, SE	
NP015	EFFECT OF POLYVYNILPYRROLIDONE-ZN GLUCONATE AND TAURINE ON CHEMOTHERAPY-INDUCED ORAL MUCOSITIS IN ALLOGENEIC STEM-CELL TRANSPLANTATION RECIPIENTS: A SINGLE CENTER EXPERIENCE <i>Poster Presenter:</i> Rosalba Daniela Minniti, IT	08:30 - 08:30
NP016	EFFECTS OF ORANGE OIL AROMATHERAPY ON THE PAIN AND ANXIETY DURING INVASIVE INTERVENTIONS IN PATIENTS WITH HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Poster Presenter:</i> Seckin Erdal, TR	08:30 - 08:30
NP018	NURSING INVOLVEMENT IN PROVIDING CONTINUITY OF CARE IN COMPLEX TRANSPLANT PATIENTS <i>Poster Presenter:</i> Taylor Stookey, GB	08:30 - 08:30
NP019	'USING INTERPROFESSIONAL EDUCATIONAL METHODOLOGY TO DELIVER TRAINING FOR A NEW CAR-T CELL SERVICE' <i>Poster Presenter:</i> Bethany Colton, GB	08:30 - 08:30
NP020	THE DEVELOPMENT OF HEALTH AND WELLBEING EVENTS FOR TRANSPLANT PATIENTS <i>Poster Presenter:</i> Nicola Knightly, GB	08:30 - 08:30
NP021	IMPORTANCE OF NURSING RECORDS IN SUSPECTED HEPATIC VENOCLUSIVE DISEASE (HEVO) <i>Poster Presenter:</i> Adama Faye Kebe Diouf, ES	08:30 - 08:30
NP022	SUPPORTING ORAL CARE IN PATIENTS LIVING WITH CANCER - A NORDIC INITIATIVE <i>Poster Presenter:</i> Lea Brandt Kristensen, DK	08:30 - 08:30
NP023	EXPANDING ANTHONY NOLAN'S PATIENT INFORMATION ON STEM CELL TRANSPLANT AS A CURATIVE TREATMENT OPTION FOR PEOPLE WITH SICKLE CELL DISEASE <i>Poster Presenter:</i> Louise Jones, GB	08:30 - 08:30
NP024	SHOULD TYA/AYA PATIENTS BE TREATED AS CHILDREN OR ADULTS? A SERIES OF CASE STUDIES <i>Poster Presenter:</i> Laura Borg, GB	08:30 - 08:30
NP026	THE POSITIVE IMPACT OF INTEGRATING A BONE MARROW TRANSPLANT CLINICAL TRIALS NURSE INTO THE WIDER BMT NURSING TEAM: THE OXFORD EXPERIENCE <i>Poster Presenter:</i> Sally Springett, GB	08:30 - 08:30
NP027	THE PSYCHOLOGICAL IMPACT OF THE COVID-19 PANDEMIC ON HAEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS <i>Poster Presenter:</i> Kevin Aguilar, GB	08:30 - 08:30
NP028	CART T IN BONE MARROW TRANSPLANTATION UNIT AND NURSING TREATMENT	08:30 - 08:30

	<i>Poster Presenter: Liya Katzir, IL</i>	
NP029	THE CLINICAL HAEMATOLOGY RESEARCH NURSE – DEVELOPING THE ROLE IN LINE WITH AN EXPANDING RESEARCH PORTFOLIO <i>Poster Presenter: Eleanor Pearce, GB</i>	08:30 - 08:30
NP030	THE IMPORTANCE OF ECP IN DEALING WITH POST-TRANSPLANTATION COMPLICATIONS <i>Poster Presenter: Petra Vodišková, CZ</i>	08:30 - 08:30
NP031	A SERVICE EVALUATION OF TWO QUALITY OF LIFE ASSESSMENT TOOLS FOR APHERESIS STAFF IN SCREENING CHRONIC GRAFT VERSUS HOST DISEASE PATIENTS FOR PSYCHOLOGICAL SUPPORT <i>Poster Presenter: Holly Hegarty, GB</i>	08:30 - 08:30
NP032	CAR T-CELL THERAPY: 2 YEARS OF EXPERIENCE AND IMPLICATIONS OF NURSING IMPROVEMENT <i>Poster Presenter: Patrícia Alexandra Pereira Pinheiro, PT</i>	08:30 - 08:30
NP033	THE IMPACT OF ONLINE TEAM MEETINGS ON CLINICAL PRACTICE, QUALITY OF CARE AND TEAMWORK IN THE TRANSPLANT UNIT: A MONOCENTRIC EXPERIENCE <i>Poster Presenter: Carmine Colella, IT</i>	08:30 - 08:30
NP034	USE OF THE ICE TEST BY NURSING IN THE MANAGEMENT OF NEUROTOXICITY INDUCED BY CART THERAPY. ABOUT A CASE <i>Poster Presenter: Sara Marcos Asensio, ES</i>	08:30 - 08:30
NP046	IMPLICATIONS OF 10-MINUTE BITESIZE TRAINING WITHIN AN ACUTE HEMATOLOGY TRANSPLANT UNIT 'TOAST TALKS' <i>Oral Presenter: Victoria Bates, GB</i>	08:30 - 08:45
<i>ePoster</i> 08:30 - 18:00		ePoster Area
Pharmacology		
P888	DOSING OF CONDITIONING CHEMOTHERAPY AND GVHD PROPHYLAXIS IN OBESITY – A SURVEY OF PRACTICE <i>Poster Presenter: Siobhan Smith, GB</i>	08:30 - 08:30
P889	ROLE OF FLUOROQUINOLONE PROPHYLAXIS IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN REGIONS WITH A HIGH PREVALENCE OF FLUOROQUINOLONE RESISTANCE <i>Poster Presenter: Ashwin Nair, IN</i>	08:30 - 08:30
P890	TARGETED VS FIXED-DOSE BUSULFAN AS PART OF REDUCED INTENSITY CONDITIONING PRIOR TO ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN MYELOFIBROSIS <i>Poster Presenter: Claudia Langebrake, DE</i>	08:30 - 08:30
P891	EARLY PREDICTION OF CYTOKINE RELEASE SYNDROME BY	08:30 - 08:30

	MEASURING PHOSPHATE AND MAGNESIUM LEVELS FOLLOWING CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY	
	<i>Poster Presenter:</i> Masahiro Yoshida, JP	
P892	INTERIM ANALYSIS OF AN AUDIT ON VARIANCE IN TARGET CICLOSPORIN CONCENTRATION FOLLOWING LOADING DOSE IN ALLOGENEIC STEM CELL TRANSPLANT RECIPIENTS	08:30 - 08:30
	<i>Poster Presenter:</i> Douglas Semple, GB	
P893	PENICILLIN ALLERGY DE-LABELLING IN THE SCOTTISH NATIONAL ADULT ALLOGENEIC STEM CELL TRANSPLANT UNIT	08:30 - 08:30
	<i>Poster Presenter:</i> Francesca McArthur, GB	
P894	ENSURING SAFETY OF PATIENTS TREATED WITH CAR-T CELL THERAPY	08:30 - 08:30
	<i>Poster Presenter:</i> Sumantha Gabriel, GB	
P895	PRIMIDONE IN ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION – A CASE REPORT WITH FOCUS ON DRUG-DRUG INTERACTIONS WITH TACROLIMUS	08:30 - 08:30
	<i>Poster Presenter:</i> Claudia Langebrake, DE	
P896	IMPACT OF HYDROXYUREA ON SOCIAL HEALTH PROBLEMS OF BETA THALASSEMIA PATIENTS WITH A MODERATING ROLE OF HEALTHCARE PROFESSIONALS' PERFORMANCE	08:30 - 08:30
	<i>Poster Presenter:</i> Affaf Sheikh, PK	
P897	CART-T CELLS THERAPY: HIGH PAYBACK, HIGH RISK? SAFETY PROFILE IN SINGLE CENTER EXPERIENCE?	08:30 - 08:30
	<i>Poster Presenter:</i> Vera Domingos, PT	
<i>ePoster</i>		
08:30 - 18:00		ePoster Area
Psychological Issues		
P880	HETEROGENEOUS PSYCHOLOGICAL ASPECTS IN PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION	08:30 - 08:30
	<i>Poster Presenter:</i> Eliana Kachaamy, LB	
P882	PATIENT CONCERNS AFTER HSCT: AN EVALUATION	08:30 - 08:30
	<i>Poster Presenter:</i> Kate N. Montague-Hellen, GB	
P883	EMBEDDED PSYCHOLOGICAL SUPPORT IN A STEM CELL TRANSPLANT SERVICE: WHAT MATTERS MOST TO THOSE WHO USE IT	08:30 - 08:30
	<i>Poster Presenter:</i> Jenna Love, GB	
P884	PSYCHOLOGICAL FACTORS OF NONCOMPLIANT PARENTAL BEHAVIOR BEFORE BONE MARROW TRANSPLANTATION	08:30 - 08:30
	<i>Poster Presenter:</i> Natalia Klipinina, RU	
P885	NARRATIVE-BASED MEDICINE ASSESSMENT DURING	08:30 - 08:30

	ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A TOOL TO PROMOTE PSYCHOLOGICAL HEALTH?	
	<i>Poster Presenter: Alessia Salemmé, IT</i>	
P886	PATIENT PERCEPTIONS OF THE PSYCHOLOGICAL SUPPORT OFFERED IN RELATION TO THEIR HAEMATOPOIETIC STEM CELL TRANSPLANT - AN EVALUATION	08:30 - 08:30
	<i>Poster Presenter: Anna Lagerdahl, GB</i>	
P887	IMPACT OF ALLO-HSCT IN ADHERENCE	08:30 - 08:30
	<i>Poster Presenter: Elmira Kolgaeva, RU</i>	
<i>ePoster</i>		
08:30 - 18:00		ePoster Area
	Quality Management	
P861	TRIPLE PROPHYLAXIS WITH MESNA, N ACETYLCYSTEINE INFUSION AND ORAL CIPROFLOXACIN AS A LOW-COST INTERVENTION TO PREVENT BK VIRUS HAEMORRHAGIC CYSTITIS IN HAPLOIDENTICAL HSCT WITH PTCY	08:30 - 08:30
	<i>Poster Presenter: Revathi Raj, IN</i>	
P862	AN APHERESIS COLLECTION AND PROCESSING FACILITY SYSTEM IN THE SOUTH AFRICAN SETTING	08:30 - 08:30
	<i>Poster Presenter: Laurel Ellen Anderson, ZA</i>	
P863	TRANSFERRING AUTOLOGOUS STEM CELL TRANSPLANTATION PATIENTS ON DAY AFTER INFUSION: A FEASIBLE PROCEDURE AND A RELIEF FOR TRANSPLANTATION CENTERS	08:30 - 08:30
	<i>Poster Presenter: Maria Calbacho Robles, ES</i>	
P864	VALIDATION MASTER PLAN FOR A COMBINED AND INTEGRATED APPROACH OF QUALITY AND RISK MANAGEMENT	08:30 - 08:30
	<i>Poster Presenter: Barbara Loconte, CH</i>	
P865	THE HOSPITAL IS MOVING TO A NEW BUILDING, CAN JACIE STANDARDS HELP IN THE PROCESS?	08:30 - 08:30
	<i>Poster Presenter: Olga López, ES</i>	
P866	QUALITY REVIEW IN THE PROCESSING UNIT: WHERE ARE WE AFTER THE CHANGE CONTROL?	08:30 - 08:30
	<i>Poster Presenter: Luisa Giaccone, IT</i>	
P867	TRANSPLANT OUTCOMES OF FRESH VS CRYOPRESERVED HEMATOPOIETIC STEM CELLS FROM RELATED AND UNRELATED DONOR DURING THE SARS-COV2 PANDEMIC	08:30 - 08:30
	<i>Poster Presenter: Antonio Bruno, IT</i>	
P868	ROLE OF EMPACT ON PROFESSIONAL AND PERSONAL DEVELOPMENTS OF NURSES IN PAKISTAN	08:30 - 08:30
	<i>Poster Presenter: Eugenia Trigosó, ES</i>	

P869	BONE MARROW PROCESSING BY CENTRIFUGATION OR SPECTRA OPTIA <i>Poster Presenter: Kitty Rood, NL</i>	08:30 - 08:30
P870	THE DYNAMICS OF UNRELATED ALLOGENEIC TRANSPLANTATIONS IN BELARUS DEPEND ON THE LOGISTICAL CHALLENGES OF RECENT YEARS <i>Poster Presenter: Volha Mishkova, BY</i>	08:30 - 08:30
P872	A 12-MONTH RETROSPECTIVE DESCRIPTIVE STUDY OF OCCURRENCES FOR THE SOUTH AFRICAN NATIONAL BLOOD SERVICES APHERESIS COLLECTION AND THE STEM CELL PROCESSING FACILITIES <i>Poster Presenter: Laurel Ellen Anderson, ZA</i>	08:30 - 08:30
P873	AUDIT SYSTEM DURING COVID-19 PANDEMIC – REMOTE AUDITING AS A CHALLENGE FOR BOTH PARTIES? <i>Poster Presenter: Katerina Steinerová, CZ</i>	08:30 - 08:30
<i>ePoster</i> 08:30 - 18:00		ePoster Area
Statistics		
P856	A NOVEL INTEGRATIVE MULTI-OMICS APPROACH TO UNRAVEL THE GENETIC DETERMINANTS OF RARE DISEASES WITH APPLICATION IN PEDIATRIC SINUSOIDAL OBSTRUCTION SYNDROME <i>Poster Presenter: Isabelle Dupanloup, CH</i>	08:30 - 08:30
P857	WMDA'S GLOBAL TRENDS REPORT ON UNRELATED HEMATOPOIETIC STEM CELL DONATION: 25 YEARS OF MONITORING ACTIVITY AND TRENDS <i>Poster Presenter: Lydia Foeken, NL</i>	08:30 - 08:30
P859	AUTOLOGOUS PERIPHERAL BLOOD STEM CELL PROCESSING IN KAUNAS, LITHUANIA 2015-2022	08:30 - 08:30
P860	USING R SCRIPTS VISUAL IN POWER BUSINESS INTELLIGENCE TO CREATE DASHBOARD FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION AND CELLULAR THERAPY CENTERS <i>Poster Presenter: Anderson João Simione, BR</i>	08:30 - 08:30
<i>ePoster</i> 08:30 - 18:00		ePoster Area
Data Management		
P838	MYELOMATRIAGE: AN INTERACTIVE WEB-BASED TOOL TO IMPROVE THE STRATEGY OF MULTIPLE MYELOMA TREATMENT PATIENTS USING R-SHINY AND NETWORK META-ANALYSIS <i>Poster Presenter: Alexander Luchinin, RU</i>	08:30 - 08:30
P839	WORLD MARROW DONOR ASSOCIATION SEARCH, MATCH	08:30 - 08:30

	&AMP; CONNECT, A GLOBAL ENVIRONMENT TO FACILITATE THE BEST MATCH FOR YOUR PATIENT <i>Poster Presenter:</i> Alicia Venter, NL	
P840	EDUCATIONAL AUDIT PROCESS FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) REPORTS <i>Poster Presenter:</i> Carmen Vergueiro, BR	08:30 - 08:30
P841	CRYOSTEM NETWORK FUELING EXCELLENCE IN TRANSLATIONAL RESEARCH ON HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) COMPLICATIONS <i>Poster Presenter:</i> Emilie Robert, FR	08:30 - 08:30
P842	BMT BRAZILIAN MAP: COMPARISON OF BMT MAP WITH EBMT ACTIVITY SURVEY AND ACTIVITY REPORT CIBMTR <i>Poster Presenter:</i> Anderson João Simione, BR	08:30 - 08:30
P843	CEDACE DONOR PANEL OPTIMIZED MANAGEMENT <i>Poster Presenter:</i> Irene Gomes, PT	08:30 - 08:30
P844	AUTOLOGOUS STEM CELL TRANSPLANTATIONS (ASCT_s) IN YEARS 1993-2022 – 1 CENTRE EXPERIENCE OF EBMT REPORTS PROCESSING <i>Poster Presenter:</i> Marie Trnkova, CZ	08:30 - 08:30
P845	ISAVUCONAZOLE OFF LABEL USE IN CHILDREN AND ADOLESCENTS: A SINGLE TERTIARY-PEDIATRIC-CARE CENTER EXPERIENCE REVIEW <i>Poster Presenter:</i> Blanca Molina, ES	08:30 - 08:30
P846	ACTIONS AND ACHIEVEMENTS FOR THE HEMATOPOIETIC STEM CELL TRANSPLANTATION BRAZILIAN REGISTRY ESTABLISHMENT, USING CENTER FOR INTERNATIONAL BLOOD AND MARROW TRANSPLANT RESEARCH INFRASTRUCTURE <i>Poster Presenter:</i> Cinthya da Silva, BR	08:30 - 08:30
P847	COMPREHENSIVE MANAGEMENT SYSTEM FOR THE IMPLEMENTATION OF ADVANCED THERAPY MEDICINAL PRODUCTS (ATMP) IN THE CLINICAL PRACTICE IN MADRID AND ITS RESULTS <i>Poster Presenter:</i> Raquel San Jose, ES	08:30 - 08:30
P848	COMPLETION OF THE PILOT PROJECT EVALUATING THE BENEFIT OF ADDITIONAL SUPPORT IN HCT RESEARCH DATA MANAGEMENT ON BEHALF OF ANTHONY NOLAN AND BSBMTCT <i>Poster Presenter:</i> Shelley Hewerdine, GB	08:30 - 08:30
P849	STEM CELL TRANSPLANT DATA REGISTRIES: ROLE AND FUTURE IN SAUDI ARABIA <i>Poster Presenter:</i> Syed Jafri, SA	08:30 - 08:30
P850	CURRENT SITUATION AND DEVELOPMENT OF HEMATOPOIETIC CELL TRANSPLANTATION CENTERS: A	08:30 - 08:30

	NATIONWIDE SURVEY IN CHINA	
	<i>Poster Presenter: Yi Fan, CN</i>	
P851	FINDING OUT THE REGULATORY REQUIREMENTS FOR THE DEVELOPMENT OF GENE AND CELL THERAPY PRODUCTS WITH THE EUROGCT RESEARCH PATHWAYS	08:30 - 08:30
	<i>Poster Presenter: Auxane Delage, FR</i>	
P852	UPDATING DONOR REGISTRIES ON THE GOOD, THE BAD AND THE UGLY. A BSBMTCT REGISTRY ANALYSIS OF PATIENT FOLLOW-UP REPORTS COMPLETED FOR DONOR REGISTRIES WORLDWIDE (2012-2022)	08:30 - 08:30
	<i>Poster Presenter: Marie Wilson, GB</i>	
P853	DEVELOPMENT OF DISTANCE CONTINUING EDUCATION FOR DATA MANAGERS, USING THE DESIGN THINKING METHODOLOGY	08:30 - 08:30
	<i>Poster Presenter: Cinthya da Silva, BR</i>	
P854	DEVELOPMENT AND MAIN RESULTS OF THE ANNUAL DATA MANAGERS MEETING AT THE BRAZILIAN SOCIETY FOR BLOOD AND MARROW TRANSPLANTATION AND CELLULAR THERAPY CONGRESS	08:30 - 08:30
	<i>Speaker: Cinthya da Silva, BR</i>	
P855	A SUSTAINABLE PIPELINE TO STAFF A DIVERSE RESEARCH DATA MANAGEMENT TEAM	08:30 - 08:30
	<i>Poster Presenter: Mary Kathleen Czepiel, US</i>	
<i>ePoster</i>		
08:30 - 18:00		ePoster Area
	Solid Tumours	
P833	CELL-FREE THERAPY BY DACTINOMYCIN LOADED INTO THE BONE MARROW MESENCHYMAL STEM CELLS-DERIVED EXOSOMES	08:30 - 08:30
	<i>Poster Presenter: Zahra Sadat Hashemi, IR</i>	
P834	OUTCOMES OF BUSULFAN VERSUS TREOSULFAN BASED REGIMENS FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANT IN CHILDREN WITH HIGH RISK EWING SARCOMA	08:30 - 08:30
	<i>Poster Presenter: Amit Dotan, IL</i>	
P835	CLINICAL CHARACTERISTICS, TREATMENT AND OUTCOME OF CHILDREN WITH HIGH-RISK NEUROBLASTOMA IN MALAYSIA: A SINGLE CENTRE EXPERIENCE	08:30 - 08:30
	<i>Poster Presenter: Sie Chong Doris Lau, MY</i>	
P836	AUTOLOGOUS TRANSPLANTATION OF HEMATOPOIETIC STEM CELLS FOR MALIGNANT NEOPLASMS IN CHILDREN: EXPERIENCE OF THE N.N. BLOKHIN	08:30 - 08:30
	<i>Poster Presenter: Teymur Aliev, RU</i>	
P837	PRESENCE OF SOLID TUMORS DOES NOT PREVENT	08:30 - 08:30

AUTOLOGOUS STEM CELL TRANSPLANTATION IN REFRACTORY/RELAPSED NHL

Speaker: Osman Ilhan, TR

ePoster

08:30 - 18:00

ePoster Area

Patient Advocacy: Patients' Reported Outcome and Expectations

- | | | |
|------|--|---------------|
| P874 | <p>SOCIAL FUNCTIONING AFTER TRANSPLANTATION AND CELLULAR THERAPY: INITIAL PATIENT-REPORTED OUTCOMES RESULTS FROM THE CIBMTR</p> <p><i>Poster Presenter:</i> Bronwen Shaw, US</p> | 08:30 - 08:30 |
| P875 | <p>THE PREDICTIVE VALUE OF PATIENT-REPORTED OUTCOMES IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: EXPLORATORY SECONDARY ANALYSIS OF A RANDOMIZED NUTRITION INTERVENTION TRIAL</p> <p><i>Poster Presenter:</i> Anne Marte Gudmundstuen, NO</p> | 08:30 - 08:30 |
| P876 | <p>NEWSRINGFORME, THE FIRST FRENCH COMPREHENSIVE COMPANION SOLUTION TO IMPROVE TRANSPLANTED PATIENTS SUPPORT</p> <p><i>Poster Presenter:</i> Emilie Robert, FR</p> | 08:30 - 08:30 |
| P877 | <p>A CROSS-SECTIONAL STUDY EXAMINING POTENTIAL DEMOGRAPHIC BARRIERS TO RECEIVING INFORMATION ON CLINICAL TRIALS IN RELAPSED/REFRACTORY PATIENTS WHO HAVE RECEIVED STEM CELL TRANSPLANTS (SCT)</p> <p><i>Poster Presenter:</i> Steven Kalloger, CA</p> | 08:30 - 08:30 |
| P878 | <p>PREQOL: A PILOT STUDY TO EVALUATE THE COLLECTION OF SOCIOECONOMIC AND QUALITY OF LIFE DATA FROM PATIENTS UNDERGOING ALLOGENEIC HAEMATOPOIETIC CELL TRANSPLANTATION IN THE UK</p> <p><i>Poster Presenter:</i> Gemma Pugh, GB</p> | 08:30 - 08:30 |

ePoster

08:30 - 18:00

ePoster Area

Nurses Posters - Research

- | | | |
|-------|---|---------------|
| NP042 | <p>THE CLINICAL TRIAL NURSE CASE MANAGER: DESIGNING A NEW ROLE</p> <p><i>Poster Presenter:</i> Martina Piazzalunga, IT</p> | 08:30 - 08:30 |
| NP043 | <p>BETWEEN PHYSICAL AND SPIRITUAL IN GVHD: QUALITY OF LIFE, EMOTIONAL COPING AND MEANING OF LIFE AMONGST MUSLIM AND JEWISH PATIENTS</p> <p><i>Poster Presenter:</i> Shada Assadi, IL</p> | 08:30 - 08:30 |
| NP044 | <p>KNOWLEDGE OF PATIENTS AFTER HEMATOPOIETIC CELLS TRANSPLANTATION ABOUT THE POST-TRANSPLANT DIET</p> <p><i>Poster Presenter:</i> Kinga Malcherczyk, PL</p> | 08:30 - 08:30 |
| NP045 | <p>ANAKINRA MANAGEMENT IN THE CYCLOCINE RELEASE</p> | 08:30 - 08:30 |

SYNDROME*Poster Presenter:* Cristina Martin Benito, ES*ePoster*

08:30 - 18:00

ePoster Area

Nurses Posters - Paediatric

- | | | |
|-------|--|---------------|
| NP035 | REDUCTION OF BACTEREMIA AND CENTRAL LINE ASSOCIATED COMPLICATION RATE AT THE PEDIATRIC HEMATO-ONCOLOGY AND BONE MARROW TRANSPLANT DEPARTMENT (PHOBMTD) OF SHEBA MEDICAL CENTER
<i>Poster Presenter:</i> Sandra Huino, IL | 08:30 - 08:30 |
| NP036 | NURSING PRELIMINARY ASSESSMENT WHEN IMPLEMENTING THE START UP OF HEMATOPOIETIC STEM CELLS TRANSPLANT CENTRE IN A MIDDLE INCOME COUNTRY: WHAT TO NOT FORGET
<i>Poster Presenter:</i> Marta Canesi, IT | 08:30 - 08:30 |
| NP037 | THE TREE OF HOPE
<i>Poster Presenter:</i> Milene Pereira, PT | 08:30 - 08:30 |
| NP038 | IMPLEMENTATION OF PDA (PERSONAL DIGITAL ASSISTANT) IN A PEDIATRIC HEMATOPOIETIC PROGENITOR TRANSPLANT UNIT
<i>Poster Presenter:</i> Teresa Álvarez Gómez, ES | 08:30 - 08:30 |
| NP039 | EFFECTIVENESS OF INCATIV-PEDIATRICO IN THE PAEDIATRIC HAEMATO-ONCOLOGY AND TRANSPLANT UNITS IN A THIRD LEVEL HOSPITAL
<i>Poster Presenter:</i> Eugenia Trigos, ES | 08:30 - 08:30 |
| NP040 | THE TRANSPLANT JOURNEY OF STEM CELL GENE THERAPY FOR METABOLIC DISEASE: THE MANCHESTER EXPERIENCE OF MLD, MPS IIIA & GAUCHER DISEASE
<i>Poster Presenter:</i> Kirsten Potter, GB | 08:30 - 08:30 |
| NP041 | CORD BLOOD TRANSPLANT IN DIFFICULT-TO-CURE LEUKAEMIA AND IN METABOLIC DISEASES: THE MANCHESTER EXPERIENCE
<i>Poster Presenter:</i> Hayley Self, GB | 08:30 - 08:30 |

ePoster

08:30 - 18:00

ePoster Area

Cellular Therapies other than CARs

- | | | |
|------|--|---------------|
| P222 | SARS-COV-2 T-CELLS FOR ADOPTIVE CELL THERAPY IN IMMUNOCOMPROMISED CANCER PATIENTS
<i>Poster Presenter:</i> Rafet Basar, US | 08:30 - 08:30 |
| P223 | EFFICACY AND SAFETY OF LIFILEUCEL TUMOR-INFILTRATING LYMPHOCYTE (TIL) CELL THERAPY IN PATIENTS WITH ADVANCED MELANOMA ENROLLED IN CONSECUTIVE COHORTS OF THE C-144-01 STUDY | 08:30 - 08:30 |

	<i>Poster Presenter:</i> Wen Shi, GB	
P224	PRECISION-ENGINEERED CELL THERAPY ORCA-T DEMONSTRATES HIGH RELAPSE-FREE SURVIVAL AT 1 YEAR WHILE REDUCING GRAFT-VERSUS-HOST DISEASE AND TOXICITY <i>Poster Presenter:</i> J. Scott McClellan, US	08:30 - 08:30
P225	MULTISTATE MODEL ANALYSIS OF PROPHYLACTIC/PRE-EMPTIVE DONOR LYMPHOCYTE INFUSION FOR HIGH-RISK ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROME IN COMPLETE HEMATOLOGIC REMISSION AFTER ALLOGENEIC STEM CELL TRANSPLANTATION <i>Poster Presenter:</i> Giuliano Filippini Velázquez, DE	08:30 - 08:30
P226	T-ALLO10 INFUSION AFTER A?DEPLETED-HSCT IN CHILDREN AND YOUNG ADULTS WITH HEMATOLOGIC MALIGNANCIES: IMPROVED IMMUNE RECONSTITUTION IN THE ABSENCE OF SEVERE GVHD <i>Poster Presenter:</i> Alice Bertaina, US	08:30 - 08:30
P227	FIRST-IN-HUMAN STUDY OF MDG1011, A TCR-T CELL THERAPY DIRECTED AGAINST HLA-A*02:01-RESTRICTED PRAME, FOR HIGH-RISK MYELOID AND LYMPHOID NEOPLASMS (CD-TCR-001) <i>Poster Presenter:</i> Simone Thomas, DE	08:30 - 08:30
P228	HIGH-THROUGHPUT ASSESSMENT OF T CELL RECEPTOR SEQUENCES WITH SPECIFICITY TO THE MOST COMMON PATHOGENS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Poster Presenter:</i> Chrysoula Pantazi, GR	08:30 - 08:30
P229	A CLINICAL TRIAL OF ADOPTIVE IMMUNOTHERAPY OF STEROID-REFRACTORY CHRONIC GVHD WITH MULTIPLE INFUSIONS OF CRYOPRESERVED DONOR-DERIVED REGULATORY T (TREG) CELLS <i>Poster Presenter:</i> Mario Arpinati, IT	08:30 - 08:30
P230	CLINICAL APPLICATION OF DIRECTLY SORTED HAPLOIDENTICAL T REGULATORY AND MEMORY T CELLS IN PATIENTS WITH REFRACTORY GVHD AND VIRAL INFECTIONS <i>Poster Presenter:</i> Viktoria Vedmedskia, RU	08:30 - 08:30
P231	PATIENT-TAILORED ADOPTIVE IMMUNOTHERAPY WITH EBV-SPECIFIC T CELLS FROM STEM CELL AND THIRD PARTY DONORS <i>Poster Presenter:</i> Britta Maecker-Kolhoff, DE	08:30 - 08:30
P232	COMBINED CAR-NK AND CAR-GD T CELLS AS A THERAPEUTIC TOOL POST ALLO-SCT <i>Poster Presenter:</i> Nassim Salem, FR	08:30 - 08:30
P233	FIRST IN HUMAN CLINICAL RESPONSES AND PERSISTENCE DATA ON TEG001: A NEXT GENERATION OF ENGINEERED ALPHA/BETA T-CELLS TARGETING AML AND MM WITH A	08:30 - 08:30

	GAMMA9DELTA2 TCR <i>Poster Presenter:</i> Moniek de Witte, NL	
P234	DONOR-DERIVED ANTI-LEUKEMIA CTLs FOR THE CONTROL OF LEUKEMIA RELAPSE IN HIGH-RISK PEDIATRIC PATIENTS GIVEN HAPLOIDENTICAL HSCT <i>Poster Presenter:</i> Daniela Montagna, IT	08:30 - 08:30
P235	A SIX-YEAR RETROSPECTIVE ANALYSIS OF THE USE OF DONOR LYMPHOCYTE INFUSION IN A NATIONAL ALLOGENEIC TRANSPLANT CENTRE <i>Poster Presenter:</i> Conor Browne, IE	08:30 - 08:30
P236	VIRUS SPECIFIC T-CELLS AGAINST ADV, EBV AND CMV IN INFECTED MULTI-TREATED POST-HSCT PATIENTS <i>Poster Presenter:</i> Esther Hazane Leroyer, FR	08:30 - 08:30
P237	DONOR LYMPHOCYTE INFUSIONS (DLI) IN MYELOFIBROSIS: TREATMENT PATTERNS, EFFICACY AND SAFETY. A EUROPEAN MULTICENTRE RETROSPECTIVE REAL-WORLD STUDY <i>Poster Presenter:</i> Alex Rampotas, GB	08:30 - 08:30
P239	INB-100: RELAPSE PROPHYLAXIS POST-HAPLOIDENTICAL BONE MARROW TRANSPLANTATION AND CYCLOPHOSPHAMIDE (HAPLO/CY) BY INFUSION OF DONOR-DERIVED EXPANDED/ACTIVATED GAMMA-DELTA (??) T CELLS: A PHASE I TRIAL <i>Poster Presenter:</i> Joseph McGuirk, US	08:30 - 08:30
P240	ROLE OF HISTOCOMPATIBILITY, ACCESSORY CELLS AND FREEZE-THAWING FOR IMMUNOSUPPRESSION BY PLACENTA-DERIVED DECIDUA STROMAL CELLS <i>Poster Presenter:</i> Olle Ringden, SE	08:30 - 08:30
P241	RAPID IMMUNE RECONSTITUTION AND ELEVATED REGULATORY T CELL FREQUENCIES IN PATIENTS TREATED WITH ORCA-T <i>Poster Presenter:</i> J. Scott McClellan, US	08:30 - 08:30
P242	MESENCHYMAL STROMAL CELLS FOR THE TREATMENT OF STEROID REFRACTORY GRAFT-VERSUS-HOST DISEASE IN CHILDREN <i>Poster Presenter:</i> Krzysztof Czyzewski, PL	08:30 - 08:30
P244	FAMILIAL CD45RA⁻ CELLS CONTAINING PATHOGEN-SPECIFIC MEMORY T-CELLS AS COMPLEMENTARY STRATEGY TO TREAT SEVERE REFRACTORY INFECTIONS AND EBV LYMPHOPROLIFERATIVE DISEASES IN IMMUNOCOMPROMISED PATIENTS <i>Poster Presenter:</i> Carlos Echevarria Parente, ES	08:30 - 08:30
P245	ADD-BACK NK CELLS FOLLOWING HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANT IN PEDIATRIC HIGH-RISK B CELLS ACUTE LYMPHOBLASTIC LEUKEMIA (B-	08:30 - 08:30

ALL)

Poster Presenter: Francesco Paolo Tambaro, IT

- P247 **EVALUATION OF THE SINGLE NEEDLE/DOUBLE NEEDLE AMICUS EXTRACORPOREAL PHOTOPHERESIS (ECP) SYSTEM WITH SOFTWARE VERSION 6.1 IN HEALTHY HUMAN SUBJECTS** 08:30 - 08:30
Poster Presenter: Thomas Gniadek, US
- P248 **THE PATIENT WAS A 39-YEAR-OLD CAUCASIAN MALE DIAGNOSED WITH AML TYPE M4 5 YEARS AGO (APRIL 2016)** 08:30 - 08:30
Poster Presenter: Mehrdad Payandeh, IR

ePoster

08:30 - 18:00

ePoster Area

Immunodeficiency Diseases and Macrophages

- P755 **OUTCOME OF HSCT ON WITH T CELL DEPLETION IN A COHORT OF INBORN ERRORS OF IMMUNITY WITH HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS** 08:30 - 08:30
Poster Presenter: Alexandra Laberko, RU
- P756 **HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH EX-VIVO T-DEPLETION IN PRIMARY IMMUNODEFICIENCY AND IMMUNE REGULATORY SYNDROMES: A MULTICENTER EXPERIENCE** 08:30 - 08:30
Poster Presenter: Stefano Giardino, IT
- P757 **PROGNOSTIC RISK FACTORS IN HEMATOPOIETIC STEM CELL TRANSPLANTATION IN INBORN ERRORS OF IMMUNITY** 08:30 - 08:30
Poster Presenter: Alexandra Laberko, RU
- P758 **OUTCOMES OF UMBILICAL CORD BLOOD TRANSPLANTATION IN CHILDREN WITH CHRONIC GRANULOMATOUS DISEASE** 08:30 - 08:30
Poster Presenter: Elizabeth Hicks, US
- P759 **OUTCOME OF PATIENTS WITH SIGNAL-TRANSDUCER AND ACTIVATOR OF OF TRANSCRIPTION 1 (STAT1) GAIN-OF-FUNCTION VARIANTS AFTER HAEMATOPOIETIC STEM CELL TRANSPLANTATION** 08:30 - 08:30
Poster Presenter: Mary A. Slatter, NL
- P760 **EMAPALUMAB AS A BRIDGE TO TRANSPLANT IN A PATIENT WITH STAT1 GOF MUTATION** 08:30 - 08:30
Poster Presenter: Alan Bidgoli, US
- P764 **HAPLOIDENTICAL STEM CELL TRANSPLANTATION FOR CHILDREN WITH PRIMARY IMMUNODEFICIENCIES: EXPERIENCE IN A CENTER FROM NORTHEAST OF MEXICO** 08:30 - 08:30
Poster Presenter: María Guadalupe González, MX
- P765 **A CASE OF LRBA DEFICIENCY WITH PERSISTENT IMMUNE DYSREGULATION POSTTRANSPLANT** 08:30 - 08:30
Poster Presenter: Delfien J. A. Bogaert, BE

P767	MINIMAL DOSE OF HEMATOPOIETIC STEM CELL TRANSPLANTATION WITHOUT MYELOSUPPRESSIVE CONDITIONING FOR T-B+NK- SEVERE COMBINED IMMUNODEFICIENCY <i>Poster Presenter: Eunsang Yi, KR</i>	08:30 - 08:30
<i>ePoster</i> 08:30 - 18:00		ePoster Area
Minimal Residual Disease, Tolerance, Chimerism and Immune Reconstitution		
P582	SEQUENTIAL QUANTIFICATION OF T-CELL RECEPTOR EXCISION CIRCLES (TREC) PREDICTS LONG-TERM OUTCOMES OF EARLY SURVIVORS AFTER ALLOGENEIC HSCT <i>Poster Presenter: Carlos De Miguel Jimenez, ES</i>	08:30 - 08:30
P583	GRADE I-II ACUTE GVHD PROTECTS FROM RELAPSE IN CHILDREN WITH ALL CONDITIONED WITH TBI AND VP-16 DESPITE MRD POSITIVITY PRE-HSCT <i>Poster Presenter: Adriana Balduzzi, IT</i>	08:30 - 08:30
P584	COMPARISON OF IMMUNE RECONSTITUTION BETWEEN MATCHED UNRELATED AND HAPLOIDENTICAL DONOR FOR ALLOGENEIC STEM-CELL TRANSPLANTATION IN PATIENTS WITH ACUTE LEUKEMIA WITH IDENTICAL CONDITIONING AND PTCY GVHD-PROPHYLAXIS <i>Poster Presenter: Radwan Massoud, DE</i>	08:30 - 08:30
P585	ROLE OF HLA EVOLUTIONARY DIVERGENCE IN SINGLE HLA-MISMATCHED UNRELATED DONOR HCT FOR MALIGNANT HEMATOLOGICAL DISORDERS: A REPORT ON BEHALF OF THE CTIWP OF THE EBMT <i>Poster Presenter: Simona Pagliuca, FR</i>	08:30 - 08:30
P586	NPM1(+) AML PATIENTS UNDERGOING ALLOGENEIC TRANSPLANTATION IN FIRST OR SECOND REMISSION: MEASURABLE RESIDUAL DISEASE PREDICTS OUTCOME <i>Poster Presenter: Eleni Paphianou, GR</i>	08:30 - 08:30
P587	HUMAN HERPESVIRUS 6 SPECIFIC T-CELL IMMUNITY IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS <i>Poster Presenter: Maddalena Noviello, IT</i>	08:30 - 08:30
P588	THE OCCURRENCE AND PROGNOSIS OF MIXED CHIMERISM POST HSCT: A MULTISTATE ANALYSIS <i>Poster Presenter: Erik G. J. Von Asmuth, NL</i>	08:30 - 08:30
P589	STABLE MIXED T-CELL CHIMERISM AFTER HCT FOR SEVERE APLASTIC ANAEMIA DOES NOT PREDICT GRAFT LOSS AND DOES NOT MANDATE IMMUNOMODULATION <i>Poster Presenter: Rubiya Nadaf, GB</i>	08:30 - 08:30
P590	THE COMPOSITE IMMUNE RISK SCORE PREDICTS OVERALL SURVIVAL AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL	08:30 - 08:30

	TRANSPLANTATION: A RETROSPECTIVE ANALYSIS OF 1838 CASES <i>Poster Presenter: Yigeng Cao, CN</i>	
P591	B-CELL RECONSTITUTION IN THE BONE MARROW FOLLOWING PEDIATRIC HSCT: HIGHER LEVELS OF B-CELL PRECURSORS AND PLASMABLASTS IN CHILDREN NOT RESPONDING TO RE-VACCINATION POST-HSCT <i>Poster Presenter: Elisa Christine Peen, DK</i>	08:30 - 08:30
P592	IMMUNE RECONSTITUTION KINETICS AFTER POST-TRANSPLANT CYCLOPHOSPHAMIDE BASED HLA-MATCHED SIBLING STEM CELL TRANSPLANTATION <i>Poster Presenter: Rebeca Bailen, ES</i>	08:30 - 08:30
P594	AGE-RELATED DYNAMICS OF IMMUNE CELL RECONSTITUTION INFLUENCE OUTCOMES AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION <i>Poster Presenter: Alizée Jandin, FR</i>	08:30 - 08:30
P595	THE EFFICACY AND SAFETY OF MODERATE-DOSE AZACYTIDINE FOR MAINTENANCE THERAPY FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION IN MYELOID MALIGNANCY <i>Poster Presenter: Yigeng Cao, CN</i>	08:30 - 08:30
P596	ROLE OF MEASURABLE RESIDUAL DISEASE QUANTIFIED BY MULTIPARAMETRIC FLOW CYTOMETRY BEFORE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR HIGH-RISK PHILADELPHIA-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA <i>Poster Presenter: Nour Abdeljelil, TN</i>	08:30 - 08:30
P597	GENE EXPRESSION PROFILING AND SIGNALING PATHWAY ANALYSIS OF TOLERANT T CELLS CIRCULATING IN ADULT PATIENTS AFTER PTCY HAPLOTRANSPLANTATION <i>Poster Presenter: Paul Szabolcs, US</i>	08:30 - 08:30
P598	CHANGES IN NATURAL KILLER IMMUNE RECONSTITUTION FOLLOWING POST-TRANSPLANT CYCLOPHOSPHAMIDE <i>Poster Presenter: Anabelle China, ES</i>	08:30 - 08:30
P599	DEFINITIONS, INCIDENCE AND OUTCOME OF POOR GRAFT FUNCTION AFTER HEMATOPOIETIC CELL TRANSPLANTATION: A SYSTEMATIC REVIEW AND META-ANALYSIS <i>Poster Presenter: Konradin F. Müskens, NL</i>	08:30 - 08:30
P600	VACCINATION WITH AN ADJUVANTED RECOMBINANT ZOSTER VACCINE (ARZV) IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS. A SINGLE CENTRE EXPERIENCE <i>Poster Presenter: Ana Belén Bocanegra, ES</i>	08:30 - 08:30
P601	POST DLI NPM-1 MINIMAL RESIDUAL DISEASE NEGATIVITY	08:30 - 08:30

	PREDICTS OVERALL SURVIVAL IN AML PATIENTS UNDERGOING REDUCED INTENSITY CONDITIONING TRANSPLANT	
	<i>Poster Presenter: Maria Fyrilla, CY</i>	
P602	PREVALENCE STUDY OF INFORMATIVE MARKERS FOR THE ANALYSIS OF CHIMERISM AMONG RECIPIENTS IN CAMPANIA REGION	08:30 - 08:30
	<i>Poster Presenter: Mafalda Caputo, IT</i>	
P603	IMMUNE MONITORING USING 13-COLOR FLOW CYTOMETRY: DURACLONE PANELS ENABLE ROBUSTNESS, PROLONGED STABILITY AND FLEXIBILITY	08:30 - 08:30
	<i>Poster Presenter: Sabine Huenecke, DE</i>	
<i>ePoster</i>		
08:30 - 18:00		ePoster Area
	Acute Leukaemia	
P666	CORD BLOOD TRANSPLANTATION FOR AML: COMPARABLE LFS IN PATIENTS WITH DE NOVO VERSUS SECONDARY AML	08:30 - 08:30
	<i>Poster Presenter: Frédéric Baron, BE</i>	
P667	TREATMENT PATTERNS AND OUTCOMES OF PATIENTS WITH PRIMARY OR SECONDARY ACUTE MYELOID LEUKEMIA BY TYPE OF SITE (ACADEMIC OR COMMUNITY/GOVERNMENT): A CONNECT® MYELOID REGISTRY STUDY	08:30 - 08:30
	<i>Poster Presenter: Bart Scott, US</i>	
P669	RECOMMENDED PHASE 3 DOSAGE OF VENETOCLAX IN THE VIALE-T STUDY OF VENETOCLAX PLUS AZACITIDINE AS MAINTENANCE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN PATIENTS WITH AML	08:30 - 08:30
	<i>Poster Presenter: Michael Heuser, DE</i>	
P671	NON MYELOABLATIVE VERSUS REDUCED INTENSITY CONDITIONING FOR ALLO-HCT FROM SIBLING OR UNRELATED DONORS IN PATIENTS WITH AML ≥65 YEARS. A STUDY FROM THE EBMT ALWP	08:30 - 08:30
	<i>Poster Presenter: Alexandros Kanellopoulos, GB</i>	
P672	ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT IN ADULT PATIENTS WITH IDH MUTATED AML AND MDS: A STUDY FROM THE GRUPO ESPAÑOL DE TRASPLANTE HEMATOPOYÉTICO Y TERAPIA CELULAR	08:30 - 08:30
	<i>Poster Presenter: Ana Pérez-González, ES</i>	
P673	SECOND ALLOGENEIC STEM CELL TRANSPLANTATION (HSCT2) FOR PRIMARY GRAFT FAILURE IN PATIENTS WITH ACUTE LEUKEMIA IN REMISSION: ON BEHALF OF THE ALWP OF THE EBMT	08:30 - 08:30
	<i>Poster Presenter: Arnon Nagler, IL</i>	
P674	AUTOLOGOUS VERSUS HAPLOIDENTICAL DONOR STEM CELL TRANSPLANTATION IN ADULT PATIENTS WITH AML IN FIRST	08:30 - 08:30

	COMPLETE REMISSION WITH UNDETECTABLE MRD: A GLOBAL REAL WORLD STUDY <i>Poster Presenter: Jia Chen, CN</i>	
P676	INTENSIVE PEGCETACOPLAN DOSING IN THE MANAGEMENT OF ACUTE HAEMOLYSIS AS PART OF THE 307 OPEN-LABEL EXTENSION STUDY <i>Poster Presenter: Morag Griffin, GB</i>	08:30 - 08:30
P677	COMBINATION OF BENDAMUSTINE AND CYCLOPHOSPHOMIDE FOR GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS IN REFRACTORY MYELOID NEOPLASMS <i>Poster Presenter: Ivan Moiseev, RU</i>	08:30 - 08:30
P678	OUTCOMES IN PATIENTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA WHO RECEIVED INOTUZUMAB OZOGAMICIN AND PROCEEDED TO HEMATOPOIETIC STEM CELL TRANSPLANTATION: A REGISTRY-BASED, OBSERVATIONAL STUDY <i>Poster Presenter: David Marks, GB</i>	08:30 - 08:30
P679	ACUTE LYMPHOBLASTIC LEUKEMIA PH POSITIVE VS PH NEGATIVE - REAL WORLD EXPERIENCE WITH ALLOGENEIC HCT OUTCOME ON BEHALF OF POLISH ADULT LEUKEMIA GROUP (PALG) <i>Poster Presenter: Jarosław Dybko, PL</i>	08:30 - 08:30
P680	ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AND LYMPHOBLASTIC LYMPHOMA: OUTCOMES AT THE NATIONAL CANCER CENTER HOSPITAL (NCCH) OF JAPAN <i>Poster Presenter: Masanori Sakata, JP</i>	08:30 - 08:30
P681	LONG-TERM SAFETY AND EFFICACY OF PEGCETACOPLAN TREATMENT IN ADULTS WITH PAROXYSMAL NOCTURNAL HAEMOGLOBINURIA <i>Poster Presenter: Régis Peffault de Latour, FR</i>	08:30 - 08:30
P682	EARLY LYMPHOCYTE IMMUNE RECONSTITUTION AS PREDICTOR FOR OUTCOMES AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR MALIGNANT INDICATIONS: A TRI-INSTITUTIONAL ANALYSIS <i>Poster Presenter: Alexandre Troullioud Lucas, US</i>	08:30 - 08:30
P683	FREQUENCY AND IMPACT OF PRE-TRANSPLANT SOMATIC MUTATIONS ON CLINICAL OUTCOMES OF AML PATIENTS RECEIVING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Poster Presenter: Waleed Da'na, JO</i>	08:30 - 08:30
P684	ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION SUB-ANALYSIS OF THE GIMEMA AML1310, A RISK ADAPTED, MRD-DIRECTED THERAPY FOR YOUNG ADULTS WITH AML <i>Poster Presenter: Francesca Bonifazi, IT</i>	08:30 - 08:30

P685	EFFICACY OF FLAG-MITOXANTRONE (M) COMBINED TO SHORT-ADMINISTRATION OF VENETOCLAX (VEN) FOLLOWED BY ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (AHSCT) IN RELAPSED/REFRACTORY (R/R) ACUTE MYELOBLASTIC LEUKEMIA (AML) <i>Poster Presenter:</i> Ahmad Ibrahim, LB	08:30 - 08:30
P686	VOLATILE PROFILING USING AN ENOSE ALLOWS DIFFERENTIATION OF HEALTHY AND LEUKEMIC BREATH SAMPLES <i>Poster Presenter:</i> Helga Maria Schmetzer, DE	08:30 - 08:30
P687	OUTCOMES OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT IN PATIENTS WITH WT1 MUTATED MYELOID NEOPLASMS	08:30 - 08:30
P688	VENETOCLAX AND HYPOMETHYLATING AGENTS FOLLOWED BY ALLOGENEIC STEM CELL TRANSPLANTATION IN PATIENTS WITH ACUTE MYELOID LEUKEMIA <i>Poster Presenter:</i> Christina Rautenberg, DE	08:30 - 08:30
P689	VENETOCLAX COMBINED WITH LOW DOSE CYTARABINE AND ACTINOMYCIN D FOR RELAPSED ACUTE MYELOID LEUKEMIA OR MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS-2 AFTER ALLOGENEIC STEM CELL TRANSPLANTATION <i>Poster Presenter:</i> Rita ?ekauskien?, LT	08:30 - 08:30
P690	INCREASED RELAPSE OF AML WITH HIGHER CYCLOSPORINE-A CONCENTRATION FIRST MONTH AFTER ALLOGENEIC STEM CELL TRANSPLANTATION WHEN COMBINED WITH ANTI-THYMOCYTE GLOBULIN <i>Poster Presenter:</i> Mikael Lisak, SE	08:30 - 08:30
P691	GENOMIC LANDSCAPE OF MYELOID SARCOMA: A PLEA FOR BETTER MOLECULAR CHARACTERIZATION AND A ROAD MAP FOR TARGETED THERAPIES	08:30 - 08:30
P692	CHIDAMIDE MAINTENANCE THERAPY FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR T CELL ACUTE LYMPHOBLASTIC LEUKEMIA <i>Poster Presenter:</i> Xing-Yu Cao, CN	08:30 - 08:30
P693	AUTOLOGOUS STEM CELL TRANSPLANTATION FOR ADULTS WITH PHILADELPHIA-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA IN FIRST COMPLETE REMISSION. A STUDY BY THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT <i>Poster Presenter:</i> Ryszard Swoboda, PL	08:30 - 08:30
P694	FEASIBILITY OF CONSOLIDATIVE ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT AFTER CAR T-CELL THERAPY IN ALL <i>Poster Presenter:</i> Nico Gagelmann, DE	08:30 - 08:30
P695	POTENTIAL MODIFICATION OF DYSREGULATED	08:30 - 08:30

	EXPRESSIONS OF INHIBITORY CHECKPOINT (ICM) AND THEIR LIGANDS ON T CELLS AND BLASTS IN AML RELAPSES AFTER STEM CELL TRANSPLANTATION (SCT) <i>Poster Presenter:</i> Helga Maria Schmetzer, DE	
P696	COMPARISON BETWEEN TRANSPLANT OUTCOMES AFTER CPX-351 VS OTHER INDUCTION REGIMENS IN NEWLY DIAGNOSED SECONDARY ACUTE MYELOID LEUKEMIA <i>Poster Presenter:</i> Gabriele Facchin, IT	08:30 - 08:30
P697	LONG TERM OUTCOME OF ACUTE LYMPHOBLASTIC LEUKEMIA FOLLOWING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: A 22 YEARS' SINGLE CENTER EXPERIENCE <i>Poster Presenter:</i> Mohammad Vaezi, IR	08:30 - 08:30
P698	AUTOLOGOUS STEM CELL TRANSPLANTATION PROVIDES COMPARABLE SURVIVAL TO ALLOGENEIC MATCHED SIBLING DONORS IN PATIENTS WITH CORE-BINDING FACTOR AML IN FIRST COMPLETE REMISSION <i>Poster Presenter:</i> Rama Al Hamed, US	08:30 - 08:30
P699	SORAFENIB MAINTENANCE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT FOR FLT3+ ACUTE MYELOID LEUKEMIA: A SINGLE CENTER EXPERIENCE <i>Poster Presenter:</i> Giuseppe Sapienza, IT	08:30 - 08:30
P700	REDUCING THE DOSE OF BUSULFAN IN TBF CONDITIONIG, FOR AML OVER THE AGE OF 60: IS IT ENOUGH TO REDUCE TRANSPLANT RELATED MORTALITY? <i>Poster Presenter:</i> Andrea Bacigalupo, IT	08:30 - 08:30
P701	FACTORS ASSOCIATED WITH ACUTE MYELOID LEUKEMIA RELAPSE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION <i>Poster Presenter:</i> Juan José Domínguez-García, ES	08:30 - 08:30
P702	TREATMENT WITH AZACITIDINE AND VENETOCLAX IS AN EFFECTIVE BRIDGE TO SECOND ALLOGENEIC TRANSPLANTATION IN PATIENTS WITH RELAPSED ACUTE MYELOID LEUKEMIA AFTER FIRST ALLOGENEIC TRANSPLANTATION <i>Poster Presenter:</i> Nadira Durakovi?, HR	08:30 - 08:30
P703	IMPAIRED ACCESS OF UKRAINIAN PATIENTS TO HEMATOPOIETIC CELL TRANSPLANTATION (HCT) DURING THE RUSSIAN AGGRESSION IN 2022 <i>Poster Presenter:</i> Kateryna Filonenko, PL	08:30 - 08:30
P704	ADVERSE PROGNOSIS OF LOW AR FLT3-ITD IN AML AND CLINICAL BENEFIT OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN AML PATIENTS WITH LOW AR FLT3-ITD AND NPM1 <i>Poster Presenter:</i> Hyeoung-Joon Kim, KR	08:30 - 08:30

P705	IMPACT OF CYTOGENETIC ABNORMALITIES DEFINING AML MYELODYSPLASIA-RELATED (WHO AND ICC 2022) IN FIRST LINE DECITABINE IN UNFIT AML PATIENTS <i>Poster Presenter: Adolfo de la Fuente, ES</i>	08:30 - 08:30
P706	FOLLOW-UP UPDATE OF THE FLAG-IDA REGIMEN AS BRIDGE THERAPY TO ALLOTRANSPLANTATION IN REFRACTORY/RELAPSED ACUTE MYELOID LEUKEMIA PATIENTS: 10 YEAR-RESULTS FROM A SINGLE CENTRE EXPERIENCE <i>Poster Presenter: Mario Delia, IT</i>	08:30 - 08:30
P707	ACUTE MYELOID LEUKEMIA AND ALLOGENEIC TRANSPLANTATION: SINGLE-CENTER EXPERIENCE <i>Poster Presenter: José María Sánchez-Pina, ES</i>	08:30 - 08:30
P708	EARLY ALLOGENEIC STEM CELL TRANSPLANTATION AFTER MELPHALAN-INDUCED APLASIA LEADS TO LONG-TERM SURVIVAL IN PATIENTS WITH PRIMARY REFRACTORY AML <i>Poster Presenter: Claudius Söhn, DE</i>	08:30 - 08:30
P709	OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN ADULT ACUTE MYELOID LEUKEMIA PATIENTS: A 30-YEAR SINGLE CENTER EXPERIENCE <i>Poster Presenter: Tanaz Bahri, IR</i>	08:30 - 08:30
P710	POST ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION MAINTENANCE WITH AZACITIDINE IN COMBINATION WITH VENETOCLAX IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA <i>Poster Presenter: Nour Moukalled, LB</i>	08:30 - 08:30
P711	POST-INDUCTION AKT EXPRESSION DOES NOT IMPACT OVERALL SURVIVAL IN PATIENTS WITH ACUTE MYELOID LEUKEMIA <i>Poster Presenter: Safa Al-Amrani, OM</i>	08:30 - 08:30
P712	ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS WITHOUT TOTAL BODY IRRADIATION: A SINGLE-CENTER EXPERIENCE <i>Poster Presenter: Fabio Serpenti, IT</i>	08:30 - 08:30
P713	MYELOID SARCOMA OF THE BREAST IN POST-ALLOGENEIC STEM CELL TRANSPLANT RELAPSE: RETROSPECTIVE ANALYSIS FROM A REFERENCE TRANSPLANT CENTER <i>Poster Presenter: Evelyn Zapata, ES</i>	08:30 - 08:30
P714	SEQUENTIAL REGIMEN AND REDUCED-INTENSITY CONDITIONED TRANSPLANTATION FOR ACUTE MYELOBLASTIC LEUKEMIA AND MYELODYSPLASTIC SYNDROMES. UNICENTRIC EXPERIENCE <i>Poster Presenter: Alejandro Avendaño Pita, ES</i>	08:30 - 08:30
P715	LONG-TERM OUTCOMES OF ALLOGENEIC STEM CELL	08:30 - 08:30

TRANSPLANTATION IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA

Poster Presenter: Anna P?otka, PL

- | | | |
|------|--|---------------|
| P716 | <p>POST-INDUCTION IDH2 EXPRESSION DOES NOT IMPACT OVERALL SURVIVAL IN PATIENTS WITH ACUTE MYELOID LEUKEMIA</p> <p><i>Poster Presenter:</i> Safa Al-Amrani, OM</p> | 08:30 - 08:30 |
| P717 | <p>CD33+ TARGETING, CONSOLIDATIVE HSCT AND INTEGRATION OF MIDOSTAURIN IN FLT3 POSITIVE AML PEDIATRIC PATIENTS: A SINGLE CENTER EXPERIENCE</p> <p><i>Poster Presenter:</i> Maria Gabelli, IT</p> | 08:30 - 08:30 |
| P718 | <p>THE OUTCOME OF SECONDARY AML PATIENTS WITH PRIOR BREAST CANCER UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION IS AS GOOD AS DE NOVO AML</p> <p><i>Poster Presenter:</i> Meltem Kurt Yüksel, TR</p> | 08:30 - 08:30 |
| P719 | <p>OUTCOMES IN SURVIVAL IN PATIENTS WITH ACUTE LEUKEMIA IN PEDIATRIC AND YOUNG ADULTS WITH ALLOGENIC HSCT AND HAPLOIDENTICAL HSCT IN A MEXICAN PUBLIC HEALTH HOSPITAL</p> <p><i>Poster Presenter:</i> Severiano Baltazar Arellano, MX</p> | 08:30 - 08:30 |

ePoster

08:30 - 18:00

ePoster Area

Paediatric Issues

- | | | |
|------|--|---------------|
| P604 | <p>UBTF-TD – IMPACT OF THE NEW KID ON THE BLOCK ON HSCT IN PEDIATRIC MDS</p> <p><i>Poster Presenter:</i> Brigitte Strahm, DE</p> | 08:30 - 08:30 |
| P605 | <p>EXCELLENT GLOBAL QOL IN ADULT SURVIVORS AFTER PEDIATRIC HCT - BUT THE CATCH IS HIDDEN IN THE DETAILS</p> <p><i>Poster Presenter:</i> Anita Lawitschka, AT</p> | 08:30 - 08:30 |
| P606 | <p>TREOSULFAN BASED CONDITIONING FOR HAEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN CHILDREN: ON BEHALF OF THE UK PAEDIATRIC BMT GROUP</p> <p><i>Poster Presenter:</i> Tom Altmann, GB</p> | 08:30 - 08:30 |
| P607 | <p>IMPACT OF ATLG GRAFALON® EXPOSURE ON ACUTE GVHD AND REMISSION-STATE SPECIFIC RELAPSE RATE AFTER HSCT IN THE PAEDIATRIC FORUM ALL COHORT</p> <p><i>Poster Presenter:</i> Lisa V.E. Oostenbrink, NL</p> | 08:30 - 08:30 |
| P608 | <p>A RETROSPECTIVE STUDY ANALYZING THE OUTCOME OF HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN AND ADOLESCENTS WITH THERAPY-RELATED MYELODYSPLASTIC SYNDROME</p> <p><i>Poster Presenter:</i> Brigitte Strahm, DE</p> | 08:30 - 08:30 |
| P609 | <p>MIXED DONOR CHIMERISM IN PAEDIATRIC B-ALL PATIENTS BRIDGED TO TRANSPLANT WITH BLINATUMOMAB – A</p> | 08:30 - 08:30 |

REPORT FROM THE UK AND IRELAND PAEDIATRIC BSBMTCT GROUP*Poster Presenter:* Oana Mirci-Danicar, GB

- | | | |
|------|--|---------------|
| P610 | EXCELLENT OUTCOMES OF REDUCED-TOXICITY EX-VIVO T-DEPLETED HAPLOIDENTICAL HAEMATOPOIETIC CELL TRANSPLANTATION WITH CD45RA-DEPLETED MEMORY T CELL ADD-BACK IN PAEDIATRIC MALIGNANT AND NON-MALIGNANT DISEASES: 8-YEAR RESULTS
<i>Poster Presenter:</i> Michaela Seng, SG | 08:30 - 08:30 |
| P611 | GUT MICROBIOTA DIVERSITY BEFORE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION AS PREDICTOR OF MORTALITY AND HIGH-GRADE AGVHD IN CHILDREN
<i>Poster Presenter:</i> Francesco Baccelli, IT | 08:30 - 08:30 |
| P612 | LONG-TERM COMPLICATIONS IN CHILDREN UNDERGOING ALLOGENEIC HSCT FOR MALIGNANCIES WITH A TREOSULFAN OR A BUSULFAN BASED CONDITIONING: RESULTS OF AN AIEOP RETROSPECTIVE STUDY
<i>Poster Presenter:</i> Francesco Saglio, IT | 08:30 - 08:30 |
| P613 | LESS SEVERE GRAFT-VERSUS-HOST-DISEASE IN PEDIATRIC PATIENTS RECOVERING WITH HIGH Vβ2+ T-CELLS AFTER ALLOGENEIC HSCT WITH UNMANIPULATED BONE MARROW GRAFTS: A SINGLE CENTER PEDIATRIC COHORT STUDY
<i>Poster Presenter:</i> Thilo Müller, DE | 08:30 - 08:30 |
| P614 | SUCCESS OF PERSONALIZED RUXOLITINIB TREATMENT BASED ON THERAPEUTIC DRUG MONITORING IN PEDIATRIC PATIENTS WITH PRIMARY AND SECONDARY HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS ALLOWING BRIDGING TO HSCT
<i>Poster Presenter:</i> Michele Massa, IT | 08:30 - 08:30 |
| P615 | THE GRANS STUDY: GRANULOCYTE TRANSFUSION DURING CBT FOR REFRACTORY AML IS ASSOCIATED WITH MASSIVE CD8 T CELL EXPANSION, SIGNIFICANT CRS, AND INDUCTION OF DISEASE REMISSION
<i>Poster Presenter:</i> Roisin Borrill, GB | 08:30 - 08:30 |
| P617 | USE OF ECULIZUMAB IN PEDIATRIC PATIENTS WITH HIGH-RISK TRANSPLANT ASSOCIATED THROMBOTIC MICROANGIOPATHY – RESULTS FROM THE SPANISH GROUP OF BONE MARROW TRANSPLANTATION IN CHILDREN (GETMON)
<i>Speaker:</i> Maria Isabel Benitez Carabante, ES | 08:30 - 08:30 |
| P618 | INFLUENCE OF SEPTIC SHOCK ON THE LONG-TERM CARDIOLOGICAL OUTCOME IN PEDIATRIC PATIENTS AFTER CHEMOTHERAPY AND STEM CELL TRANSPLANTATION
<i>Poster Presenter:</i> Marco Zecca, IT | 08:30 - 08:30 |
| P619 | NAÏVE (CD45RA+) T-CELL-DEPLETED ALLOGENEIC | 08:30 - 08:30 |

	HEMATOPOIETIC STEM CELL TRANSPLANTATION FROM HLA MATCHED DONORS IN PAEDIATRIC PATIENTS <i>Poster Presenter:</i> Marta Gonzalez Vicent, ES	
P620	SURVIVAL OUTCOMES OF YOUNG CHILDREN WITH MALIGNANT BRAIN TUMORS AFTER INTENSIVE INDUCTION, MYELOABLATIVE CHEMOTHERAPY AND AUTOLOGOUS HEMATOPOIETIC PROGENITOR CELL RESCUE WITH OR WITHOUT IRRADIATION POST-AUHCR <i>Poster Presenter:</i> Sheetal Phadnis, US	08:30 - 08:30
P621	CYCLOPHOSPHAMIDE AND THIOTEPA COMBINATION INCREASES RISK OF TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY <i>Poster Presenter:</i> Christine S Higham, US	08:30 - 08:30
P622	CD28-COSTIMULATED CD19 CAR T CELLS FOR PEDIATRIC RELAPSED AND REFRACTORY MATURE B-CELL LYMPHOMA <i>Poster Presenter:</i> Etai Adam, IL	08:30 - 08:30
P623	THE COMBINATION OF EVEROLIMUS AND MYCOPHENOLATE MOFETIL FOR GVHD PROPHYLAXIS AFTER ALLOGENEIC HSCT IN CHILDREN WITH ACUTE RENAL FAILURE – A SINGLE CENTER RETROSPECTIVE ANALYSIS <i>Poster Presenter:</i> Arend von Stackelberg, DE	08:30 - 08:30
P624	OUTCOME OF TREOSULFAN-BASED CONDITIONING IN 93 INFANTS WITH SCID – A MULTICENTRE RETROSPECTIVE COHORT ANALYSIS <i>Poster Presenter:</i> Sinéad Greener, GB	08:30 - 08:30
P625	MULTIVARIATE ANALYSIS OF THE NK CELLS FACTORS EFFECT ON ACUTE LEUKEMIA RELAPSE AND TRM AMONG CHILDREN AFTER HAPLO HSCT WITH ?? T CELL DEPLETION <i>Poster Presenter:</i> Svetlana Glushkova, RU	08:30 - 08:30
P626	HLA-HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE (HAPLO-PTCY) IN CHILDREN WITH NON-MALIGNANT DISEASES: A RETROSPECTIVE ANALYSIS OF 192 PATIENTS TRANSPLANTED IN CURITIBA, BRAZIL <i>Poster Presenter:</i> Rafaella Muratori, BR	08:30 - 08:30
P627	COMPARISON OF SUBCUTANEOUS VERSUS INTRAVENOUS ALEMTUZUMAB WITH FLUDARABINE/MELPHALAN BASED CONDITIONING IN ALLOGENEIC STEM CELL TRANSPLANTATION FOR PEDIATRIC PATIENTS WITH SICKLE CELL DISEASE <i>Poster Presenter:</i> Alexander Ngwube, US	08:30 - 08:30
P628	CMV SEROLOGY MATCH IS NOT CORRELATED WITH BETTER OUTCOMES IN PEDIATRIC MALIGNANCIES USING HLA-MATCHED SIBLING DONORS BELOW THE AGE OF 12: A PDWP/EBMT STUDY <i>Poster Presenter:</i> EL?F ?NCE, TR	08:30 - 08:30

P629	GRAFT CRYOPRESERVATION EFFECTS ON THE OUTCOMES OF ALLOGENEIC HAEMATOPOIETIC CELL TRANSPLANTS IN PAEDIATRIC POPULATION: A MULTICENTRE UK STUDY <i>Poster Presenter:</i> Angharad Pryce, GB	08:30 - 08:30
P630	TOTAL BODY IRRADIATION FOR CHILDHOOD ALL: LOWER INCIDENCE OF LATE EFFECTS WITH INCREASED FRACTIONATION <i>Poster Presenter:</i> Hilde Hylland Uhving, DK	08:30 - 08:30
P631	IMMUNE RECONSTITUTION PATTERNS AFTER HEMATOPOIETIC STEM CELL TRANSPLANT FOR PEDIATRIC PATIENTS WITH NONMALIGNANT DISORDERS <i>Poster Presenter:</i> Natalie Booth, US	08:30 - 08:30
P632	ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION ASSOCIATED THROMBOTIC MICROANGIOPATHY IN PEDIATRIC PATIENTS: CLINICAL CHARACTERISTICS AND DEFIBROTIDE THERAPY <i>Poster Presenter:</i> Guanghai Zhu, CN	08:30 - 08:30
P633	SAFETY AND POTENTIAL EFFECTIVENESS OF ANAKINRA AS THERAPY AND STEROID-SPARING AGENT IN THE MANAGEMENT OF INFLAMMATORY COMPLICATIONS IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN <i>Poster Presenter:</i> Maura Faraci, IT	08:30 - 08:30
P634	AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATIONS FOR NEWLY DIAGNOSED OR RELAPSED EWING SARCOMA IN CHILDREN AND ADOLESCENTS: EXPERIENCE OF TWO ISRAELI CENTERS <i>Poster Presenter:</i> Aharon Gefen, IL	08:30 - 08:30
P635	IMPACT OF VITAMIN D LEVEL ON OUTCOME AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDHOOD <i>Poster Presenter:</i> Bernd Gruhn, DE	08:30 - 08:30
P636	SYMPTOMATIC AVASCULAR NECROSIS OF THE BONE IN CHILDREN AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Poster Presenter:</i> Victoria Bordon, BE	08:30 - 08:30
P637	ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR JUVENILE MYELOMONOCYTIC LEUKEMIA USING INTRAVENOUS BUSULFAN, FLUDARABINE, AND MELPHALAN REGIMEN; A PROSPECTIVE SINGLE-ARM PHASE ?STUDY BY JPLSG <i>Poster Presenter:</i> Kazuo Sakashita, JP	08:30 - 08:30
P638	COMORBIDITY SCORING PREDICTS OUTCOMES AFTER HAPLOIDENTICAL TRANSPLANTATION IN PEDIATRIC NON-MALIGNANT DISEASES <i>Poster Presenter:</i> Koray Yalcin, TR	08:30 - 08:30

P639	BELATACEPT: A PROMISING ALTERNATIVE TO TRADITIONAL GRAFT VERSUS HOST DISEASE PROPHYLAXIS IN CHILDREN AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Poster Presenter: Rajinder Bajwa, US</i>	08:30 - 08:30
P640	PLASMA ST2 LEVELS ARE PREDICTIVE OF CHRONIC GVHD AFTER PEDIATRIC HSCT <i>Poster Presenter: Nakisa Kamari-Kany, DK</i>	08:30 - 08:30
P641	ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA: A STUDY OF THE KOREAN BLOOD AND MARROW TRANSPLANTATION REGISTRY <i>Poster Presenter: Hyoung Soo Choi, KR</i>	08:30 - 08:30
P642	COMBINED IMMUNOTHERAPY AFTER HAPLO-HSCT IN INFANTS ALL WITH KMT2A REARRANGEMENT <i>Poster Presenter: Liubov Tsvetkova, RU</i>	08:30 - 08:30
P643	EFFECT OF GVHD PROPHYLAXIS AND SEROTHERAPY IN 58 PEDIATRIC HEMOGLOBINOPATHY PATIENTS CONDITIONED WITH TREOSULPHAN, FLUDARABINE AND THIOTEPA <i>Poster Presenter: Ysabel Schwietzer, DE</i>	08:30 - 08:30
P644	LOW INCIDENCE OF RELAPSE AND GOOD SAFETY PROFILE IN CHILDREN WITH HIGH RISK AND RELAPSED LEUKEMIA ALLOGRAFTED WITH POSTTRANSPLANT CYCLOPHOSPHAMIDE (PTCY) <i>Oral Presenter: Francesco Baccelli, IT</i>	08:30 - 08:30
P645	HEMATOPOETIC STEM CELL TRANSPLANTATION IN INBORN ERRORS OF METABOLISM - POLISH EXPERIENCE <i>Poster Presenter: Anna Fałkowska, PL</i>	08:30 - 08:30
P646	USE OF LIVER POINT SHEAR WAVE ELASTOGRAPHY (PSWE) IN THE DIAGNOSIS OF SINUSOIDAL OBSTRUCTION SYNDROME IN CHILDREN <i>Poster Presenter: Blanca Molina, ES</i>	08:30 - 08:30
P647	SALVAGE TREATMENT OF PROGRESSIVE SEVERE CHRONIC GRAFT-VERSUS-HOST DISEASE BY IMMUNE ABLATION AND STEM CELL RESCUE IN 2 PEDIATRIC PATIENTS <i>Poster Presenter: Jaspar Kloehn, DE</i>	08:30 - 08:30
P648	SOLUBLE THROMBOMODULIN IS ASSOCIATED WITH ENDOTHELIAL DYSFUNCTION AFTER PEDIATRIC MYELOABLATIVE HSCT <i>Poster Presenter: Klaus Müller, DK</i>	08:30 - 08:30
P649	ABO BLOOD GROUP INCOMPABILITY BETWEEN RECIPIENT AND DONOR EFFECT ON TRANSPLANT RESULTS IN TRANSFUSION DEPENDENT THALASSEMIA PATIENTS <i>Poster Presenter: O.Alphan Küpesiz, TR</i>	08:30 - 08:30

P651	REAL-TIME TREOSULFAN PHARMACOKINETICS FOR SCID INFANTS IDENTIFIED BY NEWBORN SCREENING <i>Poster Presenter: Sebastian Rosser, AU</i>	08:30 - 08:30
P652	THE EFFECT OF HLA B-LEADER, AND HLA DQ HETERODIMERS MATCHING IN PEDIATRIC HAPLOIDENTICAL STEM CELL TRANSPLANTATION IN ACUTE LEUKEMIA; RETROSPECTIVE SINGLE CENTER ANALYSIS <i>Poster Presenter: Mohammed Essa, SA</i>	08:30 - 08:30
P653	ASSESSMENT OF KIDNEY FUNCTION USING DIFFERENT ESTIMATED GLOMERULAR FILTRATION RATES DURING PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Poster Presenter: Peter Lang, DE</i>	08:30 - 08:30
P654	DEVELOPMENT OF SEIZURES IN CHILDREN UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) <i>Poster Presenter: Iván López Torija, ES</i>	08:30 - 08:30
P655	NO DIFFERENCES IN EPIDEMIOLOGY AND IMPACT OF VIRAL INFECTIONS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION BETWEEN CHILDREN AND YOUNG ADULTS: A SINGLE CENTER EXPERIENCE <i>Poster Presenter: Manuela Spadea, IT</i>	08:30 - 08:30
P656	GRAFT FAILURE COMPLICATING ADENOVIRUS INFECTION: A UK NATIONAL EXPERIENCE <i>Poster Presenter: Shagun Shah, GB</i>	08:30 - 08:30
P657	MOBILISATION AND LEUKAPHERESIS FOR HAEMATOPOIETIC STEM CELL GENE THERAPY IN PAEDIATRICS INCLUDING INFANTS: A MULTIDISCIPLINARY STRATEGY FOR SUCCESS <i>Poster Presenter: Claire Horgan, GB</i>	08:30 - 08:30
P658	THE IMPACT OF RENAL ANOMALIES ON POST-HEMATOPOIETIC STEM CELL TRANSPLANTATION OUTCOME IN PEDIATRICS FANCONI ANEMIA <i>Poster Presenter: AmirAli Hamidieh, IR</i>	08:30 - 08:30
P659	PEDIATRIC AUTOLOGOUS STEM CELL TRANSPLANTS: A SINGLE CENTRE EXPERIENCE <i>Poster Presenter: Ashutosh Walawalkar, IN</i>	08:30 - 08:30
P660	CASE REVIEW OF NUTRITION MANAGEMENT FOR WOLMAN DISEASE DURING ADMISSION FOR HSCT <i>Poster Presenter: Rebecca Fisher, AU</i>	08:30 - 08:30
P661	ORAL MICROBIOME IN PEDIATRIC AND YOUNG ADULT PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE CENTER PROSPECTIVE STUDY <i>Poster Presenter: Maura Faraci, IT</i>	08:30 - 08:30
P662	EXPERIENCE OF HAPLOIDENTICAL STEM CELL TRANSPLANTATION FOR CHILDREN WITH ACUTE LEUKEMIA,	08:30 - 08:30

MYELODISPLASTIC SYNDROME IN BELARUS*Poster Presenter:* Nina Minakovskaya, BY

P663	CENTRAL NERVOUS SYSTEM INVOLVEMENT IN POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A PEDIATRIC CASE	08:30 - 08:30
P664	CLINICAL PHARMACEUTICAL CHALLENGES OF A BONE MARROW TRANSPLANT (BMT) PATIENT WITH HUMAN IMMUNODEFICIENCY VIRUS (HIV): A PAEDIATRIC PHARMACISTS PERSPECTIVE <i>Poster Presenter:</i> Poonam Lumb, GB	08:30 - 08:30
P665	REVIEW OF NUTRITION SUPPORT PRACTICES IN PEDIATRIC HSCT RECIPIENTS: A NEWLY ESTABLISHED CENTER <i>Poster Presenter:</i> Fatma SE Ebeid, EG	08:30 - 08:30

Library

08:30 - 18:00

Library

Library*Breaks*

10:00 - 10:30

AMPHITHEATRE BLEU

Coffee Break, ePoster Viewing, Visit Exhibition*Industry Symposium*

10:30 - 12:00

AMPHITHEATRE BLEU

IS06 - Chronic GVHD: What's new in 2023? | Sanofi

IS06-1	Welcome and introduction <i>Speaker:</i> Mohamad Mohty, FR	10:30 - 10:35
IS06-2	Diagnosis and grading of chronic GVHD severity: The NIH consensus <i>Speaker:</i> Steven Pavletic, US	10:35 - 10:50
IS06-3	Long-term complications of chronic GVHD <i>Speaker:</i> Zinaida Peric, HR	10:50 - 11:05
IS06-4	Best practices in lung chronic GVHD <i>Speaker:</i> Daniel Wolff, DE	11:05 - 11:20
IS06-5	Management of chronic GVHD: A real-life case	11:20 - 11:20
IS06-6	Outline of case <i>Speaker:</i> Eolia Brissot, FR	11:20 - 11:30
IS06-7	Discussion (with all faculty)	11:30 - 11:50
IS06-8	Q&A and closing remarks	11:50 - 12:00

Industry Symposium

10:30 - 12:00

Room 141

IS07 - Updates in CMV in HSCT: State of the Art | MSD*Chair:* Rafael de la Cámara, ES

IS07-1	Welcome, Introductions and Opening Remarks <i>Speaker:</i> Rafael de la Cámara, ES	10:30 - 10:35
IS07-2	CMV in HSCT: Current Challenges and Controversies <i>Speaker:</i> Per Ljungman, SE	10:35 - 10:55
IS07-3	Real World Evidence: What Has the Past CMV Experience Taught Us? <i>Speaker:</i> Mattias Stelljes, DE	10:55 - 11:15
IS07-4	Emerging New Data: Building Blocks for Future CMV Management <i>Speaker:</i> Miguel-Angel Perales, US	11:15 - 11:35
IS07-5	Panel Q&A - All	11:35 - 11:55
IS07-6	Closing Remarks <i>Speaker:</i> Rafael de la Cámara, ES	11:55 - 12:00

Industry Symposium

10:30 - 12:00

Room 143

IS08 - FINDING THE NEEDLE IN THE HAYSTACK: CHALLENGES IN DIAGNOSING HSCT-TMA PATIENTS AND UNDERSTANDING THE ROLE OF THE LECTIN PATHWAY OF COMPLEMENT IN DISEASE PATHOPHYSIOLOGY | OMEROS*Chair:* Rafael Duarte, ES

IS08-1	Welcome and Introductions <i>Speaker:</i> Rafael Duarte, ES	10:30 - 10:35
IS08-2	Understanding the HSCT-TMA Patient Journey <i>Speaker:</i> Rafael Duarte, ES	10:35 - 10:55
IS08-3	Harmonizing Diagnosis of HSCT-TMA Patients <i>Speaker:</i> Michelle L Schoettler, US	10:55 - 11:25
IS08-4	The Lectin Pathway's Role in HSCT-TMA <i>Speaker:</i> Michael Scordo, US	11:25 - 11:50
IS08-5	Q&A - All	11:50 - 12:00

Industry Symposium

10:30 - 12:00

Room 151

IS09 - HOW TO MANAGE AND TREAT PATIENTS WITH BPDCN | Stemline Therapeutics*Chair:* Marco Herling, DE

IS09-1	Introduction <i>Speaker:</i> Marco Herling, DE	10:30 - 10:40
IS09-2	Characterization and proper diagnosis of BPDCN <i>Speaker:</i> Claudio Cerchione, IT	10:40 - 11:00

IS09-3	Treatment of BPDCN: Clinical data and long-term outcomes <i>Speaker:</i> Marco Herling, DE	11:00 - 11:15
IS09-4	Real life experience in the treatment of patients with BPDCN <i>Speaker:</i> Eric Deconinck, FR	11:15 - 11:30
IS09-5	Clinical cases of BPDCN: Fit vs non fit patient cases <i>Speaker:</i> Marco Herling, DE <i>Speaker:</i> Eric Deconinck, FR <i>Speaker:</i> Claudio Cerchione, IT	11:30 - 11:45
IS09-6	Panel discussion and closing remarks <i>Speaker:</i> Marco Herling, DE	11:45 - 12:00

Patient, Family, and Donor Day
10:30 - 11:45

Room 153

PFD02 - Patient, Family and Donor Day 2 - Sexual function and sexuality after haematopoietic cell transplantation: What to expect?

Chair: Andrea Linke, DE

Chair: Peter Feenstra, FR

PFD02-1	Introductions & set up the scene by the chairs	10:30 - 10:35
PFD02-2	Patient journey: Sexual life after HSCT <i>Speaker:</i> Kirsti Scheffel, DE	10:35 - 10:45
PFD02-3	Sexual and Emotional Health after Allogeneic Hematopoietic Cell Transplantation: A Review and a presentation of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC) Guidelines <i>Speaker:</i> Tamim Alsuliman, FR	10:45 - 11:00
PFD02-4	The S-FAST Study: Sexual functioning of long-term survivors and partners after allogeneic hematopoietic cell transplantation in Europe <i>Speaker:</i> Lars Klingen Gjørde, DK	11:00 - 11:15
PFD02-5	Discussion, Q&A	11:15 - 11:45

Nurses Group
10:30 - 12:00

Room 242 AB

NG02 - Nurses Education Day 2 - Nursing challenges in 2023: Nurses impact on the top three

Chair: Thomas Jezequel, FR

Chair: Kathy Goris, BE

NG02-1	GVHD <i>Speaker:</i> John Murray, GB	10:30 - 10:55
NG02-2	Infections <i>Speaker:</i> Iris Agreiter, IE	10:55 - 11:20
NG02-3	Relapse <i>Speaker:</i> Laura Ricketts, GB	11:20 - 11:45
NG02-4	Q&A	11:45 - 12:00

Breaks

12:00 - 12:30

AMPHITHEATRE BLEU

Break, ePoster Viewing, Visit Exhibition*Patient, Family, and Donor Day*

12:15 - 13:30

Room 153

PFD03 - Patient, Family and Donor Day 3 - Emotional experiences: Coping with Grief and Psychological Consequences of Hematopoietic Stem Cell Transplant*Chair:* Noëlle Tassy, FR*Chair:* Lise-lott Eriksson, SE

PFD03-1	Introductions & set up the scene by the chairs	12:15 - 12:20
PFD03-2	Patients with multiple sclerosis after aHSCT: bereavements inherent to the disease and to access to treatment' specificities <i>Speaker:</i> Noëlle Tassy, FR	12:20 - 12:35
PFD03-3	Donor grief after unsuccessful related or unrelated stem cell transplantation <i>Speaker:</i> Yolande Arnault, FR	12:35 - 12:50
PFD03-5	Smile as a part of survivorship - parent's view on child's HSCT <i>Speaker:</i> Ludmila Hurajova, SK	12:50 - 13:05
PFD03-6	Discussion	13:05 - 13:30

Industry Symposium

12:30 - 14:00

AMPHITHEATRE BLEU

IS11 - CAR T cell therapy for LBCL: current status and future perspectives | Bristol Myers Squibb*Chair:* Anna Sureda, ES

IS11-1	Welcome and Introduction <i>Speaker:</i> Anna Sureda, ES	12:30 - 12:35
IS11-2	Optimization of CAR T cell therapy in LBCL <i>Speaker:</i> Catherine Thieblemont, FR	12:35 - 13:10
IS11-3	The pivotal role of CAR T cell therapy in LBCL <i>Speaker:</i> Bertram Glass, DE	13:10 - 13:45
IS11-4	Q&A and discussion - All faculty, moderated by: <i>Speaker:</i> Anna Sureda, ES	13:45 - 14:00

Industry Symposium

12:30 - 14:00

Room 141

IS12 - Clinical Pearls for Managing CMV in HCT Recipients: Combating Refractory or Resistant Infections | RMEI*Chair:* Roy Chemaly, US

IS12-1	Welcome and Introductions <i>Speaker:</i> Roy Chemaly, US	12:30 - 12:45
IS12-2	Panel Discussion 1: Evidence-Based Management of CMV <i>Speaker:</i> Roy Chemaly, US	12:45 - 13:05

IS12-3	Panel Discussion 2: Limitations of Conventional Antiviral Therapy: Toxicity and Resistance <i>Speaker:</i> Rafael Duarte, ES	13:05 - 13:20
IS12-4	Panel Discussion 3: Refractory and Resistant CMV in HCT Patients <i>Speaker:</i> Sophie Alain, FR	13:20 - 13:45
IS12-5	Audience Q&A and Closing Remarks <i>Speaker:</i> Roy Chemaly, US <i>Speaker:</i> Rafael Duarte, ES <i>Speaker:</i> Sophie Alain, FR	13:45 - 14:00

Industry Symposium

12:30 - 14:00

Room 143

IS13 - How I Treat Steroid Dependent/-Refractory GvHD: Expert perspectives on optimizing clinical outcomes | NOVARTIS*Chair:* Mohamad Mohty, FR

IS13-1	Welcome and Introductions <i>Speaker:</i> Mohamad Mohty, FR	12:30 - 12:35
IS13-2	How Do I Select and Optimize Therapy for Steroid-Dependent/-Refractory Acute GvHD? <i>Speaker:</i> José A. Pérez-Simón, ES	12:35 - 12:55
IS13-3	How Do I Select and Optimize Therapy for Steroid-Dependent/-Refractory Chronic GvHD? <i>Speaker:</i> Nada Hamad, AU	12:55 - 13:15
IS13-4	Case-Based Panel Discussion and Q&A – Practical Strategies for Optimizing Clinical Outcomes in Steroid-Dependent/-Refractory GvHD <i>Speaker:</i> Mohamad Mohty, FR <i>Speaker:</i> José A. Pérez-Simón, ES <i>Speaker:</i> Nada Hamad, AU	13:15 - 13:55
IS13-5	Concluding Remarks <i>Speaker:</i> Mohamad Mohty, FR	13:55 - 14:00

Industry Symposium

12:30 - 14:00

Room 151

IS14 - Practicalities of screening and diagnosis of HSCT-TMA: where are we and where should we go next? | ALEXION*Chair:* Régis Peffault de Latour, FR

IS14-1	Welcome and introduction <i>Speaker:</i> Régis Peffault de Latour, FR	12:30 - 12:35
IS14-2	Pathophysiology of HSCT-TMA <i>Speaker:</i> Christopher Dvorak, US	12:35 - 12:45
IS14-3	A harmonized approach to diagnosis of HSCT-TMA <i>Speaker:</i> Nicolaus Kröger, DE	12:45 - 13:00

IS14-4	Experience of screening and diagnosis of HSCT-TMA in paediatric patients <i>Speaker:</i> Christopher Dvorak, US	13:00 - 13:15
IS14-5	How the screening and diagnosis of HSCT-TMA differs in adult patients <i>Speaker:</i> Nicolaus Kröger, DE	13:15 - 13:25
IS14-6	Fireside chat: Case study application of the diagnosis of HSCT-TMA in pediatric and adult patients. Audience Q&A <i>Speaker:</i> Régis Peffault de Latour, FR <i>Speaker:</i> Nicolaus Kröger, DE <i>Speaker:</i> Christopher Dvorak, US	13:25 - 14:00
<i>Nurses Group</i>		
12:30 - 14:00		Room 242 AB
NG03 - Nurses Education Day 3 - Nursing challenges in 2023: Understanding ...		
<i>Chair:</i> Thomas Jezequel, FR		
<i>Chair:</i> Kathy Goris, BE		
NG03-1	Quality of life <i>Speaker:</i> Lorna Warwick, CA	12:30 - 12:55
NG03-2	Late effects <i>Speaker:</i> Lucie Lacheze, FR	12:55 - 13:20
NG03-3	Advanced care planning <i>Speaker:</i> Richard Towers, GB	13:20 - 13:45
NG03-4	Q&A	13:45 - 14:00
<i>Breaks</i>		
14:00 - 14:30		AMPHITHEATRE BLEU
Break, ePoster Viewing, Visit Exhibition		
<i>Industry Symposium</i>		
14:30 - 16:00		AMPHITHEATRE BLEU
IS16 - Debate: CAR T vs. BsAbs in R/R DLBCL KITE-GILEAD		
<i>Chair:</i> Catherine Thieblemont, FR		
IS16-1	Introduction and overview <i>Speaker:</i> Catherine Thieblemont, FR	14:30 - 14:35
IS16-2	CAR T should be used as early as possible in the treatment of R/R DLBCL	14:35 - 14:35
IS16-3	PRO <i>Speaker:</i> William Townsend, GB	14:35 - 14:45
IS16-4	CON <i>Speaker:</i> Catherine Thieblemont, FR	14:45 - 14:55
IS16-5	CAR T-cell therapy is the most recent therapy with curative potential for the treatment of R/R DLBCL	14:55 - 14:55

IS16-6	PRO <i>Speaker:</i> Miguel-Angel Perales, US	14:55 - 15:05
IS16-7	CON <i>Speaker:</i> Max Topp, DE	15:05 - 15:15
IS16-8	Debate summary <i>Speaker:</i> Catherine Thieblemont, FR	15:15 - 15:20
IS16-9	Q&A - All, moderated by Chair	15:20 - 15:25
IS16-10	Putting theory into practice	15:25 - 15:25
IS16-11	Case studies - All	15:25 - 15:45
IS16-12	Q&A - All, moderated by Chair	15:45 - 15:55
IS16-13	Summary and close <i>Speaker:</i> Catherine Thieblemont, FR	15:55 - 16:00

Industry Symposium

14:30 - 16:00

Room 141

IS17 - Challenges in managing mould and respiratory virus-associated infections in immunocompromised patients | PFIZER*Chair:* Johan Maertens, BE

IS17-1	Welcome and introduction <i>Speaker:</i> Johan Maertens, BE	14:30 - 14:35
IS17-2	Identifying the immunocompromised haematology patient at risk of COVID-19 and COVID-19-associated IMD <i>Speaker:</i> Johan Maertens, BE	14:35 - 14:55
IS17-3	Key considerations for the diagnosis and treatment of IMD in haematology patients <i>Speaker:</i> Elizabeth de Kort, NL	14:55 - 15:20
IS17-4	A focus on haematology patients at high-risk for progression to severe COVID-19 <i>Speaker:</i> Carolina Garcia-Vidal, ES	15:20 - 15:45
IS17-5	Panel Q&A - All faculty	15:45 - 15:55
IS17-6	Close <i>Speaker:</i> Johan Maertens, BE	15:55 - 16:00

Industry Symposium

14:30 - 16:00

Room 143

IS18 - The evolving management of multiple myeloma: today, tomorrow and in the future | JANSSEN*Chair:* Niels van de Donk, NL*Chair:* Mohamad Mohty, FR

IS18-1	Welcome and introduction <i>Speaker:</i> Niels van de Donk, NL	14:30 - 14:35
--------	--	---------------

IS18-2	Optimizing induction, consolidation and maintenance therapies for newly diagnosed patients with MM receiving an ASCT <i>Speaker:</i> Roberto Mina, IT	14:35 - 14:50
IS18-3	Key questions	14:50 - 14:55
IS18-4	How is the standard of care evolving for fit patients with newly-diagnosed multiple myeloma? <i>Speaker:</i> Aurore Perrot, FR	14:55 - 15:10
IS18-5	Key questions	15:10 - 15:15
IS18-6	Will CAR T-cell therapy replace ASCT in MM? <i>Speaker:</i> Mohamad Mohty, FR	15:15 - 15:40
IS18-7	Panel discussion with Q&A - All, led by: <i>Speaker:</i> Niels van de Donk, NL	15:40 - 16:00

Industry Symposium

14:30 - 16:00

Room 151

IS19 - Cell therapy: latest advances and future visions - MILTENYI*Chair:* Christian Chabannon, FR

IS19-1	Welcome & introduction <i>Speaker:</i> Christian Chabannon, FR	14:30 - 14:40
IS19-2	Use of TCR^{hi}/CD19-depleted grafts from HLA-haploidentical donors for the treatment of non-malignant disorders: is it the new black? <i>Speaker:</i> Pietro Merli, IT	14:40 - 15:00
IS19-3	Safety and efficacy of high-dose of memory (CD45RA⁺ depleted) donor lymphocyte infusion in pediatric recipients after hematopoietic stem cell transplantation <i>Speaker:</i> Antonio Perez, ES	15:00 - 15:20
IS19-4	What is the future for academic CART manufacture? <i>Speaker:</i> Claire Roddie, GB	15:20 - 15:40
IS19-5	Zamtocabtagene autoleucel - A non-cryopreserved tandem-CAR T-cell product targeting CD19 and CD20 in B-cell non-Hodgkin lymphoma (B-NHL) <i>Speaker:</i> Christof Scheid, DE	15:40 - 16:00

Nurses Group

14:30 - 16:00

Room 242 AB

NG04 - Nurses Education Day 4 - Nursing challenges in 2023: Future of transplant nursing*Chair:* Thomas Jezequel, FR*Chair:* Kathy Goris, BE

NG04-1	Gene therapy: new kid on the block <i>Speaker:</i> Kelly Hennessy, GB	14:30 - 14:55
NG04-2	Future of transplantation: what to expect in the next decade	14:55 - 15:20

	<i>Speaker:</i> Daniele Avenoso, GB	
NG04-3	Evolution of the transplant nurse - what next? <i>Speaker:</i> Kayleigh Hendriks-Wendrich, NL	15:20 - 15:45

NG04-4	Q&A	15:45 - 16:00
--------	----------------	---------------

Patient, Family, and Donor Day

15:30 - 17:30

Room 153

PFD04 - Patient, Family and Donor Day 4 - Where BMT meets CAR-T cell therapy*Chair:* Natacha Bolaños, ES*Chair:* Guy Bouguet, FR

PFD04-1	Introductions & set up the scene	15:30 - 15:35
---------	---	---------------

PFD04-2	BMT and CAR-T in practice: A timeline of events and adverse events. Similarities and uniqueness from the Nurses perspective <i>Speaker:</i> Ruth Elizabeth Clout, GB	15:35 - 15:50
---------	--	---------------

PFD04-3	Quality of life in caregivers of patients receiving CAR T-cell therapy <i>Speaker:</i> Anna Barata, US	15:50 - 16:05
---------	--	---------------

PFD04-4	Improving patient engagement and patient reported outcome measurement in (CAR-T Cell therapy) research and practice <i>Speaker:</i> Lonneke van de Poll-Franse, NL	16:05 - 16:20
---------	--	---------------

PFD04-5	Patient reported outcomes with CAR-T Cell therapy versus autologous and allogeneic Stem Cell transplant <i>Speaker:</i> Roberta Di Blasi, FR	16:20 - 16:35
---------	--	---------------

PFD04-6	Panel discussion - all speakers &: <i>Speaker:</i> Philippe Piedigrossi, FR	16:35 - 17:05
---------	---	---------------

PFD04-7	Take home messages and wrap up	17:05 - 17:10
---------	---------------------------------------	---------------

PFD04-8	Closing comments and Farewell	17:10 - 17:20
---------	--------------------------------------	---------------

Breaks

16:00 - 16:30

AMPHITHEATRE BLEU

Coffee Break, ePoster Viewing, Visit Exhibition*Industry Symposium*

16:30 - 18:00

AMPHITHEATRE BLEU

IS21 - Can emerging data change future optimal treatment strategies for CAR T cell therapy in multiple myeloma? | Bristol Myers Squibb*Chair:* Paula Rodríguez-Otero, ES

IS21-1	Introduction <i>Speaker:</i> Paula Rodríguez-Otero, ES	16:30 - 16:35
--------	--	---------------

IS21-2	Hot topics in CAR T cell therapy:	16:35 - 16:55
--------	--	---------------

IS21-3	T-cell health	16:55 - 16:55
--------	----------------------	---------------

	<i>Speaker:</i> Michael Hudecek, DE	
IS21-4	Leukapheresis <i>Speaker:</i> Halvard Bönig, DE	16:55 - 16:55
IS21-5	CAR T cell therapy in the clinic <i>Speaker:</i> Bertrand Arnulf, FR	16:55 - 16:55
IS21-6	Panel discussion: advancements in cellular therapy for MM <i>Speaker:</i> Paula Rodríguez-Otero, ES	16:55 - 17:50
IS21-7	Take-home messages <i>Speaker:</i> Paula Rodríguez-Otero, ES	17:50 - 18:00

Industry Symposium

16:30 - 18:00

MAILLOT

IS25 - Optimizing Conditioning Regimens and Advancing Allogeneic Hemopoietic Stem Cell Transplantation Practice | Medscape Oncology Global - Supported by an independent educational grant from medac

Chair: Friedrich Stölzel, DE

IS25-1	Welcome and Introductions <i>Speaker:</i> Friedrich Stölzel, DE	16:30 - 16:35
IS25-2	Setting the Stage: Where Are We Now With Conditioning Regimens <i>Speaker:</i> Friedrich Stölzel, DE	16:35 - 16:50
IS25-3	Novel Conditioning Regimens in Europe <i>Speaker:</i> Mattias Stelljes, DE	16:50 - 17:05
IS25-4	Novel Conditioning Regimens in the United States <i>Speaker:</i> Filippo Milano, US	17:05 - 17:25
IS25-5	Conditioning Regimens From The Clinic: Let's Meet Our Patients <i>Speaker:</i> Domenico Russo, IT	17:25 - 17:45
IS25-6	Future Perspective, Audience Q&A, and Concluding Remarks - Panel discussion	17:45 - 18:00

Industry Symposium

16:30 - 18:00

Room 141

IS22 - Before, during and after transplant – The management of GvHD and the role of ECP | THERAKOS

Chair: Antonio Pagliuca, GB

IS22-1	Introduction <i>Speaker:</i> Antonio Pagliuca, GB	16:30 - 16:35
IS22-2	Before and during transplant – How to prevent and minimize GvHD <i>Speaker:</i> Anna Sureda, ES	16:35 - 17:05
IS22-3	Post-transplant Part 1 – How to improve overall survival in acute	17:05 - 17:25

GvHD by applying ECP*Speaker:* Melhem M. Solh, US

IS22-4	Post-transplant Part 2 – How to reduce immunosuppressants in chronic GvHD by using ECP	17:25 - 17:45
	<i>Speaker:</i> Didier Blaise, FR	
IS22-5	Q&A session - All	17:45 - 18:00

Industry Symposium

16:30 - 18:00

Room 143

IS23 - Moving Forward: What's New for CMV Management | TAKEDA

IS23-1	Introduction	16:30 - 16:35
	<i>Speaker:</i> Mohamad Mohty, FR	
IS23-2	The Front Line: Why Managing the CMV Continuum is Challenging	16:35 - 16:50
	<i>Speaker:</i> Catherine Cordonnier, FR	
IS23-3	Challenge 1: Need to Treat (Clinical Case)	16:50 - 17:00
	<i>Speaker:</i> Catherine Cordonnier, FR	
IS23-4	Updating the Status Quo for CMV Management	17:00 - 17:25
	<i>Speaker:</i> Camille Kotton, US	
IS23-5	Challenge 2: Balancing Act (Clinical Case)	17:25 - 17:40
	<i>Speaker:</i> Catherine Cordonnier, FR	
IS23-6	Panel Discussion on Future Unmet Needs for CMV and Q&A	17:40 - 17:55
	<i>Speaker:</i> Mohamad Mohty, FR	
	<i>Speaker:</i> Catherine Cordonnier, FR	
	<i>Speaker:</i> Camille Kotton, US	
IS23-7	Concluding Remarks	17:55 - 18:00
	<i>Speaker:</i> Mohamad Mohty, FR	

Industry Symposium

16:30 - 18:00

Room 151

IS24 - Redefining treatment goals in PNH: A holistic approach of individualised patient therapy | Sobi*Chair:* Jens Panse, DE

IS24-1	A PNH patient's view on treatment goals	16:30 - 16:30
IS24-2	Introduction	16:30 - 16:40
	<i>Speaker:</i> Jens Panse, DE	
IS24-3	Nurse communication to enable holistic care	16:40 - 16:40
IS24-4	Insights from an advanced clinical practice nurse in PNH	16:40 - 16:55
	<i>Speaker:</i> Louise Arnold, GB	
IS24-5	The ongoing burden of PNH	16:55 - 16:55

IS24-6	The need to look beyond just intravascular haemolysis <i>Speaker:</i> Jens Panse, DE	16:55 - 17:10
IS24-7	Redefining treatment goals to address unmet needs	17:10 - 17:10
IS24-8	New definitions of treatment success and strategies to achieve it <i>Speaker:</i> Régis Peffault de Latour, FR	17:10 - 17:30
IS24-9	Discussing the future of PNH therapy	17:30 - 17:30
IS24-10	Panel discussion and Q&A - All faculty	17:30 - 18:00

How do I... ?

16:30 - 17:45

Room 242 AB

HDI3 - NG - How Do I... ensure the Nurse's critical role in giving VOD patients the best chance of survival? | This session is sponsored by Jazz Pharmaceuticals. Jazz Pharmaceuticals have suggested a topic for EBMT's consideration and have had no involvement in the selection, development, content or organisation of this session

Chair: Michelle Kenyon, GB*Chair:* Thomas Jezequel, FR

HDI3-1	Introduction	16:30 - 16:35
HDI3-2	Self-perceived education priorities of nurses – where does VOD fit? <i>Speaker:</i> Sarah Liptrott, CH	16:35 - 16:55
HDI3-3	Nursing role in the assessment and care of hepatic sinusoidal obstruction syndrome patients: a consensus paper by the "Gruppo Italiano Trapianto di Midollo Osseo" <i>Speaker:</i> Stefano Botti, IT	16:55 - 17:05
HDI3-4	Role modelling communication about sick patients and VOD from the bedside – the Advanced Clinical Practitioner perspective <i>Speaker:</i> Daniel Kisielewski, DE	17:05 - 17:25
HDI3-5	Discussion and close	17:25 - 17:45

Breaks

18:00 - 18:15

AMPHITHEATRE BLEU

Break, ePoster Viewing, Visit Exhibition*General*

18:15 - 19:20

AMPHITHEATRE BLEU

GS01 - Opening Ceremony*Chair:* Mohamad Mohty, FR*Chair:* Anna Sureda, ES

GS01-1	Welcome and introduction <i>Speaker:</i> Anna Sureda, ES	18:15 - 18:20
GS01-2	Welcome and introduction to the conference	18:20 - 18:25

	<i>Speaker:</i> Mohamad Mohty, FR	
GS01-3	Welcome from the Nurses Group <i>Speaker:</i> Michelle Kenyon, GB	18:25 - 18:30
GS01-4	EBMT Patient Advocacy Committee: Welcome note <i>Speaker:</i> Natacha Bolaños, ES	18:30 - 18:35
GS01-5	Honorary Member <i>Speaker:</i> Didier Blaise, FR	18:35 - 18:50
GS01-6	Introduction to the Keynote speaker <i>Speaker:</i> Mohamad Mohty, FR	18:50 - 18:55
GS01-7	Keynote lecture Post-Cyclophosphamide: past, present and future <i>Speaker:</i> Leo Luznik, US	18:55 - 19:20

Monday, 24. April 2023*Meetings*

07:00 - 08:45

Room 252 AB

BM-IDWP - Business Meeting*Meetings*

07:00 - 08:45

Room 241

BM-CMWP - Business Meeting*Meetings*

07:45 - 08:45

Room 243

IM1 - Internal Meeting 1*Meet the Expert*

08:00 - 09:00

MTE

MTE-06 - Meet the Expert 6

MTE-06

How to choose the optimal conditioning

08:00 - 09:00

Speaker: Jean El-Cheikh, LB*Meet the Expert*

08:00 - 09:00

MTE

MTE-01 - Meet the Expert 1

MTE-01

How I assess and treat VOD in adults

08:00 - 09:00

Speaker: Antonio Pagliuca, GB*Meet the Expert*

08:00 - 09:00

MTE

MTE-03 - Meet the Expert 3

MTE-03

How to assess, evaluate and use MRD peritransplant

08:00 - 09:00

Speaker: Peter Bader, DE*Meet the Expert*

08:00 - 09:00

MTE

MTE-05 - Meet the Expert 5

MTE-05

How to use ATG for GVHD prophylaxis

08:00 - 09:00

Speaker: Francesca Bonifazi, IT*Meet the Expert*

08:00 - 09:00

MTE

MTE-02 - Meet the Expert 2

MTE-02

How to establish a transplant program in a LMI country?

08:00 - 09:00

Speaker: Mahmoud Aljurf, SA

Meet the Expert

08:00 - 09:00

MTE

Meet the Expert Sessions*Meet the Expert*

08:00 - 09:00

MTE

MTE-04 - Meet the Expert 4

MTE-04

How to optimally mobilize HSC

08:00 - 09:00

Speaker: Rafael Duarte, ES*Working Party Sessions*

09:00 - 10:15

AMPHITHEATRE BLEU

IDWP - Infectious Diseases Working Party session*Chair:* Rafael de la Cámara, ES

IDWP-1

What is new in the management of neutropenic fever?

09:00 - 09:18

Speaker: Dina Averbuch, IL

IDWP-2

An old foe and new friends: Hot topics in the management of CMV

09:18 - 09:36

Speaker: Genoveva Papanicolau, US

IDWP-3

How to prevent and treat toxoplasmosis in HSCT patients - New ECIL recommendations

09:36 - 09:54

Speaker: Catherine Cordonnier, FR

IDWP-4

Top 10 papers in HSCT infections (2022-2023)

09:54 - 10:12

Speaker: Malgorzata Mikulska, IT

IDWP-5

Closing

10:12 - 10:15

Cell Therapy Day

09:00 - 10:20

MAILLOT

CTD1 - Cell Therapy Day 1 - Next wave of engineering*Chair:* Annalisa Ruggeri, IT*Chair:* Jurgen Kuball, NL

CTD1-1

Welcome

09:00 - 09:05

Speaker: Annalisa Ruggeri, IT

CTD1-2

Learning from success: What can patients teach us following complete remission of solid cancer?

09:05 - 09:30

Speaker: Andrew Sewell, GB

CTD1-3

Functional heterogeneity governing immunotherapy response

09:30 - 09:55

Speaker: Maria Alieva, ES

CTD1-4

Engineering Immunological Memory

09:55 - 10:20

Speaker: Chiara Bonini, IT

Educational

09:00 - 10:30

Room 141

E01 - Transplant indications in rare entities*Chair:* Jacques-Olivier Bay, FR*Chair:* Yves Chalandon, CH

E01-1	Systemic mastocytosis <i>Speaker:</i> Xavier Poiré, BE	09:00 - 09:30
E01-2	Is transplantation still the only curative treatment for myelofibrosis? <i>Speaker:</i> Jean-Jacques Kiladjian, FR	09:30 - 10:00
E01-3	ATLL <i>Speaker:</i> Felipe Suarez, FR	10:00 - 10:30

Joint Sessions

09:00 - 10:15

Room 143

JS01 - Joint Session: EBMT - HARMONY | Big Data innovations for bone marrow transplant professionals*Chair:* Guillermo Sanz, ES*Chair:* Juan Carlos Hernández Boluda, ES

JS01-1	The value of sharing data	09:00 - 09:00
JS01-1.1	EBMT's view on Big Data innovations to offer new opportunities for bone marrow transplant professionals <i>Speaker:</i> Anna Sureda, ES	09:00 - 09:05
JS01-1.2	Introducing the HARMONY Alliance, achievements so far and future outlook <i>Speaker:</i> Guillermo Sanz, ES	09:05 - 09:10
JS01-1.3	Making use of large databases and smart analytics services will provide new insights in prognosis of patients: the Big Data in AML story <i>Speaker:</i> Lars Bullinger, DE	09:10 - 09:20
JS01-2	Concrete opportunities for bone marrow transplant professionals in PCD/Multiple Myeloma and in MDS	09:20 - 09:20
JS01-2.1	Introduction <i>Speaker:</i> Juan Carlos Hernández Boluda, ES	09:20 - 09:25
JS01-2.2	Introduction by PCD subcommittee of the EBMT-CMWP <i>Speaker:</i> Patrick Hayden, IE	09:25 - 09:30
JS01-2.3	Presentation PCD/MM study proposal: Will R2-ISS improve the predictive value of the EBMT early relapse score which is based on ISS and performance and response status parameters? <i>Speaker:</i> Meral Beksac, TR	09:30 - 09:40
JS01-2.4	HARMONY reflection on PCD/MM study proposal <i>Speaker:</i> Mattia D'Agostino, IT	09:40 - 09:50
JS01-2.5	Introduction by MDS subcommittee of EBMT-CMWP	09:50 - 09:55

	<i>Speaker:</i> Marie Robin, FR	
JS01-2.6	Presentation MDS study proposal: Differential outcomes of patients with MDS undergoing HSCT vs non-transplant strategies <i>Speaker:</i> Carmelo Gurnari, IT	09:55 - 10:05
JS01-2.7	HARMONY reflection on MDS study proposal <i>Speaker:</i> Valeria Santini, IT	10:05 - 10:15

Psy Day

09:00 - 10:20

Room 151

PSY1 - Psy Day: Current challenges in hematopoietic stem cell transplantation I*Chair:* Didier Blaise, FR*Chair:* Patrick BenSoussan, FR

Psy1-1	Welcome & Introduction <i>Speaker:</i> Yolande Arnault, FR <i>Speaker:</i> Alice Polomeni, FR	09:00 - 09:10
Psy1-2	Current challenges in HCT and cellular therapy <i>Speaker:</i> Didier Blaise, FR	09:10 - 09:30
Psy1-3	Patient-reported and cognitive outcomes in CAR T-cell therapy recipients <i>Speaker:</i> Anna Barata, US	09:30 - 09:50
Psy1-4	Haplo-identical HCT : ethical and psychological issues <i>Speaker:</i> Alice Polomeni, FR	09:50 - 10:10
Psy1-5	Discussion	10:10 - 10:20

Educational

09:00 - 10:30

Room 153

E02 - Transplant algorithm in:*Chair:* Giorgia Battipaglia, IT*Chair:* Zafer Gulbas, TR

E02-1	MDS <i>Speaker:</i> Marie Robin, FR	09:00 - 09:30
E02-2	MPN <i>Speaker:</i> Donal McLornan, GB	09:30 - 10:00
E02-3	CMML <i>Speaker:</i> Francesco Onida, IT	10:00 - 10:30

Nurses Group

09:00 - 10:30

Room 242 AB

NG05 - Nurses Group Opening*Chair:* Michelle Kenyon, GB*Chair:* Thomas Jezequel, FR

NG05-1	Welcome and overview	09:00 - 09:10
--------	-----------------------------	---------------

	<i>Speaker:</i> Michelle Kenyon, GB	
NG05-2	Welcome to Paris <i>Speaker:</i> Thomas Jezequel, FR	09:10 - 09:15
NG05-3	Presentation of the 15th Distinguished Merit Award & Honorary Member <i>Speaker:</i> Michelle Kenyon, GB <i>Speaker:</i> Merja Stenvall, FI	09:15 - 09:30
NG05-4	Keynote lecture: Leadership in nursing - what does this mean in 2023 and beyond <i>Speaker:</i> Johan De Munter, BE	09:30 - 10:00
NG05-5	Health for everyone <i>Speaker:</i> Anne-Pierre Pickaert, FR	10:00 - 10:30

Workshop

09:00 - 10:30

Room 252 AB

W01 - Hot debates in ALL*Chair:* Thomas Cluzeau, FR*Chair:* Mutlu Arat, TR

W01-1	a) Should we transplant all patients with Philadelphia positive ALL?	09:00 - 09:05
W01-2	Should we transplant all patients with Philadelphia positive ALL? -YES- <i>Speaker:</i> Sebastian Giebel, PL	09:05 - 09:25
W01-3	Should we transplant all patients with Philadelphia positive ALL? -NO- <i>Speaker:</i> Robin Foa, IT	09:25 - 09:45
W01-4	b) Should we transplant patients with Ph- ALL who achieve MRD negativity?	09:45 - 09:50
W01-5	Should we transplant patients with Ph- ALL who achieve MRD negativity? -YES- <i>Speaker:</i> Patrice Chevallier, FR	09:50 - 10:10
W01-6	Should we transplant patients with Ph- ALL who achieve MRD negativity? -NO- <i>Speaker:</i> Nicolas Boissel, FR	10:10 - 10:30

Trainee Day

09:00 - 10:15

Room 241

TD1 - Trainee Day 1 - One world, different realities*Chair:* Yasmina Serroukh, NL*Chair:* Lars Klingen Gjørde, DK

TD1-1	The EBMT Trainee Committee: Year 2.0 <i>Speaker:</i> Claire Horgan, GB <i>Speaker:</i> Nico Gagelmann, DE	09:00 - 09:15
-------	--	---------------

TD1-2	Young LABMT: Year 1.0 <i>Speaker:</i> Laura Saavedra, VE <i>Speaker:</i> Rafaella Muratori, BR	09:15 - 09:30
TD1-3	BMT - the South African milieu <i>Speaker:</i> Justin Du Toit, ZA	09:30 - 09:45
TD1-4	CAR-T roundtable: Saviour or troublemaker? - All faculty, lead by: <i>Speaker:</i> Alvaro Urbano-Ispizua, ES <i>Speaker:</i> Roberta Di Blasi, FR	09:45 - 10:15

Special Session

09:00 - 10:15

Room 243

SS01 - Equality, Diversity and Inclusion Session | Health inequalities: why equality, diversity and inclusion matters*Chair:* John Snowden, GB*Chair:* Isabel Sánchez-Ortega, ES

SS01-1	Because you are worth it: integrating EDI in scientific societies <i>Speaker:</i> Rayne Rouce, US	09:00 - 09:20
SS01-2	The problem of representation: does the design of SCT trials discriminate non-White populations? <i>Speaker:</i> Nada Hamad, AU	09:20 - 09:40
SS01-3	Refugees can't leave their health problems at home: how to manage continuity of care of displaced patients <i>Speaker:</i> Iwona Hus, PL	09:40 - 10:00
SS01-4	Q&A	10:00 - 10:15

Transplant and Search Coordinators Day

09:00 - 10:25

Room 251

TSCD01 - EBMT-WMDA Transplant and Search Coordinators Day 1 - Introduction to Donor Optimisation*Chair:* Lydia Foeken, NL*Chair:* Anna Sureda, ES

TSCD01-1	Welcome by the WMDA President <i>Speaker:</i> Matthew Seftel, CA	09:00 - 09:10
TSCD01-2	A World of Options: Bio-Informatics and Tools <i>Speaker:</i> Alicia Venter, NL	09:10 - 09:35
TSCD01-3	Best practice for donor reservations <i>Speaker:</i> Gabi Rall, DE	09:35 - 10:00
TSCD01-4	The role of mismatched donors in the times of PTCy <i>Speaker:</i> Bronwen Shaw, US	10:00 - 10:25

Patient Advocacy Sessions

09:00 - 10:15

Room 253

PA1 - Patient Advocacy Session 1 | Inverting the patient involvement paradigm: defining patient led research*Chair:* Christian Chabannon, FR*Chair:* Natacha Bolaños, ES

PA1-1	Introduction	09:00 - 09:10
PA1-2	Roundtable. Panelists: <i>Speaker:</i> Rosanne Janssens, BE <i>Speaker:</i> Eva Jolly, SE <i>Speaker:</i> Lorna Warwick, CA	09:10 - 10:05
PA1-3	Wrap-up and last comments from panelists	10:05 - 10:15

ePoster

09:00 - 18:00

ePoster Area

ePoster Viewing*Transplant and Search Coordinators Day*

09:00 - 18:00

Library

TSCD04 - EBMT-WMDA Transplant and Search Coordinators Day 4 - Regulatory affairs*Chair:* Yehudit Eitiel, IL*Chair:* Iris Bargalló, ES

TSCD04-1	Introduction <i>Speaker:</i> Yehudit Eitiel, IL	09:00 - 09:05
TSCD04-2	Upcoming SoHo regulation: follow-up of related and unrelated donors <i>Speaker:</i> Evelyne Marry, FR	09:05 - 09:25
TSCD04-3	WMDA accreditation – a way to facilitate import and export of hematopoietic stem cells <i>Speaker:</i> Nicoletta Sacchi, IT	09:25 - 09:45
TSCD04-4	Data protection of donors and patients <i>Speaker:</i> Matti Korhonen, FI	09:45 - 10:05
TSCD04-5	Conclusions <i>Speaker:</i> Iris Bargalló, ES	10:05 - 10:15

Special Session

09:00 - 18:00

Library

SS05 - How to Get Published?

SS05-1	How to get published: a few tips <i>Speaker:</i> Mohamad Mohty, FR	09:00 - 10:00
--------	--	---------------

Transplant and Search Coordinators Day

09:00 - 18:00

Library

TSCD03 - EBMT-WMDA Transplant and Search Coordinators Day 3 - Motivating donors*Chair:* Evelyne Marry, FR*Chair:* Nina Worel, AT

TSCD03-1	Introduction <i>Speaker:</i> Evelyne Marry, FR	09:00 - 09:05
TSCD03-2	Targeted donor recruitment to diversify the global registry <i>Speaker:</i> Sarah Pinseel, BE	09:05 - 09:25
TSCD03-3	Donors' availability: before and after CT <i>Speaker:</i> Tigran Torosian, PL	09:25 - 09:46
TSCD03-4	Donor Follow-up and SPEARs <i>Speaker:</i> Grazia Nicoloso, CH	09:46 - 10:06
TSCD03-5	Conclusions <i>Speaker:</i> Nina Worel, AT	10:06 - 10:16

Library

09:00 - 18:00

Library

Library*Practise Harmonisation Day*

09:00 - 18:00

Library

HM3 - Harmonization Day 3 - European guidelines I*Chair:* Florent Malard, FR

HM3-1	Introduction <i>Speaker:</i> Florent Malard, FR	09:00 - 09:15
HM3-2	Management of patients receiving CAR T-cell therapy <i>Speaker:</i> Claire Roddie, GB	09:15 - 09:35
HM3-3	How to handle infections after CAR T-cell therapy <i>Speaker:</i> Micha Srour, FR	09:35 - 09:55
HM3-4	How to handle hematotoxicities <i>Speaker:</i> Marion Subklewe, DE	09:55 - 10:15

Practise Harmonisation Day

09:00 - 18:00

Library

HM4 - Harmonization Day 4 - European guidelines II*Chair:* Fabio Ciceri, IT

HM4-1	Introduction <i>Speaker:</i> Fabio Ciceri, IT	09:00 - 09:15
HM4-2	Management of post-transplant cytopenias in MF patients <i>Speaker:</i> Donal McLornan, GB	09:15 - 09:35
HM4-3	Management of splenomegaly before allo-HCT for Myelofibrosis <i>Speaker:</i> Nicola Polverelli, IT	09:35 - 09:55

Educational

11:00 - 12:30

Room 141

E03 - Transplant in non-malignant disorders*Chair:* Jean-Hugues Dalle, FR*Chair:* Gérard Michel, FR

E03-1	Sickle cell disease <i>Speaker:</i> Selim Corbacioglu, DE	11:00 - 11:30
E03-2	Long-Term side effects of allogeneic transplantation in SCD patients <i>Speaker:</i> Júlia Teixeira Cottas de Azevedo, BR	11:30 - 12:00
E03-3	Thalassaemia: advances in conventional transplantation & gene therapy <i>Speaker:</i> Josu De La Fuente, GB	12:00 - 12:30

Joint Sessions

11:00 - 12:00

Room 143

JS02 - Joint Session: EBMT - EHA | GoCART Coalition: Past, Present and Future*Chair:* Anna Sureda, ES*Chair:* Chiara Bonini, IT

JS02-1	EHA experience <i>Speaker:</i> Chiara Bonini, IT	11:00 - 11:20
JS02-2	EBMT experience <i>Speaker:</i> Jurgen Kuball, NL	11:20 - 11:40
JS02-3	Q&A - Discussion	11:40 - 12:00

Psy Day

11:00 - 12:15

Room 151

PSY2 - Psy Day: Current challenges in hematopoietic stem cell transplantation II*Chair:* Cecile Borel, FR

Psy2-1	Germline predisposition to hematopoietic malignancies: new ethical and psychological considerations in the patient care <i>Speaker:</i> Laurene Fenwarth, FR	11:00 - 11:20
Psy2-2	HCT accessibility: Cyprus Receiving an allogeneic hematopoietic stem cell transplant abroad: the experience of a double strangeness <i>Speaker:</i> Ioanna Dimou, CY	11:20 - 11:35
Psy2-3	Overseas therapeutic mobility for HCT: lived experience of patients from La Réunion <i>Speaker:</i> Aline Sarradon, FR	11:35 - 11:50
Psy2-4	HCT accessibility: Polynésie <i>Speaker:</i> Ollivier Legrand, FR	11:50 - 12:05
Psy2-5	Discussion	12:05 - 12:15

Workshop

11:00 - 12:30

Room 153

W02 - Maintenance and consolidation treatment pre or post-transplant in acute leukemia*Chair:* Raynier Devillier, FR*Chair:* Ahmad Ibrahim, LB

W02-1	The case for hypomethylating agents <i>Speaker:</i> Charles Craddock, GB	11:00 - 11:30
W02-2	The case for FLT3 inhibitors <i>Speaker:</i> Ali Bazarbachi, LB	11:30 - 12:00
W02-3	The case for CAR T cells <i>Speaker:</i> Elizabeth Shpall, US	12:00 - 12:30

Nurses Group

11:00 - 12:30

Room 242 AB

NG06 - Oral Session - Adult Abstract Award Finalists*Chair:* Kathy Goris, BE*Chair:* Marijke Quaghebeur, BE

	Introduction	11:00 - 11:05
NG06-01	SYMPTOMS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: PATIENTS' VOICES <i>Oral Presenter:</i> Carina Lundh Hagelin, SE	11:05 - 11:25
NG06-02	NUTRITIONAL RISK MANAGEMENT IN PATIENTS UNDERGOING HAEMATOPOIETIC STEM CELL TRANSPLANTATION: EXPERIENCE FROM A TERTIARY CARE CENTER <i>Oral Presenter:</i> Carla Amato, IT	11:25 - 11:45
NG06-03	PATIENTS' EXPERIENCES OF PERSON-CENTRED CARE IN THE CONTEXT OF ALLOGENEIC STEM CELL TRANSPLANTATION <i>Oral Presenter:</i> Anna O'Sullivan, SE	11:45 - 12:05
NG06-04	OUTCOMES OF ANXIETY AND DEPRESSION REPORTED BY CAR-T CELL THERAPY CANDIDATE PATIENTS <i>Oral Presenter:</i> Mercedes Montoro Lorite, ES	12:05 - 12:25
	Conclusions	12:25 - 12:30

Workshop

11:00 - 12:30

Room 252 AB

W03 - Immunomodulation post-transplant*Chair:* Anne Huynh, FR*Chair:* Ernst Holler, DE

W03-1	Prophylactic DLI in AML <i>Speaker:</i> Christoph Schmid, DE	11:00 - 11:30
W03-2	Check point inhibitors before and after transplantation in Hodgkin lymphoma	11:30 - 12:00

	<i>Speaker:</i> Luca Castagna, IT	
W03-3	Microbiota transfer for acute GVHD	12:00 - 12:30
	<i>Speaker:</i> Florent Malard, FR	

Trainee Day
11:00 - 12:15

Room 241

TD2 - Trainee Day 2 - What is cure to a child? Pediatric gene and cell therapy

Chair: Carmelo Gurnari, IT

Chair: Subramaniam Ramanathan, GB

TD2-1	Gene Therapy for hemoglobinopathies and metabolic disorders: what a trainee should know	11:00 - 11:20
	<i>Speaker:</i> Francesca Tucci, IT	
TD2-2	Long-term survivorship issues: does it all end with “the cure” including the family perspective- impact of having child/parent go through BMT	11:20 - 11:40
	<i>Speaker:</i> Rafaella Muratori, BR	
TD2-3	CAR-T in pediatric patients: ALL and beyond	11:40 - 12:00
	<i>Speaker:</i> Francesca Del Bufalo, IT	
TD2-4	Discussion	12:00 - 12:15

Nurses Group
11:00 - 12:30

Room 243

NG07 - Disease management: Non-malignant disease update

Chair: Kelly Hennessy, GB

Chair: Maxime Berquier, FR

NG07-1	Sickle Cell Anemia	11:00 - 11:25
	<i>Speaker:</i> Hilda Mekelenkamp, NL	
NG07-2	Autoimmune diseases	11:25 - 11:50
	<i>Speaker:</i> Ariadna Domenech, ES	
NG07-3	Aplastic Anaemia	11:50 - 12:15
	<i>Speaker:</i> Orlane Lamarre, FR	
NG07-4	Q&A	12:15 - 12:30

Transplant and Search Coordinators Day
11:00 - 12:15

Room 251

TSCD02 - EBMT-WMDA Transplant and Search Coordinators Day 2 - Solving complicated cases: the importance of good collaboration

Chair: Juliana Villa, ES

Chair: Christian Chabannon, FR

TSCD02-1	Difficult search: 5/10 Non-related donor	11:00 - 11:25
	<i>Speaker:</i> Maria Victoria Diaz, ES	
	<i>Speaker:</i> Maria Calbacho Robles, ES	
TSCD02-2	Complicated Search case: Israel	11:25 - 11:50

	<i>Speaker:</i> Moshe Israeli, IL	
TSCD02-3	Overview of matched unrelated donor search - limited experience of Romanian Voluntary Stem cell Donor Registry <i>Speaker:</i> Zsofia Varady, RO	11:50 - 12:15

Patient Advocacy Sessions

11:00 - 12:15

Room 253

PA2 - Endpoints to reach patients' unmet needs and improve access*Chair:* Kristin Page, US*Chair:* Guy Bouguet, FR

PA2-1	Introductions and set up the scene	11:00 - 11:05
PA2-2	How clinical trials could meet patients needs, beyond the hard clinical outcomes <i>Speaker:</i> Anna Barata, US	11:05 - 11:20
PA2-3	Patient reported outcome measurement in research and practice <i>Speaker:</i> Lonneke van de Poll-Franse, NL	11:20 - 11:35
PA2-4	Setting standards for the design and analysis of PRO endpoints in cancer clinical trials <i>Speaker:</i> Ahu Alanya, BE	11:35 - 11:50
PA2-5	Roundtable - Debate	11:50 - 12:10
PA2-6	Wrap up and last quotation from panelists	12:10 - 12:15

Breaks

12:30 - 13:00

AMPHITHEATRE BLEU

Lunch Break, ePoster Viewing, Visit Exhibition*Industry Symposium*

13:00 - 14:00

AMPHITHEATRE BLEU

IS27 - How has CAR T changed the treatment landscape in 2L DLBCL? | KITE-GILEAD*Chair:* Christian Chabannon, FR

IS27-1	Introduction <i>Speaker:</i> Christian Chabannon, FR	13:00 - 13:05
IS27-2	Redefining treatment paradigm in 2L DLBCL <i>Speaker:</i> Eva Wagner-Drouet, DE	13:05 - 13:10
IS27-3	How has CAR T changed the 2L DLBCL treatment landscape? <i>Speaker:</i> Miguel-Angel Perales, US	13:10 - 13:20
IS27-4	Q&A	13:20 - 13:25
IS27-5	Interactive patient management panel discussion - All, moderated by Nicolaus Kröger <i>Speaker:</i> Christian Chabannon, FR	13:25 - 13:55
IS27-6	Summary and close	13:55 - 14:00

Speaker: Christian Chabannon, FR

Industry Symposium

13:00 - 14:00

MAILLOT

IS28 - The Great Debate: are we identifying severe hepatic VOD patients every time? | Jazz

Pharmaceuticals

Chair: Mohamad Mohty, FR

Chair: Anna Sureda, ES

IS28-1	The headlines: where are we today with hepatic VOD? <i>Speaker:</i> Mohamad Mohty, FR	13:00 - 13:07
IS28-2	The Great Debate: are we identifying severe hepatic VOD patients every time? <i>Speaker:</i> Anna Sureda, ES <i>Speaker:</i> Mohamad Mohty, FR <i>Speaker:</i> Antonio Pagliuca, GB	13:07 - 13:27
IS28-3	Join the debate: audience Q&A - All faculty	13:27 - 13:37
IS28-4	New approaches to help timely identification of severe hepatic VOD patients	13:37 - 13:37
IS28-5	EBMT adult diagnostic criteria: where do we stand? <i>Speaker:</i> Mohamad Mohty, FR	13:37 - 13:44
IS28-6	Liver stiffness measurement to aid early recognition <i>Speaker:</i> Antonio Colecchia, IT	13:44 - 13:51
IS28-7	Focused evaluation: the ward round protocol <i>Speaker:</i> Michelle Kenyon, GB <i>Speaker:</i> Daniele Avenoso, GB	13:51 - 13:58
IS28-8	Summary and close <i>Speaker:</i> Mohamad Mohty, FR	13:58 - 14:00

Industry Symposium

13:00 - 14:00

Room 141

IS29 - The evolving treatment landscape for β -haemoglobinopathies | VERTEX

Chair: Jean-Hugues Dalle, FR

IS29-1	Welcome and introduction: Understanding the biology and burden of disease <i>Speaker:</i> Jean-Hugues Dalle, FR	13:00 - 13:06
IS29-2	From the bench to the clinic/al trial: An era of innovation <i>Speaker:</i> Fabio Ciceri, IT	13:06 - 13:18
IS29-3	What's on the horizon? Understanding the evolving treatment landscape <i>Speaker:</i> Josu De La Fuente, GB	13:18 - 13:30
IS29-4	Practical considerations in an era of innovation: Transplanter dialogue <i>Speaker:</i> Jean-Hugues Dalle, FR	13:30 - 13:42

	<i>Speaker:</i> Roland Meisel, DE	
IS29-5	Panel discussion and Q&A (scientific exchange) incl. close - All faculty, moderated by Chair	13:42 - 14:00
<i>Industry Symposium</i>		
13:00 - 14:00		Room 242 AB
IS30 - NG - ECP and the GvHD patient journey THERAKOS		
<i>Chair:</i> John Murray, GB		
IS30-1	Introduction <i>Speaker:</i> John Murray, GB	13:00 - 13:05
IS30-2	A holistic view of the GvHD patient journey <i>Speaker:</i> Daniel Wolff, DE	13:05 - 13:25
IS30-3	A nurse's perspective on the Therakos ECP treatment <i>Speaker:</i> Michelle Amos, GB	13:25 - 13:45
IS30-4	Q&A session - All	13:45 - 14:00
<i>Industry Symposium</i>		
13:00 - 14:00		MTE
Meet the Expert Sessions Lunch - sponsored		
<i>Industry Symposium</i>		
13:00 - 14:00		MTE
S-MTE-2 - New frontiers for the treatment of EBV+ Post-Transplant Lymphoproliferative Disease (PTLD) with tabelecleucel PIERRE FABRE		
S-MTE-2-1	Introducing EBV+ PTL <i>Speaker:</i> Simona Sica, IT	13:00 - 13:20
S-MTE-2-2	Tabelecleucel: product overview and key data <i>Speaker:</i> Susan Prockop, US	13:20 - 13:40
S-MTE-2-3	Sharing experiences: role of tabelecleucel in the EBV+ PTL patient journey <i>Speaker:</i> Eolia Brissot, FR	13:40 - 14:00
<i>Industry Symposium</i>		
13:00 - 14:00		MTE
S-MTE-1 - Treosulfan - a versatile agent for paediatric SCT conditioning MEDAC		
<i>Chair:</i> Krzysztof Kalwak, PL		
<i>Industry Theatre</i>		
13:10 - 13:45		Industry Theatre
IT2 - Controversies in the Management of Aplastic Anemia PFIZER		
<i>Chair:</i> Régis Peffault de Latour, FR		
IT2-1	Current treatment standards for AA and their potential future evolution <i>Speaker:</i> Antonio Risitano, IT	13:10 - 13:10

IT2-2 **Unmet needs in AA and future developments within the therapy area** 13:10 - 13:10
Speaker: Austin Kulasekararaj, GB

IT2-3 **Panel discussion and audience Q&A (All)** 13:10 - 13:10

Breaks

14:00 - 14:30

AMPHITHEATRE BLEU

Lunch Break, ePoster Viewing, Visit Exhibition

Plenary Session

14:30 - 16:00

AMPHITHEATRE BLEU

P01 - Best practices in haplo-identical allo-HSCT

Chair: Fabio Ciceri, IT

Chair: Ahmed Alaskar, SA

P01-1 **Management of cardio-vascular complications** 14:30 - 15:00
Speaker: Remy Dulery, FR

P01-2 **Management of haemorrhagic cystitis** 15:00 - 15:30
Speaker: Simona Sica, IT

P01-3 **Round table discussion: optimal management of use of PTCY - All faculty, lead by:** 15:30 - 16:00
Speaker: Fabio Ciceri, IT

Cell Therapy Day

14:30 - 15:45

MAILLOT

CTD3 - Cell Therapy Day 3 - New application of stem cell donor

Chair: Eliane Gluckman, FR

Chair: Katharina Fleischhauer, DE

CTD3-1 **Cord derived MSC for ARDS /Covid19** 14:30 - 14:55
Speaker: Elizabeth Shpall, US

CTD3-2 **HLA in donor selection: an evolving understanding** 14:55 - 15:20
Speaker: Katharina Fleischhauer, DE

CTD3-3 **Hematopoietic stem cell gene therapy for the treatment of inherited pediatric disorders** 15:20 - 15:45
Speaker: Alessandro Aiuti, IT

Educational

14:30 - 16:00

Room 141

E04 - Vaccination after allogeneic transplantation

Chair: Patrice Ceballos, FR

Chair: Jean El-Cheikh, LB

E04-1 **Systems biology tools to understand the vaccine immunogenicity** 14:30 - 15:00
Speaker: Stephanie Humblet, BE

E04-2 **Vaccination against SARS-Cov2** 15:00 - 15:30

	<i>Speaker:</i> Rafael de la Cámara, ES	
E04-3	Virus-specific T cells to reconstitute viral immunity <i>Speaker:</i> Helen Heslop, US	15:30 - 16:00
<i>Joint Sessions</i>		
	14:30 - 15:45	Room 143
JS03 - Joint Session: EBMT - SFH Paving the way for the future in hematology		
<i>Chair:</i> Anna Sureda, ES		
<i>Chair:</i> Thierry Facon, FR		
<i>Chair:</i> Mohamad Mohty, FR		
JS03-1	Challenges of ageing in hematology <i>Speaker:</i> Thierry Facon, FR	14:30 - 14:45
JS03-2	CAR-T versus ASCT in Myeloma <i>Speaker:</i> Salomon Manier, FR	14:45 - 15:00
JS03-3	CAR-T versus ASCT in Mantle Cell NHL <i>Speaker:</i> Sascha Dietrich, DE	15:00 - 15:15
JS03-4	Expanding the reach of CAR-T cells from hematology to solid tumors <i>Speaker:</i> Mohamad Mohty, FR	15:15 - 15:30
JS03-5	Round table discussion	15:30 - 15:45
<i>Psy Day</i>		
	14:30 - 15:45	Room 151
PSY3 - Psy Day: Current challenges in hematopoietic stem cell transplantation III		
<i>Chair:</i> Emanuela Mencaglia, IT		
Psy3-1	HCT teams: moral distress <i>Speaker:</i> Joyce Neumman, US	14:30 - 14:50
Psy3-2	Palliative care in allogeneic stem cell transplant recipients <i>Speaker:</i> Cecile Borel, FR	14:50 - 15:10
Psy3-3	What about the donor? <i>Speaker:</i> Annika Kisch, SE	15:10 - 15:30
Psy3-4	Discussion	15:30 - 15:45
<i>Practise Harmonisation Day</i>		
	14:30 - 15:45	Room 153
HM1 - Harmonization Day 1 - Practice Harmonization and guidelines		
<i>Chair:</i> Selim Corbacioglu, DE		
HM1-1	Welcome and introduction	14:30 - 14:45
HM1-2	Why do we need to harmonize practices? <i>Speaker:</i> Raffaella Greco, IT	14:45 - 15:05
HM1-3	Controversy: What do we need to harmonize practices?	15:05 - 15:05

HM1-4	Large guidelines expert-opinion-based recommendations <i>Speaker:</i> Francesco Onida, IT	15:05 - 15:25
HM1-5	Evidence-based consensus <i>Speaker:</i> Patrick Hayden, IE	15:25 - 15:45
<i>Nurses Group</i>		
14:30 - 16:00		Room 242 AB
NG08 - Back to basics. Understanding...		
<i>Chair:</i> Sandra Schoenfeld, CH		
<i>Chair:</i> Orlane Lamarre, FR		
NG08-1	Full blood counts <i>Speaker:</i> Seckin Erdal, TR	14:30 - 14:50
NG08-2	ABO blood groups <i>Speaker:</i> Madson Correia de Farias, GB	14:50 - 15:10
NG08-3	Chimerism <i>Speaker:</i> Daphna Hutt, IL	15:10 - 15:30
NG08-4	Measurable Residual Disease (MRD) <i>Speaker:</i> Christianne Bourlon, GB	15:30 - 15:50
NG08-5	Q&A	15:50 - 16:00
<i>Workshop</i>		
14:30 - 16:00		Room 252 AB
W04 - MRD as a surrogate marker of long-term outcome in:		
<i>Chair:</i> Meral Beksac, TR		
<i>Chair:</i> Gandhi Damaj, FR		
W04-1	AML <i>Speaker:</i> Christopher Hourigan, US	14:30 - 15:00
W04-2	ALL <i>Speaker:</i> Eolia Brissot, FR	15:00 - 15:30
W04-3	MRD as a surrogate marker of long-term outcome in Myeloma <i>Speaker:</i> María Victoria Mateos, ES	15:30 - 16:00
<i>Trainee Day</i>		
14:30 - 15:45		Room 241
TD3 - Trainee Day 3 - What is transplant-related morbidity and mortality?		
<i>Chair:</i> Lin-Pierre Zhao, FR		
<i>Chair:</i> Vera Radici, IT		
TD3-1	Second allo-HSCT: case <i>Speaker:</i> Kristin Rathje, DE	14:30 - 14:45
TD3-2	CMV infection after HSCT: challenges and hurdles <i>Speaker:</i> Manuela Spadea, IT	14:45 - 15:00
TD3-3	Panel discussion How to handle and communicate mortality	15:00 - 15:45

and morbidity: an interdisciplinary roundtable between physicians, nurses, patients, and trainees

Speaker: Chris Lewis, GB

Speaker: Michelle Kenyon, GB

Speaker: H el ene Schoemans, BE

Nurses Group

14:30 - 16:00

Room 243

NG09 - Oral Session - Paediatrics Abstract Award Finalists

Chair: Marjola Gjergji, IT

Chair: Hilda Mekelenkamp, NL

Introduction

14:30 - 14:35

NG09-01

THE BENEFITS OF TEACHING PILL SWALLOWING TO CHILDREN AND YOUNG PEOPLE POST STEM CELL TRANSPLANT

14:35 - 14:55

Oral Presenter: Karen Nicholson, GB

NG09-02

DISCHARGE PLANNING OF COMPLEX PAEDIATRIC STEM CELL TRANSPLANT PATIENTS: A CASE STUDY REVIEW

14:55 - 15:15

Oral Presenter: Sian Essex, GB

NG09-03

INCREASE OF HAND HYGIENE ADHERENCE AND HAND HYGIENE PRACTICE QUALITY ACCORDING TO REGULATION GUIDELINES AT THE PEDIATRIC HEMATO-ONCOLOGY AND BONE MARROW TRANSPLANT DEPARTMENT (PHOBMTD)

15:15 - 15:35

Oral Presenter: Sandra Huino, IL

NG09-04

NURSES' EXPERIENCES WITH LIMB PAIN IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

15:35 - 15:55

Oral Presenter: Emma Bavinck, NL

Conclusions

15:55 - 16:00

Data Management

14:30 - 15:45

Room 251

DM1 - Data Management 1 - OMOP Introductory Session

Chair: Maria Paula Busto, NL

DM1-1

OMOP Introductory Session

14:30 - 15:30

Speaker: Freija Descamps, BE

DM1-2

Q&A

15:30 - 15:45

Lab Technicians Day

14:30 - 15:45

Room 253

LT1 - Lab Technicians Day 1 - CAR cell manufacturing

Chair: Harry Dolstra, NL

LT1-1

CART academic setting national study

14:30 - 14:55

Speaker: Edwin Bremer, NL

LT1-2

Engineering of CAR NK cells for immunotherapy

14:55 - 15:20

	<i>Speaker:</i> Evelyn Ullrich, DE	
LT1-3	CARTreg manufacturing <i>Speaker:</i> Matteo Doglio, IT	15:20 - 15:45
<i>Breaks</i>		
	16:00 - 16:30	AMPHITHEATRE BLEU
Coffee Break, ePoster Viewing, Visit Exhibition		
<i>Industry Theatre</i>		
	16:05 - 16:25	Industry Theatre
IT3 - Kite's commitment to manufacturing excellence KITE-GILEAD		
<i>Chair:</i> Chris McDonald, US		
<i>General</i>		
	16:30 - 18:00	AMPHITHEATRE BLEU
GS02 - Presidential Symposium		
<i>Chair:</i> Anna Sureda, ES		
<i>Chair:</i> Mohamad Mohty, FR		
GS02-1	Van Bekkum Award - Introduction <i>Speaker:</i> Anna Sureda, ES	16:30 - 16:33
GS02-02	VEDOLIZUMAB FOR PROPHYLAXIS OF LOWER GASTROINTESTINAL ACUTE GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENEIC HEMATOPOIETIC STEM-CELL TRANSPLANTATION FROM UNRELATED DONORS: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY <i>Speaker:</i> Yngvar Floisand, NO	16:33 - 16:48
GS02-3	Basic Science Award - Introduction <i>Speaker:</i> Mohamad Mohty, FR	16:48 - 16:51
GS02-04	BACTERIOPHAGE-MODULATED PRODUCTION OF INTESTINAL INTERFERON I-INDUCING METABOLITES IS ASSOCIATED WITH PROTECTION IN ALLOGENEIC STEM CELL TRANSPLANTATION PATIENTS <i>Oral Presenter:</i> Erik Thiele Orberg, DE	16:51 - 17:06
GS02-05	IMPROVED OUTCOMES OVER TIME AND HIGHER MORTALITY IN CMV SEROPOSITIVE ALLOGENEIC STEM CELL TRANSPLANTATION PATIENTS WITH COVID-19: AN IDWP STUDY FROM THE EBMT REGISTRY <i>Oral Presenter:</i> Per Ljungman, SE	17:06 - 17:15
GS02-06	FACTORS ASSOCIATED WITH DURATION OF RESPONSE AFTER CD19 CAR T-CELL THERAPY FOR RELAPSED/REFRACTORY CLL: 5-YEAR FOLLOW-UP UPDATE <i>Oral Presenter:</i> Emily Liang, US	17:15 - 17:24
GS02-07	AN EARLY ENDPOINT FOR ACUTE GRAFT VERSUS HOST DISEASE CLINICAL TRIALS <i>Oral Presenter:</i> James Ferrara, US	17:24 - 17:33

GS02-08	CTX110 ALLOGENEIC CRISPR-CAS9-ENGINEERED CAR T CELLS IN PATIENTS WITH RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA: RESULTS FROM THE PHASE 1 DOSE ESCALATION CARBON STUDY <i>Oral Presenter:</i> Joseph McGuirk, US	17:33 - 17:42
GS02-09	EFFICACY AND SAFETY OF A SINGLE DOSE OF EXAGAMGLOGENE AUTOTEMCEL FOR TRANSFUSION-DEPENDENT β-THALASSEMIA AND SEVERE SICKLE CELL DISEASE <i>Oral Presenter:</i> Franco Locatelli, IT	17:42 - 17:51
GS02-10	IDECABTAGENE VICLEUCEL VERSUS STANDARD REGIMENS IN PATIENTS WITH TRIPLE-CLASS-EXPOSED RELAPSED AND REFRACTORY MULTIPLE MYELOMA: KARMMA-3, A PHASE 3 RANDOMIZED CONTROLLED TRIAL <i>Oral Presenter:</i> Paula Rodríguez-Otero, ES	17:51 - 18:00

Cell Therapy Day

16:30 - 17:45

MAILLOT

CTD4 - Cell Therapy Day 4 - Microbiome*Chair:* Florent Malard, FR*Chair:* Federico Simonetta, CH

CTD4-1	Microbiota and HCT toxicities <i>Speaker:</i> Robert Jenq, US	16:30 - 16:55
CTD4-2	Impact of the gut microbiome in CAR-T cell therapy <i>Speaker:</i> Christophe Stein-Thoringer, DE	16:55 - 17:20
CTD4-3	Gut microbiota modulation after alloHCT <i>Speaker:</i> Giorgia Battipaglia, IT	17:20 - 17:45

Educational

16:30 - 18:00

Room 141

E05 - State of the art auto-transplant in (how and when):*Chair:* Thierry Guillaume, FR*Chair:* Radovan Vrhovac, HR

E05-1	AML <i>Speaker:</i> Norbert Claude Gorin, FR	16:30 - 17:00
E05-2	Mantle cell lymphoma <i>Speaker:</i> Olivier Hermine, FR	17:00 - 17:30
E05-3	When do I still consider auto-transplant consolidation in DLBCL? <i>Speaker:</i> Mehdi Hamadani, US	17:30 - 18:00

How do I... ?

16:30 - 17:45

Room 143

HDI1 - How Do I... avoid complications of chronic GVHD? - Supported through an unrestricted educational grant by Sanofi

HDI1-1 **How do I avoid complications of chronic GVHD?** 16:30 - 17:45
Speaker: Shahrukh Hashmi, AE
Speaker: Bipin Savani, US

Psy Day

16:30 - 18:00

Room 151

PSY4 - Psy Day: Current challenges in hematopoietic stem cell transplantation III - And after HCT?*Chair:* Anna Barata, US

Psy4-1 **Hematopoietic stem cell transplant (HSCT) ... and after? The psychological impact of HCT** 16:30 - 16:50

Speaker: Patrick BenSoussan, FR*Speaker:* Yolande Arnault, FR

Psy4-2 **AYA: Fertility preservation and sexuality** 16:50 - 17:10

Speaker: Emanuela Mencaglia, IT

Psy4-3 **cGVHD: psychosocial impact** 17:10 - 17:30

Speaker: Daniel Wolff, DE

Psy4-4 **Discussion** 17:30 - 17:50

Psy4-5 **Closing of the Psy Day** 17:50 - 18:00

Speaker: Yolande Arnault, FR*Speaker:* Alice Polomeni, FR*Practise Harmonisation Day*

16:30 - 17:45

Room 153

HM2 - Harmonization Day 2 - Practice Harmonization and guidelines committee of EBMT*Chair:* John Snowden, GB

HM2-1 **An innovative way to build up guidelines** 16:30 - 17:00

Speaker: Ibrahim Yakoub-Agha, FR

HM2-2 **How to select the experts** 17:00 - 17:15

Speaker: Rafael de la Cámara, ES

HM2-3 **European/world-wide surveys versus voting rounds among experts** 17:15 - 17:30

Speaker: Isabel Sánchez-Ortega, ES

HM2-4 **EBMT guidelines and JACIE** 17:30 - 17:45

Speaker: Riccardo Saccardi, IT*Nurses Group*

16:30 - 18:00

Room 242 AB

NG10 - GVHD*Chair:* Sophie Porcheron, FR*Chair:* Sandra Schoenfeld, CH

NG10-1 **Supportive care and practical tips** 16:30 - 16:55

Speaker: Sophie Van Lancker, BE

NG10-2 **New treatments** 16:55 - 17:20

	<i>Speaker:</i> Zinaida Peric, HR	
NG10-3	Male-specific late effects: genital chronic GvHD <i>Speaker:</i> Maria Teresa Lupo Stanghellini, IT	17:20 - 17:45
NG10-4	Q&A	17:45 - 18:00
<i>Workshop</i>		
16:30 - 18:00		Room 252 AB
W05 - NGS in clinical practice		
<i>Chair:</i> Jurgen Finke, DE		
<i>Chair:</i> Sylvain Chantepie, FR		
W05-1	NGS for risk prognostication in AML <i>Speaker:</i> Christian Recher, FR	16:30 - 17:00
W05-2	NGS for Clonal Hematopoiesis evaluation: future implications <i>Speaker:</i> Lourdes Mendez, US	17:00 - 17:30
W05-3	NGS as a tool for MRD evaluation <i>Speaker:</i> Pierre Hirsch, FR	17:30 - 18:00
<i>How do I... ?</i>		
16:30 - 17:45		Room 241
HDI2 - How Do I... adapt GvHD treatment approaches? A focus on ECP - Supported through an unrestricted educational grant by Mallinckrodt		
HDI2-1	How do I adapt GvHD treatment approaches? A focus on ECP <i>Speaker:</i> Hildegard Greinix, AT <i>Speaker:</i> Nina Worel, AT	16:30 - 17:45
<i>Data Management</i>		
16:30 - 17:45		Room 251
DM2 - Data Management 2 - CART Data Collection Initiative: DM training		
<i>Chair:</i> Steffie van der Werf, NL		
DM2-1	CART Data Collection Initiative: DM training <i>Speaker:</i> Irene Groen, NL <i>Speaker:</i> Jessica Lemaitre, FR	16:30 - 17:45
<i>Lab Technicians Day</i>		
16:30 - 17:45		Room 253
LT2 - Lab Technicians Day 2 - Gene editing technologies of T/NK cells		
<i>Chair:</i> Evelyn Ullrich, DE		
LT2-1	Basic principles CRISPR-Cas9 gene editing <i>Speaker:</i> Harry Dolstra, NL	16:30 - 16:55
LT2-2	Gene editing technologies for CAR-T cell production <i>Speaker:</i> Renata Stripecke, DE	16:55 - 17:20
LT2-3	Non-viral gene engineering of NK cells <i>Speaker:</i> Tobias Bexte, DE	17:20 - 17:45

Tuesday, 25. April 2023*Meetings*

07:00 - 08:45

Room 143

BM-LWP - Business Meeting*Chair:* Bertram Glass, DE

BM-LWP-1	Introduction	07:00 - 07:05
BM-LWP-2	Current Projects	07:05 - 08:15
BM-LWP-3	New Projects	08:15 - 08:40
BM-LWP-4	Summary and Closing	08:40 - 08:45

Meetings

07:00 - 08:45

Room 151

BM-ADWP - Business Meeting*Meetings*

07:00 - 08:45

Room 242 AB

BM-CTIWP - Business Meeting*Meetings*

07:00 - 08:45

Room 243

BM-TCWP - Business Meeting*Meetings*

07:00 - 08:45

Room 251

BM-SAAWP - Business Meeting*Meetings*

07:00 - 08:45

Room 253

BM-PDWP - Business Meeting*Meetings*

07:30 - 08:45

Room 153

BM-IEWP - Business Meeting*Meet the Expert*

08:00 - 09:00

MTE

Meet the Expert Sessions*Meet the Expert*

08:00 - 09:00

MTE

MTE-12 - Meet the Expert 12

MTE-12	Long term F/U and survivorship of the elderly transplanted patient <i>Speaker:</i> Bipin Savani, US	08:00 - 09:00
--------	---	---------------

Meet the Expert

08:00 - 09:00

MTE

MTE-07 - Meet the Expert 7

MTE-07

How I prevent and treat CMV infection

08:00 - 09:00

Speaker: Per Ljungman, SE*Meet the Expert*

08:00 - 09:00

MTE

MTE-11 - Meet the Expert 11

MTE-11

How to prevent and treat post allo rel in AML

08:00 - 09:00

Speaker: Ali Bazarbachi, LB*Meet the Expert*

08:00 - 09:00

MTE

MTE-08 - Meet the Expert 8

MTE-08

Management of HLH/MAS after CAR-T cells

08:00 - 09:00

Speaker: Ibrahim Yakoub-Agha, FR*Meet the Expert*

08:00 - 09:00

MTE

MTE-10 - Meet the Expert 10

MTE-10

Indications for allo in AML CR1

08:00 - 09:00

Speaker: Jurjen Versluis, NL*Working Party Sessions*

09:00 - 10:15

AMPHITHEATRE BLEU

ALWP - Acute Leukaemia Working Party session*Chair:* Fabio Ciceri, IT*Chair:* Mohamad Mohty, FR

ALWP-1

Introduction by the ALWP chair

09:00 - 09:10

ALWP-2

New insights from AML classification

09:10 - 09:30

Speaker: Jordi Esteve, ES

ALWP-3

ATGs in HLA-matched HSCT for acute leukemias

09:30 - 09:50

Speaker: Jurgen Finke, DE

ALWP-4

Choice of donor in Haploidentical HSCT in acute leukemias

09:50 - 10:10

Speaker: Jaime Sanz, ES

ALWP-5

The ALWP lifetime achievement award in acute leukemia

10:10 - 10:15

Paediatrics Day

09:00 - 10:30

MAILLOT

Paed1 - Paediatrics Diseases Working Party Session*Chair:* Selim Corbacioglu, DE

Paed1-1

Optimising transplant outcomes in AML using cord blood as donor cell source

09:00 - 09:15

	<i>Speaker:</i> Robert Wynn, GB	
Paed1-2	CART for relapsed or refractory B-ALL in children below 3 years <i>Speaker:</i> Sara Ghorashian, GB	09:15 - 09:30
Paed1-3	TBI or not TBI as standard of care in ALL; Pro's and Con's <i>Speaker:</i> Peter Bader, DE <i>Speaker:</i> Rupert Handgretinger, DE	09:30 - 09:50
Paed1-4	Is there a role for Cord Blood in HSCT in children in the future? <i>Speaker:</i> Vanderson Rocha, BR	09:50 - 10:05
Paed1-5	Defibrotide Prophylaxis: yes or no. The eternal question <i>Speaker:</i> Selim Corbacioglu, DE	10:05 - 10:15
Paed1-6	Dietrich Niethammer Award - Introduction <i>Speaker:</i> Giovanna Lucchini, GB	10:15 - 10:20
Paed1-7	Dietrich Niethammer Award <i>Speaker:</i> Paul Veys, GB	10:20 - 10:30

Educational

09:00 - 10:30

Room 141

E06 - Refractory acute GVHD: diagnosis and therapy*Chair:* Marie Thérèse Rubio, FR*Chair:* Christof Scheid, DE

E06-1	Risk assessment in acute GVHD <i>Speaker:</i> John Levine, US	09:00 - 09:30
E06-2	Principles of therapy in acute GVHD <i>Speaker:</i> Zinaida Peric, HR	09:30 - 10:00
E06-3	Treatment of cortico-steroid refractory acute GVHD <i>Speaker:</i> Ronjon Chakraverty, GB	10:00 - 10:30

How do I... ?

09:00 - 10:15

Room 143

HDI4 - How Do I... treat relapsed or refractory LBCL after 1st line therapy? - Supported through an unrestricted educational grant by Bristol Myers Squibb

HDI4-1	How do I treat relapsed or refractory LBCL after 1st line therapy? <i>Speaker:</i> Gandhi Damaj, FR <i>Speaker:</i> Marjolein van der Poel, NL	09:00 - 10:15
--------	---	---------------

Working Party Sessions

09:00 - 10:15

Room 151

ADWP - Autoimmune Diseases Working Party session*Chair:* Raffaella Greco, IT*Chair:* Tobias Alexander, DE

ADWP-1	Long-term disease control of severe ADs by autologous HSCT <i>Speaker:</i> Riccardo Saccardi, IT	09:00 - 09:15
--------	--	---------------

ADWP-2	Efficacy of allogeneic HSCT in ADs <i>Speaker:</i> Jan Storek, CA	09:15 - 09:30
ADWP-3	New strategies in ADs: Mesenchymal stromal cells <i>Speaker:</i> Dominique Farge, FR	09:30 - 09:45
ADWP-4	New strategies in ADs: Anti-CD19 CART cells <i>Speaker:</i> Andreas Mackensen, DE	09:45 - 10:00
ADWP-5	Round Table for Q&A	10:00 - 10:15

Workshop

09:00 - 10:30

Room 153

W06 - Hot debates in transplants for Malignant Lymphoma*Chair:* Bertram Glass, DE*Chair:* Catherine Faucher, FR

W06-1	Auto-HSCT versus CAR-T cells in DLBCL <i>Speaker:</i> Catherine Thieblemont, FR	09:00 - 09:30
W06-2	Allo-HSCT post CAR-T cells for NHL <i>Speaker:</i> Arnon Nagler, IL	09:30 - 10:00
W06-3	Round table discussion: role of HSCT at the era of CAR-T cells - All faculty, lead by: <i>Speaker:</i> Bertram Glass, DE	10:00 - 10:30

Nurses Group

09:00 - 10:30

Room 242 AB

NG11 - Infections*Chair:* Cristina Baiana, BE*Chair:* Daniel Kisielewski, DE

NG11-1	Infections and HSCT setting: new and old in a changing world <i>Speaker:</i> Marta Canesi, IT	09:00 - 09:25
NG11-2	Multi-drug resistant infections <i>Speaker:</i> Robina Aerts, BE	09:25 - 09:50
NG11-3	What do nurses have to know about vaccination in HSCT patients? <i>Speaker:</i> Marijke Quaghebeur, BE	09:50 - 10:15
NG11-4	Q&A	10:15 - 10:30

Quality Management

09:00 - 10:15

Room 241

QM1 - Quality Management 1 - Center Session*Chair:* Dania Arabi, SA

QM1-1	The Accreditation Process <i>Speaker:</i> Angela Ruso, ES	09:00 - 09:15
QM1-2	Writing a quality management plan	09:15 - 09:30

	<i>Speaker:</i> Marie Nöelle Lacassagne, FR	
QM1-3	Outcome analysis <i>Speaker:</i> Anne Emmett, GB	09:30 - 09:45
QM1-4	Disaster plan <i>Speaker:</i> Deborah Richardson, GB	09:45 - 10:00
QM1-5	Q&A	10:00 - 10:15

Nurses Group

09:00 - 10:30

Room 243

NG12 - EBMT next-generation session: Nursing in 2023 and beyond*Chair:* Stavroula Chante, GB*Chair:* Fabienne Colledani, FR

NG12-1	Making your voice heard from the bedside <i>Speaker:</i> Julia Ruiz Pato, ES	09:00 - 09:25
NG12-2	Advanced practice nurse: minidoctor or maxinurse? <i>Speaker:</i> Lidia Hurtado, ES	09:25 - 09:50
NG12-3	Behavioural science for well-being, adaptability, meaningful action & recovery <i>Speaker:</i> Ross McIntosh, ES	09:50 - 10:30

Joint Sessions

09:00 - 10:00

Room 251

JS04 - Joint Session EBMT - KSBMT: How to Treat Steroid Refractory Chronic GVHD? Best sequence in the Era of JAK, BCR, ROCK Inhibitors*Chair:* Anna Sureda, ES*Chair:* Hee-Je Kim, KR

JS04-1	Introduction	09:00 - 09:05
JS04-2	Current treatment of GVHD in Korea <i>Speaker:</i> Hyoung Jin Kang, KR	09:05 - 09:25
JS04-3	How to Treat Steroid Refractory Chronic GVHD? Best sequence in the Era of JAK, BCR, ROCK Inhibitors - EBMT experience <i>Speaker:</i> Olaf Penack, DE	09:25 - 09:45
JS04-4	Discussion and conclusions	09:45 - 10:00

Pharmacists Day

09:00 - 10:30

Room 253

Pharm1 - Pharmacotherapy*Chair:* Nick Duncan, GB*Chair:* Agnes Bonnin, FR

Pharm1-1	Welcome <i>Speaker:</i> Catherine Rioufol, FR <i>Speaker:</i> Nick Duncan, GB	09:00 - 09:10
----------	--	---------------

Pharm1-2	Haplo-identical transplantation <i>Speaker:</i> Sumantha Gabriel, GB	09:10 - 09:35
Pharm1-3	The role of TDM in transplantation <i>Speaker:</i> Karen Sweiss, US	09:35 - 10:00
Pharm1-4	Dosing of conditioning chemotherapy and GvHD prophylaxis in obesity <i>Speaker:</i> Siobhan Smith, GB	10:00 - 10:25
<i>ePoster</i> 09:00 - 18:00 ePoster Viewing		ePoster Area
<i>Library</i> 09:00 - 18:00 Library		Library
<i>Special Session</i> 09:15 - 10:15 SS02 - Social Media Session <i>Chair:</i> Melanie Chaboissier, ES		Industry Theatre
SS02-1	Panel discussion How to avoid peremptory and assertive communication on Twitter? <i>Speaker:</i> Mehdi Hamadani, US <i>Speaker:</i> Yasmina Serroukh, NL <i>Speaker:</i> Razan Mohty, US <i>Speaker:</i> Nico Gagelmann, DE	09:15 - 10:15
<i>Breaks</i> 10:30 - 11:00 Coffee Break, ePoster Viewing, Visit Exhibition		AMPHITHEATRE BLEU
<i>Industry Theatre</i> 10:35 - 10:55 IT4 - Kite as the leader in cell therapy KITE-GILEAD <i>Chair:</i> Dick Sundh, SE		Industry Theatre
<i>Working Party Sessions</i> 11:00 - 12:15 CTIWP - Cellular Therapy and Immunobiology Working Party session <i>Chair:</i> Annalisa Ruggeri, IT <i>Chair:</i> Florent Malard, FR		AMPHITHEATRE BLEU
CTIWP-1	Introduction by the CTIWP chair	11:00 - 11:05
CTIWP-2	TCR gene editing, what is feasible in the GMP world <i>Speaker:</i> Dirk Busch, DE	11:05 - 11:25
CTIWP-3	Immunomonitoring after CAR-T reveals associations between fludarabine exposures and outcome	11:25 - 11:45

	<i>Speaker: Stefan Nierkens, NL</i>	
CTIWP-4	Presentation of the Jon J. van Rood Award	11:45 - 11:50
CTIWP-5	Uncovering the mode of action of engineered T cells in patient cancer organoids <i>Speaker: Maria Alieva, ES</i>	11:50 - 12:15
<i>Paediatrics Day</i>		
11:00 - 12:15		
MAILLOT		
Paed2 - Inborn Errors Working Party Session		
<i>Chair: Bénédicte Neven, FR</i>		
Paed2-1	Biology of thymus transplantation, challenges and outcomes: the European experience <i>Speaker: Graham Davies, GB</i>	11:00 - 11:20
Paed2-2	Thymus development and related diseases <i>Speaker: Georg Hollander, GB</i>	11:20 - 11:40
Paed2-3	Thymus Reconstitution and HSCT: Lessons From Mouse Models <i>Speaker: Graham Anderson, GB</i>	11:40 - 12:00
Paed2-4	Discussion	12:00 - 12:15
<i>Educational</i>		
11:00 - 12:30		
Room 141		
E07 - GVHD prophylaxis in matched sibling donor transplant		
<i>Chair: Marie Robin, FR</i>		
<i>Chair: Rafael Duarte, ES</i>		
E07-1	The role of ATG/ATLG <i>Speaker: Nicolaus Kröger, DE</i>	11:00 - 11:30
E07-2	The case for “post-cyclophosphamide” <i>Speaker: Alexandros Spyridonidis, GR</i>	11:30 - 12:00
E07-3	Round table discussion: ATG versus PtCy or both? - All faculty, lead by: <i>Speaker: Marie Robin, FR</i>	12:00 - 12:30
<i>Working Party Sessions</i>		
11:00 - 12:15		
Room 143		
LWP - Lymphoma Working Party session		
<i>Chair: Bertram Glass, DE</i>		
LWP-1	Report of LWP activities & Introduction Jiang Jiang Luan award <i>Speaker: Bertram Glass, DE</i>	11:00 - 11:15
LWP-2	JIAN JIAN LUAN: ALLOGENEIC TRANSPLANTATION IN ADVANCED CUTANEOUS T-CELL LYMPHOMAS: A PROPENSITY SCORE-MATCHED CONTROLLED PROSPECTIVE TRIAL	11:15 - 11:30

Oral Presenter: Adele de Masson, FR

LWP-3	Introduction: CART therapy replaces allogeneic SCT in treatment of r/r MCL <i>Speaker:</i> Peter Dreger, DE	11:30 - 11:35
LWP-4	CART therapy replaces allogeneic SCT in treatment of r/r MCL: YES <i>Speaker:</i> Gloria Iacoboni, ES	11:35 - 11:55
LWP-5	CART therapy replaces allogeneic SCT in treatment of r/r MCL: NO <i>Speaker:</i> Sascha Dietrich, DE	11:55 - 12:15

How do I... ?

11:00 - 12:15

Room 151

HDI5 - How Do I... select the right treatment at the right time for individual patients with multiple myeloma? - Supported through an unrestricted educational grant by Janssen

HDI5-1	How do I select the right treatment at the right time for individual patients with multiple myeloma? <i>Speaker:</i> Aurore Perrot, FR <i>Speaker:</i> Joan Blade, ES	11:00 - 12:15
--------	--	---------------

Joint Sessions

11:00 - 12:30

Room 153

JS05 - Joint Session EBMT-ASTCT-CIBMTR-APBMT-LABMT: How Do We Define Reduced Intensity Conditioning Regimens?

Chair: Anna Sureda, ES

Chair: Bronwen Shaw, US

Chair: Miguel-Angel Perales, US

Chair: Shinichiro Okamoto, JP

Chair: Amado Karduss, CO

JS05-1	Introduction	11:00 - 11:10
JS05-2	How Do We Define Reduced Intensity Conditioning Regimens? APBMT perspective <i>Speaker:</i> Yoshiko Atsuta, JP	11:10 - 11:22
JS05-3	How Do We Define Reduced Intensity Conditioning Regimens? LABMT perspective <i>Speaker:</i> Carmem Bonfim, BR	11:22 - 11:34
JS05-4	How Do We Define Reduced Intensity Conditioning Regimens? CIBMTR perspective <i>Speaker:</i> Bart Scott, US	11:34 - 11:46
JS05-5	How Do We Define Reduced Intensity Conditioning Regimens? ASTCT perspective <i>Speaker:</i> Brenda Sandmaier, US	11:46 - 11:58
JS05-6	How Do We Define Reduced Intensity Conditioning Regimens? EBMT perspective	11:58 - 12:10

	<i>Speaker:</i> Andrea Bacigalupo, IT	
JS05-7	Discussion and conclusions	12:10 - 12:30
<i>Nurses Group</i>		
11:00 - 12:30		Room 242 AB
NG13 - Advances in patient care		
<i>Chair:</i> Polona Klascek, SI		
<i>Chair:</i> Marijke Quaghebeur, BE		
NG13-1	Exercise prehabilitation in stem cell transplantation	11:00 - 11:25
	<i>Speaker:</i> Orla McCourt, GB	
NG13-3	Nurse led clinics	11:25 - 11:50
	<i>Speaker:</i> Maaïke De Ruijter, NL	
NG13-2	Ambulatory transplant care for patients and their family caregivers	11:50 - 12:15
	<i>Speaker:</i> Sabine Valenta, CH	
NG13-4	Q&A	12:15 - 12:30
<i>How do I... ?</i>		
11:00 - 12:15		Room 252 AB
HDI6 - How Do I... treat MF patients with anemia? - Supported through an unrestricted educational grant by GSK		
HDI6-1	How do I treat MF patients with anemia?	11:00 - 12:15
	<i>Speaker:</i> Hugues de Lavallade, GB	
	<i>Speaker:</i> Mathieu Wemeau, FR	
<i>Quality Management</i>		
11:00 - 12:30		Room 241
QM2 - Quality Management 2 -Challenging Standards		
<i>Chair:</i> Sandra Loaiza, GB		
QM2-1	Clinical Standards	11:00 - 11:15
	<i>Speaker:</i> Charles Crawley, GB	
QM2-2	Collection Standards	11:15 - 11:30
	<i>Speaker:</i> Olga López, ES	
QM2-3	Processing Standards	11:30 - 11:45
	<i>Speaker:</i> Sandra Loaiza, GB	
QM2-4	QM Standards	11:45 - 12:00
	<i>Speaker:</i> Renza Monteleone, IT	
QM2-5	Quality Management Abstract Award Presentation	12:00 - 12:05
	<i>Speaker:</i> Lynn Manson, GB	
QM2-6	AUTOMATING OUTCOME ANALYSIS FOR SCT PATIENTS: THE YEARLY OUTCOME REVIEW TOOL	12:05 - 12:25
	<i>Oral Presenter:</i> Erik G. J. Von Asmuth, NL	

modelling*Speaker:* Tim Morris, GB

STATS1-3	Registries and real world data: importance of clinician-biostatistician collaboration	11:50 - 12:15
	<i>Speaker:</i> Kristin Page, US	

Pharmacists Day

11:00 - 12:15

Room 253

Pharm2 - Transplant Complications*Chair:* Tiene Bauters, BE*Chair:* Katerina Nezvalova-Henriksen, NO

Pharm2-1	Management of endothelial complications of transplant – TMA and SOS	11:00 - 11:25
	<i>Speaker:</i> Mohamad Mohty, FR	
Pharm2-2	Fertility preservation and management of menorrhagia	11:25 - 11:50
	<i>Speaker:</i> Olga Aso Ferreras, ES	
Pharm2-3	Late effects of transplantation	11:50 - 12:15
	<i>Speaker:</i> Francesca Kinsella, GB	

Breaks

12:30 - 13:00

AMPHITHEATRE BLEU

Lunch Break, ePoster Viewing, Visit Exhibition*Industry Symposium*

13:00 - 14:00

AMPHITHEATRE BLEU

IS31 - Reaching for the summit: Optimizing outcomes in transplant-eligible NDMM | SANOFI*Chair:* Mohamad Mohty, FR

IS31-1	Welcome and introduction	13:00 - 13:02
	<i>Speaker:</i> Mohamad Mohty, FR	
IS31-2	Is ASCT still the pinnacle of frontline treatment for all eligible patients?	13:02 - 13:19
	<i>Speaker:</i> Mohamad Mohty, FR	
IS31-3	Charting a course for quadruplets: Future directions for induction and consolidation	13:19 - 13:36
	<i>Speaker:</i> Elias Mai, DE	
IS31-4	Looking to the horizon: Refining maintenance strategies	13:36 - 13:53
	<i>Speaker:</i> Lisa Leypoldt, DE	
IS31-5	Q&A - All - moderated by Mohamad Mohty	13:53 - 14:00

Industry Symposium

13:00 - 14:00

MAILLOT

IS32 - Optimising antifungal treatment options in patients with neutropenic haematological disease| GILEAD*Chair:* Antonio Pagliuca, GB

IS32-1	Welcome, introduction and meeting overview <i>Speaker:</i> Antonio Pagliuca, GB	13:00 - 13:05
IS32-2	Managing fungal infections in patients with AML/MDS and ALL, and patients treated with CAR-T cell therapy or stem-cell transplantation <i>Speaker:</i> Malgorzata Mikulska, IT	13:05 - 13:20
IS32-3	A Spanish National Survey: Strategies for management of IFIs and guideline application in patients with high-risk onco-haematological disease <i>Speaker:</i> Carlos Vallejo, ES	13:20 - 13:35
IS32-4	The importance of the role of low-resistance, broad-spectrum and fungicidal antifungals <i>Speaker:</i> Antonio Pagliuca, GB	13:35 - 13:50
IS32-5	Q&A and panel discussion - All faculty (Moderated by Professor Antonio Pagliuca)	13:50 - 13:58
IS32-6	Meeting summary and close <i>Speaker:</i> Antonio Pagliuca, GB	13:58 - 14:00

Meetings

13:00 - 14:00

Room 242 AB

BM-NG - EBMT Nurses Group overview opportunities and networking*Chair:* Daphna Hutt, IL

BM-NG-1	Introduction <i>Speaker:</i> Daphna Hutt, IL	13:00 - 13:05
BM-NG-2	President report <i>Speaker:</i> Michelle Kenyon, GB	13:05 - 13:15
BM-NG-3	Research committee update <i>Speaker:</i> Annika Kisch, SE	13:15 - 13:25
BM-NG-4	Scientific committee update <i>Speaker:</i> Kathy Goris, BE	13:25 - 13:30
BM-NG-5	Pediatric committee update <i>Speaker:</i> Hilda Mekelenkamp, NL	13:30 - 13:35
BM-NG-6	Global education committee update <i>Speaker:</i> Julia Ruiz Pato, ES	13:35 - 13:40
BM-NG-7	Working party nurses update <i>Speaker:</i> Maaïke De Ruijter, NL	13:40 - 13:45
BM-NG-8	Discussion & close	13:45 - 14:00

Industry Symposium

13:00 - 14:00

MTE

S-MTE-4 - Evidence-based evolution in the management of frontline advanced Hodgkin lymphoma | TAKEDA*Chair:* Ali Bazarbachi, LB*Industry Symposium*

13:00 - 13:50

MTE

Meet the Expert Sessions Lunch - sponsored*Industry Symposium*

13:00 - 14:00

MTE

S-MTE-3 - Meet the Expert Lunch - Managing GvHD with combination therapy | THERAKOS*Chair:* Zinaida Peric, HR*Industry Theatre*

13:10 - 13:45

Industry Theatre

IT5 - Redefining treatment goals in PNH: Raising the efficacy bar in PNH treatment with Aspaveli | SobiIT5-1 **The evidence behind a new era of complement inhibition** 13:10 - 13:17*Speaker:* Régis Peffault de Latour, FRIT5-2 **Real-world experience: Improving patients' lives in clinical practice** 13:17 - 13:35*Speaker:* Morag Griffin, GB*Speaker:* Andrea Patriarca, ITIT5-3 **Q&A** 13:35 - 13:45*Speaker:* Andrea Patriarca, IT*Speaker:* Morag Griffin, GB*Speaker:* Régis Peffault de Latour, FR*Breaks*

14:00 - 14:30

AMPHITHEATRE BLEU

Lunch Break, ePoster Viewing, Visit Exhibition*Plenary Session*

14:30 - 16:00

AMPHITHEATRE BLEU

P02 - Management of CAR-T cell toxicities*Chair:* David Beauvais, FR*Chair:* Peter Dreger, DEP02-1 **CRS** 14:30 - 15:00*Speaker:* He Huang, CNP02-2 **Neurotoxicity** 15:00 - 15:30*Speaker:* Ibrahim Yakoub-Agha, FRP02-3 **Prophylaxis and treatment of infectious complications** 15:30 - 16:00*Speaker:* Stephan Mielke, SE

Paediatrics Day

14:30 - 15:45

MAILLOT

Paed3 - Paediatric Diseases Oral Session

Chair: Krzysztof Kalwak, PL

Chair: Petr Sedlacek, CZ

Paed3-01	LOW TOXICITY WITH MYELOABLATIVE CHEMO-BASED CONDITIONING FOR CHILDREN WITH ALL BELOW 4 YEARS OF AGE. RESULTS FROM THE PROSPECTIVE MULTINATIONAL FORUM-TRIAL <i>Oral Presenter:</i> Christina Peters, AT	14:30 - 14:39
Paed3-02	UPDATED RESULTS FROM PHASE 3 STUDY TABELCLEUCEL FOR POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE FOLLOWING ALLOGENEIC HEMATOPOIETIC CELL OR SOLID ORGAN TRANSPLANT AFTER FAILURE RITUXIMAB(R) OR R+CHEMOTHERAPY (ALLELE) <i>Oral Presenter:</i> Sylvain Choquet, FR	14:39 - 14:48
Paed3-03	THE IMPACT OF PRE-TRANSPLANT EXTRAMEDULLARY DISEASE ON THE OUTCOME OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA IN CHILDREN - ON BEHALF OF PDWP/EBMT <i>Oral Presenter:</i> Juliana Montibeller F Silva, GB	14:48 - 14:57
Paed3-04	SPECIFIC CYTOGENETIC ABNORMALITIES AT DIAGNOSIS PREDICT SURVIVAL AFTER HEMATOPOIETIC CELL TRANSPLANT IN POOR-RISK PEDIATRIC ACUTE MYELOID LEUKEMIA: A PDWP/EBMT STUDY <i>Oral Presenter:</i> Brenda Gibson, GB	14:57 - 15:06
Paed3-05	RUXOLITINIB IN PEDIATRIC PATIENTS WITH TREATMENT-NAÏVE OR STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE: PRIMARY FINDINGS FROM THE PHASE I/II REACH4 STUDY <i>Oral Presenter:</i> Franco Locatelli, IT	15:06 - 15:15
Paed3-06	ACUTE LYMPHOBLASTIC LEUKEMIA: CD19-CAR-T CELLS ARE AN EFFECTIVE THERAPY FOR POSTTRANSPLANT RELAPSE <i>Oral Presenter:</i> Peter Bader, DE	15:15 - 15:24
Paed3-07	ALLOGENIC STEM CELL TRANSPLANTATION WITH TCR^{??+}/CD19⁺-DEPLETION IN INFANT LEUKEMIA, SINGLE CENTER EXPERIMENT <i>Oral Presenter:</i> Larisa Shelikhova, RU	15:24 - 15:33
Paed3-08	OUTCOMES OF MATCHED SIBLING DONOR HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN WITH SICKLE CELL DISEASE – DOES DONOR SICKLE CELL TRAIT STATUS MATTER? <i>Oral Presenter:</i> Mohamed Bayoumy, SA	15:33 - 15:42

Educational

14:30 - 16:00

Room 141

E08 - Refractory chronic GVHD: diagnosis and therapy*Chair:* Leonardo Magro, IT*Chair:* Michaël Loschi, FR

E08-1	Diagnosis and risk assessment in chronic GVHD <i>Speaker:</i> Steven Pavletic, US	14:30 - 15:00
E08-2	Principles of therapy in chronic GVHD <i>Speaker:</i> Gérard Socie, FR	15:00 - 15:30
E08-3	Treatment of cortico-steroid refractory chronic GVHD <i>Speaker:</i> Robert Zeiser, DE	15:30 - 16:00

Working Party Sessions

14:30 - 15:45

Room 143

SAAWP - Severe Aplastic Anaemia Working Party session*Chair:* Régis Peffault de Latour, FR*Chair:* Beatrice Drexler, CH

SAAWP-1	AA PNH and COVID: all what you want to know in 2023 <i>Speaker:</i> Morag Griffin, GB	14:30 - 14:50
SAAWP-2	HLA-haploidentical stem cell transplantation in children with inherited bone marrow failure syndromes <i>Speaker:</i> Stefano Giardino, IT	14:50 - 15:00
SAAWP-3	BMT in paediatric FA: an update <i>Speaker:</i> Su Han Lum, GB	15:00 - 15:10
SAAWP-4	RACE bio: state of the art <i>Speaker:</i> Austin Kulasekararaj, GB	15:10 - 15:30
SAAWP-5	Questions and Conclusion	15:30 - 15:45

General

14:30 - 15:30

Room 151

GS03 - General Assembly*Chair:* Anna Sureda, ES*Chair:* John Snowden, GB*Chair:* Harry Dolstra, NL

GS03-1	President's Report <i>Speaker:</i> Anna Sureda, ES	14:30 - 14:55
GS03-2	Secretary's Report <i>Speaker:</i> John Snowden, GB	14:55 - 15:05
GS03-3	Treasurer's Financial Report <i>Speaker:</i> Harry Dolstra, NL	15:05 - 15:15
GS03-4	Election Results 2023 <i>Speaker:</i> John Snowden, GB	15:15 - 15:20

SS03-1	Introduction <i>Speaker:</i> Norbert Claude Gorin, FR	14:30 - 14:32
SS03-2	Multiple center study of the combination of Fludarabin, Busulfan and Melphalan (BMF) as conditioning regimen pretransplant in China <i>Speaker:</i> Hu Jiong, CN	14:32 - 14:49
SS03-3	Challenges in global access to novel cell therapies <i>Speaker:</i> William Hwang, SG	14:49 - 15:06
SS03-4	Novel drugs and access to hematopoietic stem cell transplantation in Latin America <i>Speaker:</i> Gregorio Jaimovich, AR	15:06 - 15:23
SS03-5	Stem cell transplantation landscape and challenges in Saudi Arabia <i>Speaker:</i> Ahmed Alaskar, SA	15:23 - 15:40
SS03-6	Reducing inequities in stem cell transplantation: the experience from Middle East <i>Speaker:</i> Ali Bazarbachi, LB	15:40 - 15:57
SS03-7	Conclusion	15:57 - 16:00

Quality Management

14:30 - 16:00

Room 241

QM3 - Quality Management 3 - How I manage ...?*Chair:* John Fitzgerald, IE

QM3-1	Donor safety: before, during and after the collection <i>Speaker:</i> Eugenia Trigos, ES	14:30 - 14:45
QM3-2	Stem cell products: storage, release and transportation <i>Speaker:</i> Monique Grommé, NL	14:45 - 15:00
QM3-3	Adverse events: report, investigation and follow up <i>Speaker:</i> Phuong Huynh, BE <i>Speaker:</i> Anne Emmett, GB	15:00 - 15:15
QM3-4	Collecting evidence for training and competencies: nurses / QM / AHP professionals <i>Speaker:</i> Ruth Elizabeth Clout, GB	15:15 - 15:30
QM3-5	Q&A	15:30 - 15:50
QM3-6	Closing Remarks <i>Speaker:</i> Lynn Manson, GB	15:50 - 16:00

Nurses Group

14:30 - 16:00

Room 243

NG16 - Paediatric: Nutritional support*Chair:* Ida Bremer, NL*Chair:* Hilda Mekelenkamp, NL

NG16-1	Enteral and parenteral nutrition in pediatric HSCT – principles and practice <i>Speaker:</i> James Evans, GB	14:30 - 14:55
NG16-2	Nutrition post-SCT and the 'Graft Diet' <i>Speaker:</i> Nina van der Linden, NL	14:55 - 15:20
NG16-3	Perceptions of nutrition support from professionals, patients and parents (video & discussion)	15:20 - 15:45
NG16-4	Q&A	15:45 - 16:00

Statistics

14:30 - 15:30

Room 251

STATS2 - Statistics Workshop*Chair:* Ariane Boumendil, FR*Chair:* Richard Szydlo, GB

STATS2-1	Comparing transplant and non-transplant treatment based on observational data – the case of CMML <i>Speaker:</i> Marie Robin, FR <i>Speaker:</i> Liesbeth de Wreede, NL	14:30 - 15:30
----------	--	---------------

Pharmacists Day

14:30 - 15:45

Room 253

Pharm3 - Cellular Therapies*Chair:* Estela Moreno Martinez, ES*Chair:* Claudia Langebrake, DE

Pharm3-1	Update on the GoCART Coalition activities <i>Speaker:</i> Christian Chabannon, FR	14:30 - 14:50
Pharm3-2	Infection prevention in CAR-T patients – panel discussion <i>Speaker:</i> Friso Calkoen, NL <i>Speaker:</i> Ana Carolina Caballero, ES <i>Speaker:</i> Raakhee Shah, GB <i>Speaker:</i> Alice Tam, GB <i>Speaker:</i> Gilda Teixeira, PT	14:50 - 15:10
Pharm3-3	Management of CRS and ICANS (Tocilizumab and beyond) – panel discussion <i>Speaker:</i> Friso Calkoen, NL <i>Speaker:</i> Ana Carolina Caballero, ES <i>Speaker:</i> Raakhee Shah, GB <i>Speaker:</i> Alice Tam, GB <i>Speaker:</i> Gilda Teixeira, PT	15:10 - 15:30
Pharm3-4	Q&A	15:30 - 15:45

Breaks

16:00 - 16:30

AMPHITHEATRE BLEU

Coffee Break, ePoster Viewing, Visit Exhibition

Plenary Session

16:30 - 18:00

AMPHITHEATRE BLEU

P03 - Non CAR-T cell therapies and immunomodulation

Chair: Stéphanie Nguyen Quoc, FR

Chair: Alejandro Madrigal, GB

P03-1	NK cells: next generation cell therapies for cancer <i>Speaker:</i> Katy Rezvani, US	16:30 - 17:00
P03-2	Gamma delta T cell inspired therapies <i>Speaker:</i> Jurgen Kuball, NL	17:00 - 17:30
P03-3	Updates and future directions in Treg cell-based therapies <i>Speaker:</i> Raffaella Greco, IT	17:30 - 18:00

Paediatrics Day

16:30 - 17:45

MAILLOT

Paed4 - Inborn Errors Oral Session

Chair: Michael Albert, DE

Chair: Maria Ester Bernardo, IT

Paed4-01	OUTCOMES OF HLA-MISMATCHED HSCT WITH TCR$\alpha\beta$/CD19 DEPLETION OR POST-TRANSPLANT CYCLOPHOSPHAMIDE FOR INBORN ERRORS OF IMMUNITY: ANALYSIS BY EBMT IEWP HAPLOHSCT IN IEI STUDY GROUP <i>Oral Presenter:</i> Su Han Lum, GB	16:30 - 16:39
Paed4-02	LENTIVIRAL-MEDIATED EX-VIVO GENE THERAPY FOR PEDIATRIC PATIENTS WITH SEVERE LEUKOCYTE ADHESION DEFICIENCY-I (LAD-I): INTERIM RESULTS FROM AN ONGOING PHASE 1/2 STUDY <i>Oral Presenter:</i> Donald Kohn, US	16:39 - 16:48
Paed4-03	CLINICAL AND NEUROLOGICAL OUTCOME IN PURINE NUCLEOSIDE PHOSPHORYLASE DEFICIENT CHILDREN AFTER ALLOGENEIC HSCT - A MULTI-CENTER STUDY <i>Oral Presenter:</i> Tayfun Güngör, CH	16:48 - 16:57
Paed4-04	OUTCOME OF FLUDARABINE AND TREOSULFAN CONDITIONING FOR HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN 415 CHILDREN WITH NON-SCID IEI: A MULTICENTRE RETROSPECTIVE COHORT ANALYSIS <i>Oral Presenter:</i> Su Han Lum, GB	16:57 - 17:06
Paed4-05	MICROGLIAL REPLACEMENT BY HEMATOPOIETIC CELL TRANSPLANTATION FOR THE TREATMENT OF CSF1R-RELATED LEUKOENCEPHALOPATHY <i>Oral Presenter:</i> Ernesto Ayala, US	17:06 - 17:15
Paed4-06	BIOCHEMICAL ENGRAFTMENT AND CLINICAL OUTCOMES OF EX-VIVO AUTOLOGOUS STEM CELL GENE THERAPY FOR MUCOPOLYSACCHARIDOSIS TYPE IIIA <i>Oral Presenter:</i> Anthea Guha, GB	17:15 - 17:24
Paed4-07	OUTCOME OF SECOND ALLOGENEIC HSCT IN NON-SCID INBORN ERRORS OF IMMUNITY (IEI): AN INTERNATIONAL	17:24 - 17:33

COHORT ANALYSIS (EBMT IEWP SECOND ALLO STUDY GROUP)

Oral Presenter: Zohreh Nademi, GB

Paed4-08	WHAT WE HAVE DONE AND WHAT WE HAVE FAILED TO DO: THE STORY OF LIBMELDY AS A NOW LICENSED STEM CELL GENE THERAPY FOR MLD	17:33 - 17:42
	<i>Oral Presenter:</i> Claire Horgan, GB	

Educational
16:30 - 18:00

Room 141

E09 - Transplant in bone marrow failures

Chair: Sebastien Maury, FR

Chair: Christina Peters, AT

E09-1	Severe aplastic anemia	16:30 - 17:00
	<i>Speaker:</i> Carlos Vallejo, ES	
E09-2	PNH	17:00 - 17:30
	<i>Speaker:</i> Régis Peffault de Latour, FR	
E09-3	Strategies of stem cell transplantation in pediatric MDS	17:30 - 18:00
	<i>Speaker:</i> Charlotte Niemeyer, DE	

Workshop
16:30 - 18:00

Room 143

W09 - Hot topics in transplant for AML

Chair: Eleni Gavriilaki, GR

Chair: Harry Dolstra, NL

W09-1	Second allo-HSCT or DLI for relapsed AML?	16:30 - 17:00
	<i>Speaker:</i> Mohamed Kharfan-Dabaja, US	
W09-2	Transplant indication in AML with FLT3-ITD mutation: modulated by allelic ratio & co-mutations?	17:00 - 17:30
	<i>Speaker:</i> Jordi Esteve, ES	
W09-3	Round table discussion: optimal management of difficult to treat AML patients - All faculty, lead by:	17:30 - 18:00
	<i>Speaker:</i> Harry Dolstra, NL	

Special Session
16:30 - 17:45

Room 151

SS04 - The EBMT Case report forum

Chair: Shahrukh Hashmi, AE

Chair: Mauricette Michallet, FR

SS04-0	Introduction by the chairs	16:30 - 16:35
SS04-1	A difficult case of CAR-T toxicity	16:35 - 16:35
SS04-1.1	Presentation:	16:35 - 16:42
	<i>Speaker:</i> Razan Mohty, US	

SS04-1.2	Discussion: <i>Speaker:</i> Olalekan O. Oluwole, US	16:42 - 16:49
SS04-2	A difficult case of refractory chronic GVHD	16:49 - 16:49
SS04-2.1	Presentation: <i>Speaker:</i> Kordelia Barbullushi, IT	16:49 - 16:56
SS04-2.2	Discussion: <i>Speaker:</i> Linde Morsink, NL	16:56 - 17:03
SS04-3	A difficult case of refractory ALL	17:03 - 17:03
SS04-3.1	Presentation: <i>Speaker:</i> Reyes Martín Rojas, FR	17:03 - 17:10
SS04-3.2	Discussion: <i>Speaker:</i> Eolia Brissot, FR	17:10 - 17:17
SS04-4	A difficult case of refractory acute GVHD	17:17 - 17:17
SS04-4.1	Presentation: <i>Speaker:</i> Giorgia Battipaglia, IT	17:17 - 17:24
SS04-4.2	Discussion: <i>Speaker:</i> Florent Malard, FR	17:24 - 17:31
SS04-5	Conclusion	17:31 - 17:41

Workshop
16:30 - 18:00

Room 153

W08 - Transplant in older patients

Chair: Jean-Luc Harousseau, FR

Chair: John Snowden, GB

W08-1	The case for AML <i>Speaker:</i> Didier Blaise, FR	16:30 - 17:00
W08-2	The case for myeloma <i>Speaker:</i> Thierry Facon, FR	17:00 - 17:30
W08-3	Round table discussion: how to define eligibility for allo and auto HSCT in elderly patients - All faculty, lead by: <i>Speaker:</i> John Snowden, GB	17:30 - 18:00

Nurses Group
16:30 - 18:00

Room 242 AB

NG17 - Late complications

Chair: Michelle Kenyon, GB

Chair: Marina Ben Izhak, IL

NG17-1	Secondary cancers <i>Speaker:</i> Bipin Savani, US	16:30 - 16:55
NG17-2	Post HSCT gynaecological health and fertility implications and	16:55 - 17:20

	management	
	<i>Speaker:</i> Zoe Schaedel, GB	
NG17-3	Growth impairment	17:20 - 17:45
	<i>Speaker:</i> Martine Mol, NL	
NG17-4	Q&A	17:45 - 18:00
<i>Working Party Sessions</i>		
16:30 - 17:45		Room 252 AB
TCWP - Transplant Complications Working Party session Complications of stem cell transplantation and cell therapy - what's new?		
<i>Chair:</i> Zinaida Peric, HR		
<i>Chair:</i> Ivan Moiseev, RU		
TCWP-1	New aspects in the management of CAR-T complications	16:30 - 16:45
	<i>Speaker:</i> Christian Koenecke, DE	
TCWP-2	New EBMT consensus recommendations for the management of GVHD	16:45 - 17:00
	<i>Speaker:</i> Olaf Penack, DE	
TCWP-3	New insights on chronic GVHD from the EUROGRAFT COST Action	17:00 - 17:15
	<i>Speaker:</i> H�el�ene Schoemans, BE	
TCWP-4	Updated HCT survivorship guidelines - an international consensus effort	17:15 - 17:30
	<i>Speaker:</i> Rachel Phelan, US	
TCWP-5	Questions & Conclusion	17:30 - 17:45
<i>Nurses Group</i>		
16:30 - 18:00		Room 243
NG18 - Cell collection		
<i>Chair:</i> Daphna Hutt, IL		
<i>Chair:</i> Elin Ofverberg, SE		
NG18-1	Mobilisation challenges	16:30 - 16:55
	<i>Speaker:</i> Charlotte Mestdagh, BE	
NG18-2	Donor evaluation	16:55 - 17:20
	<i>Speaker:</i> Annika Kisch, SE	
NG18-3	Choosing to be the donor	17:20 - 17:45
	<i>Speaker:</i> Audrey Grain, FR	
NG18-4	Q&A	17:45 - 18:00

Joint Sessions

16:30 - 18:00

Room 251

JS06 - Joint Session EBMT - WBMT | Update on The Global Data for Hematopoietic Stem Cell Transplantation*Chair:* Mahmoud Aljurf, SA*Chair:* Mickey Koh, GB

JS06-1	Introduction	16:30 - 16:40
JS06-2	Global Stem Cell Transplantation Activities Including Cellular Therapies <i>Speaker:</i> Helen Baldomero, CH	16:40 - 17:05
JS06-3	Global Data on HSCT for Multiple Myeloma <i>Speaker:</i> Dietger Niederwieser, DE	17:05 - 17:30
JS06-4	Global Data on HSCT for Acute Myeloid Leukemia <i>Speaker:</i> Molly Tokaz, US	17:30 - 17:55
JS06-5	Conclusion	17:55 - 18:00

Pharmacists Day

16:30 - 17:45

Room 253

Pharm4 - Best Abstract Awards*Chair:* Vera Domingos, PT*Chair:* Rick Admiraal, NL

Parm4-01	ANALYSIS OF THE PATIENT-PHARMACIST INTERACTION THROUGH AN MHEALTH PLATFORM IN THE MANAGEMENT OF ALLOGENEIC STEM CELL TRANSPLANT RECIPIENTS (MYMEDULA STUDY) <i>Oral Presenter:</i> Estela Moreno Martinez, ES	16:30 - 16:55
Pharm4-02	BUSULFAN TARGET EXPOSURE ATTAINMENT IN CHILDREN UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: A SINGLE DAY VERSUS A MULTIDAY THERAPEUTIC DRUG MONITORING REGIMEN <i>Oral Presenter:</i> T. Bognàr, NL	16:55 - 17:20
Pharm4-03	ASSOCIATION OF CYCLOSPORINE TROUGH CONCENTRATIONS AND THE INCIDENCE OF ACUTE GRAFT VERSUS HOST DISEASE IN PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Oral Presenter:</i> Daniel Kurnik, IL	17:20 - 17:45

Meetings

18:00 - 20:00

Room 252 AB

IM2 - Internal Meeting 2*Quality Management*

18:00 - 19:00

MTE

QM MTE-03 - Annual assessment of competencies & Outcome Analysis

QM MTE-03.1	Annual assessment of competencies	18:00 - 18:30
-------------	--	---------------

	<i>Speaker: Julie Dolva, NO</i>	
	<i>Speaker: Julia Ruiz Pato, ES</i>	
QM MTE-03.2	Outcome Analysis	18:30 - 19:00
	<i>Speaker: Victoria Bordon, BE</i>	
<i>Quality Management</i>		
18:00 - 19:00		
MTE		
QM MTE-01 - Validation and change control & Labelling		
QM MTE-01.1	Validation and change control	18:00 - 18:30
	<i>Speaker: Olga López, ES</i>	
	<i>Speaker: Valerie Lapierre, FR</i>	
QM MTE-01.2	Labelling	18:30 - 19:00
	<i>Speaker: ?lknur Kozano?lu, TR</i>	
	<i>Speaker: Songül Tepebas?, TR</i>	
<i>Quality Management</i>		
18:00 - 19:00		
MTE		
QM MTE-04 - Outcome Analysis & Annual assessment of competencies		
QM MTE-04.1	Outcome Analysis	18:00 - 18:30
	<i>Speaker: Victoria Bordon, BE</i>	
QM MTE-04.2	Annual assessment of competencies	18:30 - 19:00
	<i>Speaker: Julie Dolva, NO</i>	
	<i>Speaker: Julia Ruiz Pato, ES</i>	
<i>Quality Management</i>		
18:00 - 19:00		
MTE		
QM MTE-02 - Labelling & Validation and change control		
QM MTE-02.1	Labelling	18:00 - 18:30
	<i>Speaker: ?lknur Kozano?lu, TR</i>	
	<i>Speaker: Songül Tepebas?, TR</i>	
QM MTE-02.2	Validation and change control	18:30 - 19:00
	<i>Speaker: Olga López, ES</i>	
	<i>Speaker: Valerie Lapierre, FR</i>	
<i>Quality Management</i>		
18:00 - 19:00		
MTE		
QM Meet the Expert Sessions		

Wednesday, 26. April 2023

Meet the Expert
08:00 - 09:00

MTE

MTE-15 - Meet the Expert 15

MTE-15 **Transplantation criteria in ALL focusing on MRD** 08:00 - 09:00
Speaker: Eolia Brissot, FR

Meet the Expert
08:00 - 09:00

MTE

MTE-16 - Meet the Expert 16

MTE-16 **Auto-HSCT at home: for which patient and how?** 08:00 - 09:00
Speaker: Francesc Fernández Avilés, ES

Meet the Expert
08:00 - 09:00

MTE

MTE-17 - Meet the Expert 17

MTE-17 **How I treat severe aplastic anemia** 08:00 - 09:00
Speaker: Antonio Risitano, IT

Meet the Expert
08:00 - 09:00

MTE

MTE-13 - Meet the Expert 13

MTE-13 **Supportive care for transplant in SCD** 08:00 - 09:00
Speaker: Selim Corbacioglu, DE

Meet the Expert
08:00 - 09:00

MTE

MTE-14 - Meet the Expert 14

MTE-14 **Long term F/U and survivorship in transplanted children: The Price of Cure** 08:00 - 09:00
Speaker: Christina Peters, AT

Meet the Expert
08:00 - 09:00

MTE

Meet the Expert Sessions

Meet the Expert
08:00 - 09:00

MTE

MTE-18 - Meet the Expert 18

MTE-18 **How to treat the resistant gram-negative bacteria in HCT patients?** 08:00 - 09:00
Speaker: Dina Averbuch, IL

Plenary Session

08:30 - 10:00

AMPHITHEATRE BLEU

P04 - Immune modulation and cellular therapy in non-hematological diseases

Chair: Pavel Jindra, CZ

Chair: Christian Chabannon, FR

- | | | |
|-------|--|---------------|
| P04-1 | ASCT for multiple sclerosis
<i>Speaker:</i> Basil Sharrack, GB | 08:30 - 09:00 |
| P04-2 | Cellular therapy in primary ciliary dyskinesia - Towards a proof of concept for chronic respiratory diseases
<i>Speaker:</i> John De Vos, FR | 09:00 - 09:30 |
| P04-3 | Microbiota in the pathophysiology of non-malignant diseases
<i>Speaker:</i> Joël Doré, FR | 09:30 - 10:00 |

Oral Sessions

08:30 - 09:45

MAILLOT

OS01 - Oral Session 1 | Acute Leukemia (I)

Chair: Nour Moukalled, LB

Chair: Martina Calabrò, FR

- | | | |
|---------|---|---------------|
| OS01-01 | GILTERITINIB AND ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IMPROVE OUTCOME IN RELAPSED/REFRACTORY <i>FLT3</i>-MUTATED ACUTE MYELOID LEUKEMIA PATIENTS: REAL-WORLD DATA FROM A MULTICENTER ANALYSIS
<i>Oral Presenter:</i> Desiree Kunadt, DE | 08:30 - 08:39 |
| OS01-02 | DETECTION OF PRE-TRANSPLANT LEUKEMIC STEM CELLS IS MORE PREDICTIVE FOR EARLY RELAPSES THAN FLOW MRD IN AML PATIENTS UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION IN CR
<i>Oral Presenter:</i> Evgeny Klyuchnikov, DE | 08:39 - 08:48 |
| OS01-03 | COMPLEX KARYOTYPE NOT OTHER CYTOGENETIC ABNORMALITIES AFFECTS POST-TRANSPLANT SURVIVAL OF PATIENTS WITH <i>NPM1</i>-MUTATED ACUTE MYELOID LEUKEMIA: A STUDY FROM THE EBMT ACUTE LEUKEMIA WORKING PARTY
<i>Oral Presenter:</i> Nour Moukalled, LB | 08:48 - 08:57 |
| OS01-04 | IMPACT OF ALLO-HCT IN FIRST COMPLETE REMISSION (CR1) IN ADDITION TO <i>FLT3</i> INHIBITION WITH QUIZARTINIB IN AML WITH <i>FLT3</i>-ITD: RESULTS FROM THE QUANTUM-FIRST TRIAL
<i>Oral Presenter:</i> Radovan Vrhovac, HR | 08:57 - 09:06 |
| OS01-05 | ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR EARLY PRECURSOR T-CELL (ETP) AND NEAR-ETP ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOMA (ALL/LBL) IN REMISSION: A MULTICENTER PHASE III STUDY
<i>Oral Presenter:</i> Yu Wang, CN | 09:06 - 09:15 |
| OS01-06 | USE OF CYCLOSPORIN A VERSUS TACROLIMUS COMBINED WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE FOR | 09:15 - 09:24 |

AML IN FIRST COMPLETE REMISSION: A STUDY FROM THE ACUTE LEUKEMIA WORKING PARTY (EBMT)

Oral Presenter: Gesine Bug, DE

OS01-07 **THE IMPACT OF ALLOGENEIC STEM CELL TRANSPLANTATION IN PH-LIKE PATIENTS: A REPORT FROM THE NATIONAL TREATMENT PROTOCOLS GIMEMA 1913 AND GIMEMA 2317** 09:24 - 09:33

Oral Presenter: Giuliana Rizzuto, IT

OS01-08 **HAPLOIDENTICAL VERSUS HLA-MATCHED DONOR HEMATOPOIETIC STEM-CELL TRANSPLANTATION FOR PEDIATRIC PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA IN SECOND REMISSION** 09:33 - 09:42

Oral Presenter: José L Fuster, ES

Educational

08:30 - 10:00

Room 141

E10 - State of the art of auto-transplant in:

Chair: Eric Deconinck, FR

Chair: Kate Cwynarski, GB

E10-1 **PTCL** 08:30 - 09:00

Speaker: Christian Gisselbrecht, FR

E10-2 **Hodgkin lymphoma** 09:00 - 09:30

Speaker: Anna Sureda, ES

E10-3 **Round table discussion: intensive chemotherapy versus immunotherapy - All faculty, lead by:** 09:30 - 10:00

Speaker: Kate Cwynarski, GB

Multi-stakeholder Forum on Innovative Cellular Therapies

08:30 - 09:45

Room 143

MSF01 - Multi-stakeholder Forum on Innovative Cellular Therapies I - Access to innovative therapies

Chair: Natacha Bolaños, ES

Chair: Tuula Rintala, GB

MSF01-1 **Gene Therapy Pricing: How pharma manufacturers price their drugs and how insurers and purchasers respond** 08:30 - 08:45

Speaker: Marc A Rodwin, US

MSF01-2 **Medicine reimbursement policies in Europe** 08:45 - 09:00

Speaker: Neil Grubert, GB

MSF01-3 **Patient testimony** 09:00 - 09:15

Speaker: Natacha Bolaños, ES

MSF01-4 **Crossing international borders for Cell based treatments: cause for concern?** 09:15 - 09:30

Speaker: Mickey Koh, GB

MSF01-5 **Q&A** 09:30 - 09:45

Educational

08:30 - 10:00

Room 151

E11 - Gene therapy in Inborn errors*Chair:* Bénédicte Neven, FR*Chair:* Arjan Lankester, NL

- | | | |
|-------|---|---------------|
| E11-1 | Overview of gene therapy in Inborn errors of immunity
<i>Speaker:</i> Donald Kohn, US | 08:30 - 09:00 |
| E11-2 | Gene therapy in metabolic diseases
<i>Speaker:</i> Maria Ester Bernardo, IT | 09:00 - 09:30 |
| E11-3 | Gene therapies in hemoglobinopathies
<i>Speaker:</i> Marina Cavazzana, FR | 09:30 - 10:00 |

Workshop

08:30 - 10:00

Room 153

W10 - New ways of improving patient outcome after HSCT/cell therapy*Chair:* Amandine Charbonnier, FR*Chair:* Francesco Lanza, IT

- | | | |
|-------|--|---------------|
| W10-1 | Long term side effects after HSCT: where do we stand?
<i>Speaker:</i> Bipin Savani, US | 08:30 - 09:00 |
| W10-2 | Patient engagement in research & care - a mind shift?
<i>Speaker:</i> Hélène Schoemans, BE | 09:00 - 09:30 |
| W10-3 | There Is No Place Like Home
<i>Speaker:</i> Jonas Mattsson, CA | 09:30 - 10:00 |

Nurses Group

08:30 - 10:00

Room 242 AB

NG19 - Nurses Group & Pharmacists Joint Session*Chair:* Nick Duncan, GB*Chair:* Michelle Kenyon, GB

- | | | |
|--------|--|---------------|
| NG19-1 | “Bench to Bedside” – how new drugs get from the laboratory to the patient
<i>Speaker:</i> Antonio Melo Gouveia, PT | 08:30 - 08:50 |
| NG19-2 | Drug monitoring
<i>Speaker:</i> Karen Sweiss, US | 08:50 - 09:10 |
| NG19-3 | Supporting adherence in the early post-transplant phase
<i>Speaker:</i> Lynn Leppla, DE | 09:10 - 09:30 |
| NG19-4 | Panel discussion - collaborative working at bedside | 09:30 - 10:00 |

Educational

08:30 - 10:00

Room 252 AB

E12 - Cord Blood Transplantation*Chair:* Jakob Passweg, CH*Chair:* Edouard Forcade, FR

- | | | |
|-------|--------------------------------------|---------------|
| E12-1 | In adults with acute leukemia | 08:30 - 09:00 |
|-------|--------------------------------------|---------------|

	<i>Speaker:</i> Annalisa Ruggeri, IT	
E12-2	Ex vivo expansion of CBT <i>Speaker:</i> Frédéric Baron, BE	09:00 - 09:30
E12-3	Round table discussion: future of CBT - All faculty, lead by: <i>Speaker:</i> Jakob Passweg, CH	09:30 - 10:00

Oral Sessions
08:30 - 09:45

Room 241

OS02 - Oral Session 2 | Multiple myeloma

Chair: Julia Campe, DE

Chair: Sarita Jaiswal, IN

OS02-01	CILTA-CEL EFFICACY AND SAFETY IN PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA (MM) AFTER NON-CELLULAR ANTI-BCMA IMMUNOTHERAPY <i>Oral Presenter:</i> María Victoria Mateos, ES	08:30 - 08:39
OS02-02	UNDERSTANDING IMMUNE CELLULAR PROCESSES SHAPING SARS-COV-2 VACCINE RESPONSES IN PATIENTS WITH MULTIPLE MYELOMA <i>Oral Presenter:</i> Julia Campe, DE	08:39 - 08:48
OS02-03	CARTITUDE-2 COHORT B 18-MONTH FOLLOW-UP: CILTACABTAGENE AUTOLEUCEL (CILTA-CEL), A BCMA-DIRECTED CAR-T CELL THERAPY, IN PATIENTS WITH MULTIPLE MYELOMA (MM) AND EARLY RELAPSE AFTER INITIAL THERAPY <i>Oral Presenter:</i> Tessa Kerre, BE	08:48 - 08:57
OS02-04	ABATACEPT AND IL-15 INDUCED NK CELL INFUSION (ABANI-15) FROM HAPLOIDENTICAL FAMILY DONOR FOLLOWING AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION: A NOVEL APPROACH FOR HIGH RISK MYELOMA <i>Oral Presenter:</i> Sarita Jaiswal, IN	08:57 - 09:06
OS02-05	BONE MARROW MEASURABLE RESIDUAL DISEASE AND IMMUNE MICROENVIRONMENT IN MYELOMA LONG-TERM SURVIVORS AFTER AUTOLOGOUS OR ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION <i>Oral Presenter:</i> Jean-Sebastien Claveau, CA	09:06 - 09:15
OS02-06	EXTERNAL VALIDATION OF THREE EXISTING EARLY MYELOMA RELAPSE SCORES (BY EBMT, CIBMTR, AND GIMEMA) IN A SINGLE CENTER SHOWS MAJOR DIFFERENCES <i>Oral Presenter:</i> Meral Beksac, TR	09:15 - 09:24
OS02-07	COST-EFFECTIVENESS OF EARLY VERSUS DELAYED AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) FOR MULTIPLE MYELOMA (MM) <i>Oral Presenter:</i> Amar Kelkar, US	09:24 - 09:33
OS02-08	RESPONSE RATES AND OUTCOMES IN NEWLY-DIAGNOSED	09:33 - 09:42

**MULTIPLE MYELOMA (NDMM) PATIENT SUBGROUPS
RECEIVING RVD±ASCT PLUS LENALIDOMIDE MAINTENANCE
UNTIL PROGRESSION IN THE PHASE 3 DETERMINATION TRIAL**

Oral Presenter: Hani Hassoun, US

Nurses Group

08:30 - 10:00

Room 243

NG20 - Research Committee Workshop: How to become a successful researcher

Chair: Sabine Valenta, CH

Chair: Annika Kisch, SE

NG20-1	Writing an abstract:	08:30 - 08:30
NG20-1.1	Writing an abstract <i>Speaker:</i> Isabel Salcedo, ES	08:30 - 08:50
NG20-1.2	Workshop/Group exercise	08:50 - 09:20
NG20-2	How to get published:	09:20 - 09:20
NG20-2.1	How to get published <i>Speaker:</i> Simona Calza, IT	09:20 - 09:35
NG20-2.2	Workshop/Discussion	09:35 - 10:00

Oral Sessions

08:30 - 09:45

Room 251

OS03 - Oral Session 3 | Hemoglobinopathies

Chair: Elisabeth Dovern, NL

Chair: Gaurav Kharya, IN

OS03-01	IMPROVED T-CELL CHIMERISM AND SUCCESSFUL WITHDRAWAL OF IMMUNOSUPPRESSION AFTER NON-MYELOABLATIVE STEM CELL TRANSPLANTATION FOR SICKLE CELL DISEASE WITH AZATHIOPRINE/HYDROXYUREA PRECONDITIONING ADDED TO ALEMTUZUMAB/TBI CONDITIONING <i>Oral Presenter:</i> Elisabeth Dovern, NL	08:30 - 08:39
OS03-02	PRE-TRANSPLANT IMMUNE SUPPRESSION AND POST-TRANSPLANT CYCLOPHOSPHAMIDE (APOLLO PROTOCOL) BEYOND HAPLOIDENTICAL FAMILY DONOR HEMATOPOIETIC STEM CELL TRANSPLANT FOR HEMOGLOBINOPATHIES: DOES IT HELP CONSOLIDATE OUR GAINS? <i>Oral Presenter:</i> Gaurav Kharya, IN	08:39 - 08:48
OS03-03	IMPROVED CEREBRAL PERFUSION AND OXYGEN METABOLISM AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH SICKLE CELL DISEASE <i>Oral Presenter:</i> Elisabeth Dovern, NL	08:48 - 08:57
OS03-04	OUTCOME OF HEMATOPOIETIC STEM CELL TRANSPLANTATION IN THALASSEMIA MAJOR PATIENTS: A	08:57 - 09:06

30-YEAR EXPERIENCE FROM A SPECIALIZED CENTER IN TEHRAN, IRAN

Oral Presenter: Mohammad Biglari, IR

- | | | |
|---------|--|---------------|
| OS03-05 | MATCHED SIBLING AND HAPLO-IDENTICAL ALLOGENEIC STEM CELL TRANSPLANTATION OUTCOME OF SICKLE CELL DISEASE: EXPERIENCE OF 104 PATIENTS
<i>Oral Presenter:</i> Mostafa F. Mohammed Saleh, SA | 09:06 - 09:15 |
| OS03-06 | EXCELLENT GVHD-FREE, DISEASE-FREE SURVIVAL AFTER HAPLOIDENTICAL HSCT WITH PTCY FOR SICKLE CELL DISEASE
<i>Speaker:</i> Tanja C. Vallée, DE | 09:15 - 09:24 |
| OS03-07 | HAPLOIDENTICAL ?? T CELL DEPLETED HSCT REPRESENTS A CURATIVE ALTERNATIVE TO MSD IN PATIENTS WITH TRANSFUSION DEPENDENT THALASSEMIA
<i>Oral Presenter:</i> Katharina Kleinschmidt, DE | 09:24 - 09:33 |
| OS03-08 | HEMATOPOIETIC STEM CELL TRANSPLANTATION IN SICKLE CELL DISEASE: RETROSPECTIVE STUDY ON BEHALF OF THE BRAZILIAN BONE MARROW TRANSPLANTATION AND CELL THERAPY SOCIETY (SBTMO)
<i>Oral Presenter:</i> Luiz Guilherme Darrigo Junior, BR | 09:33 - 09:42 |

Oral Sessions

08:30 - 09:45

Room 253

OS04 - Oral Session 4 | Inborn errors

Chair: Claire Horgan, GB

Chair: Tayfun Güngör, CH

- | | | |
|---------|--|---------------|
| OS04-01 | HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH MUCOPOLYSACCHARIDOSIS-IVA: A PRELIMINARY REPORT
<i>Oral Presenter:</i> Koray Yalcin, TR | 08:30 - 08:39 |
| OS04-02 | PAEDIATRIC INTENSIVE CARE ADMISSION FOLLOWING ALLOGENEIC HSCT FOR INBORN ERRORS OF IMMUNITY: RETROSPECTIVE STUDY
<i>Oral Presenter:</i> Christo Tsilifis, GB | 08:39 - 08:48 |
| OS04-03 | COMBINED ALLOGENEIC BONE MARROW TRANSPLANTATION AND INTRACEREBROVENTRICULAR ENZYME REPLACEMENT THERAPY FOR PATIENTS WITH NEURONOPATHIC MUCOPOLYSACCHARIDOSIS TYPE II
<i>Oral Presenter:</i> Hirotooshi Sakaguchi, JP | 08:48 - 08:57 |
| OS04-04 | NEWBORN SCREENING FOR HURLER SYNDROME LEADS TO EARLY TREATMENT AND EXCELLENT OUTCOMES WITH UNRELATED UMBILICAL CORD BLOOD TRANSPLANT
<i>Oral Presenter:</i> Vinod K Prasad, US | 08:57 - 09:06 |
| OS04-05 | OFF-LABEL USE OF LETERMIVIR FOR CMV PROPHYLAXIS IN VERY HIGH-RISK PEDIATRIC HSCT RECIPIENTS
<i>Oral Presenter:</i> Thibaut César, FR | 09:06 - 09:15 |

OS04-06	EXTENDED CLINICAL PHENOTYPE AND TREATMENT MODALITIES IN 23 JAGN1 DEFICIENT PATIENTS - AN EBMT IEWP MULTI-CENTER STUDY <i>Oral Presenter:</i> Julia Fekadu-Siebold, DE	09:15 - 09:24
OS04-07	TEN-YEAR SINGLE-CENTER EXPERIENCE OF TCR$\alpha\beta$/CD19 DEPLETION FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION IN INBORN ERRORS OF IMMUNITY <i>Oral Presenter:</i> Alexandra Laberko, RU	09:24 - 09:33
OS04-08	ALLOGENEIC HCT RESOLVES INFLAMMATORY AND INFECTIOUS MANIFESTATIONS OF CHRONIC GRANULOMATOUS DISEASE IN AFFECTED FEMALE X-LINKED CARRIERS <i>Oral Presenter:</i> Christo Tsilifis, GB	09:33 - 09:42
<i>ePoster</i> 09:00 - 15:00 ePoster Viewing		ePoster Area
<i>Library</i> 09:00 - 15:00 Library		Library
<i>Breaks</i> 10:00 - 10:30 Coffee Break, ePoster Viewing, Visit Exhibition		AMPHITHEATRE BLEU
<i>Oral Sessions</i> 10:30 - 11:45 OS05 - Oral Session 5 GVHD (Clinical) <i>Chair:</i> Domenico Russo, IT <i>Chair:</i> Antoine Capes, FR		AMPHITHEATRE BLEU
OS05-01	EFFICACY AND SAFETY OF RUXOLITINIB IN PATIENTS WITH STEROID-REFRACTORY CHRONIC GRAFT VERSUS HOST DISEASE AFTER CROSSOVER IN THE PHASE 3 REACH-3 STUDY <i>Speaker:</i> Franco Locatelli, IT	10:30 - 10:39
OS05-02	POST-TRANSPLANT CYCLOPHOSPHAMIDE (PTCY) VERSUS ANTI-THYMOCYTE GLOBULIN (ATG) VERSUS COMBINATION FOR GRAFT-VERSUS-HOST DISEASE PREVENTION IN HAPLOIDENTICAL TRANSPLANTATION FOR ADULT ACUTE MYELOID LEUKEMIA: A REPORT FROM THE EBMT <i>Oral Presenter:</i> Abdul-Hamid Bazarbachi, US	10:39 - 10:48
OS05-03	THIRD-PARTY FECAL MICROBIOTA TRANSPLANTATION FOR THE TREATMENT OF HIGH-RISK TREATMENT-NAIVE ACUTE GRAFT-VERSUS-HOST DISEASE OF THE LOWER GASTROINTESTINAL TRACT <i>Oral Presenter:</i> Zachariah DeFilipp, US	10:48 - 10:57

OS05-04	SYSTEMIC COMPLEMENT ACTIVATION INFLUENCES OUTCOMES AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: A PROSPECTIVE FRENCH MULTICENTER TRIAL <i>Oral Presenter:</i> Marie Thérèse Rubio, FR	10:57 - 11:06
OS05-05	MACHINE LEARNING-BASED IDENTIFICATION OF THREE DISTINCT PATHWAYS IN PRIMARY AND SECONDARY OPERATIONAL TOLERANCE AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) USING THE PROSPECTIVE ABLE1.0 PEDIATRIC STUDY COHORT <i>Oral Presenter:</i> Kirk R. Schultz, CA	11:06 - 11:15
OS05-06	GVHD PROPHYLAXIS INCORPORATING METHOTREXATE IN ALLO-HCT FOR CHRONIC MYELOID MALIGNANCIES AND SAML: A RETROSPECTIVE ANALYSIS FROM THE CMWP OF THE EBMT <i>Oral Presenter:</i> Thomas Luft, DE	11:15 - 11:24
OS05-07	SURVIVAL OUTCOMES AT 1-YEAR POST-ALLOGENEIC HCT BETWEEN PATIENTS TREATED WITH ABATACEPT IN COMBINATION WITH CNI+MTX VERSUS ATG OR PT-CY: A REAL-WORLD EVIDENCE COMPARISON <i>Oral Presenter:</i> Leslie S Kean, US	11:24 - 11:33
OS05-08	POOLED FECAL ALLOGENIC MICROBIOTHERAPY FOR REFRACTORY GASTROINTESTINAL ACUTE GRAFT-VERSUS-HOST DISEASE: RESULTS FROM THE EARLY ACCESS PROGRAM IN FRANCE <i>Oral Presenter:</i> Florent Malard, FR	11:33 - 11:42

Oral Sessions
10:30 - 11:45

MAILLOT

OS06 - Oral Session 6 | Acute Leukemia (II)

Chair: Yishan Ye, CN

Chair: Bhagirathbhai R Dholaria, US

OS06-06	FREQUENCY AND IMPACT OF PRE-TRANSPLANT SOMATIC CO-OCCURRING MUTATIONS ON CLINICAL OUTCOMES OF AML PATIENTS RECEIVING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: ON BEHALF OF THE EBMT ALWP <i>Oral Presenter:</i> Ali Bazarbachi, LB	10:30 - 10:39
OS06-08	RESTORATION OF GUT MICROBIOTA DIVERSITY WITH ORAL POOLED FECAL MICROBIOTHERAPY IN ACUTE MYELOID LEUKEMIA PATIENTS AFTER INTENSIVE CHEMOTHERAPY: THE PHASE 1B CIMON TRIAL <i>Oral Presenter:</i> Florent Malard, FR	10:39 - 10:48
OS06-01	PERIPHERAL BLOOD STEM CELL VS. BONE MARROW GRAFT FOR PATIENTS > 60 YEARS UNDERGOING HAPLOIDENTICAL TRANSPLANTATION FOR AML: AN ANALYSIS OF THE ALWP OF EBMT <i>Oral Presenter:</i> Raynier Devillier, FR	10:48 - 10:57

OS06-02	T REPLETE HAPLOIDENTICAL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE IN PATIENTS WITH SECONDARY VERSUS DE NOVO AML: A STUDY FROM THE ALWP /EBMT <i>Oral Presenter:</i> Arnon Nagler, IL	10:57 - 11:06
OS06-03	OUTCOMES OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FROM DIFFERENT DONOR TYPES IN PRIMARY REFRACTORY ACUTE MYELOID LEUKEMIA: A REPORT FROM THE ALWP OF THE EBMT <i>Oral Presenter:</i> Kordelia Barbullushi, IT	11:06 - 11:15
OS06-04	COMPARATIVE STUDY FOR HAPLO-, MSD AND MUD ALLO-HCTS FOR AML PATIENTS WITH KMT2A REARRANGEMENT: A STUDY ON BEHALF OF THE EBMT GLOBAL COMMITTEE AND ALWP <i>Oral Presenter:</i> Yishan Ye, CN	11:15 - 11:24
OS06-05	PRE-TRANSPLANT BLINATUMOMAB DECREASES TRANSPLANT RELATED MORTALITY IN B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS WHO UNDERGO ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION <i>Oral Presenter:</i> Ayman Sayyed, CA	11:24 - 11:33
OS06-07	ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) IS EQUALLY EFFECTIVE IN THERAPY-RELATED ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) COMPARED TO DE-NOVO ALL – A REPORT FROM THE EBMT REGISTRY <i>Speaker:</i> Jan Zaucha, PL	11:33 - 11:42

Oral Sessions
10:30 - 11:45

Room 141

OS07 - Oral Session 7 | GVHD and immunomodulation: pre-clinical

Chair: Giorgio Orofino, IT

Chair: Katia Beider, IL

OS07-04	THE DNA-SENSOR AIM2 PROMOTES BCR-ACTIVATED B CELLS IN CHRONIC GRAFT-VERSUS-HOST-DISEASE <i>Oral Presenter:</i> Jonathan Visentin, US	10:30 - 10:39
OS07-01	HUMAN MICROBIOTA-REACTIVE DP8? REGULATORY T CELLS EXPRESSING CD73 ARE LACKING IN ACUTE GVHD PATIENTS AND PREVENT DISEASE DEVELOPMENT IN A PRE-CLINICAL HUMANIZED MOUSE MODEL <i>Oral Presenter:</i> Emmanuelle Godefroy, FR	10:39 - 10:48
OS07-02	ROCK 1/2 INHIBITION REDUCES ACUTE GRAFT-VERSUS-HOST-DISEASE IN MICE <i>Oral Presenter:</i> Kristina Maas-Bauer, DE	10:48 - 10:57
OS07-03	MOCRAVIMOD AMELIORATES CHRONIC GRAFT-VERSUS-HOST DISEASE AFTER MOUSE ALLOGENEIC HSCT <i>Oral Presenter:</i> Zixuan Zhang, JP	10:57 - 11:06
OS07-05	MEMORY CD4⁺ T CELLS EFFICIENTLY RECOGNIZE	11:06 - 11:15

DIVERGENT HLA-DP IMMUNOPEPTIDOMES RELEVANT IN ALLOGENEIC HCT*Speaker:* Esteban Arrieta Bolaños, DE

OS07-06	CIRCULATING EXTRACELLULAR VESICLES RELEASED BY ANTI-HUMAN THYMOCYTE GLOBULINS (ATG)-EXPOSED MONONUCLEAR CELLS CAN CONTRIBUTE TO IMMUNE MODULATION IN ALLOGENEIC STEM CELL TRANSPLANTATION	11:15 - 11:24
	<i>Oral Presenter:</i> Katia Beider, IL	
OS07-07	AZITHROMYCIN PROMOTES RELAPSE BY DISRUPTING T CELLS METABOLISM AND SIGNALING AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION	11:24 - 11:33
	<i>Oral Presenter:</i> Nicolas Vallet, FR	
OS07-08	LETERMOVIR CYTOMEGALOVIRUS PROPHYLAXIS IMPACTS ON POLYCLONAL IMMUNO-RECONSTITUTION DYNAMICS IN HSCT RECIPIENTS	11:33 - 11:42
	<i>Oral Presenter:</i> Giorgio Orofino, IT	

Multi-stakeholder Forum on Innovative Cellular Therapies
10:30 - 11:45

Room 143

MSF02 - Multi-stakeholder Forum on Innovative Cellular Therapies II - Hospital Exemption*Chair:* Rafael Duarte, ES*Chair:* Raquel San Jose, ES

MSF2-1	Proposed EU Regulation on Substances of Human Origin	10:30 - 10:44
	<i>Speaker:</i> Stefaan Van der Spiegel, BE	
MSF2-2	Academic needs for HE – technical perspective	10:44 - 10:51
	<i>Speaker:</i> Ulrike Koehl, DE	
MSF2-3	NK cell based therapies - Pharma perspective on challenges and opportunities	10:51 - 11:03
	<i>Speaker:</i> Jan Spanholtz, NL	
MSF2-4	The ATMP regulation and the implementation of Hospital exemption	11:03 - 11:15
	<i>Speaker:</i> Paschalia Koufokotsiou, BE	
MSF2-5	Academic needs for HE – clinical perspective	11:15 - 11:27
	<i>Speaker:</i> Raquel San Jose, ES	
MSF2-6	Q&A	11:27 - 11:45

Oral Sessions
10:30 - 11:45

Room 151

OS08 - Oral Session 8 | Infectious complications (I)*Chair:* Olaf Penack, DE*Chair:* Jessica S. Little, US

OS08-01	INFLUENCE OF PRE-EXISTING INVASIVE ASPERGILLOSIS ON ALLO-HSCT OUTCOME IN ACUTE LEUKEMIA PATIENTS: A	10:30 - 10:39
---------	--	---------------

**PROSPECTIVE STUDY OF THE EBMT INFECTIOUS DISEASES
WORKING PARTY**

Oral Presenter: Olaf Penack, DE

- | | | |
|---------|---|---------------|
| OS08-02 | A PHASE 3 RANDOMIZED, PLACEBO-CONTROLLED TRIAL EVALUATING SAFETY AND EFFICACY OF LETERMIVIR PROPHYLAXIS EXTENDED FROM 100 TO 200 DAYS POST-TRANSPLANT IN CYTOMEGALOVIRUS-SEROPOSITIVE ALLOGENEIC HSCT RECIPIENTS | 10:39 - 10:48 |
| | <i>Oral Presenter:</i> Sanjeet Dadwal, US | |
| OS08-03 | FINAL CLINICAL AND BIOMARKER DATA FROM A PHASE 2 TRIAL OF POSOLEUCEL, AN OFF-THE-SHELF, MULTIVIRUS-SPECIFIC T-CELL THERAPY, FOR PREVENTION OF CLINICALLY SIGNIFICANT VIRAL INFECTIONS POST-HCT | 10:48 - 10:57 |
| | <i>Oral Presenter:</i> Sanjeet Dadwal, US | |
| OS08-04 | DONOR NKG2C+ADAPTIVE NATURAL KILLER CELL (ANK) GENOTYPE AND ANK RECONSTITUTION KINETICS DETERMINE THE OUTCOME OF CMV REACTIVATION FOLLOWING HAPLOIDENTICAL HCT WITH ABATACEPT AND PTCY | 10:57 - 11:06 |
| | <i>Oral Presenter:</i> Sarita Jaiswal, IN | |
| OS08-05 | CYTOMEGALOVIRUS (CMV)-SPECIFIC T-CELL IMMUNE RECONSTITUTION IN HEMATOPOIETIC CELL TRANSPLANT (HCT) RECIPIENTS FOLLOWING LETERMIVIR PROPHYLAXIS USING T-SPOT.CMV | 11:06 - 11:15 |
| | <i>Oral Presenter:</i> Danniell Zamora, US | |
| OS08-06 | OPPORTUNISTIC INFECTIONS IN PATIENTS RECEIVING POST-TRANSPLANT CYCLOPHOSPHAMIDE (PTCY): OUTCOMES IN HAPLOIDENTICAL VERSUS MATCHED OR MISMATCHED UNRELATED DONOR (MUD/MMURD) ALLOGRAFTS | 11:15 - 11:24 |
| | <i>Oral Presenter:</i> Jessica S. Little, US | |
| OS08-07 | FREQUENCY, MANAGEMENT AND NEW TREATMENT MODALITIES OF EBV-DNA-EMIA AND EBV-PTLD AFTER ALLO-HCT: SURVEY OF IDWP-EBMT | 11:24 - 11:33 |
| | <i>Oral Presenter:</i> Jan Styczynski, PL | |
| OS08-08 | AN OPEN-LABEL, SINGLE-ARM STUDY OF LETERMIVIR (LTV) FOR PREVENTION OF RECURRENT CMV INFECTION IN HIGH-RISK ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT (HCT) RECIPIENTS | 11:33 - 11:42 |
| | <i>Oral Presenter:</i> Genoveva Papanicolau, US | |

Oral Sessions
10:30 - 11:45

Room 153

OS09 - Oral Session 9 | Infectious complications (II)

Chair: Lara Chavaz, CH

Chair: Rama Al Hamed, US

- | | | |
|---------|---|---------------|
| OS09-01 | REAL-WORLD OUTCOMES OF LETERMIVIR USE IN PRIMARY PROPHYLAXIS IN ADULT CYTOMEGALOVIRUS SEROPOSITIVE | 10:30 - 10:39 |
|---------|---|---------------|

**ALLOGENEIC HCT RECIPIENTS: A MULTICENTER
RETROSPECTIVE COHORT IDWP STUDY FROM THE EBMT
REGISTRY**

Oral Presenter: Jan Styczynski, PL

OS09-02	CMV REACTIVATION AFTER STOPPING LETERMOVIR PRIMARY PROPHYLAXIS IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS	10:39 - 10:48
	<i>Oral Presenter:</i> Lara Chavaz, CH	
OS09-03	CYTOMEGALOVIRUS REACTIVATION AFTER MATCHED UNRELATED DONOR AND HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION	10:48 - 10:57
	<i>Oral Presenter:</i> Joseph McGuirk, US	
OS09-04	REINFORCEMENT OF CELL-MEDIATED IMMUNITY DRIVEN BY TUMOR-ASSOCIATED EPSTEIN-BARR VIRUS (EBV)-SPECIFIC T CELLS DURING TARGETED B-CELL THERAPY WITH RITUXIMAB	10:57 - 11:06
	<i>Oral Presenter:</i> Sabine Tischer-Zimmermann, DE	
OS09-05	CLINICAL OUTCOMES OF COCCIDIOIDOMYCOSIS IN HEMATOPOIETIC CELL TRANSPLANT (HCT) AND CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY (CART) RECIPIENTS	11:06 - 11:15
	<i>Oral Presenter:</i> Deepa Nanayakkara, US	
OS09-06	INCIDENCE AND RISK FACTORS OF POST-ENGRAFTMENT OPPORTUNISTIC INFECTIONS IN AUTOLOGOUS STEM CELL TRANSPLANTATION: A NATIONWIDE, POPULATION-BASED COHORT STUDY IN KOREA	11:15 - 11:24
	<i>Oral Presenter:</i> Dajung Kim, KR	
OS09-07	OBSERVATIONAL STUDY OF 361 NON-TRANSPLANT APLASTIC ANAEMIA AND/OR PNH PATIENTS WHO RECEIVED COVID-19 VACCINATION; JOINT REPORT FROM SEVERE APLASTIC ANAEMIA & INFECTION; INFECTIOUS DISEASES EBMT WORKING PARTIES	11:24 - 11:33
	<i>Oral Presenter:</i> Morag Griffin, GB	
OS09-08	MULTINATIONAL STUDY ASSESSING TREATMENT PATTERNS, OUTCOMES, AND HEALTHCARE RESOURCE UTILIZATION IN HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS WITH REFRACTORY/RESISTANT CYTOMEGALOVIRUS INFECTION, OR INTOLERANCE TO ANTI-CYTOMEGALOVIRUS THERAPIES	11:33 - 11:42
	<i>Oral Presenter:</i> María Laura Fox, ES	

Nurses Group
10:30 - 12:00

Room 242 AB

NG21 - Cellular therapy & Closing

Chair: Michelle Kenyon, GB

Chair: Kathy Goris, BE

NG21-1	Everything you always wanted to know about BiTes, but were afraid to ask	10:30 - 10:50
--------	---	---------------

	<i>Speaker:</i> Tessa Kerre, BE	
NG21-2	CAR for everything <i>Speaker:</i> Maxime Berquier, FR	10:50 - 11:10
NG21-3	TIL, NK and TCR: what does it all mean? <i>Speaker:</i> Daan Dierickx, BE	11:10 - 11:30
NG21-4	Best of the best <i>Speaker:</i> Michelle Kenyon, GB	11:30 - 11:40
NG21-5	Highlights of physicians sessions <i>Speaker:</i> Ali Bazarbachi, LB	11:40 - 11:55
NG21-6	Presentation of Annual Meeting 2024 <i>Speaker:</i> Lorna Welsh, GB	11:55 - 12:00

Oral Sessions

10:30 - 11:45

Room 252 AB

OS10 - Oral Session 10 | Features, prevention, and management of late effects*Chair:* Michaël Loschi, FR*Chair:* Alina Gerrie, CA

OS10-01	ACCELERATED COGNITIVE AGEING AMONG SURVIVORS OF HEMATOPOIETIC STEM CELL TRANSPLANTATION COMPARED WITH A MATCHED GENERAL POPULATION SAMPLE – THE MOSA STUDY <i>Oral Presenter:</i> B. Wauben, NL	10:30 - 10:39
OS10-02	PROGNOSTIC IMPACT OF PSYCHOSOCIAL FACTORS IN PATIENTS UNDERGOING AN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Oral Presenter:</i> Maria Huguet Mas, ES	10:39 - 10:48
OS10-03	THE VALUE OF USING PATIENT-REPORTED OUTCOMES FOR HEALTH SCREENING DURING LONG-TERM FOLLOW-UP AFTER PEDIATRIC STEM CELL TRANSPLANTATION FOR NONMALIGNANT DISEASES <i>Oral Presenter:</i> Joëll E. Bense, NL	10:48 - 10:57
OS10-04	RISK FACTORS FOR CHRONIC DISEASE FOLLOWING ALLOGENEIC HAEMOPOIETIC STEM CELL TRANSPLANTATION <i>Oral Presenter:</i> Tricia Wright, AU	10:57 - 11:06
OS10-05	PERSONALIZED NUTRITIONAL MANAGEMENT AND NUTRITIONAL SUPPORT AFTER ALLOGENEIC STEM CELL TRANSPLANTATION SIGNIFICANTLY DECREASE MALNUTRITION AND IMPROVE QUALITY OF LIFE: RESULTS OF THE ALLONUT TRIAL <i>Speaker:</i> Sophie Estran, FR	11:06 - 11:15
OS10-06	ALTERATIONS OF SERUM CYTOKINES IN RESPONSE TO PHYSICAL TRAINING PROGRAMME IN ADULT PATIENTS POST BLOOD AND MARROW TRANSPLANT (BMT)	11:15 - 11:24

	<i>Oral Presenter:</i> David Ma, AU	
OS10-07	A PARTIALLY SUPERVISED EXERCISE PROGRAM FOLLOWING ALLOGENEIC STEM CELL TRANSPLANT IMPROVES EARLY POST-TRANSPLANT QUALITY OF LIFE AND PHYSICAL FUNCTIONING: RESULTS OF A RANDOMIZED CONTROLLED TRIAL	11:24 - 11:33
	<i>Oral Presenter:</i> Alina Gerrie, CA	
OS10-08	PATIENTS REPORTED OUTCOMES (PROS) IN ROUTINE PRACTICE SUPPORT THE IMPACT OF GVHD ON LONG-TERM WORSENING OF QUALITY OF LIFE: ANALYSIS ON 105 PROSPECTIVE PATIENTS	11:33 - 11:42
	<i>Oral Presenter:</i> Maria Teresa Lupo Stanghellini, IT	
<i>Oral Sessions</i>		
10:30 - 11:45		Room 241
OS11 - Oral Session 11 Stem cell collection and manipulation		
<i>Chair:</i> Francesca Kinsella, GB		
<i>Chair:</i> Blanca de Felipe Noguerales, ES		
OS11-01	DONOR GRAFTS WITH ABUNDANT HAEMOPOIETIC STEM CELLS AND MONOCYTES, BUT FEWER T CELLS, INDEPENDENTLY PREDICT CLINICAL OUTCOME FOLLOWING REDUCED INTENSITY CONDITIONED ALLOGENEIC STEM CELL TRANSPLANTATION	10:30 - 10:39
	<i>Oral Presenter:</i> Francesca Kinsella, GB	
OS11-02	RATIONAL USE OF PLERIXAFOR USING A COMBINED ALGORITHM OF CD34 COUNT IN PERIPHERAL BLOOD AND PREDICTED BLOOD VOLUMES TO PROCESS ACCORDING TO COLLECTION EFFICIENCY COEFFICIENT	10:39 - 10:48
	<i>Oral Presenter:</i> Pablo Palomo Rumschisky, ES	
OS11-03	HIGH-DOSE CYCLOPHOSPHAMIDE 4 GR/M² AND STEM-CELL COLLECTION AFTER DARATUMUMAB-BASED QUADRUPLET INDUCTION IN NEWLY DIAGNOSED TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA PATIENTS: A SINGLE-CENTER EXPERIENCE	10:48 - 10:57
	<i>Oral Presenter:</i> Carmine Liberatore, IT	
OS11-04	VALIDATION OF AN APPLICABLE PREDICTION MODEL BASED ON COLLECTION EFFICIENCY (CE₂) FOR PERIPHERAL BLOOD STEM CELL COLLECTION IN CANDIDATES FOR AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION	10:57 - 11:06
	<i>Oral Presenter:</i> Blanca de Felipe Noguerales, ES	
OS11-05	TCR$\alpha\beta$ DEPLETION USING CLINIMACS PRODIGY VS. CLINIMACS PLUS SYSTEMS: A HEAD TO HEAD COMPARISON	11:06 - 11:15
	<i>Oral Presenter:</i> Asaf D Yanir, IL	
OS11-06	PERIPHERAL BLOOD STEM CELL COLLECTION FROM SICKLE CELL TRAIT DONORS: A FEASIBILITY STUDY	11:15 - 11:24
	<i>Oral Presenter:</i> Jürgen Föll, DE	

- OS11-07 **IN HOUSE BONE MARROW COLLECTION SET: THE CATALAN BONE MARROW TRANSPLANTATION GROUP EXPERIENCE** 11:24 - 11:33
Oral Presenter: Jesus Fernandez-Sojo, ES
- OS11-08 **G-CSF ONLY VS CHEMOTHERAPY PLUS G-CSF MOBILISATION FOR AUTOLOGOUS HAEMATOPOIETIC STEM CELL TRANSPLANT – ASSESSING A CHANGE IN REGIME DUE TO THE COVID-19 PANDEMIC** 11:33 - 11:42
Oral Presenter: Marina Karakantza, GB

Oral Sessions
 10:30 - 11:45

Room 251

OS12 - Oral Session 12 | Aplastic anemia and bone marrow failures

Chair: Simona Pagliuca, FR

Chair: Ryotaro Nakamura, US

- OS12-01 **ORAL IPTACOPAN MONOTHERAPY HAS SUPERIOR EFFICACY TO ANTI-C5 THERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA AND RESIDUAL ANEMIA: RESULTS FROM THE PHASE III APPLY-PNH STUDY** 10:30 - 10:39
Oral Presenter: Antonio Risitano, IT
- OS12-02 **HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION USING EX VIVO T CELL-DEPLETED GRAFT FOR PEDIATRIC PATIENTS WITH ACQUIRED SEVERE APLASTIC ANEMIA** 10:39 - 10:48
Oral Presenter: Ho Joon Im, KR
- OS12-03 **CONDITIONAL SURVIVAL AND STANDARDIZED MORTALITY RATIOS OF PATIENTS WITH SEVERE APLASTIC ANEMIA SURVIVING AT LEAST ONE YEAR AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION OR IMMUNOSUPPRESSIVE THERAPY** 10:48 - 10:57
Oral Presenter: Ryotaro Nakamura, US
- OS12-04 **THE IMPACT OF PATIENT-REPORTED ETHNICITY ON HAEMATOPOIETIC CELL TRANSPLANT OUTCOME: THE UK EXPERIENCE** 10:57 - 11:06
Oral Presenter: John Snowden, GB
- OS12-05 **OPTICAL GENOME MAPPING AS A NEW TOOL TO OVERCOME CONVENTIONAL CYTOGENETICS' LIMITATIONS IN PATIENTS WITH BONE MARROW FAILURE** 11:06 - 11:15
Oral Presenter: June Iriondo Alzola, ES
- OS12-06 **ORAL COMPLEMENT FACTOR B INHIBITOR IPTACOPAN MONOTHERAPY IMPROVES HEMOGLOBIN TO NORMAL/NEAR-NORMAL LEVELS IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA PATIENTS NAÏVE TO COMPLEMENT INHIBITORS: PHASE III APPOINT-PNH TRIAL** 11:15 - 11:24
Poster Presenter: Antonio Risitano, IT
- OS12-07 **THE PNH CLONE SIZE AT THE START OF APLASTIC ANEMIA ARE CLOSELY ASSOCIATED WITH TRANSFORMATION IN CLINICAL SIGNIFICANT PNH** 11:24 - 11:33

Oral Presenter: Zalina Fidarova, RU

- | | | |
|---------|--|---------------|
| OS12-08 | CURRENT USE OF ANDROGENS IN BONE MARROW FAILURE DISORDERS: A REPORT FROM THE SEVERE APLASTIC ANEMIA WORKING PARTY (SAAWP) OF THE EBMT | 11:33 - 11:42 |
| | <i>Oral Presenter:</i> Simona Pagliuca, FR | |

Oral Sessions

10:30 - 11:45

Room 253

OS13 - Oral Session 13 | Autoimmune diseases

Chair: Maynara Santana-Gonçalves, BR

Chair: Mathieu Puyade, FR

- | | | |
|---------|--|---------------|
| OS13-01 | HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR TREATMENT OF MULTIPLE SCLEROSIS IN SWEDEN: AN OBSERVATIONAL COHORT STUDY | 10:30 - 10:39 |
| | <i>Oral Presenter:</i> Thomas Silfverberg, SE | |
| OS13-02 | AUTOLOGOUS STEM CELL TRANSPLANTATION FOR AUTOIMMUNE DISEASES AT ST VINCENTS HOSPITAL, SYDNEY – 25 YEARS AND 159 PATIENTS: AN ANALYSIS OF DISEASE SPECIFIC OUTCOMES AND SAFETY | 10:39 - 10:48 |
| | <i>Oral Presenter:</i> David Ma, AU | |
| OS13-03 | OUTCOME OF SARS-COV2 INFECTION IN HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS FOR AUTOIMMUNE DISEASES | 10:48 - 10:57 |
| | <i>Oral Presenter:</i> Raffaella Greco, IT | |
| OS13-04 | AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR MS. THE DUTCH EXPERIENCE OF PATIENTS GOING ABROAD | 10:57 - 11:06 |
| | <i>Oral Presenter:</i> Ellen PA Kramer, NL | |
| OS13-05 | AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION MODULATES THE INFLAMMATION-FIBROSIS PATHOLOGICAL AXIS IN SYSTEMIC SCLEROSIS PATIENTS | 11:06 - 11:15 |
| | <i>Oral Presenter:</i> Djúlio César Zanin-Silva, BR | |
| OS13-06 | THYROID DISEASES POST AUTOLOGOUS STEM CELL TRANSPLANTATION FOR AUTO-IMMUNE A DISEASE: A RETROSPECTIVE COHORT STUDY | 11:15 - 11:24 |
| | <i>Oral Presenter:</i> Mathieu Puyade, FR | |
| OS13-07 | DISTINCT PATTERNS IN THE TREG AND T-HELPER SUBSET RECONSTITUTION AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN JUVENILE-ONSET SYSTEMIC SCLEROSIS PATIENTS | 11:24 - 11:33 |
| | <i>Oral Presenter:</i> Paul Szabolcs, US | |
| OS13-08 | INFLAMMATION AND IMMUNOREGULATION-RELATED MOLECULES IN THE SERUM OF PATIENTS WITH SYSTEMIC SCLEROSIS TREATED WITH AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION | 11:33 - 11:42 |

Oral Presenter: Maynara Santana-Gonçalves, BR

Breaks

11:45 - 12:30

AMPHITHEATRE BLEU

Lunch Break, ePoster Viewing, Visit Exhibition

Special Session

12:30 - 13:45

MAILLOT

SS06 - GOCART ongoing projects

Chair: Jurgen Kuball, NL

Chair: Christian Chabannon, FR

SS06-1	Comparison of allogeneic hematopoietic stem cell transplantation with chimeric antigen receptor T-cells in relapsed and refractory large B cell lymphoma <i>Speaker:</i> Bertram Glass, DE	12:30 - 12:42
SS06-2	Impact of Preceding therapy of CART Cells in B-ALL and impact of consolidative HCT following complete remission post CART <i>Speaker:</i> Valentin Ortíz-Maldonado, ES	12:42 - 12:54
SS06-3	Autoimmune and auto inflammatory complications after CAR-T cell therapy <i>Speaker:</i> Matteo Doglio, IT	12:54 - 13:06
SS06-4	Efficacy and toxicity of CAR T cell therapy in patients with primary and secondary central nervous system lymphoma. A Retrospective Analysis of the Lymphoma WP of the EBMT <i>Speaker:</i> Anna Laube, DE	13:06 - 13:18
SS06-5	Infections following CAR-T therapy A retrospective collaborative study between the Infectious Diseases Working Party (IDWP), the Cellular Therapy and Immunobiology Working Party (CTIWP), the Transplant Complications Working Party (TCWP) of the EBMT, the European Hematology Association (EHA), and the Medical College of Wisconsin <i>Speaker:</i> Dina Averbuch, IL	13:18 - 13:30
SS06-6	Q&A	13:30 - 13:45

Oral Sessions

12:30 - 13:45

Room 141

OS14 - Oral Session 14 | Early Complications post HSCT: prediction and outcome

Chair: Mariano Berro, AR

Chair: Hannah Wardill, AU

OS14-02	DEVELOPMENT AND VALIDATION OF A CONCISE OBJECTIFIABLE RISK EVALUATION (CORE) SCORE FOR NON-RELAPSE MORTALITY AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Oral Presenter:</i> Gunnar Weise, DE	12:30 - 12:39
OS14-03	OUTCOMES OF DEFIBROTIDE-TREATED PATIENTS WITH VENOCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION	12:39 - 12:48

(VOD/SOS) FOLLOWING ALLOGENEIC-HAEMATOPOIETIC CELL TRANSPLANTATION (HCT): RESULTS FROM THE DEFIFRANCE REGISTRY

Oral Presenter: Mohamad Mohty, FR

- | | | |
|---------|---|---------------|
| OS14-04 | <p>OUTCOMES IN OLDER AND YOUNGER ADULT DEFIBROTIDE-TREATED PATIENTS WITH VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME (VOD/SOS) AFTER ALLOGENEIC-HAEMATOPOIETIC CELL TRANSPLANTATION (HCT): RESULTS FROM THE DEFIFRANCE REGISTRY</p> <p><i>Oral Presenter:</i> Didier Blaise, FR</p> | 12:48 - 12:57 |
| OS14-05 | <p>THE CHICKEN AND THE EGG: UNRAVELLING THE FACTORS THAT SHAPE GUT DYSBIOSIS IN HSCT RECIPIENTS</p> <p><i>Oral Presenter:</i> Hannah Wardill, AU</p> | 12:57 - 13:06 |
| OS14-06 | <p>NON-GVHD ENTEROCOLITIS FOLLOWING CORD BLOOD TRANSPLANT IS REAL, WITH POORLY UNDERSTOOD PATHOPHYSIOLOGY, AND REQUIRES DISTINCT MANAGEMENT FROM GVHD, WITH EVENTUAL RESOLUTION WITHOUT IMMUNE SUPPRESSION</p> <p><i>Oral Presenter:</i> Claire Horgan, GB</p> | 13:06 - 13:15 |
| OS14-07 | <p>ENDOTHELIAL GLYCOCALYX: A MORPHOLOGICAL SUBSTRATE FOR EASIX</p> <p><i>Oral Presenter:</i> Thomas Luft, DE</p> | 13:15 - 13:24 |
| OS14-08 | <p>IMPACT OF TACROLIMUS TIME IN THERAPEUTIC RANGE (TTR) IN TRANSPLANT OUTCOMES</p> <p><i>Oral Presenter:</i> Mariano Berro, AR</p> | 13:24 - 13:33 |
| OS14-01 | <p>THE SIMPLIFIED COMORBIDITY INDEX STRATIFIES NON-RELAPSE MORTALITY IN PATIENTS RECEIVING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT AFTER REDUCED-INTENSITY CONDITIONING: A CIBMTR VALIDATION STUDY</p> <p><i>Oral Presenter:</i> Roni Shouval, US</p> | 13:33 - 13:42 |

Oral Sessions
12:30 - 13:45

Room 143

OS15 - Oral Session 15 | Conditioning regimens

Chair: Tamim Alsuliman, FR

Chair: Anne Banet, FR

- | | | |
|---------|--|---------------|
| OS15-01 | <p>MATCHED-PAIRED COMPARISON OF 12-GY OR 8-GY TOTAL BODY IRRADIATION FOR ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS IN FIRST COMPLETE REMISSION. ON BEHALF OF THE ALWP OF EBMT</p> <p><i>Oral Presenter:</i> Alexandros Spyridonidis, GR</p> | 12:30 - 12:39 |
| OS15-02 | <p>A RANDOMIZED PHASE 3 STUDY OF ALLOGENEIC HCT WITH IOMAB-B VERSUS CONVENTIONAL CARE IN OLDER PATIENTS WITH ACTIVE, RELAPSED/REFRACTORY AML: PIVOTAL SIERRA TRIAL RESULTS</p> | 12:39 - 12:48 |

	<i>Oral Presenter:</i> Boglarka Gyurkocza, US	
OS15-03	LONG TERM FOLLOW-UP OF THE MULTICENTRE, RANDOMIZED PHASE 3 TRIAL COMPARING BUSULFAN-FLUDARABINE VERSUS BUSULFAN-CYCLOPHOSPHAMIDE AS CONDITIONING REGIMEN IN ACUTE MYELOID LEUKEMIA PATIENTS UNDERGOING ALLOGENEIC TRANSPLANTATION <i>Oral Presenter:</i> Gianluca Cavallaro, IT	12:48 - 12:57
OS15-04	LONG-TERM DATA OF THE RANDOMIZED TRIAL COMPARING TBI-CONTAINING CONDITIONING REGIMEN TO A CHEMOTHERAPY-BASED PREPARATION IN CHILDREN WITH ALL. RESULTS OF THE FORUM RANDOMIZED CLINICAL TRIAL <i>Oral Presenter:</i> Franco Locatelli, IT	12:57 - 13:06
OS15-05	VALIDATION IN A CONTEMPORARY ELDERLY POPULATION OF THE TRANSPLANT CONDITIONING INTENSITY (TCI) SCORE FOR ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION <i>Oral Presenter:</i> Alexandros Spyridonidis, GR	13:06 - 13:15
OS15-06	DOSE OF IV BUSULFAN IN REDUCED TOXICITY CONDITIONING REGIMEN FOR OLDER AND/OR FRAIL PATIENTS WITH AML OR MDS <i>Oral Presenter:</i> Raynier Devillier, FR	13:15 - 13:24
OS15-07	ASSOCIATION OF BUSULFAN PHARMACOKINETICS AND PHARMACOGENETICS WITH ALLOGENEIC STEM CELL TRANSPLANTATION OUTCOMES IN PEDIATRIC PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA: RESULTS FROM THE ALL SCTPED-FORUM STUDY <i>Oral Presenter:</i> Khalil Ben Hassine, CH	13:24 - 13:33
OS15-08	IMPACT OF BUSULFAN, ETOPOSIDE AND HIGH-DOSE ARA-C (BEA) CONDITIONING FOR AUTOLOGOUS STEM CELL TRANSPLANTATION IN AML <i>Oral Presenter:</i> Jaime Sanz, ES	13:33 - 13:42

Oral Sessions
12:30 - 13:45

Room 151

OS16 - Oral Session 16 | Novel and old agents in HSCT

Chair: Suhag Parikh, US

Chair: Nour Abdeljelil, TN

OS16-01	REAL-WORLD OUTCOMES OF ADULT B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS TREATED WITH BLINATUMOMAB AND INOTUZUMAB: A RETROSPECTIVE SINGLE-CENTER ANALYSIS <i>Speaker:</i> Ankita Sen, CA	12:30 - 12:39
OS16-02	ANTI-CD45 ANTIBODY-DRUG CONJUGATES AS TARGETED CONDITIONING AGENTS FOR TRANSPLANTATION/GENE THERAPY WITH POTENT ANTI-LEUKAEMIC PROPERTIES <i>Oral Presenter:</i> Aiyin Liao, GB	12:39 - 12:48
OS16-03	RETROSPECTIVE COMPARISON OF CYCLOPHOSPHAMIDE	12:48 - 12:57

	AND HORSE-ANTI-THYMOCYTE-GLOBULIN VERSUS FLUDARABINE, CYCLOPHOSPHAMIDE AND RABBIT-ANTI-THYMOCYTE-GLOBULIN CONDITIONING REGIMEN FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH ACQUIRED APLASTIC ANEMIA	
	<i>Speaker:</i> Nour Abdeljelil, TN	
OS16-04	CURRENT USE OF FECAL MICROBIOTA TRANSPLANTATION IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES: A SURVEY ON BEHALF OF THE CELLULAR THERAPY AND IMMUNOBIOLOGY WORKING-PARTY OF THE EBMT	12:57 - 13:06
	<i>Speaker:</i> Giorgia Battipaglia, IT	
OS16-05	ANTITHYMOCYTE GLOBULIN - OR ALEMTUZUMAB-BASED GVHD PROPHYLAXIS IN REDUCED-INTENSITY CONDITIONING ALLO-HCT FOR ACUTE LYMPHOBLASTIC LEUKEMIA IN CR1: A STUDY FROM THE ACUTE LEUKEMIA WORKING PARTY (EBMT)	13:06 - 13:15
	<i>Oral Presenter:</i> Gesine Bug, DE	
OS16-06	ANTI-CD117 ANTIBODY AND LOW DOSE TOTAL BODY RADIATION ENABLES ALLOGENEIC HEMATOPOIETIC STEM CELL ENGRAFTMENT AND REVERSES AUTOIMMUNE DISEASE IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) MOUSE MODELS	13:15 - 13:24
	<i>Oral Presenter:</i> Andrew Wells, US	
OS16-07	LIMITATIONS OF BUSULFAN/FLUDARABINE-BASED PREPARATIVE REGIMEN IN CTLA-4 HAPLOINSUFFICIENCY TO ACHIEVING DISEASE PHENOTYPE CORRECTION	13:24 - 13:33
	<i>Speaker:</i> Suhag Parikh, US	
OS16-08	A PROSPECTIVE STUDY OF ALLOGENEIC STEM CELL TRANSPLANTATION OF ??? T-LYMPHOCYTE DEPLETED GRAFT CONDITIONED WITH A REDUCED INTENSITY REGIMEN IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES	13:33 - 13:42
	<i>Oral Presenter:</i> Roni Tamari, US	

Oral Sessions
12:30 - 13:45

Room 153

OS17 - Oral Session 17 | MDS and MPNs

Chair: Nicola Polverelli, IT

Chair: Alicia Rovó, CH

OS17-01	IMPACT OF COMORBIDITIES AND BMI ON THE OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN MYELOFIBROSIS: AN INTERNATIONAL ANALYSIS ON BEHALF OF THE CMWP OF EBMT	12:30 - 12:39
	<i>Oral Presenter:</i> Nicola Polverelli, IT	
OS17-02	EXCELLENT OUTCOME OF HEMATOPOIETIC CELL TRANSPLANTATION (HCT) IN PATIENTS WITH SYSTEMIC MASTOCYTOSIS (SM)-WITH ASSOCIATED HEMATOLOGIC NEOPLASM (AHN)	12:39 - 12:48

	<i>Oral Presenter:</i> Christian Niederwieser, DE	
OS17-03	PROSPECTIVE VALIDATION OF THE PROGNOSTIC IMPACT OF HIGH MOLECULAR RISK MUTATIONS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN MYELOFIBROSIS <i>Oral Presenter:</i> Maria Chiara Finazzi, IT	12:48 - 12:57
OS17-04	OUTCOMES OF CMML PATIENTS UNDERGOING ALLOGENEIC HCT IN COMPARISON WITH MDS PATIENTS - A RETROSPECTIVE ANALYSIS ON BEHALF OF THE CMWP OF THE EBMT <i>Oral Presenter:</i> Alicia Rovó, CH	12:57 - 13:06
OS17-05	OUTCOME PREDICTION IN PATIENTS WITH MYELOYDYSPLASTIC SYNDROME UNDERGOING HEMATOPOIETIC CELL TRANSPLANT IN THE MOLECULAR ERA OF IPSS-M <i>Oral Presenter:</i> Carmelo Gurnari, IT	13:06 - 13:15
OS17-06	IMPACT OF GVHD ON RELAPSE IN MYELOFIBROSIS UNDERGOING HEMATOPOIETIC CELL TRANSPLANTATION <i>Oral Presenter:</i> Sofia Oechsler, DE	13:15 - 13:24
OS17-07	PRE-TRANSPLANT SPLENIC RADIOTHERAPY IN PATIENTS AFFECTED BY HIGH-RISK IDIOPATHIC/SECONDARY MYELOFIBROSIS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL THERAPY (HSCT) <i>Oral Presenter:</i> Edoardo Campodonico, IT	13:24 - 13:33
OS17-08	ASCIMINIB AS A BRIDGE - THERAPY BEFORE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR CHRONIC MYELOID LEUKEMIA <i>Oral Presenter:</i> Julia Vlasova, RU	13:33 - 13:42
<i>Oral Sessions</i> 12:30 - 13:45		Room 252 AB
OS18 - Oral Session 18 Optimizing outcome after HSCT		
<i>Chair:</i> Nina Worel, AT		
<i>Chair:</i> Irene Romera Martínez, FR		
OS18-01	HLA-DP PERMISSIVE MISMATCH SUBSETS CONFER REDUCED GVHD RISKS AND IMPROVED DISEASE CONTROL AFTER HCT FOR ACUTE LEUKEMIA AND MDS: A STUDY BY THE EBMT CTIWP <i>Speaker:</i> Katharina Fleischhauer, DE	12:30 - 12:39
OS18-02	OPTIMIZING HAPLOIDENTICAL DONOR SELECTION FOR PEDIATRIC HEMATOPOIETIC CELL TRANSPLANT <i>Speaker:</i> Kristin Page, US	12:39 - 12:48
OS18-03	THE EFFECT OF HUMAN LEUKOCYTE ANTIGEN EPI TOPE MATCHING ON OUTCOMES AFTER HAPLOIDENTICAL TRANSPLANTATION DEPENDS ON GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS AND PRETRANSPLANT DISEASE STATUS	12:48 - 12:57

	<i>Oral Presenter:</i> Makoto Iwasaki, JP	
OS18-04	A NOVEL DONOR SEARCH AND SELECTION ALGORITHM FACILITATES A COMPARABLE INCIDENCE OF TRANSPLANT FOR PATIENTS REGARDLESS OF BASELINE SEARCH PROGNOSIS: REPORT FROM BMTCTN 1702 TRIAL <i>Oral Presenter:</i> Jason Dehn, US	12:57 - 13:06
OS18-05	COMPARABLE OUTCOMES FOLLOWING NON-FIRST-DEGREE AND FIRST-DEGREE RELATED DONOR HAPLO-HCT FOR ACUTE LEUKEMIA PATIENTS IN CR: A STUDY FROM THE GLOBAL COMMITTEE AND ALWP OF EBMT <i>Oral Presenter:</i> Yishan Ye, CN	13:06 - 13:15
OS18-06	SERIOUS ADVERSE EVENTS OR REACTIONS IN RELATED DONORS AFTER HPC DONATION. A REPORT FROM THE EBMT DONOR OUTCOME REGISTRY <i>Oral Presenter:</i> Nina Worel, AT	13:15 - 13:24
OS18-07	BONE MARROW (BM) VERSUS PERIPHERAL-BLOOD-STEM-CELL (PBSC) GRAFT IN HAPLOIDENTICAL TRANSPLANTS (HAPLO) USING POST CYCLOPHOSPHAMIDE (PTCY) IN ADULTS WITH MALIGNANT DISORDERS, ON BEHALF OF CTIWP-EBMT <i>Oral Presenter:</i> Vanderson Rocha, BR	13:24 - 13:33
OS18-08	ASSOCIATIONS BETWEEN HLA EVOLUTIONARY DIVERGENCE AND OUTCOME OF MATCHED RELATED OR UNRELATED HCT: A STUDY FROM THE EBMT CELLULAR THERAPY AND IMMUNOBIOLOGY WORKING PARTY <i>Oral Presenter:</i> Katharina Fleischhauer, DE	13:33 - 13:42

Oral Sessions

12:30 - 13:45

Room 241

OS19 - Oral Session 19 | Lymphoma and CLL*Chair:* Adele de Masson, FR*Chair:* Joanna Drozd-Sokolowska, PL

OS19-01	IMPROVEMENTS IN OUTCOMES OF HAEMATOPOIETIC STEM CELL TRANSPLANTATION FOR RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA BETWEEN 1990-2019. A RETROSPECTIVE ANALYSIS OF THE LWP OF THE EBMT <i>Oral Presenter:</i> Philipp Berning, DE	12:30 - 12:39
OS19-02	TRANSIENT CD19 MASKING WITH TAFASITAMAB DIMINISHES CART19 APOPTOSIS AND TUMOR PYROPTOSIS, RESULTING IN INCREASED THERAPEUTIC INDEX OF CART19 THERAPY IN PRECLINICAL MODELS <i>Oral Presenter:</i> Reona Sakemura, US	12:39 - 12:48
OS19-03	CONSOLIDATION OF RESPONSE WITH AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION FOR T-CELL PROLYMPHOCYTIC LEUKEMIA. RETROSPECTIVE STUDY ON BEHALF OF THE CHRONIC MALIGNANCIES WORKING PARTY OF THE EBMT	12:48 - 12:57

	<i>Oral Presenter:</i> Joanna Drozd-Sokolowska, PL	
OS19-04	EFFICACY OF SUBCUTANEOUS EPCORITAMAB VERSUS CHEMOIMMUNOTHERAPY AND AXI-CEL IN R/R LBCL: AN INDIRECT COMPARISON <i>Oral Presenter:</i> Anthony Wang, US	12:57 - 13:06
OS19-05	STRUCTURED MANAGEMENT OF RELAPSE/PROGRESSION AFTER CAR T-CELLS IN LARGE B-CELL LYMPHOMA FOLLOWING THE GLA ALGORITHM – A SINGLE-CENTER EXPERIENCE <i>Oral Presenter:</i> Peter Dreger, DE	13:06 - 13:15
OS19-06	T-CELL SUB GROUP ANALYSIS AND T-CELL EXHAUSTION AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION IN LYMPHOMA PATIENTS <i>Oral Presenter:</i> Kayra Somay, TR	13:15 - 13:24
OS19-07	BRENTUXIMAB VEDOTIN PLUS BENDAMUSTINE VERSUS PLATINUM-BASED REGIMENS AS 1ST SALVAGE THERAPY AND “BRIDGE” TO AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR RELAPSED/REFRACTORY HODGKIN LYMPHOMA <i>Oral Presenter:</i> Mohammed Al Darweesh, SA	13:24 - 13:33
OS19-08	UPDATED PHASE 1/2 RESULTS OF SUBCUTANEOUS EPCORITAMAB + R-DHAX/C IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA ELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANT <i>Oral Presenter:</i> Pau Abrisqueta, ES	13:33 - 13:42

Oral Sessions
12:30 - 13:45

Room 251

OS20 - Oral Session 20 | Cellular therapy in lymphoma and leukemia

Chair: Xiaowen Tang, CN

Chair: Roni Shouval, US

OS20-01	A REPRODUCIBLE INFLAMMATORY BIOMARKER SIGNATURE IDENTIFIES NON-HODGKIN LYMPHOMA PATIENTS AT HIGH RISK OF CAR-T TREATMENT FAILURE ACROSS DIFFERENT COHORTS <i>Oral Presenter:</i> Roni Shouval, US	12:30 - 12:39
OS20-02	BCMA AND CD229 DUAL-TARGETED CAR T CELL EFFECTIVELY CONTROLS MULTIPLE MYELOMA WITH LOSS OF BCMA EXPRESSION <i>Oral Presenter:</i> Luis Gerardo Rodríguez-Lobato, ES	12:39 - 12:48
OS20-03	HLA-MATCHED TREG/TCON ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION ENSURES REMARKABLE CHRONIC GVHD/LEUKEMIA FREE SURVIVAL IN HIGH-RISK LEUKEMIA PATIENTS <i>Oral Presenter:</i> Antonio Pierini, IT	12:48 - 12:57
OS20-04	DUAL ANTIGEN TARGETING WITH CO-TRANSDUCED CD19/22	12:57 - 13:06

	CAR T CELLS MAY PREVENT ANTIGEN-NEGATIVE RELAPSE AFTER CAR T CELL THERAPY FOR RELAPSED/REFRACTORY ALL	
	<i>Oral Presenter:</i> Giovanna Lucchini, GB	
OS20-05	LONG-TERM SAFETY AND EFFICACY OF CD38-TARGETED CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA: A SINGLE-ARM, OPEN-LABEL, PHASE 1-2 TRIAL	13:06 - 13:15
	<i>Oral Presenter:</i> Xiaowen Tang, CN	
OS20-06	CRISPR/CAS9 KNOCKOUT OF IMMUNE CHECKPOINT RECEPTOR NKG2A IMPROVES THE ANTI-LEUKEMIC EFFICACY OF PRIMARY CD33-TARGETING CAR-NK CELLS	13:15 - 13:24
	<i>Oral Presenter:</i> Evelyn Ullrich, DE	
OS20-07	HIGH SAFETY AND EFFICACY OF ANTI-CD7 CAR-T CELLS IN TREATING RELAPSED OR REFRACTORY CD7+ ACUTE MYELOID LEUKEMIA: FIRST-IN-HUMAN PHASE I STUDY	13:24 - 13:33
	<i>Oral Presenter:</i> Mingming Zhang, CN	
OS20-08	CD19 CART-CELL THERAPY FOR ADULTS WITH B-ALL: A LARGE REAL-WORLD SERIES FROM ACUTE LEUKEMIA WORKING PARTY OF THE EBMT	13:33 - 13:42
	<i>Oral Presenter:</i> Eolia Brissot, FR	
 <i>Oral Sessions</i>		
	12:30 - 13:45	Room 253
OS21 - Oral Session 21 Novel approaches in HSCT		
<i>Chair:</i> Simona Sestili, FR		
<i>Chair:</i> Abdul-Hamid Bazarbachi, US		
OS21-01	LONG-TERM SURVIVAL AND TREATMENT RELATED TOXICITIES OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ACUTE LYMPHOBLASTIC LEUKEMIA WITH PREVIOUS CHIMERIC ANTIGEN RECEPTOR-MODIFIED T-CELL THERAPY	12:30 - 12:39
	<i>Oral Presenter:</i> Luxin Yang, CN	
OS21-02	CAREFULLY ENGINEERED CD117 VARIANTS RESULT IN FULL PROTECTION OF SHIELDED HEMATOPOIETIC STEM AND PROGENITOR CELLS FROM A HIGHLY POTENT CD117-DIRECTED ANTIBODY DRUG CONJUGATE IN VIVO	12:39 - 12:48
	<i>Oral Presenter:</i> Romina Marone, CH	
OS21-03	NOVEL IMMUNOTHERAPY FOR AML	12:48 - 12:57
	<i>Oral Presenter:</i> Edmund K. Waller, US	
OS21-04	MAINTENANCE OF SUPPRESSIVE POTENTIAL IN CRYOPRESERVED GMP-PURIFIED DONOR T REGULATORY (TREG) CELLS FOR INFUSION IN PATIENTS WITH STEROIDE-REFRACTORY CHRONIC GVHD	12:57 - 13:06
	<i>Speaker:</i> Mario Arpinati, IT	
OS21-05	NAVIRE, FRENCH REAL-LIFE OBSERVATORY OF EFFICACY	13:06 - 13:15

AND RESISTANCE TO ANTI CMV MOLECULES IN STEM CELL RECIPIENTS. FIRST DATA ANALYSIS

Oral Presenter: Pascal Turlure, FR

OS21-06	TARGETING FOLLICULAR HELPER T CELL OFFERS NOVEL APPROACH FOR DESENSITIZATION OF PATIENTS BEFORE HLA-MISMATCHED ALLOGRAFTING: AN <i>IN VITRO</i> AND <i>IN VIVO</i> STUDY	13:15 - 13:24
	<i>Oral Presenter:</i> Ning Ma, CN	
OS21-07	LARGE NUMBERS OF HIGHLY POTENT CORD BLOOD-DERIVED REGULATORY T CELLS COULD BE ACQUIRED BY USING CULTURE PLATFORM OF CORD BLOOD-DERIVED MESENCHYMAL STEM CELLS	13:24 - 13:33
	<i>Oral Presenter:</i> Young-Ho Lee, KR	
OS21-08	PRE-CLINICAL MODELS OF ACUTE MYELOID LEUKEMIA DEMONSTRATE AFM28 EFFICIENTLY DIRECTS ALLOGENEIC NK CELLS TO CD123⁺ LEUKEMIC BLASTS AND STEM CELLS	13:33 - 13:42
	<i>Oral Presenter:</i> Jana-Julia Siegler, DE	

General

13:45 - 14:15

AMPHITHEATRE BLEU

GS04 - Closing Session

Chair: Anna Sureda, ES

Chair: Mohamad Mohty, FR

GS04-1	Presentation of the Springer Nature Poster Awards	13:45 - 13:50
	<i>Speaker:</i> Anna Sureda, ES	
GS04-2	Best Young Abstracts	13:50 - 13:55
	<i>Speaker:</i> Harry Dolstra, NL	
GS04-3	Congress President closing remarks	13:55 - 14:00
	<i>Speaker:</i> Mohamad Mohty, FR	
GS04-4	Presentation of the 50th Annual Meeting of the EBMT	14:00 - 14:10
	<i>Speaker:</i> Victoria Potter, GB	
GS04-5	EBMT President closing remarks	14:10 - 14:15
	<i>Speaker:</i> Anna Sureda, ES	